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ABSTRACT 
Spasticity is a common presentation in a wide variety of neurological disorders 
like cerebral palsy (CP), multiple sclerosis, and spinal cord injury. 
Management of spasticity involves multiple modalities such as physical and 
occupational therapy, oral medicines, Botulinum toxin injection, and 
orthopaedic and neurosurgical intervention. Intrathecal Baclofen (ITB) therapy 
is one neurosurgical intervention to control spasticity in CP patients. The ITB 
pump is implanted subcutaneously or sub-facially in the abdomen which 
delivers the baclofen directly to the intrathecal space via a catheter. As a 
result of by-passing the blood-brain-barrier, intrathecal administration of a 
hundredth part of the oral baclofen dose is sufficient to relieve spasticity and 
therefore preventing the peripheral side-effects seen with oral administration.  
Although the ITB delivery systems demonstrate significant effectiveness in 
improving spasticity, the ITB delivery system is associated with a high 
complication rate which could interfere with the desired effect of ITB therapy. 
Therefore, in a retrospective observational study we aimed to analyse the ITB 
complications in a large (n=222) consecutive series of patients. The 
complication rate in relation to the long period of follow-up (939 pump years), 
was found to be similar or less than those reported in literature. Dystonia, 
young age and presence of gastrostomy tube were significantly associated 
with infective complications. Catheter complications were influenced by 
presence of dystonia and the surgical technique, whether it was a subfascial 
or subcutaneous implantation. 
The pump is refilled by baclofen solution. The frequency of refilling is 
dependent on the daily dosing regime and the concentration of the aqueous 
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solution of baclofen in the pump. Baclofen solutions are available as 
commercial and compounded products. An experimental controlled study was 
conducted to evaluate the safety of using higher concentrations of 
compounded baclofen in comparison to commercial baclofen. Baclofen 
concentration of the compounded solution was found to be less accurate than 
the commercial product although it was within an acceptable range from the 
expected value. The number of invisible particulates was significantly higher in 
the compounded solution than in commercial baclofen. However, no clinical 
complications were reported in the compounded or in the commercial baclofen 
groups.  
As patients receiving ITB therapy may have clinical benefits of reduction of the 
severity of spasticity, they could also have improvements in their functional 
status and quality of life. A survey study to evaluate changes in functional 
status and heath related quality of life, showed improvement in both aspects, 
moreover, the improvement in the health related quality of life was more 
significant than the change in functional status. 
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1.1 Neurophysiology of spasticity 
One of the vital functions of the human motor system is to regulate the correct 
joint positions and movements. Furthermore, a motor system also integrates 
the motor intention and the muscle tone and body position information from 
the musculoskeletal system to maintain the individual‟s posture and makes a 
state of readiness for the muscle to act quickly and smoothly to carry out a 
future task (1). 
Muscle tone is the constant muscular activity or resistance that is necessary 
as a background to actual movement in order to maintain the basic attitude of 
the body particularly against the force of gravity (2). This resistance or muscle 
tone is controlled by two factors (3): firstly, a non-neuronal factor caused by 
elasticity and compliance of the tissues that is due to viscoelastic a(4) 
properties of connective tissue, tendons and muscles crossing the joint, 
secondly, neural control of the stretch reflex which is modulated by supra-
spinal and spinal pathways (4). The stretch reﬂex is a simple reflex in which 
the muscle contracts in response to a stretching force applied to it. The 
muscle spindle is the sensory receptor for this reﬂex. Muscle spindles are 
innervated with sensory neurons (Ia and II afferents) that relay information to 
the spinal cord about changes in muscle length. Type Ia and II afferent 
neurons synapse with α-motor neurons in the anterior horn cells (AHC) in the 
spinal cord grey matter, which, in turn, innervate the muscle. Lengthening of 
the muscle fibres stretches muscle spindles and consequently stimulates the 
sensory neurons (Ia and II) leading to the release of excitatory 
                                                 
 
a Viscosity is the resistance of tissue to deforming forces whereas elasticity is the ability of a 
tissue to return to its original position after being stretched. Viscosity resists stretch; elasticity 
pulls the muscle back to its original position (4). 
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neurotransmitters; aspartate or glutamate. Subsequently, glutamate stimulates 
α-motor neurons in the spinal cord, causing a rapid contraction of the 
stretched muscle to counter muscle lengthening (5).  
In normal states, the supra-spinal pathways send their balanced input to α-
motor neurons. The α-motor neurons send the contraction signals to the 
muscle. However, feedback regarding the activity of the muscle cell is 
controlled by stretch reflex (5). 
The supra-spinal pathways are descending motor tracts, originating in the 
cerebral cortex or brain stem, that directly or indirectly influence the excitability 
of the lower motor neuron or AHC. These pathways include the cortico-spinal 
(or pyramidal) tract from the cortex, which conveys direct excitatory input to 
the AHC. In addition, there are descending motor pathways originating in the 
brain stem that indirectly influence the excitability of the AHC. These include 
the predominantly excitatory medial reticulo-spinal tract (MRT) and lateral 
vestibule-spinal tract, and the inhibitory dorsal reticulo-spinal tract (DRT). The 
inhibitory DRT receives facilitatory input from the cortex via cortico-reticular 
fibres. Importantly, the DRT runs close to the cortico-spinal tract. Accordingly, 
both are usually simultaneously affected by the same pathologic condition (2, 
5). However,  The DRT is the main inhibitory pathway that releases the 
inhibitory neurotransmitter γ-aminobutyric acid (GABA) (6). 
The mechanisms causing spasticity are not well understood. However it is 
hypothesised that it is caused by the increase in the reaction of the stretch 
reflex, as a consequence of loss of inhibitory signals from the cerebral cortex 
to α- motor neurons of the spinal cord. Damage to the cerebral cortex (as in 
cerebral palsy, cerebral stroke, traumatic brain injury, multiple sclerosis), or 
the cortico-spinal tract (as in cases of spinal cord injury, spinal tumour, 
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epidural abscess, and transverse myelitis) results in a decreased inhibition of 
the stretch reflex therefore causing spasticity (5), Figure 1-1. 
1.2 Spasticity  
1.2.1 Definition  
Several attempts have been made to define spasticity. The most often cited 
definition is the one by Lance in 1980 “ A motor disorder characterised by a 
velocity dependent increase in tonic stretch reflexes and increased tendon 
jerks resulting from disinhibition of the stretch reflex, as one component of an 
upper motor neurone lesion” (7). According to this definition, it is only the 
increased resistance to passive movement (i.e. muscle tone) that is defined as 
spasticity. Other features of the upper motor neurone (UMN) syndrome, such 
as spasms or clonus that are characterised by brief frequent repetitive 
episodes of muscle contraction, are excluded. 
However, in 2005 the Support Programme for Assembly of a database for 
Spasticity Measurement (SPASM) project, as a part of a review of spasticity 
measurement and evaluation, defined spasticity as “ disordered sensorimotor 
control, resulting from an upper motor neurone lesion, presenting as 
intermittent or sustained involuntary activation of muscles” (8). Nevertheless, 
this description is broader and less specific and lets more features of the UMN 
syndrome to be involved under the definition of spasticity, such as spasms 
and clonus (8). 
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Figure 1-1 Neural control regulating muscle 
contraction 
The 
extrapyramidal 
system corrects 
the force of 
contraction of 
the muscles  
Stretch  
The cerebellum coordinates the 
speed and direction of 
movement.  
 
The nerve impulse arising from the 
cerebral motor cortex is also sent 
to the basal ganglia and the 
extrapyramidal system nuclei.  
The corticospinal pyramidal 
tracts carry movement order to 
the lower motor neuron.  
The motor cortex is 
responsible for planning 
voluntary movement.  
The lower motor neuron sends 
contraction impulse to the 
muscle through the peripheral 
nerve. This is the final common 
pathway from the nervous 
system to the muscle.  
Muscle spindles in the contracting 
muscle, golgi tendon organs in the 
tendons and mechanoceptors in 
the joints send information on the 
degree of contraction to the 
medulla spinalis, cerebellum and 
the somatosensory cortex.  
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1.2.2  Causes of spasticity in children 
Following the successful eradication of poliomyelitis and the dramatic fall in 
the prevalence of spina bifida, the most common motor disorder in children in 
developed countries is cerebral palsy (CP) which is the most frequent cause 
of spasticity in children (9). In their observational study, Hutchinson and 
Graham reported that 79% of spasticity in children is due to cerebral palsy, 
followed by acquired brain injury in 6%, then spina bifida in 5%, spinal cord 
injury in 2 %, and other causes in 8% (10).  
In the UK, the incidence of cerebral palsy is not known, but its prevalence is 
186 per 100,000 population, with a total of 110,000 people affected (11). The 
prevalence of spasticity in CP has been reported in two studies where 
spasticity occurred in over 90% of all CP cases (12). In addition, Yeargin et al. 
stated that spasticity was found in 77% of CP patients in three centres in the 
United States (13). 
1.2.3 Consequences of spasticity 
Although the primary upper motor neuron lesion inducing spasticity is non-
progressive, the resulting pathology is permanent and its consequences are 
progressive over time. Prolonged disinhibition of the stretch reflex results in a 
decreased stimulation threshold in response to triggers and physiologic 
shortening of the muscle fibres to the extent that complete relaxation becomes 
difficult and patients lose their range of motion (14). Furthermore, spasticity 
causes apparent muscle shortening due to a decrease in the number of 
sarcomeres along the myofibrils (15). 
Long-term spasticity leads to muscle tightness and contractures. Once 
contractures have occurred, they are difficult to treat and can lead to major 
functional implications such as decreasing joints‟ range of motion; limiting the 
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sitting posture and putting the patients at risk of pressure sores and frequent 
infections (16). They also impede self-care functions such as feeding, 
dressing, and bathing. Increasing spasticity also hinders the nursing care such 
as urinary catheterisation and hygiene procedures especially with severe 
spasticity of hip adductors (17). This can put children at risk of pressure sores 
and frequent infections, which in turn may increase severity of spasticity and 
spasms. These consequences lead to restricted community mobility and 
increasing social isolation (16, 18).   
These children are dependent on their caregivers for most of their activities of 
daily living which has a significant and lifelong impact on the children, their 
caregivers and families, and on the agencies responsible for their wellbeing 
(19). 
Sleep disorders are more common in children with spastic CP than in typically 
developing children (20). The prevalence of sleep difficulties in children with 
CP was reported by Newman et al, to be as high as 44% (21). Sleep 
disturbance was attributed to various elements that are common in CP such 
as muscle spasms, other forms of movement abnormalities, and the 
decreased ability to change body position during the night (21). Moreover, 
chronic pain, a frequent secondary problem in 60% of children with CP, was 
also reported to contribute to sleep disturbances (22, 23).  
These difficulties can result in high demands for long-term care that by far 
exceed the usual requirements for typical children. These children are 
dependent on their caregivers for most of their activities of daily living. Such 
dependence has a significant and lifelong impact on the children, their 
caregivers and families, and the agencies responsible for their wellbeing (19). 
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1.2.4 Cognitive state and spastic cerebral palsy 
Although CP is predominantly a disorder of movement and posture, there is a  
correlation between severity of motor deficit and a group of developmental 
disorders such as disturbances of sensation, perception, cognitive difficulties, 
communication disorders, behavioural disorders, and seizures (24, 25).  
Bilateral spastic CP is predominantly associated with periventricular 
leukomalacia (PVL) which is a type of brain damage that encompasses 
dilation of the ventricles and reduction of the white matter. Interruption of the 
motor tracts is the cause of movement deficits in children with bilateral spastic 
CP. However, it has been hypothesised that white matter tracts connecting 
prefrontal and posterior brain regions, the basal ganglia, and related 
dopaminergic pathways may also be compromised, affecting the fine tuning of 
brain functioning and the development of cognition (26-28). 
Middle cerebral artery infarction in children with CP can affect normal 
cognitive development. The middle cerebral artery supplies the lateral cortical 
surfaces of the parietal and temporal lobes, in addition to subcortical areas 
such as basal ganglia, internal capsule, and thalamus. Early brain stroke of 
these areas affect the development of focused attention, motor-executive 
function and language functions (29, 30). 
Children with CP frequently have learning and memory problems (31). 
Memory can be impaired either due to lesions affecting neural framework as 
basal ganglia or the hippocampus, or as a result of encoding difficulties due to 
primary perceptual impairments (30).  
Himmelmann et al. reported that the rate of learning disabilities varies 
depending on the clinical type of CP. It occurred in 100%, 17%, 49% and 62% 
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in quadriplegics, hemiplegics, diplegics, and in dyskinetic types, respectively 
(32).  
1.2.5 The impact of caring for a child with spastic cerebral palsy 
The parental caregiving is a natural role of being the parents of a young child. 
However, this role can be utterly different when a child experiences functional 
limitations and possible long-term dependence such as in CP. One of the 
central challenges for parents is to cope with their child‟s chronic health 
problems effectively while maintaining the requirements of everyday living. In 
some cases, the delivery of such care can be detrimental to parents‟ physical 
health and their psychological well-being. Furthermore, it has an impact on 
family income, family functionality, and sibling adjustment (33). 
A Canadian population-based study has demonstrated that parents of children 
with CP suffered greater distress and more emotional and cognitive problems 
than the general population of caregivers. Further, they had a greater 
likelihood of physical problems, including back problems, migraine headaches, 
gastric ulcers and high blood pressure. These results demonstrate that CP 
can have a profound impact on the quality of life (QOL) of parents (34).  
In a qualitative study on the QOL of parents of children with CP, parents 
reported that they face many challenges. In this study, parents indicated that 
caring for their child affected all aspects of their life (35). They specifically 
pointed to the intense impact of the physical demands associated with caring 
for a child with a physical disability on their own physical health especially 
when the child grows and becomes heavier.  
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“Physically I’m finding it challenging lately because she’s grown so much and 
she is so dependent mobility-wise, so I’m finding that much more demanding.”  
(Mother of Michelle aged 9 years, GMFCS Level V) (35). 
 
They also indicated that caring for their child often involves interrupted sleep 
because of their child‟s dependence throughout the night. 
 
“Six years of her life waking up most nights. It can be anything from once to 
three times a night. So it’s broken sleep and it’s not great, so I find I have to 
pace myself. ” (Mother of Meredith aged 6 years, GMFCS Level V) (35). 
 
Moreover, marital relationships and strain on a marriage were also affected by 
caring a child with CP. 
“Well I suppose the fact that we can’t leave her anywhere makes it really 
difficult because we can’t do things as a couple, so our relationship is 
obviously changed a lot and we always have to think about where she is.” 
(Mother of Molly aged 3 years, GMFCS Level II) (35). 
 
Furthermore, due to the constant needs of children with CP, these parents feel 
that they have limited freedom, and they struggle to find times for themselves 
and often find it impossible to do their own tasks.  
“Well it impacts on everything because there is nothing that you can do 
spontaneously. I guess I miss that at times.” (Mother of Scott aged 16 years, 
GMFCS Level V) (35). 
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1.3 Assessment of spasticity  
A quantitative evaluation of spasticity and spasms is vital for assessment of 
potential efficacy of different treatment modalities. Appropriate measures for 
spasticity are also important from a research perspective to better understand 
the underlying pathophysiologic mechanisms associated with spasticity, and 
to assess the effectiveness of novel potentially beneficial treatments (36).  
Spasticity may be evaluated clinically or through using laboratory tests. 
Clinical evaluation is usually quick, simple, and can be carried out in any 
environment. The Ashworthb (37) and Tardieu scalesc (38) are frequently 
utilised for clinical assessment. They measure tone intensity, yet they do not 
assess the effect of spasticity on functional states (39). On the other hand, 
laboratory assessment usually requires special equipment, but has the 
advantage of quantifying subtle manifestations, and can provide information 
regarding the underlying pathophysiological mechanisms. Electromyography 
(EMG) and Hoffman reflex (H reflex)d (40) are frequently employed in 
laboratory evaluation of spasticity (41).  
1.4 Management of spasticity and decision-making 
Treatment of spasticity involves multiple modalities that usually include 
observation, physiotherapy and occupational therapy, orthotics, oral 
                                                 
 
b The Ashworth scale is a 5-point ordinal scale for ordering the resistance 
encountered during passive muscle stretching. A score of one represents no 
increase in muscle tone; two represents a slight increase in tone, giving a catch 
during stretch; three represents a more marked increase in tone, yet the limb is 
easily mobilized; four represents considerable increase in tone, making passive 
movements difficult; and five represents rigidity without any possible passive 
mobilization (37).  
c Tardieu is a scale for measuring spasticity with takes into account resistance to 
passive movement at both slow and fast speed (38) 
d Hoffman reflex is a reflectory reaction of muscles after electrical stimulation of 
type Ia sensory fiber which are primary afferent fibers that constantly monitor 
how fast a muscle stretch changes (40).  
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medicines, intramuscular injections, and both neurosurgical and orthopaedic 
surgery. Sometimes, combinations of methods are employed to increase the 
beneﬁcial effects of each modality synergistically. Selection of the most 
suitable treatment modality for a child with spastic CP requires that all parties 
to be involved. These parties include the caregivers and a multidisciplinary 
team including: paediatricians, physiotherapists and occupational therapists, 
orthotists, orthopaedic surgeons, neurosurgeons, and other healthcare 
professionals (42). 
Treatment should be adapted to meet every individual patient‟s needs aiming 
at: i) enhancing functional activity and mobility; ii) to decrease the risk of 
preventable complications (e.g. orthopaedic deformity, pressure sores, 
surgery); and iii) to allow stretching of shortened muscles, strengthening of 
antagonist muscles and facilitating physiotherapy so alleviating spasm and 
pain (43). 
1.4.1 Factors affecting decision making for spasticity treatment: 
The decision-making for treating spasticity in a child with spastic CP depends 
on multiple factor including its duration, severity, distribution as well as the 
cost. The duration of spasticity has an influence on treatment goals and 
choice of interventions. For instance, recent UMN lesions with minimal 
spasticity can be managed by local chemo-denervation, oral medication and 
other conservative methods aiming to balance muscle tone, delaying 
contractures and helping the rehabilitation efforts. However, chronic spasticity 
may benefit from either temporary or permanent long-term management (44). 
The severity of spasticity governs the choice of management modalities, as 
mild spasticity can often be managed successfully with a combination of 
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physiotherapy and oral medication. However, severe spasticity may need 
more aggressive measures to achieve a significant change in function. In 
addition, the distribution of the spasticity determines whether to treat a patient 
focally or systemically (45).  
 
 
Figure 1-2 Spasticity management modalities 
 
The cost of spasticity treatments should be considered. It is clear that the cost 
of treating spasticity complications could also be extremely expensive. 
Contractures are one of the most significant consequences of spasticity. In 
1995, the cost of surgical correction of spasticity contractures in brain-injured 
patients ranged from $13,000 to $21,000 per patient (46). Patients with severe 
spasticity could avoid high cost corrective orthopaedic surgery if they are 
treateded early (47). 
Spasticity management modalities can be classiﬁed using a four-way 
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Focal/permanent 
Peripheral neuro-
tomy 
Orthopaedic surgery 
Focal/reversible 
Intramuscular 
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Casting and orthoses 
 
General reversible 
Physical therapy 
Medical treatment 
Intrathecal baclofen 
 
General/permanent 
Selective dorsal 
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compass according to whether treatments are focal or general in effect and 
whether the effects are permanent or temporary. According to the four-way 
matrix (permanent-temporary, focal-general) practical clinical guidelines may 
be outlined (48, 49), Figure 1-2. 
1.5 Modalities of spasticity management  
1.5.1 Non-pharmacological Therapy: 
Physiotherapy and occupational therapy, orthotics, and casting are the 
foundation of spasticity treatment. The target of a physical programme is to 
preserve or improve the existing level of function, increase joint range of 
motion, strengthen muscles, decrease pain or discomfort and to avoid 
secondary complications such as contractures or adverse skin changes such 
as pressure sores (18, 50).   
1.5.2 Pharmacological management of spasticity (general and reversible) 
Systemic anti-spastic medications have been considered as “non-invasive 
treatment” in comparison to botulinum toxin and phenol injections or surgical 
interventions. The ability to titrate the dose with relative effectiveness, in 
addition to reverse the effects if necessary, are important advantages or oral 
medications (51). However, all anti-spastic drugs bind to various receptors in 
the central nervous system other than the target receptor. This can cause 
undesirable effects as they may inhibit higher centers leading to alternation in 
alertness, mood and cognitive changes which may be subtle and not easy to 
notice in the patients (52). 
Oral anti-spastic medications are classified according the site of action into 
centrally acting agents as baclofen, benzodiazepine and tizanidine, or 
peripherally acting agents like dantrolene sodium. According to their 
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mechanism of action, centrally acting medications include drugs acting 
through the GABAergic system (baclofen, benzodiazepines, piracetam, 
progabide); or drugs acting as α2 adrenergic agonist (tizanidine, clonidine) 
(53). 
1.5.2.1 Agents Acting Through the GABAergic System 
Gamma-amino butyric acid (GABA) is the main inhibitory neurotransmitter in 
the CNS. GABA is generated from glutamic acid by the action of glutamic acid 
decarboxylase (GAD). GABA appears to be stored in vesicles in the nerve 
terminal, and is released into the synaptic cleft through a Ca2+ sensitive 
mechanism. Following its release, it binds to postsynaptic receptors. GABA 
receptors are classified into two major classes either inotropic GABAA 
receptors (ligand-gated ion channels) or metabotropic GABAβ receptors (G 
protein-coupled) (53).    
Benzodiazepines  
Benzodiazepines were the earliest anti-spastic medications used in 
widespread clinical practice.  Benzodiazepines are GABAA agonists that 
facilitate the binding of existing GABA to the GABAA receptor. GABA exerts its 
inhibitory effects by activation of the fast hyperpolarising GABAA receptor at 
the post-synaptic site. This initiates an increase in chloride conductance 
through the channel facilitating chloride entry into the post-synaptic neuron 
resulting in hyperpolarisation. Such hyperpolarization also increases 
presynaptic inhibition and reduces monosynaptic and polysynaptic reflexes 
throughout the spinal cord by making it less excitable and decreasing the 
ability to raise the neuron potential to its firing threshold (54, 55). 
Chapter 1                                                                                           General Introduction  
 16 
Several trials in 1966s pointed out the effectiveness of diazepam in reducing 
spasticity, especially in younger children and those with athetosis (56)e (57, 
58). In 2005, Mathew et al. reported in a double-blind, placebo-controlled, 
randomised trial the clinical efficacy of a low-dose diazepam in enhancing 
movement in children with spastic cerebral palsy after a significant reduction 
of hypertonia and improvement in the range of passive movement (59, 60).  
The primary side effect commonly encountered with diazepam are sedation 
and a general reduction in psychomotor ability (61). It can also produce 
tolerance and physical dependence, and sudden withdrawal can cause 
seizures, anxiety, agitation, tachycardia, and even death. Likewise, an 
overdose with diazepam can result in coma or death. Therefore, this drug 
might be more beneficial for the short-term management of acute muscle 
spasms (54).  
Gabapentin  
Gabapentin was first approved by the FDA in 1993 as a new treatment for 
partial seizures (62, 63). It is structurally similar to GABA (64), but it does not 
appear to bind to conventional GABAA, GABAβ, glycine, or glutamate 
receptors. Nevertheless, Gabapentin has been shown to inhibit presynaptic 
glutamate release by modulating Ca2+ channels (65). 
                                                 
 
e Athetosis is a condition in which abnormal muscle contraction causes involuntary 
writhing movements. It affects some people with cerebral palsy, impairing speech 
and use of the hands (56). 
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Baclofen  
Historical review of Baclofen  
Baclofen was originally developed in the 1920s for use as an anti-epileptic 
agent. When used to treat adults with epilepsy who also had spasticity, it was 
noted that this drug had little effect on seizures but led to a reduction of 
spasticity. Such observations led to desertion of baclofen as antiepileptic drug. 
By the 1970s, Baclofen was first used as an oral agent in the management of 
spasticity (66). 
Baclofen is structured chemically as beta-chlorphenyl-gamma-aminobutyric 
acid, which acts selectively on GABAβ receptor (67), Figure 1-3. 
GABAβ receptors are responsible for the later and slower component of 
inhibitory transmission (68). GABAβ receptors are concentrated in Ia sensory 
afferent neurons or the interneurons and some are located post-synaptically at 
the motor neurons in Rexed laminae I−IV of the spinal cord (69). They are 
also found in other sites in the central nervous system especially the thalamus 
(70). 
Figure 1-3 - Chemical structure of Baclofen. 
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Pharmacodynamics  
Baclofen achieves its effect by activating the GABAB receptors presynapticaly 
by restricting calcium influx into Ia presynaptic terminals and through inhibiting 
the calcium high voltage activated gates. Reducing the influx of calcium into 
the presynaptic terminals of afferent fibres suppresses the release of 
excitatory neurotransmitters such as glutamate and aspartate (71). 
Balcofen can also act at postsynaptic GABAβ receptors, where GABAβ 
receptor effects are principally facilitated by direct binding, and hence 
activation of G protein-gated inwardly rectifying K+ (GIRK) channels. This 
leads to an outward K+ current which hyperpolarises the membrane and 
consequently increases the threshold of nerve cell excitability (72). 
Saito, 1975 reported the analgesic effect of baclofen through specific 
antagonism of substance P (73). Different mechanisms have been put forward 
to explain the later effect. Henry in 1982 has attributed the analgesic effect of 
baclofen to the reduced release of sub-stance P from nociceptive afferent 
nerve terminals (74). However, later in 1988, Nakajima reported that 
substance P blocks inward rectifying K+ conductance while baclofen 
increases inward rectifying K+ conductance (75).  
Pharmacokinetics 
Baclofen can be administered systematically by oral administration or centrally 
by intrathecal injection. 
Absorption  
Baclofen is rapidly and completely absorbed from the gastrointestinal tract, 
with peak plasma levels achieved after 1 to 2 hours post-administration (76). 
Distribution: 
Baclofen is bound to plasma proteins to the extent of up to 30%. It crosses the 
Chapter 1                                                                                           General Introduction  
 19 
blood-brain barrier and its concentrations in the CSF are up to 10% of the 
plasma level (77).  
Elimination  
Baclofen plasma half-life is approximately 3.5 hours (range from 2 to 6.8 
hours). Approximately, 85% of baclofen is eliminated by the kidneys in an 
unchanged form within 72 hours. Renal clearance of baclofen is high and 
equals to creatinine clearance, which signifies the importance of kidney in the 
excretion mechanism of baclofen. Therefore, it may be necessary to reduce 
baclofen oral dose in patients with renal impairment (78, 79). About 15% of a 
dose of baclofen is metabolised by deamination in the liver. The main 
metabolite by-product is 3-(4-chlorophenyl)-4-hydroxybutyric acid and is 
pharmacologically inactive (76).  
Dosage  
The recommended oral dosage in children is 0.75-to 2.5 mg/kg of body 
weight. The treatment is usually initiated with low divided doses four times 
daily, with gradual increase at approximately 3-days intervals until a 
therapeutic response is achieved. The maximum recommended doses for 
children aged 2-7 years is 30 mg up to 60 mg for children 8 years or older 
(53). 
Clinical trials involving patients with multiple sclerosis and spinal cord lesions 
have proven that baclofen is effective in reducing spasticity (80, 81). A large 
multicenter, double-blind, placebo-controlled trial involving 106 patients with 
spasticity secondary to multiple sclerosis has also conﬁrmed that baclofen 
was effective in relieving symptoms of spasticity such as ﬂexor spasms, 
clonus, pain, stiffness, resistance to passive movement of joints and tendon 
stretch reﬂex (82).  
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Currently, there are a few studies investigating the effect of oral baclofen in 
children with CP. These paediatric studies reported that oral baclofen is more 
effective than placebo in reducing spasticity (83, 84). Another case series 
study has reported the effectiveness of baclofen in children without fixed 
contractures facilitating the nursing care and physiotherapy (85). 
However, most of the studies failed to demonstrate improvement of mobility 
and activities of daily living performances and ambulation (86). Even though, 
Pedersen et al. have reported that ambulation and muscle strength have 
deteriorated during baclofen treatment (87). In comparative studies, baclofen 
has been found more effective in reducing the spasticity than diazepam (86, 
88), with considerably less day-time sedation effect and without evidence of 
rapid drug tolerance even after many years (89). 
There is a low incidence of adverse effects, and these usually take place on 
initial treatment with large doses or in the treatment of patients with spasticity 
of cerebral origin that have additional cognitive impairment (90). These 
adverse effects rarely require withdrawal of the medication and are frequently 
mild and transient. Modifying the dosage may diminish the adverse effects. 
For instance, transient drowsiness is a common side effect when initiating 
baclofen therapy, which disappears within a few days of starting the treatment 
(91). The most frequently reported adverse effects in clinical practice are 
sedation, drowsiness, weakness, paraesthesia, dry mouth, nausea and 
vomiting. Other reported effects also include psychosis and dyskinesias (92, 
93). Baclofen may reduce the seizure threshold, so it should be used with 
caution in patients with convulsions. Importantly, sudden withdrawal should be 
avoided in all individuals, as it may precipitate seizures, confusion, anxiety 
and hallucinations (94).  
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1.5.2.2 Central α-2 adrenergic receptor agonists 
Clonidine, quanfacine, and tizanidine, have α-2 adrenergic effects. They are 
α-2 agonists, which act at both the spinal and supraspinal levels. The 
physiological result of this treatment is predominantly a decrease in 
presynaptic activity of the excitatory inter-neurons (95, 96).  
Alpha 2 adrenergic agonists have an anti-nociceptive effect, which may assist 
in their tone-reducing abilities because pain is known to increase spasticity. It 
is possible that this effect is mediated through the release of substance P in 
the spinal cord (97). However, little information exists to support the 
effectiveness of using these drugs to treat spasticity in children.  
1.5.2.3 Peripheral acting muscle relaxant 
Dantrolene Sodium 
Dantrolene sodium exerts its action directly on skeletal muscle cells by 
inhibiting the release of calcium from the sarcoplasmic reticulum within the 
muscle cell during excitation. This subsequently limits myofilament cross-
bridging between actin and myosin filaments resulting in decreased muscle 
contraction (98). 
Chapter 1                                                                                           General Introduction  
 22 
1.5.3 Surgical management of spasticity  
1.5.3.1 Orthopaedic Surgery:  
In general, orthopaedic procedures aimed to improve the biomechanics of 
patients with spasticity by treating the long-term consequences of spasticity on 
the musculoskeletal system. The general principles of orthopaedic surgery are 
lengthening of contracted muscles, balancing of joint forces, fusion of unstable 
joints, and control of painful spasticity. The surgical techniques include 
tenotomy, arthrodesis, osteotomy, and tendon transfer or lengthening. The 
procedures are individualised according to the clinical situation and age of the 
patient (99). 
1.5.3.2 Neurosurgical management of spasticity: 
Neurosurgical treatments of spasticity can be performed by: i) interrupting the 
stretch reflex to reduce excitation at different locations, or ii) alternatively by 
attempting to encourage the inhibitory influence on motor neurons in the 
supra-spinal centres. Neurosurgical procedures for spasticity can be 
categorised into peripheral procedures (rhizotomy, neurectomy, or muscle 
injections) or central procedures (cordotomy, stereotactic ablative procedures, 
or implantation of intrathecal infusion of antispasticity medication to increase 
inhibitory influences) (49, 100, 101). 
1.5.3.3 Anterior rhizotomy and peripheral neurotomy 
The efferent limb of the spinal stretch reflex arc consists of the motor neuron 
in the anterior horn and the motor nerve fibre running into the ventral spinal 
nerve root and distally in the appropriate peripheral nerve. The peripheral 
nerve acts on the muscle unit at the neuromuscular junction. Accordingly, 
spasticity can be reduced by interrupting the efferent limb of the stretch reflex 
at different sites along its course by anterior rhizotomy, peripheral 
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neurectomy, peripheral nerve block, or neuromuscular junction block (102). 
Anterior Rhizotomy is rarely used because of the resulting flaccid paralysis 
and muscle atrophy (103). Peripheral neurectomy is also not a practical 
procedure as the peripheral nerves are mixed nerves containing both motor 
and sensory fibres. Peripheral nerve division, consequently, may lead to 
adverse effects such as weakness, atrophy, and loss of sensation (102).  
1.5.3.4 Chemodenervation 
Chemodenervation, also known as neurolysis, or neuromuscular blockage, 
involves using injectable materials to preclude nerve muscle transmission. 
The most commonly used techniques are peri-neural injection of phenol, 
ethanol, and botulinum toxins. Phenol and ethanol cause denervation via non-
permanent axonal degeneration. The duration of the effect ranges from a few 
months up to 2 years, till the functional re-innervation occurs (104).  
Although phenol is a low-cost chemodenervation in comparison to botulinum 
toxin, the adverse effects like pain, dysesthesia (due to necrosis of sensory 
axons in peripheral nerves), lethargy and nauseaf limit its use in children 
(105). 
Since 1988, injections of Botulinium toxin (BTX) have been used increasingly 
in place of ethanol and phenol for chemodenervation. BTX acts at the 
neuromuscular junction to block the release of acetylcholine at the 
neuromuscular junction leading to selective, temporary muscular chemo-
denervation for approximately 8–12 weeks. It acts locally, hence, it is not 
effective in reducing global spasticity (106). The general indications for BTX 
are for temporary management of focal spasticity and to evaluate the effects 
                                                 
 
f lethargy and nausea are secondary effects to systemic absorption  
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of denervating a spastic muscle (107). Adverse effects of BTX injection are 
usually mild and transient, consisting of pain on injection, occasionally mild ﬂu-
like syndrome, and excess weakness. As the botulinum neurotoxin is 
immunogenic, repeated injections could lead to immune-resistance and loss of 
its effectiveness (108, 109). 
1.5.3.5 Selective dorsal rhizotomy (SDR) or interruption of afferent limb of the 
stretch reflex 
Selective posterior rhizotomy has become a widely used neurosurgical 
technique for treatment of lower extremity spasticity in children with CP. The 
principal goal of the procedure depends on a child‟s motor abilities. It relieves 
the spasticity that is predominantly seen in the lower limbs with the main aim 
to improve mobility, pain, independence and easiness of care. In other words, 
improving the spasticity or the range of movement is not the goal of the SDR 
treatment but it is the means to achieve the aims (110). 
1.5.3.5.1 SDR Mechanism 
Spasticity prominently depends on the sensory–motor reflex arc (stretch 
reflex) between muscles and spinal cord nerves. The aim of SDR is to reduce 
the sensory input. The principle of dorsal rhizotomy is a reduction of the 
sensory input into the spinal interneuron pool by cutting the sensory afferent 
within the posterior roots. This leads to a decrease in the net excitatory output 
via the alpha motor neurons and ultimately reduces spasticity (111). 
Strict selection criteria for the SDR are recommended, as it is a permanent 
and irreversible surgical intervention. It can also damage motor function by 
weakening the muscle and worsening gait in patients lacking sufficient 
antigravity strength (112). Importantly, patient selection and treatment should 
be evaluated by a multidisciplinary team with specialist training and expertise 
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in the care of spasticity, along with access to the full range of treatment 
options. The team could consist of the following medical professionals: 
paediatric neurosurgeon, a neurologist, an orthopaedic surgeon, a 
physiotherapist, an occupational therapist, and a nurse clinician. The team 
should discuss the irreversibility of the treatment, the known complications 
and the uncertainties over long-term outcomes with children and young people 
as well as their parents or carers (113).   
Early in 1987, Peacock et al. suggested the SDR selection criteria. They 
concluded that the greatest benefit from SDR is seen in children with i) 
spasticity only that affects mainly the lower limbs, ii) who were able to side-sit 
independently with some degree of walking ability, iii) were not severely 
cognitively impaired and, iv) did not receive orthopaedic interventions before 
SDR. In contrast, they considered the presence of severe contractures, 
increased weakness in antigravity muscles, or a diagnosis of either marked 
athetosis, dystonia or ataxia as contraindications for SDR (114). 
Grunt et al. have systematically reviewed the literature for SDR selection 
criteria. The results have demonstrated the absence of an international 
consensus regarding the selection of patients for SDR, despite the fact that 
this is an invasive and irreversible procedure that should be offered only to 
those who will derive substantial benefit (112).  
The National Institute for Health and Care Excellence (NICE) has issued full 
guidance to the NHS in England, Wales, Scotland and Northern Ireland on 
SDR for spasticity in CP. It has recommended considering SDR to improve 
walking ability in children and young people with spasticity at GMFCS level II 
or III (Table 1-1), in children between 3 and 9 years old; abnormal tone with 
pure spasticity; good leg muscle strength; straight legs and minimal muscle 
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shortening; good selective motor control in the legs; good cognitive skills; and 
not being overweight (113). 
1.5.3.5.2 Contraindication of SDR 
The risks of inappropriate SDR decision-making are signiﬁcant, with possible 
negative outcomes including long-term post-operative weakness and loss of 
postural support due to reduction in muscle tone. Therefore, it is important to 
confirm that the disturbance in muscle tone is due to spasticity and not due to 
dystonia, rigidity, athetosis or ataxia. This is because rigidity and dystonia may 
coexist with spasticity in patients with basal ganglia damage particularly in 
children younger than five years. Further, dystonia may develop anytime 
during the first five years of life. Thus, in the setting of basal ganglia damage, 
the best is to wait until the age of five when the predominance of dystonia can 
more reliably be ascertained (111, 112). 
Table 1-1 Gross Motor Function Classification System 
Gross Motor Function Classification System (115) 
 
Level I 
Can walk indoors and outdoors and climb stairs without using hands 
for support 
Can perform usual activities such as running and jumping 
Has decreased speed, balance and coordination 
 
Level II 
Can climb stairs with a railing 
Has difficulty with uneven surfaces, inclines or in crowds 
Has only minimal ability to run or jump 
 
Level III 
Walks with assistive mobility devices indoors and outdoors on level 
surfaces. 
May be able to climb stairs using a railing 
May propel a manual wheelchair (may require assistance for long 
distances or uneven surfaces). 
 
Level IV 
Walking ability severely limited even with assistive devices 
Uses wheelchairs most of the time and may propel own power 
wheelchair 
Standing transfers, with or without assistance 
 
 
 
Level V 
Has physical impairments that restrict voluntary control of movement 
Ability to maintain head and neck position against gravity restricted 
Impaired in all areas of motor function 
Cannot sit or stand independently, even with adaptive equipment 
Cannot independently walk but may be able to use powered mobility 
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Children who have undergone previous orthopaedic procedures such as 
tendon lengthening or neurectomy should be screened carefully. The latter 
procedures may result in muscle group weakness, which may be exacerbated 
by rhizotomy (112, 116). Pre-existing scoliosis is a relative contraindication as 
spinal deformity can be exacerbated by a multilevel laminotomy or by a wide, 
single-level thoracolumbar laminectomy (112, 117).  
NICE in its guidelines put the predominant dystonia, athetosis, ataxia, and 
severe cognitive delay, severe scoliosis or hip dislocation, as exclusion criteria 
for SDR surgery (113). 
1.5.3.5.3 Complications of SDR 
In the early postoperative phase, the complications are often quite rare. CSF 
fluid leak (118) and infection have been reported (119). Transient 
dysesthesias lasting up to a few weeks have been reported in 2.5 to 40% of 
patients (120, 121). Urinary incontinence is probably the most troublesome 
problem. Urinary retention is frequent, with an incidence of between 1.25 and 
24% (122, 123). Urinary sphincter complications, including incontinence and 
retention, can be significantly reduced or totally eliminated by pudendal 
monitoring and limiting the amount of the dorsal root of S2 cut to less than 
35% (111, 124). 
Permanent complications are now rare after SDR (110), however Grunt et al. 
stated that back pain and spinal abnormalities such as kyphosis, scoliosis, 
lumbar lordosis, spondylosis and spondylolisthesis are frequent after SDR 
(125). 
1.5.3.5.4 Outcome of SDR 
The effectiveness of SDR has been evaluated by using quantitative 
assessments of spasticity as myometry, dynamometry, or the Ashworth scale. 
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Three randomised controlled trials have shown signiﬁcant reduction of 
spasticity following SDR and physiotherapy compared with a control group of 
patients having physiotherapy alone (126-128). 
Two randomised controlled studies by Subramanian and Langerak have 
performed long-term evaluation of the effect of SDR on patients‟ gait. Patients 
were examined preoperatively and then at 1, 3, and 10 years after surgery in 
both trials and at 20 years in the second trial only. A computer-assisted gait 
analysis system was used to assess gait performance. Locomotor function 
including step length and velocity had significantly improved postoperatively 
(129, 130).  
One comparative study evaluated the long-term effectiveness of both SDR 
and botulinum toxin BTX injection on gait performance. BTX demonstrated 
rapid improvement in gait performance but the improvement became 
insignificant after 12 months even with repeated injections at 4-month 
intervals. In contrast, the SDR has resulted in slow improvement of gait 
parameters during the first 3 months followed by progressive improvement 
from 6 months (131). 
In addition to the impact of SDR on the lower limbs, there have been well-
documented improvements in upper limb function and speech. In his study, 
Fasano has initially reported these supra-segmental phenomena (132), which 
have been reported in several recent studies (133, 134). There is a single 
small study that has suggested improvement in cognitive function following 
SDR (135). The phenomena may be explained on the basis that posterior root 
neurons have collaterals that ascend in the spinal cord giving branches to 
spinal AHC at many levels as well as brain stem motor nuclei. Thus, upon 
division of the lumber posterior rootlets, facilitatory influences would be 
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reduced not only within the lumber segments of the spinal cord but also in 
motor neuron at higher levels. Improvement of upper limb functions may also 
be due to the patient having more stable sitting base and therefore a 
decreased need to use the arms to maintain his balance (136). 
The effects of SDR on the need for orthopaedic surgery have been tested in 
some reports which showed SDR performed at an early age had lower rates 
of orthopaedic surgery than those for whom SDR were performed at a later 
age. This was particularly true for certain operations, such as heel cord, 
hamstring, and adductor releases, rather than for orthopaedic procedures on 
the bone and joint. This could be explained by the fact that SDR decreases 
spasticity and hence reduces the need for release procedures, whereas bone 
deformities are fixed and not influenced by spasticity reduction (137, 138). 
Recent evidence by Rouck et al. suggests that urinary bladder volume 
increased and high bladder pressure decreased in 62% of the study patients 
after SDR (139). Chiu et al. reported that SDR significantly improved urgency, 
frequency, incontinence, and urodynamic bladder capacity in spastic CP 
children (140).   
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1.5.3.6 Intrathecal baclofen therapy 
Oral administration of 30–90 mg of baclofen per day is associated with plasma 
baclofen level of 68–650 ng/ml and corresponding CSF levels of 12–95 ng/ml 
(77). Increasing oral levels of baclofen eventually leads to side effects, such 
as sedation, confusion, urinary frequency, and insomnia. Nevertheless, 
infusion of 400 μgg of intrathecal baclofen (ITB) per day is associated with 
nearly 380 ng/ml in the CSF (141, 142). 
ITB infusion provides an effective improvement in the spasticity at 1000 times 
lower than the doses of oral baclofen with a significant reduction of side 
effects (143, 144). In addition, the anti-spastic effects of baclofen occur at 
spinal level regardless of the cause of spasticity whether being cerebral or 
spinal. The spinal cord being only 2% of the mass of the brain and it receives 
proportionately a lower blood supply as a fraction of the cardiac output. 
Therefore, cerebral side effects often ensue with oral baclofen before 
observing the therapeutic anti-spastic effects (145, 146). 
In the mid-1980s, Penn and Kroin provided the first report of ITB used in adult 
patients with spasticity of spinal origin (147, 148).The first report of utilising the 
ITB therapy to treat spasticity in children with CP was published in 1980s by 
Dralle (149). In 1991, Albright described a double-blind screening trial of ITB 
therapy in children with spastic CP (150). This was followed by many studies 
in the 1990s demonstrating a reduction in spasticity and dystonia (151-153). 
The Food and Drug Administration (FDA) approved ITB therapy in the form of 
Medtronic Synchromed implantable infusion pump for spasticity of spinal 
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origin in 1992. Its use in the treatment of children with spasticity of cerebral 
origin was approved by FDA in 1996 (154). 
1.5.3.6.1 Pharmacokintics of ITB (Intrathecal distribution of baclofen)  
The drug infusion into the thecal space results in its mixing with the CSF. The 
amount of mixing depends on the composition of the drug, its lipid solubility, 
density and mode of delivery, whether bolus or continuous infusion (155). 
The first factor affecting the initial distribution of intrathecal drug is the baricityh 
(156). The density of baclofen is isobaric (1.003) at 24 °C and hypobaric 
(0.999) at 37 °C body temperature which is lower than the CSF density 
(1.00049 -1.0007mg/mL). Therefore, baclofen behaves like a hypobaric 
compound with subsequent distribution against gravity (157). However, with 
the slow infusion rates used from implantable pump systems factors that can 
influence bolus injection, such as drug volume or density may have little role in 
the drug distribution (158, 159). Instead, the conjunction of baricity with the 
position of the patient during drug infusion has a determining effect on drug 
distribution. A recent study used animal model to administer hyperbaric 
baclofen (2mg/ml in 7.5% dextrose) to anesthetised pigs while positioned 
either horizontally or vertically. Baclofen was administered for 6 hours at T12. 
The spinal cord was cut into 1 cm thick sections. Each of these sections was 
further subdivided into anterior and posterior halves. Baclofen concentration 
was measured in each piece using radiotracer methods. Drug was distributed 
almost exclusively caudal to the T12 infusion point in the vertical position; 
while was distributed more symmetrically around the infusion point in the 
                                                 
 
h Baricity refers is the ratio of the density of the infused drug compared to the 
density of CSF which average 1.003 g/ml at 37 °C. Baricity is used in anesthesia 
to determine the manner in which a particular drug will spread in the intrathecal 
space (156) . 
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horizontal group. Drug concentration dropped rapidly as far from the infusion 
point in both groups. Based on these findings, the patterns of drug distribution 
in the horizontal compared to the vertical position were significantly different. 
However the baricity of the solution will affect drug distribution only until it 
sufficiently diluted by CSF (158).  
Drug distribution in the CSF is also controlled by the normal circulation of the 
CSF from the ventricles, where it is produced, to the spinal canal along the 
dorsal aspect of spinal cord to sacral cul de sac. It then flows rostrally along 
the anterior aspect of the spinal cord to reach the basal cistern. This cycle 
takes 2-2.5 hours. Furthermore, the CSF moves with the to and fro pulsatile 
motion of the brain with each cardiac beat. These two mechanisms help in 
mixing and distributing of the infused drug (160). 
1.5.3.6.2 Drug elimination  
Baclofen is eliminated from the CSF by spinal cord uptake or diffusion to the 
capillary then to be absorbed by epidural fat (158). The ITB elimination half-life 
ranges from 0.9-5.0 hours in comparison to 3.6 hours in the plasma. However, 
the total clearance ranges from 8-13 hours (161).  
The spinal cord presents two different environments to drug molecules. The 
outer layer or the white matter, which is rich in myelin and lipid, is the 
preferred environment for hydrophobic drugs. On the other hand, the grey 
matter with low lipid is an accumulating location for hydrophilic drugs. The site 
of action of a baclofen is in the substantia gelatinosa in the gray matter of the 
spinal cord (laminae II and III). Therefore, using hydrophilic baclofen 
intrathecally allows smaller volumes, longer half-lives, and deeper penetration 
into nervous tissues (158, 162). 
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1.5.3.6.3 Selective criteria for ITB therapy in children 
Many study groups (163-165) have put criteria for the selection of ITB therapy 
patients. They agree broadly on these categories: 
Inclusion criteria for ITB therapy 
1. Severe spasticity more than 3 on Ashworth score. 
2. Spasticity-causing pain, interrupts sleep, and interferes with posture or 
hygiene procedures. 
3. Patients should be clinically stable. 
4. Patient age and size: product guidelines allow treatment of children as 
young as 4 years, who should have sufficient body mass to support the 
reservoir pump (though Albright implanted ITB pump in 9-month old 
child weighting 9-kg (166). 
5. Motivation and commitment of patients and caregivers.  Patients and 
caregivers must be diligent with respect to follow-up responsibilities, 
which include scheduled pump refill at 4-12 week intervals. Caregiver 
must also be prepared for an effective rehabilitation program. 
Exclusion criteria  
1. Infection is an explicit contraindication to ITB therapy. Systemic 
infection may interfere with assessment of the patient response to a 
screening trial. In addition, infection may increase the risk of surgical 
complications and complicate the dosing regimen after implantation.  
2. Allergy and hypersensitivity to oral baclofen is another contraindication 
of ITB. 
The National Institute for Health and Care Excellence (NICE) in its guidelines 
has recommended the ITB treatment in children and young people with 
spasticity or dystonia that, even with the use of non-invasive treatments, still 
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have difficulties in posturing, pain or muscle spasms control, function and self-
care (113). Furthermore, the NICE guidelines stated that patients who benefit 
from ITB are the children who have bilateral spasticity affecting upper and 
lower limbs and have moderate or severe motor dysfunction (GMFCS level III, 
IV or V) (11).   
NICE guidelines put the small size of the children to accommodate the ITB 
pump and systemic intercurrent infection as contraindications to ITB therapy 
(113). Similarly the presence of co-existing medical conditions (such as 
uncontrolled epilepsy or coagulation disorders), a previous spinal fusion 
procedure, malnutrition or respiratory disorders with risk of respiratory failure 
were also considered as potential contraindications to ITB treatment (113).  
Before pump implantation, a test dose is given to predict the potential 
therapeutic effect of ITB therapy to control spasticity. This screening process 
is performed by measuring the response to an intrathecal bolus of baclofen 
(25-50 μg) injected via a lumbar puncture or by continuous infusion of 
baclofen via intrathecal catheter in some conditions like dystonia (167). 
The intra-thecal pump is a small battery-powered device, which is implanted in 
the abdominal area connected to the intrathecal space by a thin flexible 
catheter. The pump stores and delivers baclofen into the thecal space either 
at a constant or variable rate that is adjusted and programmed according to 
clinical needs. An external programmer (telemetry) is used to communicate 
with and programme the pump during refill and check-up sessions (167). 
Implanting techniques for the ITB pump have changed noticeably since the 
advent of the procedure in 1985 (148). Initially, the pump was implanted 
subcutaneously. However, this technique was associated with poor healing 
and wound dehiscence especially in children with CP (168). 
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In 1998, Grabb and Pittman described a subfascial technique for implanting 
the pump (169). This technique provided more coverage for the pump, 
reducing the risk of skin dehiscence, and improving the cosmetic appearance 
of the abdomen by reducing the pump profile in paediatric patients. Due to the 
underlying disease, these patients are usually significantly underweight and 
often lack adequate soft tissue mass to effectively cover the pump (169). The 
subfascial technique is performed by dissection of the subcutaneous plane 
until the anterior rectus abdominus and the external oblique fascia are 
identified. An incision is then made in the anterior rectus and external oblique 
sheaths. Using a combination of blunt and sharp dissection techniques, a 
plane is developed between the fascial and muscle layers. The final pocket 
lies immediately between the anterior rectus sheath and rectus abdominis 
muscle (169). 
Implantation technique of ITB pump in the Nottingham University Hospitals 
(NUH) started in 1998. In the first 5 years of practice, the subcutaneous 
implantation was used. However, due to high rate of complications, the 
subfascial technique was then adapted and modified.   
1.5.3.6.4 Description of subfascial technique used in NUH 
After positioning the child in the left decubitus position with the hips and knees 
flexed to facilitate access to the thecal sac, antibiotic is administered at the 
time of induction of anaesthesia. The operating field is prepared with 
chlorhexidine and adhesive sterile draping. The preferred surgical side is 
usually the right to avoid scarring from previous abdominal surgery for left-
sided gastrostomies (170).  
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A transverse skin incision is made in the right hypochondrium at the level of 
the upper third of a line running between the xiphoid process and the pubic 
ramus to allow fashioning of a pocket inferiorly and to avoid contact with the 
lower end of the thoracic cage (170).  
The incision is deepened through the subcutaneous fat to the anterior rectus 
sheath (RS), and both lateral and medial edges of the rectus abdominis 
muscle are identified. The fascia of the rectus sheath is incised horizontally 
and the incision is continued laterally into the full thickness of the external 
oblique muscle EOM (170), Figure 1-4 A. 
The anterior layer of the fascia of the internal oblique muscle merges with its 
posterior fascial layer over the lateral edge of the rectus abdominis (RA) 
muscle at a variable distance along the line of linea semilunaris. Cutting in 
between these internal oblique layers helps to open a natural plane between 
the external oblique muscle anteriorly, and the internal oblique, transversus 
abdominis, and peritoneum posteriorly (170), Figure 1-4 B. 
 
  
Figure 1-4 Intraoperative photograph of dissecting RS from RA, (B) Illustration of 
cutting the anterior layer of the IOA 
A B 
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Figure 1-6 (A) insertion of the catheter into the thecal space, (B) Tunnelling 
from abdominal wound to spinal wound 
 
The implantation pouch is created starting beneath the anterior rectus sheath 
medially, continuing laterally under EOM. The internal oblique, the transversus 
abdominis, and the peritoneum constitute the posterior wall of this pouch, 
Figure 1-5 (170).  
A B 
B A 
Figure 1-5 (A) Intraoperative photograph of the subfascial pouch (B) The final 
location of the ITB pump 
 
A B 
A B 
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The subfascial implantation technique is not novel and has been described 
with its outcomes and complications (169, 171-174). Albright et al. have 
described incising the covering fascia of the external oblique muscle laterally 
and the fascia of the rectus abdominis muscle medially, and then degloving 
the fascia to fashion a subfascial pocket cranially and more caudally to the 
transverse fascial opening. This would leave the suture line of the fascia 
crossing over the pump increasing risk of infection and dehiscence (172). 
Kopell et al. have modified the same technique by cutting the linea 
semilunaris, which provides an adequate pouch for the pump below the fascia, 
but we assume this could interrupt the integrity of the anterior wall of the 
pouch (169). 
In the Nottingham University Hospital‟s technique, the transverse opening of 
the fascia is extended more laterally to incise the red muscle fibres of the 
external oblique to allow dissection of the space between external and internal 
oblique muscles. This provides complete coverage of the pump by the muscle 
below the level of the fascial opening. Furthermore, cutting the anterior lamella 
of the internal oblique aponeurosis caudally under the external oblique muscle 
helps preserve the integrity of the external oblique muscle anteriorly (170). 
Spinal Access 
The catheter is tunnelled from abdominal wound toward the back to be 
inserted in the thecal space at level of L3–4 as it is less mobile than L4–5 
(170), Figure 1-6. 
Approaching the dural sac for inserting the intrathecal catheter in CP children 
with spinal deformities may be a challenge, due to distorted anatomy or 
presence of metallic instruments and the bony fusion mass that grows after 
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spinal fixation. In this situation, the thoracocervical approach for inserting the 
catheter intrathecally is an alternative to lumbar insertion of the catheter (175). 
1.5.3.6.5 Maintenance of intrathecal baclofen therapy 
The initial ITB daily dose after implantation is usually between 50-100 μg or 
twice the amount of successful trial dose. In cases of dystonia, the normal 
initial dose is 200 to 300 μg /day, according to severity of the condition (142, 
176). The daily dose may be increased by 10–30%, to keep sufficient 
symptom control. Similarly, the daily dose may be decreased by 10–20% if 
patients experience adverse effects. On average, the dose of ITB for 
treatment of spasticity rises by a factor of 2.8 over the ﬁrst year. Up to 86% of 
patients reach a steady dosage by the ﬁfth year (177, 178). 
The reservoirs of the pumps need to be refilled at various time intervals. The 
refill intervals depend on three elements: reservoir size, baclofen 
concentration, and daily dosage. The period between refills varies from every 
3 weeks to every 6 months. Refills are recommended at no more than 6-
month intervals because of uncertainty about baclofen stability beyond that 
time (179).  
The FDA approved formulations of ITB are in concentrations of 500 μg/mL 
and 2000μg/mL. Most patients are able to achieve a period of 60-90 days 
between reﬁlls (180). The SynchroMed II System has enabled some patients 
to beneﬁt from an increase in this reﬁll interval. For instance, stability data in 
the SynchroMed II System supports reﬁll intervals up to 180 days. However, 
certain populations of patients require higher daily doses of baclofen, and 
obtaining a desirable length of time between reﬁlls for these patients becomes 
difﬁcult (181). 
The sole manufacturer (Novartis Pharma) labels the stability of baclofen 
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intrathecal for up to 6 months in a Synchromed II delivery device. They have 
analysed concentrations greater than 2000 μg/mL, and concluded that the 
higher concentrations did not meet stability requirements without the formation 
of precipitates (182). 
Recent research is investigating the role of microspheres coated in baclofen, 
injected in a gel, as an alternative vector for baclofen delivery. This may let 
higher concentrations of baclofen be delivered than the current form, which 
would be useful particularly in dystonia patients who usually need greater 
baclofen doses. It might also decrease the rate of pump reﬁlls, as well as 
device replacements (183). 
However in actual practice, compounding pharmacies advertise 
concentrations up to 8000 μg/mL for physicians who seek to reduce the 
frequency of patient reﬁlls and/or reduce the cost (179, 184). 
At Nottingham University Hospital (NUH), different concentrations of baclofen 
are used in refilling. The commercial baclofen concentrations (500 mcg/ml and 
2000 mcg/ml) are used if the daily dosage was less than 100 mcg. However; 
the higher concentration of compounded baclofen (3000 mcg/ml) is used if the 
daily requirement of ITB exceeds 100 mcg  
The compounded 3000 mcg/ml baclofen concentration has been used in the 
NUH practice from July 2002 till now. This is to maximise the benefit to the 
patient by longer refill intervals and accordingly decrease the risk of infection 
due to frequent refills. 
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1.5.3.6.6 Intrathecal baclofen complications 
Continuous ITB infusion is associated with a signiﬁcant number of potential 
complications in all patients groups (185). Although complication rates may 
vary between centres, the complication rate has been reported up to be 30% 
(186). 
The potential ITB complications can be caused by the surgical procedure, the 
device fault (pump error or mechanical complications of the catheter), or 
pharmacological side effects of baclofen (185). 
Surgical complications may include CSF leakage, accumulation of CSF 
subcutaneously that may cause pseudomeningocoelesi which are more 
frequent in paediatric patients, because they have smaller volumes of 
paraspinal muscles and subcutaneous tissues. In these cases, dural repair is 
essential for correction of the CSF leakage and pseudomeningocelle (187). 
Other surgical complications include pump migration and flipping especially in 
paediatric patients due to creation of an over-sized subfascial pocket (185).  
Infection is by far the most serious surgical complication of intrathecal pump 
systems. It can result in significant rates of morbidity that may lead to spread 
of infection along the catheter causing meningitis and explantation of the 
pumps (188). 
Superficial wound infection at the site of implantation, although potentially 
serious, may be managed successfully with systemic antibiotics and local 
wound care. A deep infection at the site of the hardware, however, will likely 
                                                 
 
i Spinal pseudomeningoceles are extradural collections of CSF that follow a breach 
in the dural–arachnoid layer. They may occur due to an incidental durotomy, 
during surgery, or from trauma or congenital abnormality. The majority are 
iatrogenic and occur in the posterior lumbar region following surgery. Although 
they are often asymptomatic, they may cause low-back pain, headaches, and 
even nerve root entrapment (187). 
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require removal of the infected equipment to avoid meningitis; a rare but a 
more serious complication and difficult to treat (189, 190). 
The pharmacological adverse effects of Baclofen might be seen during 
screening trial, immediately postoperatively, or during maintenance therapy 
especially after refilling. The most common acute side effect associated with 
ITB therapy is urinary retention, that may require intermittent catheterisation 
for 2–3 days (164). Nausea and vomiting, insomnia, and headache are also 
reported in 11–12% of the patients, which usually resolve spontaneously (181, 
191). 
Excess hypotonia caused by baclofen can lead to serious complications such 
as paralytic ileus (192), or deep venous thrombosis (DVT) due to stagnation of 
blood in the gastro-soleus venous plexus (193, 194). 
Acute overdose or withdrawal of ITB, can be life threatening events (195). 
Overdosage of baclofen may present clinically as drowsiness, light-
headedness, dizziness, somnolence, respiratory depression, seizures, and an 
altered level of consciousness progressing to coma (91). Although overdose 
from mechanical system malfunction has been reported (196), the literature 
review has shown that cases of ITB overdosage are more likely related to 
human errors at the time of surgery, reﬁlls, or programming (197, 198).    
Acute withdrawal syndrome 
Abrupt discontinuation of baclofen can cause acute withdrawal syndrome, 
which resembles Benzodiazepine and alcohol withdrawal. In April 2002, the 
Food and Drug Administration (FDA) of USA included a drug label warning for 
baclofen withdrawal syndrome (199). This most commonly occurs as a result 
of a problem within the delivery system. The clinical presentation includes: 
high fever, pruritus, hypotension, parasthesias, and altered mental status in 
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the form of dysphoria, visual, auditory and tactile hallucinations, and paranoia. 
Other clinical presentations also include exaggerated rebound spasticity, 
seizures, and muscle rigidity that in rare cases may advance to 
rhabdomyolysis, and even multiple organ-system failure (143, 200, 201).  
The mechanism of withdrawal syndrome includes down-regulation of GABAβ 
receptors in the CNS and spinal cord after long-term ITB infusion. This lead to 
decreased sensitivity to baclofen (202). Therefore, abrupt ITB withdrawal 
results in a predominance of excitatory effects that simulates other conditions 
that are associated with CNS hyper-excitability, leading to severe spasticity 
that may not be overcome by low dosage of baclofen (203).  
Several reports described varied psychiatric symptoms related to ITB 
withdrawal, such as “hallucinations”, “manic psychosis”, ﬂuctuation of 
consciousness, memory impairments, or perceptual disturbances (204). 
Neuropsychiatric effects of abrupt baclofen withdrawal are thought to involve 
the GABA system. Baclofen, like GABA, inhibits CNS pathways involving 
monoamine neurotransmitter systems. Long use of baclofen can cause 
continuous inhibition of monamine neurotransmitter systems which leads to 
emergence of supersensitive dopamine and noradrenergic receptors. Sudden 
withdrawal of baclofen would cause a disinhibition of previously suppressed 
monoamine pathways, causing a release of norepinephrine and dopamine on 
to supersensitised receptors. This ultimately leads to autonomic arousal (e.g. 
tachycardia, hypertension, agitation, restlessness) and delusions, 
hallucinations, and delirium (204).  
It is noteworthy that ITB withdrawal should be differentiated from autonomic 
dysreﬂexia, malignant hyperthermia (MH), and neuroleptic-malignant 
Chapter 1                                                                                           General Introduction  
 44 
syndrome (NMS) as the underlying pathophysiology and treatments are 
different. 
Management of withdrawal syndrome 
Definitive therapy of acute ITB withdrawal requires resuming of ITB delivery. 
Saulino et al. recommended starting a bolus dose of ITB via lumbar puncture 
or continues infusion with an indwelling catheter (205). 
Oral baclofen should be started for management of withdrawal symptoms until 
ITB therapy can be resumed as soon as possible (206). However, oral 
baclofen, even in amounts at or near the maximum tolerated dosage may not 
halt progression of the developing withdrawal syndrome (207, 208). In such 
cases, parenteral benzodiazepinej (143) infusion was the most rational 
treatment for the loss of central GABAergic neurotransmission (195).  
Drug delivery system (DDS) related complications  
The baclofen delivery system consists of the catheter and the pump device. 
Complications related to the DDS much more often involve the catheter as 
compared to the pump (185).  
The pump complications include overfilling of the pump, battery failure, pump 
torsion (or flipping) and pump failure, which requires replacement with a new 
device (209-211).  
The catheter is the most vulnerable part of the infusion system, and its 
complications are the most common cause of ITB therapy failure (212, 213). 
The reported catheter complication rate is as high as 40% in patients with 
implanted ITB pumps (145, 214, 215). Common catheter-related problems 
include: kinking, disconnections, breaks, occlusions, and migration of the 
                                                 
 
j Benzodiazepines activate GABAa-receptor complexes in the spinal cord to relieve 
spasticity by different mechanisms to baclofen. ITB-induced GABAb-receptor 
down-regulation should not interfere with the antispasticity efﬁcacy of 
benzodiazepines. In addition benzodiazepines have antiepileptic effects (143). 
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catheter (216, 217).  
1.5.3.6.7 Outcomes of intrathecal baclofen therapy 
The first report of successfully treated children with ITB was by Dralle et al. 
who successfully treated a 4-year-old child with hypertonicity after brain injury 
caused by near drowning (149). Then, Muller reported significant 
improvements in spasticity in 20 children treated with ITB, where the spasticity 
had significantly decreased in 90%- 95% of patients (218).    
In 1993, Albright et al. conducted a prospective non randomised trial in 37 
patients with cerebral causes of spasticity (25 were functionally capable of 
self-care and 12 were non-functional). The ITB infusion reduced the muscle 
tone in upper and lower limbs at dose of 27-800 μg/day. In the functional 
group, 19 patients reported improved upper-extremity function and 10 
reported improved ambulation and speech, as well as scores on a personal 
independence scale (219).  
Fitzgerald et al. reported the outcome of 52 tetraparetic children treated by 
ITB in Nottingham University Hospitals from 1998 to 2003. This study 
represented a large homogeneous series of ITB therapy in children with 
severe spasticity of cerebral origin. In 49 cases, carers reported improvements 
in nursing care. All of these saw a reduction in spasticity and an improved 
range of motion in unﬁxed joints. Of the 17 who were ambulant prior to 
initiating treatment, walking was improved in nine cases. Only one previously 
non-ambulant patient began to mobilise with walking aids. In addition, most 
cases had improvements in bulbar function (better speech and swallowing, 
less drooling) and upper limb function. In two cases pre-existing divergent 
squints disappeared. Many children appeared to become more socially 
interactive (220, 221). 
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Gerszten et al. have demonstrated the outcome of ITB on gait in 24 patients 
(21 with spastic CP and 3 with spasticity secondary to traumatic brain injury). 
The level of ambulation improved in 9 patients, was unchanged in 12 patients, 
and became worse in 3 patients. The study concluded that ITB is not 
contraindicated in patients who rely upon their spasticity for support during 
ambulation (222).  
Guillaume et al. in a non-comparative, multicenter, prospective study on 129 
children with intractable spasticity evaluated the impact of ITB therapy on 
standard measures of spasticity, pain, subjective improvement and outcomes 
of functional independence. A signiﬁcant improvement in muscle tone 
(Ashworth score) was observed in both lower and upper extremities for 
patients with spasticity of cerebral or spinal origin. Patients‟ pain assessments 
using a numeric rating scale (NRS)k (160), showed significant reductions in 
pain after implantation. Pain relief increased steadily over the 12 months of 
follow-up. Both motor and cognitive functions improved after initiation of ITB 
therapy using the FIM instrument or WeeFIM for children. A signiﬁcant 
improvement in motor function was observed at 12 months and in cognitive 
function at 3 months post-implantation. Patient performance and satisfaction 
on the Canadian Occupational Performance Measure (COPM) showed 
signiﬁcant improvements (223). 
Krach et al. reported the changes in function of 100 children and their 
caregiver assistant after ITB therapy. The results showed improvement in 
these function categories, positioning (69%), transfers (58%), dressing (69%), 
                                                 
 
k In a pain assessment using a numeric rating scale (NRS), patients were asked to evaluate 
their pain using a numeric rating (0 [no pain] to 10 [the worst pain imaginable]) for 4 
parameters: worst pain, least pain, average pain in the past week, and pain right now (160). 
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toileting/hygiene (51%), decreased startle (54%), improved sleep (43%), and 
improved comfort (53%). Although 22% of this group experienced 32 events 
related to the ITB hardware or surgery, 88 patients said they would undergo 
the ITB therapy again (224). 
Gooch et al. evaluated care provider outcomes in 80 patients that had 
undergone ITB therapy for one year. After pump implantation, most 
participants had tone reduction (on the Ashworth scale) in both lower and 
upper extremities. All care providers reported improvement in scores of the 
Caregiver Questionnaire. Pain and joints deformities were decreased in 91% 
of patients. Ease of care improved in 88%. Ninety-five percent of the 
caregivers would have the implantation again (225).  
ITB outcome in dystonia 
Narayan et al. reported the use of ITB therapy effect in dystonic children. They 
successfully treated an 18-year-old adolescent with dystonia due to CP (226). 
In 1995, Penn, et al. reported that ITB improved focal dystonia in some adults 
(213).  
In 2001, Albright et al. used the ITB in 89 children with severe generalised 
dystonia; mainly due to CP. In this study, dystonia improved in 90% of cases. 
Patients‟ questionnaires have indicated that quality of life and ease of care 
significantly improved in 86% and speech/function improved in 33% (214).   
Woon et al. reported on ITB benefits in 8 patients with dystonia. Three of them 
(with primary dystonia) had satisfactory results after ITB was considered with 
a deep brain stimulator (DPS). They have postulated that ITB is beneﬁcial in 
children with both primary dystonia and dystonia secondary to CP. However, 
the beneﬁt is subjectively greater in children with dystonia secondary to 
cerebral palsy, possibly due to the larger spastic component, which is known 
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to respond to ITB (227). 
Recently, many other reports confirmed the effectiveness of ITB in treating 
focal and generalised dystonia (228-234). 
Weight and height gain after ITB therapy 
Children with spasticity are often below the normal centiles for height and 
weight when compared with healthy children without disability of the same age 
and sex (235, 236). Weight gain has been observed clinically in patients 
undergoing ITB therapy, although published reports of this side effect are rare. 
In their report, Hemingway et al. have noted that calorie requirements of a 
patient undergoing ITB therapy while on a calorie-controlled ketogenic diet 
was decreased by approximately 34%. Interestingly, this reduction 
corresponds to the estimates of spasticity reduction of 30% to 40% (237). 
Albright et al. have also noted an increase in growth parameters in children 
receiving ITB therapy (181). A mechanism proposed to explain weight gain is 
that caloric expenditure, which is spent to sustain involuntary muscular 
contraction owing to spasticity, could be shifted to normal linear growth (238).   
ITB therapy outcome with Orthopaedic deformities 
Gerszten et al. have retrospectively reviewed the need for orthopaedic surgery 
of the lower extremities in 48 patients with spastic CP who were treated with 
ITB. Subsequent orthopaedic surgery was planned in 28 patients (58%) at the 
time of pump placement. However, only 10 patients (21%) underwent 
orthopaedic surgery after ITB therapy, which was already planned at the time 
of initial evaluation for ITB therapy (47).  
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ITB outcome with spinal deformities  
Many orthopaedic surgeons who treat spastic quadriplegic patients have 
reported a trend toward marked progressive scoliosis following the 
administration of ITB (239-241). In one retrospective study the Cobb angle of 
scoliosis in non-ambulant children with spastic CP was evaluated pre and post 
ITB implantation. The results demonstrated a significant increase in the rate of 
scoliotic curve progression (9.02 degrees /year) after ITB pump placement 
when compared with the published disease natural history data (4.5 degrees 
/year) (240). However, a prospective comparative study has shown no 
significant difference in the progression of scoliotic curve between ITB patients 
and the control group (242). In a recent study from the NUH, a retrospective 
comparison of scoliosis progression in quadriplegic spastic CP patients with 
and without ITB pumps, showed significant curve progression over time and 
the peak curve progression was similar between the groups. The investigators 
concluded that ITB pumps do not appear to alter the natural history of curve 
progression in these patients (243).  
1.5.3.6.8 Relationship between ITB Pump and the patient 
While the clinical outcome of ITB therapy has been discussed in many 
studies, only one study has reported the functional relationship between ITB 
therapy, and the patient. Twenty patients have been enrolled into this study 
(14 patients with multiple sclerosis and 6 patients had spinal cord injury). A 
structured questionnaire was designed to ask the patients whether they would 
have the pump implanted again, would be willing to implant the ITB pump 
privately in the absence of public funding and asked about their relationship 
with the pump inside them. Fifteen of the 20 patients who were unable to pay 
for the costs of the pump answered that they would pay for it if they could. The 
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pump was considered as a foreign body by two thirds of enrolled patients. In 
other words, these patients considered their pumps as only therapeutic tools. 
In contrast (35%) felt the pumps as part of their bodies and the presence of 
pump did not interfere with the rehabilitation or wearing of their clothes. 
Furthermore, the study reported that half of the patients were anxious about 
pump failure, and one third of them were afraid of the onset of the alarm 
signal. These results suggested that patients had a positive feeling about the 
therapeutic effect of the pump, and could also mean that there was a degree 
of dependence on ITB therapy (244). 
1.5.3.6.9 Cost-benefit analysis   
Sampson et al. have conducted a systematic review in 2002 to estimate the 
effect of ITB infusion on function and quality of life measures in patients with 
severe spasticity (245). Outcomes were related to standard QOL scores to 
estimate potential gains in quality-adjusted life years (QALYs)l(246). 
Information on the costs of continuous ITB infusion was obtained from year 
1999 data from three hospitals in the United Kingdom in which the operation 
was performed. Depending on the severity of disability, the cost/QALY(quality-
adjusted life years) for ITB ranged from £6,900 to £12,800 (245), which is less 
than the NICE £20,000 threshold for willingness to pay for a QALY (113). 
Since 2000, cost-effectiveness analyses, particularly in USA, usually use the 
value of $50,000 (≈ £36800) per quality-adjusted life-year (QALY) as a 
threshold for evaluating the cost-effectiveness of health interventions (17, 
                                                 
 
l The quality-adjusted life year (QALY) is a generic measure of disease burden, including both 
the quality and the length of life lived. It is used to assess the value for money of medical 
interventions. The QALY is calculated by the change in utility status [Utility status of health is 
expressed on a numerical scale ranging from 0 to 1, in which 0 represents the "utility" of the 
state "Dead" and 1 the utility of a state lived in “perfect health”] induced by the treatment, 
multiplied by the duration of the treatment effect (246). 
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247). More recent reports from Europe and the United States, between 2007 
and 2009m, have evaluated the cost effectiveness of ITB therapy where cost 
per QALY ranged from $10.550 (≈ £7.800) to $19.570 (≈£14.450) was below 
the $50,000(≈ £36800) for one QALY (248-250). 
 
                                                 
 
m In 2007, Lissovoy et al. published a study from France. The medical costs of ITB therapy 
were measured for the year 2006 (248). 
In 2009, Hoving et al. published a Dutch study of ITB costs, and the costs were estimated for 
the year 2003 (249). 
In 2009, Bensmail et al. published a study from the USA. All costs were adjusted to base year 
2003 using the medical care consumer price index (250). 
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1.6 Aim of thesis and study design:  
Randomised controlled trials (RCTs) are essential part of drug licensing, and 
considered as the gold standard in evaluating the short-term efficacy and 
safety of developing treatments or interventions. RCTs have long been 
considered the mainstay of evidence-based research due to their strong 
internal validity, which depends principally on the power of randomisation to 
confirm that the only difference between two treatment arms is the exposure 
to the treatment of interest (251, 252). This will optimise the internal validity, 
minimise the risk of bias by confounding and assess true cause and effect 
between an intervention and an outcome (253).  
However RCTs applicability in clinical practice can be limited because the 
chronic conditions that affect broad and heterogeneous patient populations 
are under-represented in RCTs. In addition, patients and practitioners in RCTs 
are different from those in routine clinical practice (251). Moreover, the high 
financial cost of RCTs limits their ability to assess the safety of the treatment 
and to detect uncommon drug-related events over long-term follow-up (253). 
Further, research governance and administrative delays many cause 
additional difficulties in conducting RCTs (253).  
In comparison, observational studies have been described as a way of “letting 
the rats out of the cage and seeing what happens in real life” (253). These 
observational studies are pursued to appraise how interventions work in the 
variety of patients treated in routine clinical practice when managed in clinical 
scenarios that broadly are diverse within and between countries. In addition, 
they rarely replicate the highly interventional nature of efficacy trials (251, 
253). The principal advantage of observational studies is their proximity to 
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“real life situations” as the greater heterogeneity of medical interventions and 
patient populations are closer to clinical practice (254). Furthermore they are 
easily designed, inexpensive to conduct in comparison to RCTs, and are 
useful to explore rare outcomes and unusual side effects (255). Importantly, 
observational studies can be complementary to RCTs as they are crucial for 
creating new hypotheses and representing the external validity of RCTs that 
have been already completed. In addition, they can clarify which patient 
groups will get benefit from each alternative intervention (255, 256). RCTs 
typically measure efficacy (i.e. treatment effects under strictly controlled 
conditions), observational studies are best suited to measure effectiveness, or 
treatment effects under realistic conditions (257). 
ITB has been established as a treatment of spasticity in CP patients through 
different study designs. Hoving et al. 2009, in an RCT were able to prove that 
continuous infusion of ITB is effective in treating spasticity in carefully selected 
children with intractable spastic CP after 18 months of treatment (258). 
Albright et al. 1993 in prospective, un-blinded trial have reported the 
significant reduction of spasticity of cerebral origin after the treatment with ITB 
(219). Moreover, the National Institute for Health and Care Excellence (NICE) 
has identified eight studies to establish the guidelines for indications, 
effectiveness and complications of ITB (11, 188, 259).  
The current study is a retrospective observational study aimed at evaluating 
ITB practice in Nottingham University Hospitals as a regional referral centre 
for the procedure. 
As this study is assessing the outcome of the current ITB practice against the 
standard national guideline, the conclusions derived from this study will be 
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invaluable auditing measures for the procedure and could highlight areas for 
improvement and provide a constructive evaluation of the quality of care. 
Audit was defined by Department of Health in the white paper Working for 
Patients as: “the systematic, critical analysis of the quality of medical care, 
including the procedures used for diagnosis and treatment, the use of 
resources, and the resulting outcome and quality of life for the patient” (260). 
Clinical audit is different from clinical research as the later aims to define the 
characteristics of good practice on an unknown land, while the audit compares 
the current practice against well-defined and established standards (261). 
On the other hand, service evaluation measures how well a service is in 
achieving its intended aims. It is undertaken to benefit the people using a 
particular healthcare service and is planned and conducted with the only 
purpose of defining or judging the current service. The results of service 
evaluations are mostly used to produce information that can be utilised to 
inform local decision-makers (262). 
1.6.1 Structure of the audit cycle (263, 264), Figure 1-7.  
1-Preparation 
A- Choosing the topic and defining a clear purpose 
A Literature Review: To find out whether there are any recommended national 
standards on which to base the standards, then to find out any previous 
studies, which have been conducted on this topic to help in designing the 
method of data collection and setting standards. The aim of the current study 
is to evaluate the ITB implantation process in NUH and its outcome including 
morbidity and mortality rate, was well as patients‟ quality of life. 
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2-Setting standards  
Standards may be based on one, or any combination, of the following: 
• National guidance or standards (e.g. Patients‟ Charter). 
• College or professional organisation guidelines. 
• Laws (e.g. Mental Health Act 1983). 
• Previously agreed local guidelines/protocols (e.g. through consultation with 
commissioners). 
• Standards used locally by colleagues or competitors (e.g. your neighbouring 
trust, ward, etc.). 
• Research evidence (from which standards can be developed). 
• Literature review of other clinical audits that have published their 
standards/results. 
• Current knowledge from clinical experience. 
• Current practice (observes and assesses current practice). 
For the purpose of this study; the selection criteria, which was published by 
NICE in 2012, were considered as the standards for ITB implantation (11)  
The audit criteria for ITB outcome were based on the literature review and 
research-based evidence. Cochrane Database of Systematic Reviews has 
reported the rate of significant complications to be around 30% over the long-
term in those receiving ITB therapy (device-related complications: occurring in 
10% to 30% of individuals and pump-related infections: occurring in around 
8% to 11%) (265).  
3-Measuring level of performance  
-Data collection and analysis: collecting the data will be from computerised 
records, manual collection, or both. It may be retrospective or prospective. 
Data should be stored in such a way that it is both secure and conforms to 
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legal requirements. All personal data on a computer should be “secure from 
loss or unauthorised disclosure” (Data Protection Act 1984) (263). 
The collected data will be analysed to compare the actual performance with 
the set standards. 
In this study the data were collected and ascertained manually by one 
investigator (AA) from medical records, clinic letters and validated 
questionnaires. Full details of data extraction process are provided in chapter 
two.  
-Compare the performance with criteria: 
The collected data are compared to criteria and standards to conclude how 
the standards have been met.  In case the standards have not been met, the 
reasons should be identified and areas of potential improvement should be 
suggested.  
 
Figure 1-7 Clinical audit cycle  
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4-making improvements 
Data collection has no chance of making any impact unless they are conveyed 
to the relevant team to start the more difficult stage of implementing changes. 
First, the results need to be presented and discussed with the relevant teams 
in the organisation. Second, the results should be used to develop an action 
plan, specifying: i) what needs to be done; ii) how it will be done; iii) who is 
going to do it; and iv) when to be done. 
In the current study, the results have been discussed with the clinicians who 
perform the procedure and have been presented at the neurosurgery clinical 
audit meeting as well as national neurosurgical meeting (The Society of British 
Neurological Surgeons). 
5-Sustaining improvements  
This stage is critical to the successful outcome of an audit: it differentiates 
whether the implemented changes had an effect in practice and whether 
further improvements are needed to achieve the standards required. This can 
be achieved by a re-audit to complete the full audit cycle using the same 
strategies to ensure the original audit is comparable. 
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2 CHAPTER TWO: COMPLICATIONS OF 
INTRATHECAL BACLOFEN THERAPY 
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2.1 Introduction  
ITB has become an established treatment modality to control medically 
refractory spasticity (166). Nevertheless, there are frequent complications 
related to the intricate implantation technique and prolonged duration of ITB 
therapy (206). This is reflected in the literature with an increase in frequency 
of reported adverse events over the years in proportion to increased usage 
(266). 
Gooch et al. demonstrated that reporting and defining the adverse events of 
ITB is crucial to the clinical practice for two reasons: firstly, precise information 
about ITB complications is essential to develop the hardware device and 
improve the surgical procedure. Secondly, to provide patients‟ families with 
enough knowledge to make informed choices about the benefits and risks of 
implanting ITB pump (210). 
These adverse events are related to surgical implantation technique, adverse 
effects of baclofen, and hardware related complications as for instance 
catheter complications or pump failure (171). The most commonly reported 
adverse events are infections and device related problems (164, 267). 
Pharmacological ITB adverse effects include sedation, lethargy, drowsiness, 
hypotonia, headache, nausea, vomiting, constipation and a new onset of 
seizures or increased seizure frequency (206). 
Implantation of ITB pumps started at Nottingham University Hospital (NUH) in 
1998. Since then, more than 250 pumps have been implanted to treat 
spasticity in the paediatric population.  
All patients are followed up, and pumps refilled at NUH for a minimum of one 
year until the baclofen dosage is optimised. After this period, approximately 
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45% of patients continue to be followed at NUH annually, while the remaining 
patients receive ITB pump refills at their local hospitals.  
2.1.1 The Aim  
This chapter will explore and analyse the complications and identify the risk 
factors related to ITB treatment at Nottingham University Hospitals. Following 
reviewing the literature thoroughly, the following questions were chosen:  
1 What types of complications are associated with ITB therapy? 
2 What is the frequency of these complications? 
3 Is there a difference between the local rate of complications and the 
published literature?   
4 What are the risk factors for these complications e.g. surgical techniques, 
patient‟s weight and age at implantation time, dystonia, and the presence 
of a gastrostomy tube? 
5 Does the complication rate remain constant or improve with surgeon 
experience? 
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2.2 Material and Methods 
2.2.1 Study design 
This is a retrospective observational study aimed at analysing ITB pump 
complications and adverse effects. All patients were operated by one 
paediatric neurosurgeon (MHV). All ITB pumps were inserted in the 
Department of Neurosurgery at Nottingham University Hospital over a period 
of 13 years (from 1998-2011). This study has been conducted as a part of 
service evaluation and clinical audit (number 14-337C). 
2.2.2 Data collection 
The principal source of the clinical data was the patients‟ medical records. 
Laboratory results were collected from the Nottingham Information System 
(NotIS).  
Patient population 
This is a retrospective observational study of 286 consecutive cases of 
spasticity and dystonia referred to the paediatric neurosurgery service in NUH 
from October 1998 to December 2011. The study follow-up period was 
extended to December 2012 and thus all the patients had a minimum of one 
year follow up after the initial ITB implantation. This sampling period was long 
enough to capture a wide range of complications and possible changes in 
complications over time that are relevant to chosen study questions (268). 
The patients‟ medical records, including all data related to ITB and 
complications of the patients undergoing ITB implantation, were reviewed. 
A literature review was conducted to develop our guidelines and to design the 
data extraction manual (269-271). 
Chapter 2                                                                                Complications of ITB Therapy  
62 
 
2.2.3 Guidelines for collecting the retrospective data 
2.2.3.1  The data source and extraction method  
Medical records have various sections that describe similar information. The 
relevant information may be dispersed throughout the clinical notes, nursing 
notes, drug charts, operative notes, clinic letters, and investigation reports. To 
increase the reliability of the medical record review (MRR), a data extraction 
manual was created to outline rules and considerations. This was used to 
identify where to find the information as well as inclusion and exclusion criteria 
for this data. Each variable was extracted based on the knowledge of which 
section of the medical records tend to hold that information consistently. 
Demographic data including patient‟s age, sex, ID number, and referral 
destination were collected from the medical notes.  
Implantation date, weight at time of implantation, surgical technique (e.g., 
subcutaneous or sub-fascial pump placement), American Society of 
Anesthesiologists (ASA) grade, operative time, and any surgical revisions 
were extracted from the operative notes. 
The date of complication was defined as the date of presentation to clinic, GP, 
or unplanned review in the neurosurgery department. 
Distribution of spasticity (quadriplegic or diplegic), ambulatory state, and 
spinal deformities were collected from physiotherapy documentation in the 
clinical continuation sheets. 
Orthopaedic deformities or complications (such as contractures or fixed 
deformities of the hips, knees and ankles) were identified as binary data. 
These data were extracted from physiotherapy assessment documentations, 
intraoperative assessment under sedation by operating neurosurgeon during 
test dose trial, and/ or from referral letters. 
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Associated co-morbidities such as epilepsy, visual difficulties, degree of 
cognitive impairment, and the presence of a percutaneous endoscopic 
gastrostomy (PEG) tube were collected from paediatricians‟ referral and clinic 
letters. 
Cognitive impairment was classified using information from referral letter and 
assessments from paediatricians, neurosurgeons, GPs and orthopaedic 
surgeons. This was classified into poor, fair and intact cognition. 
In addition, refilling dose administered, concentration of baclofen used and 
interval between refills were collected from the print-out of the ITB pump 
programmer (telemetry). 
2.2.3.2 Data abstraction tool 
The list of patients, for whom ITB implantation has been performed from 1998 
to 2011, has been obtained from the surgical logbook of the lead clinician 
(MHV). Following completion of the audit registration process, the medical 
notes were retrieved by Audit office from the medical records department. The 
medical notes were reviewed at the neurosurgery department by one 
investigator (AA).  
An electronic data form was designed using Microsoft Access 2007. The main 
table was used for recording the patient‟s demography, complications and 
other variables recorded in this investigation. Another table was designed to 
collect ITB refilling data (daily dose, baclofen concentration and duration 
between refills) for each patient, Figure 2-1. 
2.2.3.3  Assessment of reliability 
The data has been extracted by the one investigator (AA). To verify the 
collected data, intra-rater reliability of data extraction was tested in a sample 
Chapter 2                                                                                Complications of ITB Therapy  
64 
 
of 40 random medical records (11) (18% of the investigated cases) after 6 
months from commencement of the project (272). 
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Figure 2-1 Microsoft Access 2007 displaying patients' records and linked to side table displaying the refill data for each record. 
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2.2.4 Identification of Outcomes (Dependent Variables) 
In this study, the examined clinical outcomes (dependent variables) were the 
complications and adverse events in implanted ITB patients. 
2.2.4.1 Definition of complications 
Sokol et al. defined a surgical complication (SC) as any undesirable and 
unexpected result of an operation affecting the patient (273). 
According to the literature review, ITB adverse events (AEs) were classified 
into three categories; (a) device-related AEs e.g. pump and the catheter 
complications (b) surgical procedure related e.g. infections and wound 
dehiscence (c) pharmacological effects of baclofen e.g. constipation, 
withdrawal syndrome and baclofen overdose (180, 206, 223). 
In the data extraction process, major complications were defined as events 
that required surgical intervention (e.g. deep infections and device related 
complications). The number of complications experienced by each patient was 
documented according to the chronological occurrence, into: initial, second, 
third, and fourth events. 
Identification of infection complications 
Superficial wound infection, at the site of implantation, is potentially serious 
but it can be managed successfully with systemic antibiotics and local wound 
care. However, a deep infection, at the site of the hardware, will likely require 
removal of the infected equipment (189, 190). Therefore, it is important to 
differentiate between severity of ITB infection to guide its proper management 
(274). 
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According to the definitions of the Centres for Disease Control and Prevention 
(CDCP), ITB infections were classified as superficial, deep, and organ space 
infections (275, 276). 
Superficial infection was defined when it included at least one of the following: 
(1) occurs within 30 days after the surgical procedure; (2) includes skin and 
subcutaneous tissue of the incision; (3) presents by purulent discharge with 
isolated organisms from the incisional site associated with one of cardinal 
signs of inflammation (pain, tenderness, localized swelling, redness or 
hotness); (4) intentionally explored  by the physician and is culture-positive or 
not cultured; and/or (5) identification of superficial SSI by the surgeon or 
attending physician (275). 
On the other hand, deep surgical site infection is diagnosed when at least one 
of the following were found: (1) it happens within 30 days of the surgery if 
there is no implanted foreign body at the surgical site or within 365 days with 
an implant in situ; (2) drainage of purulent discharge from the deep incision 
and culture positive or not cultured and associated with fever or localised pain 
and tenderness; (3) deep incision spontaneously dehisced or deliberately 
opened by a surgeon; and/or (4) diagnosed by a surgeon or a physician as 
deep incisional surgical site infection (275).  
Organ or anatomical space surgical site infection was diagnosed if at least 
one of the following was involved: (1) any part of the body related to surgical 
procedures other than skin or muscle; (2) Occurrence within 30 days if no 
implant left in place or less than 365 days if implant is in situ; (3) presence of 
purulent discharge or isolation of organisms from the organ or body space; 
and/or (4) evidence of infection or abscess involving the organ or body space 
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by direct examination, reoperation, or by histopathological or radiological 
examination (275).  
Data pertaining to the causative organism of the ITB infection and time to 
diagnose the infection was collected from NotIS. 
Catheter complication  
Catheter-related complications included catheter dislocation, fracture, 
occlusion, migration, and connector breakdown. Catheter complications were 
identified if the patients presented with symptoms of acute baclofen 
withdrawal, or the patient reported a reduction in the therapeutic effect of the 
ITB , or being unresponsive to escalation of infusion rate (185, 212).  
During follow-up visits, the ITB pump function was checked regularly and the 
daily ITB infusion dose was adjusted according to response of symptoms, and 
the clinical outcomes and possible adverse events were evaluated.  
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2.2.5 Statistical Analysis 
2.2.5.1 Descriptive Statistics  
For normally distributed variables, continuous data was presented as mean 
and standard deviation for normally distributed variables. For the non-normally 
distributed parameters, median and the interquartile range [25th–75th 
percentile] were used. 
2.2.5.2 Logistic Regression Analysis 
Spearman‟s correlation co-efficient was used to define the significant 
associations between assumed variables (e.g. age, weight, dystonia and 
presence of PEG) with two outcomes; surgical site infection, and catheter 
complications. Potentially correlated variables for each outcome were then 
used in a multivariate binary logistic regression to recognise statistically 
significant complication predictors. A P-value < 0.05 (two-tailed) was 
considered significant. 
2.2.5.3 Survival analysis 
The functional survival of the ITB pumps and the temporal distribution of 
complications were analysed using univariate analyses Log-rank tests.  
Kaplan Meier plots were used to visualise the differences in distribution 
fraction of patients remaining complication free. Complication free survival 
was defined as the duration between catheter implantation and the diagnosis 
of complications. The observation period closed on 31 December 2012. 
  
Chapter 2                                                                                Complications of ITB Therapy  
70 
 
2.3 Results 
A total of 286 consecutive patients were referred from 65 clinical practices 
either via paediatric neurology, paediatric orthopaedics or their General 
Practitioner. Out of 258 patients found to be responsive to ITB test dose. 
Thirty-six patient declined ITB treatment while the remaining 222 received in 
total 265 ITB implantations over the 13-year period, Table 2-1. 
Table 2-1 the results of test dose screening 
Screened patients 286 
No response to ITB test dose 28 
Positive response to ITB test dose 258 
x Implanted patients 222 
x Patients declined ITB treatment 36 
2.3.1 Children with failed response to ITB test dose trial 
Twenty eight patients failed to response to ITB screening dose. Table 2-2 
demonstrates their different diagnosis.  
 
Table 2-2 diagnosis of the children with failed response to ITB trial 
Cerebral Palsy   27 
x Hypoxic brain injury 17 
x Neonatal intra-ventricular haemorrhage 2 
x Perinatal encephalitis 6 
x Foetal alcohol syndrome  1 
x Twin to twin transfusion syndrome 1 
Primary dystonia 1 
 
2.3.2 The demography and clinical characteristic of implanted cases 
This cohort comprised of 222 children (135 male and 87) female. The mean 
age at the time of implantation was 10.9 years, (9 months-19.5 years). Nine 
children were below the age of 4 years old when they received ITB 
implantation, Table 2-3. 
Chapter 2                                                                                Complications of ITB Therapy  
71 
 
The cumulative follow up duration of the entire population was 11269 pump 
months (939 pump years) with a median 4.02 years (IQR 2.24-5.87) years. 
The mean daily dose of ITB that was needed to attain the optimal response in 
this series was 307 µg/day (range 80-1150 µg/day, SD±194).  
 
  Figure 2-2  Number of cases per referring centre to NUH 
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Table 2-3 The demography and clinical charchtersitic of the patients 
 
Of all the 222 patients who had ITB implantation, 203 had spastic 
quadriplegia, 19 patients were paraplegic, 158 patients were wheelchair 
bound, 59 were walking with aid and only 5 patients were independently 
ambulant. Ninety-one (40.9%) patients had associated epilepsy, 118 patients 
had severe cognitive impairment, 83 had mild cognitive impairment and 21 
had normal cognition. Thirty-four (15.3%) patients had visual impairments. 
Twelve (5.4%) patients had prior ventriculo-peritoneal shunt implantations. 
Sixty-one (27.5%) patients had gastrostomy tube for feeding due to difficult 
swallowing and/or associated oesophageal spasm. Muscle contractures and 
orthopaedic deformities were manifest in 145 (65%) patients, 51 (22.9%) of 
whom had previous surgical corrections. Spinal deformity, such as 
kyphoscoliosis, was present in 103 (46%) patients. Nine patients had received 
spinal deformity corrective surgery prior to ITB implantation, whilst 10 patients 
had spinal surgery post-implantation. Four patients were waiting for correction 
surgery. Figure 2-3 depicts these comorbodities and their precentages.  
Age  Mean 10.9 ± 4.25 
Sex  M: F 135:87 
Weight Median 25.2 Kg (IQR=19-36) 
 
Follow- up  Median 4.02 years (IQR =2.24-5.87)  
Epilepsy  91 (41%) 
Visual impairment 34 (15.3%) 
Associated VP shunt 12(5.4%) 
Gastrostomy  61(27.4%) 
MSK deformities 145(65%) 
Spinal deformities  
Cognitive status Severe impairment  118 
Fair cognition 83 
Intact cognition 21 
 
Spasticity distribution Quadriplegic    203  
Diplegic            19  
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Figure 2-3 Frequency of associated comorbidities in the study patients. 
The main indication for ITB implantation in this population was cerebral palsy 
which was a consequence of various neonatal causes. Other indications 
included primary dystonia, Table 2-4. 
Table 2-4 Indications of ITB implantation in the study population 
Indication of implantation Number of 
patients 
1-Cerebral palsy  210 
x Perinatal hypoxia   131 
x Perinatal encephalitis                                                                  55
x X-linked adrenoleukodystrophy Demyelination                         13 
x Neuronal migration disorder and corpus callosum 
agenesis         
5 
x Other congenital brain anomalies                                                         5 
x Chromosome  18 abnormality                                                       1
2-Primary dystonia                                                                                                                   7
x Hallervorden Spatz                                             3 
x Idiopathic 2 
x Leighs Syndrome                                                                                               2
3-Traumatic brain injury (TBI)                                                      1 
4-Transverse Myelitis                                                                                                                 1
5-Hereditary Spastic Paraplegia                                                                                           2 
6-Near drowning                                                                                                                         1 
67 patients of the 222 cerebral palsy patients had  mixed spasticity and 
dystonia                                                              
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The peak time of ITB implantation in NUH was between 2006 and 2007,Table 
2-5. 
 
Table 2-5 Distribution of ITB implantations per years of practice 
 
No of 
primary 
implantation
s/ y 
Total no. of 
implantations/y 
Re-implantation 
due to infections 
Re-implantation after 
battery depletion 
1998 2 2 0 0 
1999 7 7 0 0 
2000 13 13 0 0 
2001 13 14 1 0 
2002 14 17 3 0 
2003 14 15 1 0 
2004 16 17 1 0 
2005 17 22 4 1 
2006 31 35 3 1 
2007 37 38 1 0 
2008 17 22 4 1 
2009 20 23 2 1 
2010 15 19 1 3 
2011 6 21 4 11 
Total 222 265 25 18 
 
ITB implantations was most frequent in children between 8 and 12 years old 
(69 patients) and the lowest number of implantations was in children below the 
age of 4 (9 patients). Implantation according to age group was normally 
distributed, Figure 2-4. 
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Figure 2-4 The number of implantations per age group 
 
2.3.3 Implantation technique 
In the first 4 years of ITB service, 35 patients received ITB implantations using 
the subcutaneous technique with all subsequent implants from 2003 
performed with a sub-fascial implantation technique, Table 2-6. 
Table 2-6  Surgical techniques and ITB pump models used for implantation 
Number of the 
patients 
222 patients Initial implantation 
Total No of 
implantations 
265 (222 patients) 43 planned replacement: 
x 25 replacements after 
complications (23 infections and 
2 pump failures) 
x 18 elective implantation after 
battery depletion  
Level of implant 35 Subcutaneous and 
187 Subfascial 
 
ITB Pump 
models 
57 EL (10 ml) 208 (II 
20 ml ) 
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Two hundred and twenty-one patients received ITB implants with catheter 
insertion at lumbar region, while 20 patients had their catheter inserted at the 
cervico-thoracic region due to associated spinal deformities or previous spinal 
surgery, Table 2-7.  
Table 2-7 Indication for inserting baclofen catheter in the cervico-thoracic region 
Indications of inserting baclofen catheter at the cervico-thoracic region No 
x Severe untreated scoliosis  4 
x Previous spinal surgery with fusion mass or metal work 9 
x Re-insertion of the catheter due to iatrogenic transection of lumbar 
ITB catheter during corrective spinal surgery 
7 
 
Of all the 265 ITB implants, 253 had implantations on the right side of the 
body. However 12 patients had implants on the left side due to previous 
abdominal surgery or prior ITB explantation due to infection on the right side. 
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2.3.4 Adverse events related to screening trial: 
In 286 patients who had screening trial, 20 (7.3%) patients had mild symptoms 
of nausea and vomiting, 12 (4.1%) patients had headache. These symptoms 
were managed conservatively. Seventeen (5.9%) patients had CSF leakage at 
lumbar puncture site that in the majority resolved spontaneously but 2 patient 
needed suturing of the skin to control the CSF leakage. Four patients (1.3%) 
experienced hypotonia and insomnia which resolved spontaneously. One 
patient (0.69%) had numbness in his lower limbs which recovered after 
removal of the lumbar catheter. None of these patients were documented to 
have post procedure infection. 
2.3.5 Adverse events after ITB implantation 
During 13 years of practice, a total of 118 adverse events were documented in 
84 patients. Twenty six of these 84 patients (26/84, 30.9%) had two 
consecutive AEs, while 6 and 2 patients experienced three and four adverse 
events respectively, Table 2-8. 
These 118 AEs included 29 (13%) pharmacological side effects of intrathecal 
baclofen, and 85 procedures and device related complications which 
necessitated surgical revision. 
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Table 2-8 Types and chronological frequency of documented complications in the study population   
 Initial adverse 
events 
No  
Second adverse 
events 
No  
Third adverse 
events  
No  
Fourth adverse 
events 
No  
No of patient 84 26 6 2 
Time to complications 253 days SD ±425 
days 
(6 – 2505 days) 
Mean 616 days 
SD±795 days 
(7 - 1853 days) 
  
Wound complications:  
x CSF leakage 
x Seroma 
x Wound dehiscence  
x Infection   
40 
x 3 
x 3 
x 6 
x 28 
9 
x 1 
x 0 
x 1 
x 7 
2 
x 0 
x 0 
x 0 
x 2 
 
Catheter complication:  
x Migration   
x Iatrogenic fracture after spine 
surgery  
x Kink and occlusion 
x Fracture 
x Catheter disconnection  
38 
x 18 
x 5 
 
x 5 
x 7 
x 3 
10 
x 3 
x 1 
 
x 0 
x 5 
x 1 
4 
x 1 
x 1 
 
x 0 
x 0 
x 2 
2 
x 1 
x 0 
 
x 0 
x 0 
x 1 
Device errors 2  0 0 
Pharmacological 
x Constipation 
x Overdose  
x Psychosis 
x Withdrawal syndrome 
 
x 24/222 
x 3/222 
x 2/222 
x 0 
0 0 0 
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2.3.6 Pharmacological adverse events. 
Constipation was documented in 23 (10.5%) patients as the most common 
pharmacological side effect of ITB therapy and was conservatively managed. 
Urine retention and worsening of swallowing was reported only in 2 patients. 
Three children had overdose symptoms ranging from hypotonia, and 
drowsiness. One patient, of the later three, needed admission in paediatric 
intensive care for respiratory support due to apnoea that followed ITB pump 
refill. Two patients developed psychosis and presented with delusions and 
confusional state that was controlled by decreasing the baclofen dose. 
In this series, ITB therapy did not affect the frequency of epileptic seizures, 
nor did it cause no complications with ventriculo-peritoneal shunts. Moreovere, 
baclofen withdrawal syndrome was not observed in this series. 
2.3.7 Surgical and device related complications of ITB. 
Eighty-five secondary surgical procedures were documented in this cohort 
during 939 pump years of follow up. Ex-plantation was performed in 29 ITB 
pumps; 25 pumps were removed after deep infections in 23 patients and 4 
cases due to family requests for perceived lack of efficacy. Seven patients 
required revision due to malfunction after spinal surgery, 47 revisions of ITB 
catheter due to various reasons and 2 pump replacements after recognising 
pump errors. 
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2.3.7.1 Device related complications 
A total of 56 device related complications out of 265 implants (21.13 %) were 
recorded in (40/222, 16.3 %) patients. Pump malfunction only occurred in 2 
patients (<1%) who presented with ITB under-infusion that did not improve 
after increasing the dose and were also associated with alarm fault. ITB 
pumps were replaced and the patients resumed the therapeutic effects. No 
cases of pump flipping or intraperitoneal migration were documented in this 
study.  
Catheter complications were responsible for the most ITB pump revisions in 
this cohort, which occurred 54 times in 38 patients. The most frequent 
complications were catheter migrations, which occurred 23 times (8.6% of 265 
implanted pumps). Spontaneous catheter fractures were the second most 
common complications that occurred in 12 (4.5%), followed by catheter 
disconnections from the ITB pump that reported in 7 (2.6%) cases. Seven 
(2.6%) iatrogenic catheter transection happened after spinal surgeries, and 
lastly, 5 (1.9%) catheters were revised due to kink or occlusion.  
Ten patients required surgical revisions for catheter malfunctions on 2 
occasions each, and 4 patients had revision surgery on 3 occasions. The 
median time between implanting the ITB pump and catheter revision was 641 
days (21.6 months) and ranged from 49 to 2505 days. 
2.3.7.2 surgical wound complications  
A total 51 (19.2%) surgical wound complications were found. Four events of 
CSF leakage occurred in 3 patients, which subsided spontaneously or by 
secondary suturing. Three patients had a postoperative subcutaneous seroma 
in the abdominal wound that resolved after aspiration under sterile conditions.  
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Surgical site infection 
Surgical site infection (SSI) was reported in 44 (16.6%). cases out of 265 
implantations. Superficial infection presenting as erythema, swelling, and 
tenderness was recognised in 18 cases (6.8%), who responded successfully 
to conservative management and antibiotic administration. Deep infection was 
reported in 25 cases (9.43%) and presented with erythema, purulent 
discharge, swelling and wound dehiscence that necessitated urgent removal 
of the ITB pump. One of those patients, who was under 4 years old, 
experienced two deep infections. One case (0.37%) of organ space infection 
with meningitis was reported and the patient required admission to intensive 
care for treatment of septic shock. 
One patient had recurrent superficial infection, however salvage of the ITB 
pump was achieved by surgical revision, pump removal was avoided. Five 
patients had experienced 2 of wound complications. 
The median time elapsed between ITB pump implantation and diagnosis of 
infection was 25 days (6-111 days). 
2.3.7.3 Microbiological results 
Microbiology cultures were obtained from surgical sites of all infected cases. 
Of the 51 surgical wound complications, organisms were isolated in 21 
(41.2%) samples by microbiology culture Table 2-9. 
The most frequent causative organism was Staphylococcus aureus that was 
positively cultured in 11/51 (21.5%) of all infection events. In one patient the 
infection was caused by 2 different types of bacteria (S. aureus and 
Abiotrophia specie). Pseudomonas aeruginosa was isolated in two patients 
(4%); one of them was colonised at their tracheostomy site and the other 
patient had isolated pseudomonas aeruginosa following spinal fixation surgery 
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complicated by wound infection. Other bacteria cultivated were group A Beta-
hemolytic Streptococcus in 2%, coagulase-negative Staphylococcus species 
(9.8%), and Pseudomonas aeruginosa in 4%. In 58% of cases the culture was 
negative.   
Table 2-9 Types of infecting organism in patients with surgical wound complications.  
Staphylococcus aureus                                            11 
Group A  Beta-haemolytic Streptococcus  1 
Abiotrophia species                                               2 
Coagulase negative Staphylococcus CONS       
x Staphylococcus epidermidis                   
x Staphylococcus haemolyticus                 
5 
3 
2 
Pseudomonas aeruginosa                                    2 
Culture negative SSI                                            30 
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2.3.8 Predictive factors of catheter complications 
Univariate analysis of potential risk factors related to catheter complications 
revealed that catheter complications were correlated with dystonia and level of 
implantation (subcutaneous or sub-fascial), Table 2-10. 
 
Table 2-10 Correlation of risk factors and catheter complications (Spearman‟s 
correlation test) 
Risk factors Correlation P value 
Dystonia 0.398 0.002* 
Implantation level (subcutaneous 
and subfascial) 
-0.163 0.015* 
Distribution of spasticity  0.086 0.200 
Epilepsy -0.081 0.228 
Spinal deformity 0.047 0.480 
Gastrostomy -0.040 0.553 
Insertion method of the catheter 
(LP or Laminectomy) 
0.033 0.623 
Weight at implantation time 0.029 0.670 
Operative duration 0.014 0.830 
Age of implantation -0.003 0.969 
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The multivariate binary regression analysis revealed that dystonia and the 
level of ITB implantations were the most significant factors that determine the 
frequency of catheter complications (p =0.001 and 0.02 respectively). 
Distribution of spasticity (quadriplegia or diplegic), associated epilepsy, degree 
of spasticity, spinal deformity, and presence of gastrostomy was not 
statistically significant, Table 2-11. 
 
Table 2-11 Result of multivariate analysis of catheter complications 
Risk factors P value Odds ratio (95% CI) 
Dystonia 0.001* 8.970(3.970-20.2690 
Level of 
implantation(subcutaneous /sub-
fascial technique) 
0.020* 0.322(.124-.835) 
Insertion method of the catheter 
(LP or Laminectomy) 
0.198 0.344(.0671-.765) 
Epilepsy 0.368 0.682.(296--0.570) 
Spinal deformity 0.426 1.378(0.6263.-029) 
Distribution of spasticity 
(Diplegia or Quadreplegia) 
0.493 1.806(.3339-0.792) 
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2.3.9 Predictive factors of wound infections 
Univariate analysis of risk factors associated with intrathecal baclofen 
infections was conducted to investigate the predictive factors of infection, 
Table 2-12. 
Table 2-12 Correlation of risk factors and wound infections (Spearman‟s correlation 
test) 
Risk factors Correlation P value 
Gastrostomy 0.410 0.001* 
Age at implantation time -0.298 0.005* 
Associated dystonia 0.279 0.001* 
Weight at implantation -0.174 0.009* 
Visual impairment -0.027 0.689 
VP shunts 0.015 0.826 
ASA grade 0.118 0.101 
Previous procedures 0.12 0.079 
Epilepsy  0.059 0.378 
Operative time 0.066 0.327 
Level of implantation  0.007 0.919 
 
Significant associations were found between occurrence of infection and; 
young age and low weight at implantation time, associated dystonia, and the 
presence of gastrostomy tube. However, no significant correlations were 
found with operative duration, technique of pump implantations (subfascial or 
subcutaneous), distribution of spasticity (quadriplegia or diplegic) visual 
impairment, ventriculo-peritoneal shunt, associated epilepsy, ASA grade and 
previous revision surgery. 
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The multivariable binary regression model for infection complications showed 
that most surgical site infections had significant associations with age, 
dystonia, and presence of gastrostomy. On the other hand, there were no 
significant associations with weight, operative time, ASA grade, and previous 
surgical revisions, Table 2-13. 
Table 2-13 Results of multivariate regression analysis for infection 
Risk factors P value Odds ratio (95% CI) 
Dystonia 0.0001* 0.162 (0.065-0.405) 
Gastrostomy 0.002* 0.084 (0.028-0.254) 
Age at implantation time 0.02* 0.982 (0.972-.994) 
Operative time 0.090 1.015 (0.997-1.033) 
Infection after secondary 
procedure 
0.305 1.681 (0.623-4.534) 
Weight at implantation time 0.825 0.995(0.955-1.037) 
ASA grade 0.932 1.034 (0.478-2.236) 
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2.3.10 Complication free pump survival 
The Kaplan Meier curve showed the cumulative complication-free pump 
survival for all the patients. The plot in Figure 2-5 presented 2 curves 
illustrating catheter (blue curve) and infection (green curve) complications over 
time. The X-axis represents the time in months. As the graph demonstrates, 
infections events happened earlier following pump implantation, while catheter 
complications have been reported at any time during patients‟ follow-up. 
Infection tended to occur only during the first 8 weeks following implantation, 
with no further infections reported later on during the follow-up time. 
Interestingly, complications were not observed after a period of 82 months, 
even after planned pump replacement. 
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Figure 2-5 Kaplan Meier plot showing complication free patient 
survival of all patients with an ITB pump.  
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2.3.11 Complication rate throughout practice 
The complications rate was higher in early practice; however, it gradually 
declined with time. Figure 2-6 demonstrates increased implantation rate 
throughout years of practice however, the major complication did not parallel 
this. Figure 2-7 shows the percentage of complications per year.  
 
 
Figure 2-6 Number of major complications related to number of implantations per 
year. 
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Figure 2-7 Percentage of complication per year. 
 
 
 
2.3.12  Mortality with ITB therapy 
Eight patients (3%) died with no evidence that their death was related to ITB 
therapy. All of them had severe grade of cerebral palsy with impaired mobility 
and cognitive impairment and died due to causes related to the underlying 
cerebral palsy. 
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2.4 Discussion 
2.4.1 The demography and clinical characteristic of implanted cases 
The indication for ITB therapy in this study conforms to previous series (which 
was conducted on 90% of this cohort) as cerebral palsy was the commonest 
indication for ITB therapy in children and most of the patients had spastic 
quadriplegia 88% (181, 185, 210, 266, 277, 278). 
The annual implantation rate increased gradually from 1998 until the peak in 
2007, and then gradually decreased after 2008 due to commencement of 
selective dorsal rhizotomy as a surgical treatment for spasticity in paraplegic 
patients. 
The male to female ratio in this cohort was approximately 3:2, in concordance 
with previous studies (181, 225, 278), which is partly explained by the greater 
preponderance of cerebral palsy in males compared with females (2.2 and 1.7 
per 1000 births respectively) (279, 280). An alternative theory proposed is that 
parents of female patients are dissuaded by the large abdominal incision 
required for implanting the relatively sizeable pump, in comparison to parents 
of male patients who might pursue more aggressive treatments in the hope of 
increasing their activities (181).  
In the present study, more than two thirds (71%) of implantations occurred in 
children above 8 years and the mean age at time of implantation was 10.9 
years. This is slightly younger than average in other series, which vary 
between 11.2-13.6 years (173, 210, 274, 277, 278). The development of 
spasticity in children with cerebral palsy usually increases up to the age of 4 
years, then decreases gradually to 12 years of age. After the age of 12 years 
children will retain that level of spasticity (281).  
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2.4.2 Screening trial 
Gilmartin et al. reported that 94% of patients with spasticity of cerebral origin 
have demonstrated a positive response to the screening test for ITB therapy 
(188), and Penn et el. reported 97% response in patients with spasticity of 
spinal origin (145). Albright et al. stated that 90% of 69 patients who had 
dystonia responded to ITB trial by decreased dystonia scores (214). Philips et 
al. have reported 89.7 % response to ITB trial in a cohort of adults with 
multiple diagnoses (282). 
In the current study 28 (9.7%) out of 286 children has failed the ITB test dose 
and the response rate was 90.3%. This finding broadly agrees with the 
previous studies (145, 188, 214, 282). The observed low response in this 
cohort could be related to possible association of spasticity with other 
neurological conditions such as severe dystonia which was difficult to be 
confirmed through this retrospective review.  
Furthermore, a thorough literature search revealed no mention of using the 
ITB therapy for treating twin-twin transfusion syndromen (283) or foetal alcohol 
syndromeo (284). 
Future prospective studies on the ITB therapy should take into account the 
prevalence and causes of failed trial dose. 
                                                 
 
n Twin-twin transfusion syndrome is a condition that affects identical twin pregnancies. It 
results from intertwine vascular connection within the placenta. It is associated with a high risk 
of perinatal mortality of around 90%, and neurological sequelae are found in 20-40% (283). 
o Foetal alcohol syndrome: a group of conditions that can occur in children, and is associated 
with heavy maternal alcohol consumption. Foetal death is the extreme outcome of this 
syndrome. Other features include : an abnormal  facial appearance, short height, low body 
weight, small head size, poor coordination, low intelligence, behaviour problems, and 
problems with hearing or seeing (284). 
Chapter 2                                                                                    Complications of ITB Therapy  
94 
 
2.4.3 Pharmacological adverse events related to ITB 
There is paucity in reporting drug related adverse events of ITB therapy in the 
literature (10) as the majority of publications focus on infection and device 
related complications (278). The most common ITB adverse effects reported 
in the literature include constipation (10–31%) (209, 214, 285), nausea and 
vomiting (11–14%) (181, 191), headache (11–12%) (168, 181), and new onset 
or increased frequency of seizures (13%) (206, 286). Constipation is the 
commonest problem in the CP population and is exacerbated after ITB 
therapy (287). In this study 11% of the patients experienced worsening 
constipation which was managed conservatively.  
Psychosis or personality changes occurred after an over-dosage of ITB in 
0.9% of this cohort which goes in line with the results of another study that 
reported it in less than 1% (166).  
Withdrawal syndrome is one of the most crucial drug related adverse event of 
ITB therapy, and may be life threatening (288). It has been documented in ITB 
patients as case reports (207, 289-293). Studies suggest that patients could 
experience withdrawal symptoms close to their scheduled refill dates. 
Catheter-related complications, infected pump removal, empty reservoir 
volume, end of battery life and iatrogenic programming error are considered 
as causes of ITB withdrawal syndrome (195). Rebound spasticity is the 
earliest symptom of withdrawal and can be associated with tachycardia and 
fever. Samson-Fang et al. stated that identification of withdrawal syndrome is 
very difficult in patients with cerebral palsy (207), especially if they present to 
a clinician who is unfamiliar with ITB therapy (206). 
In this cohort, no clear documentation of ITB withdrawal symptoms was found. 
However, reduced effect of ITB due to catheter malfunction might be 
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considered as mild or early symptoms of withdrawal. Intermittent catheter 
dysfunction, due to partial occlusion or kink, can cause mild symptoms such 
as increasing spasticity (185, 294). These early, mild symptoms might be 
managed promptly before progression to abrupt withdrawal. 
No withdrawal symptoms were found after acute removal of infected pumps. 
This is because the infection usually happens early after ITB implantation 
before GABAβ receptor down-regulation has occurred (274). Additionally it is 
routine practice to start oral baclofen replacement once the clinician has 
removed the infected pump (205). 
Withdrawal symptoms are similar to other serious conditions e.g. autonomic 
dysreflexia, malignant hyperthermia, neuroleptic malignant syndrome, 
serotonin syndrome (295), and status dystonicus (296). Alden et al. suggested 
checking the functional integrity of the ITB system in all children with ITB 
therapy if they present with fever or unexplained systemic illness (289). Coffey 
et al. recommended meticulous care to ITB pump refilling and programming, 
in addition to educating the caregivers and paediatric emergency team to 
recognise the symptoms of withdrawal syndrome (143). 
2.4.4 Surgical and device related complications of ITB therapy 
Previous studies (166, 173, 206, 274, 297) reported a complication rate 
ranging from 20%–30% in ITB therapy patients. However these values and 
the rate of each event may vary among published works according to the 
features of the assessed population, the implantation technique, and the 
follow-up period. Furthermore, many complications could be reported under 
several different categories. For instance, a kinked catheter could be 
categorised under catheter problems, device-related problems or baclofen 
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withdrawal. Also, different methods are used to calculate rates which can be 
reported as simple frequencies, number of events, or by frequency of events 
by treatment years (266). 
2.4.4.1 Pump malfunction 
Several studies stated that the effectiveness of intrathecal baclofen therapy in 
treating spasticity and dystonia could be compromised by device related 
complications such as catheter and pump related complications (214, 298, 
299).  
In the present study, only 2 (1%) patients experienced pump error that 
required ITB pump replacement to resume therapeutic effect. This result is 
consistent with Motta et al. who reported 4 incidents in 430 patients ≈ 1% 
(278). However, Borowski et al. reported 4 (2.4 %) pump failure in 161 
implants (173).   
In general, device-related errors are rare with the existing ITB pump systems 
(299), although the possibility of errors has been described by the device 
manufacturer (Medtronic, Inc, Minneapolis, MN). They recommend routine 
verification of pump function at each refill where the actual delivered volume 
should be within 10% of the intended volume determined by the pump. They 
stated potential causes for pump errors are; exposure to MRI, missing pump 
propellant, and gear shaft wear. The commonest error is related to pump 
switch off after exposure to MRI. Hence, it is crucial to interrogate all ITB 
pumps after MRI exposure, to confirm their functional status to avoid an 
abrupt change to ITB delivery (300).  
2.4.4.2 Catheter complications 
In this study, catheter complications were the main cause of surgical revision 
of ITB implantation and occurred in 20% of implantations.  
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In early practice of ITB therapy, Albright et al. (301) and Penn et al. (212) , 
both reported that frequency of catheter complications may be as high as 31-
40%. Furthermore long-term follow-up studies have suggested higher rates of 
around 37%–55% (302, 303).  
Cochrane Database of Systematic Reviews revealed the rate of device related 
complications to be between 10%-30% over the long term in those receiving  
ITB (265).  
Catheter migration is the single most common complication encountered with 
pump catheters in this study, which is consistent with previous studies (304, 
305) 
However, Vender et al. found pump connector fracture and disconnection to 
be the most frequent catheter complication (185). Gooch et al. had the same 
results.(210) The higher rate of hub connector fractures was attributed to the 
old straight connector that was used in early ITB practice. This complication 
has been reduced since introduction of a new hub connector angled at 45° 
which reduces the strain and decreases the risk of fracture (185).  
In comparison to the above, this cohort had lower catheter complications. In 
addition hub connector fracture was seen less than other catheter 
complication types. This could be explained by the early adoption of the 
modified 45 degree connector.  
2.4.4.3 Surgical site infection after ITB implantation 
Postoperative surgical site infection is a major problem in ITB practice, 
especially when it occurs in a compromised host such as a child with CP 
(274).  
Comparing infection rates between studies could be difficult as many studies, 
report their infection rate per patient rather than per number of procedures. 
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Furthermore, few studies only define the severity of infections such as being 
superficial or deep infection (274). In this cohort, the infection rate was 
recorded per number of procedures.  
Infection in this cohort is the second most commonly documented type of 
complication. Deep infection occurred in 9.43% of patients which necessitated 
explantation of the ITB pump. 
Since introducing ITB as a treatment of spasticity in children, the ex-plantation 
rates after deep ITB infection reported in literature vary from 4-44% (168, 185, 
285, 301, 306). 
However, our rates seem to be similar to recent studies. Fjelstad et al reported 
deep infections in 10% of 91 paediatric patients (307). Motta et al. reported 30 
pumps (7%) explantations in 430 patients due to infection (278). Bayhan et al. 
reported 29 ITB infections in 298 children with cerebral palsy (308). 
Cochrane Database of Systematic Reviews revealed that the rate of infections 
to be around 8% to 11% (265). 
In our study, the average time for infection to manifest, was less than one 
month. This finding is consistent with those of Dickey et al. who reported the 
median time to have ITB infection was 14 days (274), and similarly Fjelstad, et 
al. reported the same observation in a series of 163 patients (307). These 
findings further support the idea that Staphylococcus colonisation happens 
early at the time of device implantation (309). It happens by inoculation with 
only a few microorganisms from the patient‟s skin during implantation or the 
pathogens may be transmitted from surgical or clinical staff (310-312). Albright 
et al. asserted that when infection occurred within 8 weeks postoperatively, it 
should be classified as a procedure related complications (181). 
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In this study, Staphylococcus aureus was the most frequent cultivated 
organism followed by Coagulase-negative staphylococcip. Staphylococci 
organisms have the ability to adhere to the devices and to build a biofilm. The 
later film acts as a mechanical barrier allowing colonisation of the organisms 
and preventing the patient‟s immune mechanisms from eradicating the 
bacteria related to the infected device. In addition, antibiotics are rarely 
capable of treating these infections, in spite of the use of the sensitive anti-
bacterials which are of proven in vitro activity. Therefore it has been 
established in clinical practice, that staphylococcal infections of implantable 
devices generally necessitate removal (310). However, in one of our patients 
who had previous ITB pump explantation after deep infection, wound 
dehiscence and signs of infection developed 10 days after elective pump 
replacement. An attempt to salvage the device was considered to circumvent 
the necessity for removal of the device. The surgical wound was revised in 
theatre by debridement, washing with antiseptic solution, followed by 4 weeks 
of intravenous antibiotics tailored to the pathogen. The procedure successfully 
allowed the pump to survive. 
This manoeuvre had been tried successfully in previous studies when the 
infection was caused by non-adherent bacteria which are not capable of 
producing the biofilm, thus allowing the patients to respond to treatment by 
antibiotics (189, 309, 313, 314). 
  
                                                 
 
p Coagulase-negative staphylococci are by far the most common cause of 
bacteraemia related to indwelling devices. Most of these infections are 
hospital acquired, and studies over the past several years suggest that 
they are often caused by strains that are transmitted among hospitalized 
patient (310). 
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2.4.4.3.1 Culture negative infection 
In this study, the causative organism was identified only in one third of the 
infected cases whilst the rest did not show bacterial growth. Negative culture 
or no bacterial growth is a common difficulty in the treatment of postoperative 
SSI. Previous studies have reported the incidence of culture negative SSIs up 
to 30% (315). 
Several explanations have been given for culture negative infection at surgical 
sites. The most common reason is commencing antibiotics before culturing 
the infected site. Secondly, the infection may be caused by atypical organisms 
that do not grow on standard culture media or grow rather slowly resulting in 
discarding  the plates before the bacteria becomes apparent (315). Lastly, 
common contaminants such as Staphylococcus epidermidis or 
Corynebacterium species are generally not considered pathogenic, though 
they may actually be responsible for the infection at a surgical site (316, 317). 
 Surgical site infection increases the cost to the health service. Generally, the 
cost of (SSI) is tripled due to the expense of hospital stays, the economic 
burden on community health services, and the increase in social and financial 
dependency of the patient (318).  
In the United States, postoperative SSI cost was estimated to be three times 
the cost on uncomplicated postoperative course.(319) In the UK, the Public 
Health Laboratory Service (PHLS) estimated a 2.5 times cost increase for 
patients who was complicated with SSI compared to patients without 
postoperative SSI. Furthermore, it valued the cost of the patients SSI episode 
in 2000, on average between £1618 and £2398 per patient (320). No previous 
study has investigated the cost of ITB pump infection; however ITB 
implantation is already an expensive procedure which costs £13,895 
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according to the NICE guidelines in 2012. The NICE calculated the costs of 
implanting the ITB pump from Sampson et al, study in 2002 and converted to 
2010/11 costs by using the hospital and community health services pay and 
prices index uplift (113). 
2.4.5 Complication free survival in ITB patients  
Both catheter and infection complications, in this cohort were infrequently 
observed after 6.8 years. 
Catheter complications occurred within an average of 2 years post-
implantation, and were rare after 6.8 years. The clustering of catheter 
complications in the first two years could be related to incomplete therapeutic 
effect of baclofen during the first 12 to 18 months of ITB therapy when the 
individual dose titration is managed (321). Subsequently the uncontrolled 
spastic movements and differential motion generated between the pump in the 
abdomen and spine may contribute to repetitive pulling on the catheter, 
leading to its disconnection or migrations (322). The low incidence of late 
catheter complications was related to body tolerance to ITB catheter (278), in 
addition to reaching the therapeutic effect of the ITB (322).  
Ghosh et al. suggested that better tolerance of the foreign body produces little 
reaction after several years (277). Furthermore improvement in weight (238, 
323), and immunity with age are possible reasons to explain such results 
(277). This also accords with earlier observations, that adults have less 
complication than children (185, 307). 
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2.4.6 Predisposing factors for ITB pump complications 
2.4.6.1 Age at implantation time 
The occurrence of infection in this cohort was negatively correlated with the 
age at implantation time. This finding is consistent with Albright et al‟s results, 
that the incidence of serious ITB complications is significantly higher in 
children younger than 8 years old (181). Similarly, Murphy et al. who reported 
that ITB explantation rate was more often in their young than in their older 
patients (168). Further work is required to establish the safety and 
effectiveness of ITB therapy in paediatric patients below the age of 4 years 
(324). 
2.4.6.2 Gastrostomy tube 
The presence of gastrostomy tube was found as a risk factor of infection 
developing. Jevsevar and Karlin stated that the nutritional status of CP 
patients is a significant risk factor for developing infection (325). This is 
because malnourished CP children often have disturbances in their immune 
systems, predisposing them to infections (169, 326). Therefore, gastrostomy 
often helps in the nutritional optimisation especially in the perioperative period. 
However, in this study the presence of a gastrostomy tube was associated 
with SSI.  
Murphy et al. also reported that patients with gastrostomy tubes are more 
liable to ITB pump infection and ex-plantation (36). In multivariate analysis to 
identify the risk factors of ITB pump infection, Fjelstad, et al. stated that the 
frequency of deep SSI was significantly related to the presence of 
gastrostomy tubes (168, 307). In addition, it was also found to have a 
significant correlation with deep wound infections after instrumented spinal 
fusion in children with cerebral palsy (327).  
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A gastrostomy tube is a foreign body, and hence it creates and maintains a 
potential focus for bacterial colonisation (328). One tenth of children with 
gastrostomies develop erythema and tenderness around insertion site of tube 
(329), with a tendency to harbour polymicrobial colonies of organism (330, 
331). 
Increased bacterial colonisation is sometimes difficult to identify in these 
wounds, which could be missed before ITB pump implantation and 
subsequently precipitate later wound infection (332). 
2.4.6.3 Dystonia   
Generalised dystonia affects 15 to 25% of people with CP (333, 334). In a 
recent study, Lin et al. reported secondary dystonia due to cerebral palsy in 
150 of 230 patients (53.7%) (335). The presence of dystonia was found to be 
a predisposing factor for catheter complications and SSI in this study. These 
findings are consistent with previous results (174, 233, 274, 336). Albright et 
al. explained this observation due to the dystonic patients having less 
response to ITB therapy and more dystonic movements (219). These dystonic 
movements can place pressure on the pump and catheter insertion sites and 
contribute to surgical site breakdown and catheter stress (274). In addition the 
patients are typically undernourished due to the high metabolic needs of 
dystonic movements leading to increased susceptibility to infection (337).   
This idea was supported by Turner et al. who presented 22 patients with 
intractable spasticity or dystonia who had received intra-ventricular baclofen 
(IVB) therapy after their experiences of multiple ITB therapy complications. 
The surgical revision rateq was less in IVB patients (0.50) in comparison to 
                                                 
 
q the average number of surgical revisions per average number of follow-up years (336). 
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0.84 in ITB therapy (336). Same result was presented by Haranhalli et al. who 
also used IVB therapy in two patients who had multiple catheter revisions due 
to excessive twisting from dystonic movements in the trunk (174). 
Recently, Rocque et al. stated that insertion of the intraventricular catheter 
can often be much easier technically than inserting intrathecal catheter 
especially in patients with severe dystonia not responding to ITB therapy 
(234), or in patients with spinal fusions (337).  
In this study, IVB therapy was not used however; it should be considered as 
an alternative to ITB especially when catheter complications are likely to be a 
problem. 
2.4.6.4 Implantation site 
Results from several studies have shown that the subfascial technique was 
statistically associated with fewer infections in comparison to implantation in 
subcutaneous tissue (173, 278, 307). It was explained by offering more 
coverage and protection to the pump. This may minimise the possibility of 
wound dehiscence and skin ulceration in very thin children (278). 
Contrary to expectations, this study did not find a significant difference in 
infections between subfascial and subcutaneous techniques. This may be 
explained by small number of patients who had implantation at subcutaneous 
sites in comparison to the subfascial group.  
Interestingly, a significant association between using subfascial technique and 
the decline in incidence of catheter migration in comparison to the 
subcutaneous technique was noted and could be related to catheter 
tunnelling. In the subcutaneous technique, the catheter runs in the 
subcutaneous layer of the skin surrounded by the fat until it connects with the 
pump nozzle. This slippery fatty tissue may increase migration risks. Whereas 
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in subfascial techniques the anterior half of the catheter‟s tunnel passes 
between the muscles layers before it arrives in the subcutaneous tissues. This 
muscular surrounding of the catheter may restrict its movement and 
decreases the incidence of migration. In addition, nearly at the midaxillary line, 
where the catheter changes its plane from inter-muscular to subcutaneous 
tissue, the change in direction and depth may act as a natural anchor for the 
catheter, helping to prevent its migration. Additionally, the muscular coverage 
of the catheter connector could reduce the risk of catheter fracture 
complications (170), Figure 2-8. 
The manufacturer produced a new type of two-piece catheter (The Ascenda® 
intrathecal catheter) (338), that has more resistance to mechanical stretch and 
kink, which is an improvement in a necessary part of the ITB device. It 
became available in last 5 years. Tiara et al. have recommend its use to 
minimise the complication rate of ITB therapy (304).  
 
 
Figure 2-8 Tunnelling path of the catheter from ITB pump site to intraspinal 
space 
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Although, subfascial pump placement may be associated with a lower 
complication rate, the refilling of subfascially implanted pumps can be more 
difficult and may require fluoroscopy to locate the refilling port. Another risk of 
the subfascial technique is the possibility of pump migration to the peritoneal 
cavity as the continuous tone of the muscular abdominal wall might induce 
chronic pressure of the pump against the inner abdominal fascia resulting in 
progressive erosion (339). 
2.4.6.5 Weight  
In cerebral palsy patients, the weight-for-age and height-for-age often track 
below the 5th percentiles on growth charts for general populations, especially 
in patients without feeding tubes (340). These undernourished patients have a 
dearth of subcutaneous tissue, while ITB pumps are relatively bulky devices, 
leading to stretching and continuous compression of the skin against it. This 
impairs the blood supply, which could lead to skin necrosis and subsequent 
infection (309). 
In our study, the multivariate analysis did not show a significant relationship 
between patients‟ weight at time of implantation and infection events. This is 
possibly because the weight is a poorer indicator of malnutrition compared to 
for instance, the body mass index (BMI) (341, 342). However, it is not feasible 
to use the BMI in severely spastic quadriplegic children as their muscle 
contractures and spinal scoliosis make measurements of the body length 
inaccurate (343). Consequently, it is not consistently reliable enough to utilise 
the BMI in these particular patients.   
Kong et al. suggested that using triceps skinfold thickness instead of weight-
for-height percentile may be a more appropriate anthropometric measure of 
state in children with quadriplegic CP (344). Arm circumference (AC) is 
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another tool to measure the nutritional state however Samson-Fang et al. 
reported that AC is a poor  screening tool in comparison to triceps skinfold 
thickness (342). 
2.4.7 Complication rate throughout practice 
Penn et al. reported that catheter complication rates and performance do not 
decline with the surgeon‟s experience (145). This was not true in our study; as 
the frequency of complication has declined gradually overtime throughout 
practice. This could be explained by multiple factors: the cumulative surgical 
experience that was gained from a long period of ITB practice; using the 
modified subfascial technique; and the use of the new SynchroMed II infusion 
pump device (20). The surgeon's experience was found to significantly 
correlate to the survival of hardware implantation in neurosurgery practice 
(345-348).  
In a multidisciplinary conference, the “ITB Therapy Best Practice Forum,” in 
March 2004, Minneapolis, Minnesota, USA a significant correlation between 
surgeons‟ level of experience and treatment outcomes was presented. The 
recommendation is that neurosurgeons involved in ITB implantation are to 
perform 10 or more implantations per year to maintain satisfactory expertise in 
the procedure (171).   
2.4.8 Mortality with ITB therapy 
Although the adverse effects and complications are very common with the ITB 
therapy in children with cerebral palsy, death related to ITB therapy was not 
reported in the literature even in large series (173, 206, 278). The eight deaths 
recorded in our results were related to underlying disabilities and other 
comorbidities, which is in agreement with the findings of Motta el al. (278). Life 
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expectancy in children with cerebral palsy is curtailed by the presence and 
severity of mental retardation as well as associated physical impairments 
(349) . Unfortunately, improvements in medical care have not clearly altered 
the poor prognosis for the most severely disabled children (349) . 
2.4.9 Practical considerations and management recommendations  
2.4.9.1 Intrathecal baclofen withdrawal syndrome 
Intrathecal baclofen withdrawal syndrome can be severe and sometimes life 
threating, needing early and urgent management (210). It is crucial that all 
patients, caregivers, family members, and their family physician be educated 
and provided with leaflets outlining the signs of over- and under-dose, 
including the name and contact information of their provider in case of 
emergency. Patients should also have bracelets with drug dose, physician and 
manufacturer‟s contact details (350).  
Boster et al. consulted multidisciplinary groups of clinicians involved in ITB 
management to provide expert consensus on the best ITB practices. The 
panel recommends that the clinician should emphasise every at refill, 
regarding low reservoir alarm dates and the need to comply with pump refill 
schedules to avoid the potential for life-threatening withdrawal syndrome if the 
patient missed a refill date. Alarms should also be shown to the patients every 
refill to ensure that the alarms can be heard. In addition, the patients need to 
be familiar with the critical and noncritical alarm sounds (351). 
The consensus also suggests to increase the low-reservoir alarm volume 
(e.g., from 2 mL to 3 mL) for patients who occasionally miss their refill 
appointments. So, their appointments should be few days earlier to avoid the 
risk of withdrawal due to low-reservoir volume (351). 
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Boster et al. also recommend having a structured, consistent on-call system 
for patients in every practice managing ITB therapy. The on-call system 
should include direct communication between the managing clinician, 
implanting surgeon, emergency department, and critical-care team. Patients 
should be encouraged to use the on-call system if they have any concern 
regarding the ITB (351). 
Emergency department should have a protocol to guide diagnosis and 
management of acute ITB withdrawal or overdose. An ITB pump programmer 
should be available and easily accessible to ED and critical care teams. They 
should be trained and familiar with its manual (205). Furthermore, ITB drug 
delivery teams should meet routinely to review emergency protocols, therapy 
outcomes, and optimization protocols (205, 350). 
The incidence of withdrawal syndrome in the literature is based on case 
reports and case series indicating the scarceness of cases  encountered in 
ITB practice (350). 
The wide variety of reported complication rates is related to the lack of precise 
definition to ITB adverse events, therefore it is necessary to propose a 
consensus definition of ITB complications e.g. using the International 
Classification of Diseasesr (ICD) (352), and modifying its code according to 
each complication especially with acute complications such as withdrawal 
syndrome. This unique definition of withdrawal syndrome and its manifestation 
could help in planning a prospective study in multicentre or national audits, 
aiming to identify an accurate incidence of the syndrome.  
                                                 
 
r ICD is the international standard diagnostic tool for epidemiology, health management and 
clinical purposes which provides a system of diagnostic codes for classifying diseases to 
promote international comparability in the collection, classification, and presentation of 
statistics (352). 
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Intrathecal baclofen therapy is an advanced technology that has undergone 
several developments since its invention, as a result of unmet clinical needs. 
Physicians are an important source of medical device innovation as their 
knowledge and feedback about the medical devices can contribute to the 
shaping and development of new technology. Better communication between 
physicians and manufacturers of ITB pumps is recommended for improving 
the hardware and troubleshooting (353).  
To reduce the risk of ITB complications and to prolong the survival of the ITB 
system, it is recommended that implantation should be limited to specialised 
centres where health-care staff are familiar with ITB systems and the 
operating surgeons are expert with ITB procedures and their complications. 
2.4.9.2 Diagnosis of catheter complications 
Catheter complications are usually identified when cessation of ITB effect 
occurs especially after steadiness of therapeutic level of ITB daily dose (210). 
However, the diagnosis sometimes can be difficult and be several months 
after onset of the complications (210). They can be due to gradual occlusion 
of the catheter lumen or intermittent kinking of the catheter (185). Prompt 
diagnosis and troubleshooting for possible ITB system complications would 
enhance the ITB effectiveness and decrease the expense of ITB therapy 
(354).  
Bardutzky et al. proposed a diagnostic algorithm for defining the source of ITB 
errors: firstly, examine the pump programming and reservoir volume by 
interrogating the appropriate pump hardware and software; secondly, perform 
an abdominal radiographic X-ray including AP and lateral views to identify 
catheter displacement or disconnection; lastly, scintigraphy or injection of 
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intrathecal contrast material (such as Omnipaque) through the catheter 
access port to identify any leakage from the system (355).  
Diagnosis of catheter complications, according to NUH practice, was 
dependent on clinical observation when the patient lost the therapeutic effects 
of ITB therapy and did not respond to increments of their daily dose. Our 
protocol for diagnosing catheter complications is supported by Dvorak„s 
opinion that although the plain radiography is the initial method to evaluate the 
suspected catheter malfunction, it is only able to detect 35.1% of all catheter 
malfunctions (356). Furthermore, scintigraphy has a high false-negative result 
and limited ability to detect catheter migrations and microscopic perforations 
or leaks (357).  
Dvorak et al. suggested two potential developments in the ITB system that 
would contribute to troubleshooting: the ability to interrogate the ITB pump and 
obtain a precise measure of the reservoir volume which would circumvent the 
necessity of invasive access to the reservoir in order to check the volume of 
baclofen in the pump; the other is the ability to measure the pressure that ITB 
pump has to apply to drive the baclofen into the catheter. So, a reduction in 
the pressure that pump exerts to drive a given volume of baclofen would be 
suspicious of catheter disconnection or leakage. On the other hand, 
increasing the pressure would point to catheter kinking or occlusion (356).  
2.4.9.3 Alternative techniques to lumbar insertion of ITB catheter 
Iatrogenic failure of the catheter system after spinal surgery is a big challenge 
in ITB practice. Manufacturers of the ITB pump warn that shortwave diathermy 
can damage the ITB system and thus should be avoided within 30 cm of the 
pump or catheter. In this study, 7 children with previous lumbar ITB systems 
presented with loss of ITB effect due to iatrogenic transection of the ITB pump 
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catheter after corrective spinal surgery. As a result of these challenges, 
insertion of the intrathecal catheter via a posterior cervical approach was 
developed to be the standard technique in the following situations: for 
implantation in children who had spinal fusion surgery or metalwork that 
obstruct lumber spinal access; iatrogenic damage after corrective surgery for 
scoliosis; in cases with difficult access to the lumbar thecal sac; or if spinal 
instrumentation is under consideration. This technique was implemented 
uneventfully in 20 patients.  
Recently the intraventricular approach was also suggested as a new 
alternative technique to overcome the difficulties with the insertion of ITB 
catheter in patients with spinal deformities, after multiple ITB catheter 
complications, or in patients with severe dystonia (336). 
2.4.9.4 Recommendations to reduce the risk of infection 
Wong et al. recommended some actions to reduce infection rate: the number 
of personnel attending during the ITB implantation procedure should be 
restricted to the absolutely essential staff; traffic through the operating theatre 
should be limited. It is also essential to inspect more carefully preoperative 
preparations and perioperative procedures. Double gloving is much 
recommended during implantation surgery (358). In addition, applying the no-
touch technique to confirm that the operating surgeon is the only one to touch 
the pump.(359). 
To decrease the risk of infection associated with gastrostomy tubes (PEG), 
Albright et al. recommended inserting the ITB pump on the opposite side to 
the PEG tube (171). Fjelstad, et al. highlighted the necessity to isolate the 
gastrostomy tube intra-operatively and to have vigilant care postoperatively 
(307). 
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In cases of infection events it is crucial to have continuous liaison between the 
ITB therapy team and the microbiologist to allow accurate diagnosis and 
treatment. 
2.4.10 Limitation of the study 
This is a retrospective study where the collected data were not designed 
initially for research purposes. However, the guidelines of collecting 
retrospective data were followed, to be minimise bias due to missing data 
(271, 360).  
2.5  Conclusion 
This study summarises the experience in a large cohort of ITB recipients at a 
regional tertiary referral hospital over a period of more than 13 years. Although 
the ITB therapy offers the option for long-term and modulated management of 
spasticity, it has a significant risk of complications and medical problems that 
could deprive the child benefiting ITB. The following conclusions can be drawn 
from the present study: 
1. ITB therapy is associated with pharmacological and surgical (device 
related and SSI) adverse events.   
2. Device related complications (pump and catheter malfunction) were the 
most prevalent. Other complications such as withdrawal syndrome was 
not documented which could be looked at carefully in a prospective 
study/audit to avoid under- or mis-diagnosis.  
3. The rates of ITB complications in this cohort were similar to what had 
been reported in other paediatric populations treated with ITB therapy.  
4. It has been proven that young age, presence of dystonia and 
gastrostomy tubes are significant risk factors for infection development. 
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While the incidence of catheter complication was significantly increased 
with the presence of dystonia and decreased by using subfascial 
technique.  
5. The frequency of complications in this study showed a gradual decline 
with on-going practice due to cumulative surgical experience, adoption 
of new surgical technique and the use of new pump device. 
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3.1 Introduction  
Intrathecal baclofen (ITB) pumps require the reservoir to be refilled regularly to 
maintain drug infusion. The available reservoir capacities of the pumps are 10, 
20 and 40ml. However, due to small size and lack of adequate soft tissue 
cover in children, the 20ml pump is usually the most suitable size. The 
frequency of refilling depends on reservoir size, concentration of baclofen in 
the pump and daily dosage (221, 361). 
In turn, the daily dosage varies depending on diagnosis, function, and severity 
of symptoms (163, 167, 221). For instance, 50mcg/day is used in cases with 
moderate spasticity and up to 2000 mcg/day in dystonia patients (214, 362, 
363).  
Commercial ITB (Lioresal®) is available in two concentrations, 500 and 
2000mcg/ml. These concentrations can necessitate frequent refills every 2-3 
weeks, especially in patients with high daily requirements or in patients using 
the older 10ml pump. The frequent refills may increase the risk of infection 
(364, 365). Additionally, the distress of repeated punctures for access, long 
journeys in specially-equipped vehicles to access the refill service and the 
resultant incurred costs, add to the burden.  
Dario et al. in a study to appraise the relationship between the patient and ITB 
pump, one fifth of patients have reported discomfort due to frequent pump 
refills although they were highly satisfied with ITB treatment (366). In a long-
term follow-up study of 40 patient with ITB pump implantation, 12% of the 
patient have expressed dissatisfaction with the frequency of pump refills (177).  
The manufacturer of Lioresal® recommends renewing ITB at 6 months if not 
all used. Additionally, they assert that concentrations greater than 2000 
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mcg/ml do not meet stability requirements without the formation of 
precipitates. However, pharmacists create higher concentrations of baclofen 
at 3000-8000 mcg/ml to decrease the cost and frequency of refill (179, 367). 
Whilst the FDA guidelines generally tolerate a 10% deviation from labelled 
concentration in compounded products (368), there are no FDA studies 
evaluating ITB or the pharmacopoeia criteria regarding ITB quality.  
Baclofen is a derivative of GABA with a molecular weight 213.661 g/mo (369). 
Baclofen contains an amino and a carboxylic group that are able to form 
zwitterions structure in neutral solutions (close to physiological pH value) 
(182). Stored baclofen in aqueous formulation forms the degradation product 
4-(4-chlorophenyl)-2-pyrrolidone (4CPP) with molecular weight 195.65 g/mol 
(369). Tempreture and moisture may provide a favourable enviroment for 
degradation as they contribute to intramolecular water loss yielding the 
degradation (370). Chemically, 4-Amino-3-(4-chlorophenyl)butanoic acid 
(213.6 g/mol) is transformed into: 4-(4-chlorophenyl)-2-pyrrolidinone (195.6 
g/mol) and water (18g/mol), Figure 3-1. 
 
Figure 3-1 Degradation of Baclofen into 4CPP and water 
                                                 
 
s Zwitterion is a chemical compound that is electrically neutral through a net cancellation of 
formal positive and negative charges within the compound. Zwitterions are polar and usually 
have a higher solubility at acid and basic pH values where a net charge exists in the 
compound. However, at physiologic pH a net zero charge often reduces solubility(182). 
Baclofen (213.6) g/mol)  Water (18g/mol) 4CPP (195.6g/mol) 
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Recently, Yue et al. have evaluated baclofen (3mg/ml) solubility, stability and 
its chemical and physical compatibility within programmable IT infusion pumps 
when subjected to multiple flow rates conditions. The study showed that 
3mg/ml baclofen concentration was stable during long-term storage at 25°C 
and remained stable under conditions simulating those encountered in clinical 
practice i.e. 37°C (371). 
At Nottingham University Hospital (NUH), variable concentrations of baclofen 
are used in pump refilling. Commercial baclofen 500 mg/ml concentration is 
used if the daily dosage rate is below 100mcg/24hrs; 2000 mcg/ml is used If 
the daily dosage rates surpass 100 mg/24hrs; and 3000 mcg/ml compounded 
baclofen concentration is the choice if 24 hours dosages exceed 300 
mgs/24hrs. This product is manufactured by Boots Contract Manufacturing 
(BCM) to NUH practice based on individual prescription.  
No more than 3000 mcg/ml compounded baclofen concentration were used in 
NUH. This is because baclofen in normal saline is stable at 3600 mcg/ml 
concentration at room temperature (25⁰C) and at 3900 mcg/ml concentration 
at body temperature (37⁰C); otherwise baclofen might be precipitated in the 
solution. This limits the potential of using higher concentration of injectable 
baclofen safely more than 3000 mcg/ml. This limitation is to avoid precipitation 
that could cause CNS complications and/or pump malfunctions (369). 
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3.1.1 Objective  
In this study, high concentration compounded baclofen (3000 mcg/ml) is 
compared with commercial baclofen (2000mcg/ml) to assess the accuracy of 
concentration and the percentage of baclofen degradation product (4CPP). 
Additionally, the invisible particulates will be quantified and the risk of 
infectious contamination will be evaluated.  
Specific study questions that will be addressed: 
1. Do the compounded and commercial baclofen concentrations match 
the label? 
2. Does baclofen concentration degrade after injection into the pump? 
3. Does the rate of baclofen degradation correlate with the rate of 
baclofen fall? 
4. Is the number of particles in the baclofen solution acceptable? 
5. Is there any correlation between baclofen degradation product and 
particulate formation? 
6. Is the compounded baclofen solution sterile? 
7. Does the use of compounded baclofen cause baclofen pump failure 
e.g. pump failure or catheter obstruction? 
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3.2 Material and methods 
3.2.1 Study Design 
During the refill procedure, any residual ITB solution in the reservoir is 
removed before replenishing with fresh ITB (commercial 2000 mcg/ml or 
compounded 3000 mcg/ml). The retrieved sample is routinely sent for 
microbiological investigation. 
In this study, fresh unused ITB (compounded and commercial) was analysed 
for the actual potency of concentration, degradation, precipitation of baclofen 
and number of particulates in the solution. A sample of the same batch of ITB 
retrieved during refill after staying in the pump chamber at normal body 
temperature for variable time intervals was also sent to the same analysis for 
direct comparison.  
The methodology was discussed with the ethics committee, who decided that 
a prior approval from the committee was not required, as it was a quality 
control study based on a waste product i.e. the retrieved fluid from the pump 
reservoir at the time of its planned refill. 
3.2.2 Setting: 
The experimental work was conducted at Pharmaceutical Quality Control 
Laboratory, F Floor, West Block, and Queen Medical Centre Campus of 
Nottingham University Hospital by a professional senior chemistry technician 
(R.B.). 
3.2.3 Samples: 
Thirty eight retrieved samples were collected from patients while in clinic visits 
for routine ITB refills. On-shelf vial of baclofen batches that were used for 
refilling the patients‟ pump had undergone the same tests and compared with 
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patients‟ samples results. Each sample (approximately 2 ml) was placed in a 
capped syringe and stored at 37°C to resemble the normal body 
environments. Every 10 samples were analysed as one set. Forty five 
samples were analysed. These were 38 retrieved pump‟s samples in addition 
to samples from their refilling vials batch (2 commercial batches and 5 
compounded batches from BCM) 
3.2.4 Main outcome Measures: 
1-The concentration level of baclofen in different solutions  
2-The concentration level of baclofen degradation product 4CPP 
3- The particle number in the ITB solution (particle size ≥10 µm and ≥25 µm) 
4- Sterility of baclofen solution. 
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3.2.5 Laboratory analysis 
3.2.5.1 Concentration analysis of baclofen and its degradation 
Concentrations of the baclofen and 4CPP were analysed using high-
performance liquid chromatography (HPLC) method according to British 
Pharmacopeia protocol of assessing oral solution for baclofen preparation 
(372). 
Apparatus 
The HPLC used is the Agilent HP 1100 system consisting of G1310A isocratic 
pump with solvent cabinet, G1328A manual injector (MI), G1314A variable 
wavelength detector (VWD) with standard flow cell (10mm path length, 14µl 
volume, 40 bar maximum pressure) and G2220AA 2D-Value Solution 
ChemStation.  
Column 
The used column was NUCLEOSIL C18,  5µm (Macherey-Nagel). 
Chemical 
Ten grams of Sodium Dodecyl Sulfate (Fisher scientific) were dissolved in 
1290 ml of water (Baxter), to which 10ml orthophosphoric acid was added 
(Fisher scientific). Volume was completed to 2L using acetonitrile HPLC grade 
(Fisher scientific).  
Reference baclofen was purchased from British Pharmacopoeia Reference 
Standards (BPCRS). 
The flow rate of the HPLC system was set to 1.50ml/min. For each sample, a 
volume of 50μL was loaded onto the column via an Autosampler from the 
sample tray. The column was re-equilibrated at initial conditions for 3 minutes 
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before the next analysis. Each sample was analysed twice. The data of 
samples was collected by an Agilent G1314A.  
3.2.5.2 Counting particulate numbers in baclofen solutions 
The sub-visible particles were examined according to British Pharmacopeia 
protocol using the light obscuration particle count test (373). Light obscuration 
(LO) is the compendial method of choice listed in British and Europian 
pharmacopeias (373, 374). It also referred to as Single Particle Optical 
Sensing (SPOS). The mechanism of light obscuration technology is based on 
passing a dilute stream of particles in a liquid suspension between a light 
source and a detector. The light source in this case is a laser diode, which 
illuminates the individual particles in the stream and results in a shadow or 
blockage on a light-sensitive detector. This light blockage is termed 
obscuration. The detector measures this reduction in light intensity and 
processes the signal to determine the size of the particle (375), Figure 3-2. 
 
Figure 3-2 Schematic diagram showing the mechanism of light 
obscuration technology used in calculation of particles‟ size and number  
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HIAC 9703 apparatus was used to allow automatic determination of the size 
and the number of particles. The apparatus was standardised by using 
suitable certified reference materials consisting of dispersions of spherical 
particles of known sizes between 10µm and 25µmt (376). These standard 
particles are dispersed in particle-free water (373, 374), Figure 3-3. 
 
Figure 3-3 HIAC 9703 apparatus used in quality  control unit to 
quantify the particles‟ size 
                                                 
 
t symbol: μm is referred to one micrometre also known as a micron. It is one millionth of a 
metre, "micro=10−6" (376).  
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3.2.5.2.1 Steps of light obscuration technique: 
1. The used glassware and filtration equipment were carefully washed, 
with avoidance of introduction of air bubbles into the preparation.  
2. 1ml of the sample was mixed with 25ml of distilled water. 
3. Gas bubbles were eliminated by standing the solution for 2 minutes.     
4. Five portions of the solution, each of not less than 5 ml were aspirated 
by the apparatus.    
5. The numbers of particles equal to or greater than 10µm and 25µm were 
counted.   
6. The obtained result of the first solution portion was disregarded and the 
mean number of particles in the other four portions was calculated.    
7. The preparation complies with the test if the average number of 
particles present in the units tested does not exceed 6000 per container 
equal or greater than 10µm and does not exceed 600 per container 
equal or greater than 25µm (the number of particles detected at 25 µm 
needs to be added to the number detected at 10 µm) (373).   
3.2.5.3  The sterility of compounded baclofen solution 
The retrieved samples were sent to the microbiology laboratory for detection 
of solution contamination. Gram stain and culture and sensitivity test were 
also performed.  
3.2.6 Review of medical records  
The medical records of these patients were retrospectively reviewed to 
determine the indication of ITB implantation, duration of ITB pump 
implantation, daily dose of ITB, duration of usage of compounded baclofen, 
refill interval and any reported complications (catheter malfunction, device 
error, overdose, withdrawal, or infection).  
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The method of extracting and verification of the clinical data from medical 
records was discussed in details in chapter two.  
3.2.7 Statistical analysis 
Statistical analyses were conducted using SPSS version 21 (SPSS Inc, 
Chicago, IL, USA). 
1- Descriptive statistics were used to define the features of the laboratory 
results in the study. 
2- Wilcoxon Signed Ranks test was used to compare between the mean 
concentrations of the baclofen vial and pump samples. 
3- Simple linear regression analysis was performed to analyse associations 
between the difference of baclofen potency from refilling vial after a stay in the 
pump as dependent variable and interval refill duration as independent 
variable.  A P value < 0.05 was considered significant. 
Differences of baclofen potency= mean of vials concentration – mean of pump 
samples concentration 
4- Multivariate linear regression analysis was also used to adjust the 
association between Baclofen degradation content (4CPP) as dependant 
variable, and interval refill duration and the difference in baclofen potency as 
independent variables. The significance level was also set at P < 0.05.  
5- The correlation between baclofen degradation products and particle 
number in baclofen solution was tested by using Pearson correlation 
coefficient.  
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3.3 Results 
Each sample was analysed twice by HPLC, and the mean value of these 
duplicates was used as the sample concentration value for subsequent 
comparison of accuracy. 
3.3.1 Accuracy of sample concentrations  
3.3.1.1 Compounded vial: 
For samples of 5 different batches of unused compounded baclofen (off the 
shelf samples) with an expected concentration of 3000mcg/ml, the mean 
concentration was 2814.6mcg/ml (93.8% of the expected value) with a range 
of 2792-2840mcg/ml (SD± 17.24). On average, they missed the expected 
concentration by 6.2%. No samples were within 5% variance from the 
expected concentration. 
3.3.1.2 Pump‟s samples (refilled by compounded baclofen): 
The mean concentration of 33 retrieved samples which were refilled by 
compounded baclofen (BCM) was 2785.22 mcg/mL (92.84 % of the expected 
value), SD± 46.58, within a range of (2711-2919 mcg/ml). The mean of 
retrieved samples missed the expected concentration by 7.15%. None of the 
samples missed 10 % variance from the labelled concentration.  
The mean of decreased baclofen concentration was 29.52 mcg/ml (2814.6-
2785.22 mcg/mL) (SD± 25.00, Range = 8-97). It is 0.96% reduction from the 
unused compounded baclofen vial (p< 0.001). 
Linear regression analysis did not show any significant relation between 
baclofen concentration decrease and duration of baclofen stay inside the 
pump (p=0.76).  
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3.3.1.3 Commercial vials: 
The mean concentration of two unused different batches of commercial 
baclofen was 1883.35 mcg/ml (SD± 7.8, range 1873.4-1889.6 mcg/ml) which 
was 94.17% from the expected (nearly within 5% variance from the expected 
concentration). 
3.3.1.4 Pump‟s samples (refilled by Commercial baclofen): 
The mean concentration of 5 retrieved baclofen samples was 1811.33 
mcg/mL (SD ±17.1 range=1794-1839 mcg/ml). It was 90.6% of the expected 
value. The mean concentration of the commercial retrieved samples missed 
the expected concentration by 9.4%. None of the 5 samples missed >10% 
variance from the labelled concentration, Table 3-1.  
Thus, an overall significant decrease of the retrieved baclofen concentrations 
[by 72.7mcg/ml (3.57%), Wilcoxon Signed Ranks Test p=0.043] compared 
with the unused original commercial vial after staying in ITB pump for different 
durations was observed. Importantly, this change in baclofen concentration 
was significantly correlated with the duration of baclofen stay inside the pump 
(p=0.009). 
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Table 3-1 Results of baclofen accuracy analysis of commercial and compounded 
products 
 Commercial 
Baclofen 
(Vial) 
 
Commercial 
baclofen 
(Pump) 
 
 
Compounded 
baclofen 
(Vial) 
 
 
Compounded 
baclofen 
(Pump) 
 
 
Expected 
concentration 2000 µg/ml 2000 µg/ml 3000 µg/ml 3000 µg/ml 
Number of 
samples 2 5 5 33 
Mean baclofen 
concentration 
µg/ml 
1883.35 
µg/ml 1811.33 µg/ml 
2814.72 
µg/ml 2785.2 µg/ml 
Difference of 
mean from 
expected 
value 
116.67 
(5.8%) 188.65 (9.4%) 185.3 (6.2%) 214.78(7.15%) 
Range of 
existing 
concentration  
(1873.4-
1889.6) 
µg/ml 
(1794.0-1839) 
µg/ml 
(2792-2839) 
µg/ml 
(2710-2919) 
µg/ml 
 
3.3.2 Concentration of 4-(4-chlorophenyl) -2-pyrolidinone (4CPP) 
The mean concentration of 4CPP in compounded baclofen vials was 
25.6mcg/ml (0.91%) which increased to 41.33mcg/ml (1.48%) in retrieved 
samples.  
The mean concentration of 4CPP in the commercial baclofen vials was 
13.9mcg/m (0.69%) which was increased in retrieved sample by more than 4 
folds to 56mcg/ml (3.09%). 4-CPP percentage changes are shown in Figure 
3-4. 
On multivariate liner regression analysis, there was no significant increase of 
4CPP in proportion to baclofen falls of 3000 mcg/ml concentration (p = 0.099). 
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Unsurprisingly, 4CPP was significantly correlated with the longer stay of ITB in 
the pump (p <0.001).  
In regard to the commercial product, the multivariate analysis revealed that 
the increase of 4CPP concentration was significantly correlated to both 
baclofen concentration fall (p = 0.012) and increased duration of ITB inside the 
pump (p = 0.044). 
 
Figure 3-4 The percentage of baclofen degradation product to baclofen 
concentration 
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3.3.3 Subvisible particulates numbers 
The results of subvisible particulates analysis showed that the particle number 
in compounded baclofen was five times more than the particle number in 
commercial baclofen. There were little changes in particle number of both 
products after staying in pumps for variable durations, Table 3-2 and Figure 
3-5. 
There was no significant correlation between baclofen degradation product 
(4CPP) level and the particle number in the solution after staying inside the 
pump (p=0.123, 0.230) for particles equal to or greater than 25 µm and 10 µm 
respectively).  
Table 3-2 Particle concentrations  in both compounded baclofen and commercial 
baclofen solutions 
Sample type 
Mean (range) of 
Particle ≥ 10µm 
[Counts/mL] 
Mean (range) of 
Particle ≥ 25 µm 
[Counts/mL] 
Commercial unused vial (n=2) 43 (13-70)/ml 5 (0-10)/ml 
Commercial retrieved samples 
(n=5) 
41(12-82)/ml 4 (3-13)/ml 
Compounded unused vial (n=5) 216 (20-243)/ml 14 (10-61)/ml 
Compounded retrieved samples 
(n=33) 
245 (28-927)/ml 15 (0-58)/ml 
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Figure 3-5 The difference in particle number between both products 
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3.3.4 Clinical data review  
In reviewing the medical records for this group of patients, spasticity was the 
most frequent indication for implanting the ITB pump, Table 3-3.  
The mean implantation duration was 68.9 months in the compounded 
baclofen group in comparison to 34 months in the commercial group. The 
mean refill interval was 83.4 and 179 days in compounded and commercial 
groups, respectively. No complications were reported in both groups.   
The mean of daily dose in the compounded baclofen group was 512.7 mg/ml 
in comparison to 172mcg/ml for commercial group. 
 
Table 3-3 Indications, refill interval, and daily dose of ITB 
 
3000 mcg/ml 
samples (33 
records) 
2000 mcg/ml samples 
(5 medical records) 
Indication of ITB implant 
26 spasticity and 7 
secondary dystonia 
Spasticity 
Longevity of ITB implant 
(months) 
68.85 (24-126) 
months 
34 (28-39) months 
Refill interval (days) 83.39 (28-196) days 179 (147-196) days 
Daily ITB dose at time of 
sampling   µg/ml 
512.73 (200-930) 
µg/ml 
172(100-250) µg/ml 
Complications 0 0 
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In review of previous refill data for spasticity and dystonia patients, random 
cases were selected to demonstrate the pattern of daily dose infusion and its 
relation to used concentration. It was found that the daily dose requirement 
was progressively increased in all patients until the therapeutic dose and 
titration level was achieved, Figure 3-6. As expected, the daily dose required 
in patients with spasticity alone was lower than those with dystonia, Figure 3-7 
and Figure 3-8 respectively.  
   
 
Figure 3-6 Examples of ITB daily dose escalation in patients 
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Daily dose of 
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Figure 3-7 Example of a pattern of daily doses of Baclofen in a patient with 
spasticity. 
 
Figure 3-8 Example of a pattern of daily doses of Baclofen in a patient with dystonia. 
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3.4 Discussion 
In this study, the main indications for implantation of the ITB pump were 
spasticity and dystonia secondary to cerebral palsy. The pattern of daily dose 
escalation of ITB showed a higher daily requirement of ITB to clinically control 
dystonia which go in line with findings of related studies (227, 231, 266, 377). 
Accordingly, there is a clinical need for higher concentration aqueous 
solutions of baclofen with acceptable pharmaceutical properties, including 
stability in a variety of storage conditions and for extended periods of time.  
Ideal baclofen solutions must be accurate in their concentration, with no 
significant amounts of particulates and must stay in solution without 
precipitation before and after administration (179). Baclofen must also be 
sterile to prevent serious infectious complications (378-380). Unfortunately, 
baclofen has poor solubility in water and easily precipitates out of solution. 
Only baclofen solutions with concentrations of 2000mcg/ml which has been 
validated to remain stable for extended periods of time (up to six months) 
(182). Previous studies stated that, compounded higher ITB concentrations to 
an upper limit of 4300 mcg/ml have been manufactured. However, the method 
of drug preparation in this study may not be commercially reproducible (381, 
382). 
Whilst the FDA guidelines generally tolerate a 10% deviation from labelled 
concentration in compounded products (368), there are no FDA studies 
evaluating ITB. In addition, there are no specific criteria for the quality of 
intrathecal or injectable baclofen established by the United States 
Pharmacopeia (USP), European Pharmacopoeia or British Pharmacopoeia 
(BPC). Only the Handbook of Injectable Drugs lists baclofen for intrathecal 
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use and includes pH, available concentrations, and sodium content in the 
product description, but it does not refer to the acceptable accuracy range of 
concentration (383). 
BPC has established standard criteria for baclofen oral solution with the 
following requirements: The content of baclofen should be between 95.0 to 
105.0% of the stated amount, with baclofen degradation not exceeding 2% of 
obtained solution (372). 
Several studies have investigated the stability of ITB. Alvarez et al. has tested 
the stability of commercial products of Baclofen-Clonidine admixture. The 
study has shown good stability of the admixture and compatibility with ITB 
pump at body temperature (384). Shields et al. compared stability of 
admixtures combining ziconotide with commercially formulated or 
compounded baclofen during simulated intrathecal infusion under laboratory 
conditions at 37°C. Ziconotide-baclofen admixtures were more stable with 
compounded baclofen rather than the commercial baclofen formulation (385). 
Medtronic PLC, in cooperation with Novartis (the commercial baclofen 
manufacturer) published a “white paper,” describing their investigations of 
using higher concentrations other than those used for the commercially 
available baclofen. Solubility and physical stability of 3 and 4 mg/ml aqueous 
baclofen solutions were evaluated. The study demonstrated that precipitation 
occurred in a concentrations more than 2 mg/ml (182), but this study has not 
been successfully replicated independently.  
Moberg-Wolff et al. evaluated compounded ITB obtained from several 
pharmacies in comparison to commercial baclofen. Twenty seven samples of 
compounded ITB from 6 different compounding pharmacies with labelled 
concentrations of 2000, 3000, 4000, 5000, and 6000 mcg/ml were compared 
Chapter 3                                             Use of Higher Concentration Compounded ITB 
 
 
138 
with 2 different batches of Lioresal ITB 2000 mcg/ml. The sample passed the 
accuracy test if the assay was within 5% from the expected concentration. The 
Lioresal® samples were reported to have no concentration deviation, whereas 
11 of 27 compounded baclofen samples (41%) were not within 5% variation of 
the aimed concentration and 22% of samples were not within 10%. Samples 
from compounding pharmacies have greater variation in concentration from –
35% to 12% than labelled value (179). However, this study was limited 
because of insufficient number of samples from each compounding pharmacy, 
un-reporting the concentration values of assayed samples and lack of 
statistical calculations. 
Farid and co-workers analysed ITB from a national compounding pharmacy in 
the United States (AnazaoHealth) and compared it with commercial baclofen 
(Lioresal®) in regard to the accuracy of baclofen concentration and the 
content of the baclofen degradation product. The study showed that analysis 
of nine samples of Lioresal® was within 5% of the expected concentration. 
Out of 27 samples from compounding pharmacy (AnazaoHealth), 22 were 
more than 5% while 8 were more than 10% different from the labelled 
concentration. Importantly, no baclofen degradation product (4CPP) was 
detected in any of the compounded samples tested. All samples of Lioresal® 
contained 4CPP less than 1% of the baclofen concentration. The study 
concluded that Lioresal was more precise in concentration than compounded 
ITB (AnazaoHealth) (386). It is noteworthy that Farid et al. study presented the 
details of ITB assay of samples including statistical analysis of variation 
between samples (386). However, the study analysed only the ITB vials as 
production quality control and it did not appraise baclofen stability after 
administration into the pump. 
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In a 2010 patent,  “High concentration baclofen preparations” the authors state 
that they prepared baclofen solutions at concentrations of 4000, 5000 and 
6000mcg/ml which remained clear and free of particulates for 12 months when 
stored at room temperature and additionally stable for 60 days at 37° C (387). 
However, these samples were not analysed following administration into drug 
delivery systems (388).  
3.4.1 Precision of compounded baclofen concentration versus commercial 
product 
Our study demonstrates that the precision of off-shelf vial of commercial 
baclofen concentration is more accurate than the compounded baclofen vial 
that was supplied from the compounding pharmacy (BCM) in keeping with 
findings from similar studies (179). However, analysis from retrieved samples 
after administration into the pump showed that there was a statistically 
significant change in the accuracy of concentrations in commercial ITB 
compared to a minimal change of the compounded ITB concentrations. The 
findings of the current study are consistent with those of Yue and co-
investigators who assessed physical and chemical stability of baclofen 3 
mg/mL in prefilled syringes over 36 months (at 3, 6, 9, 12, 18, 24, and 36 
months) with storage at 25° C where the compounded baclofen content 
remained unchanged and no precipitation was observed (371). 
In addition, the stability of ITB 3000 mcg/ml was evaluated in simulated clinical 
study. Intrathecal 3mg/ml formulation was placed in SynchroMed II and 
Codman Medstream pumps at 37° C for study durations of 218 days, and 
evaluated at different flow rates (110 µl/day - 400 µl/day). The exposed pumps 
to baclofen 3mg/ml were then dissected and evaluated for signs of 
deterioration. The results showed that ITB 3mg/ml formulation was stable at 
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different flow rates and throughout different expected residence times for both 
pump models. Moreover, the components from both pumps did not reveal any 
noticeable deterioration after exposure to the 3 mg/ml formulation (371). 
Our findings bear important implications for the stability of the compounded 
baclofen rather than the commercial ITB after administration in the pump 
under normal body temperature for extended duration. However, with a small 
sample of the commercial ITB and its longer stay inside the pump (mean of 
refill duration was 179 day compared to 83.39 days for compounded 
samples), caution must be applied, as the findings might not be transferable to 
clinical practice. 
3.4.2 Baclofen degradation content 4-(4-chlorophenyl)-2-pyrolidone 
(4CPP) 
During long-term storage and upon heating, baclofen forms a poorly soluble 
degradation product with lactamic structure 4CPP. This degradation reduces 
the potency of baclofen in solution (182, 389). It is not known if 4CPP can 
cause the same side effects as baclofen. However The Analytical Profiles of 
Drug Substances suggests that 4CPP is less toxic than baclofen, given that 
oral toxicological testing in male rats showed the LD50u of baclofen was 228 
mg/kg and 841 mg/kg for 4CPP (382). The British Pharmacopeia recommends 
that 4CPP should not exceed >2% of the concentration in oral baclofen 
solution but no exact values for ITB solution have been recommended (373).  
The current study showed a four times increase of baclofen degradation 
product in commercial ITB after being in the pump in comparison to slight 
                                                 
 
u An LD50 is an abbreviation for "Lethal Dose, 50%" or median lethal dose. It is the amount of 
the substance required (usually per body weight) to kill 50% of the test population i.e. the 
lower the LD50 dose, the more toxic the pesticide (382). 
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increase in compounded product. As expected the degradation in both 
products was affected by long-term stay in the ITB pump. However, the 
degradation was not related to drop of baclofen 3000 mcg/ml concentration 
which was not the case in commercial baclofen 2000 mcg/ml concentration.  
Yue et al. have evaluated the degradation of baclofen at 3000 mcg/ml 
concentration and reported that the percentage of 4CPP degradation product 
has steadily increased over 36 months of the study. Degradation levels started 
at 0.128%, then increased to 0.14% after 12 months, 0.154% after 24 months 
and increased to 0.17% at 36 months (371). 
Our findings are in agreement with Farid et al‟s study that showed more 
degradation in commercial ITB as compared with compounded ITB solution 
(386). This was attributed to the method of sterilisation of the ITB solution. 
Commercial ITB was sterilised using thermal methods thus being exposed to 
higher temperaturesvi (389) compared with compounded ITB whose 
sterilisation was achieved using filtration (386). 
These findings suggest less stability of the commercial ITB in comparison to 
compounded 3000mcg/ml after stay inside the pump. However, this could be 
explained by the longer stay of commercial baclofen inside the pump in our 
study group. However, the relatively small number of samples in our study 
could be an additional reason.  
3.4.3 Invisible particulates 
Baclofen is known for poor solubility in water. Dissolved baclofen, especially at 
higher concentrations, is inclined to precipitate into particles in the solution 
                                                 
 
v Common sterilization protocol is using a heating regimen at 121.1° C. for 30 minutes. It was 
hypothesized that shorter heating times may lead to a solution with fewer degradation 
products, as the baclofen would have less time under the stress of heating to degrade (389). 
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over time leading to a reduced concentration of baclofen in addition to the 
undesirable particulate matter. It is not known if these particulates inside the 
pump can block the filter between the pump reservoir and catheter which 
potentially carries the risk of reducing or completely blocking the infusion of 
ITB.   
The current study is the first attempt to assess the particles‟ numbers and 
revealed significantly low particulate levels in commercial baclofen with little 
changes after being inside the pump. The compounded solution had higher 
particulate number; nearly 5 times more than the commercial solution though 
it was still compliant with USP and BPC requirements (373). 
3.4.4 Correlation between baclofen degradation product and particulate 
formation 
The number of particles observed in ITB solution was not correlated with the 
assay value of baclofen degradation product. This finding is consistent with 
the study of Sigg et al. which examined the nature of the particulates by 
filtration of the solutions. The infiltered-out particulates were re-dissolved and 
analysed by HPLC. Interestingly, the results confirmed that the precipitate was 
baclofen and the particulate formation was not related to the amount of 
degradation product present in the formulation (182). 
3.4.5 Relationship between compounded baclofen and device related ITB 
complications 
In the current study, review of patients‟ medical records did not demonstrate 
that using the higher ITB concentration was associated with catheter or ITB 
pump malfunction, or increasing demand of daily ITB dose. In addition, no 
withdrawal syndrome was documented as a result of cessation of baclofen 
infusion. However, we did not review all patients whose pumps were refilled 
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by compounded baclofen as many children received their refill service in 
peripheral hospitals. They might have experienced ITB pump complications 
that were not presented to NUH. 
3.4.6 The sterility of ITB solutions 
The potential threat of patient harm related to compounded sterile 
preparations such as ITB could also be due to possible inconsistency in 
sterility assurance. This risk is well recognised and has resulted in several 
reported outbreaks with other compounded products (378, 380, 390). 
Recently, a multicentre outbreak of fungal meningitis among patients, who 
received a compounded steroid injection into the spinal region, resulted in 64 
deaths and 750 illnesses (391). 
CNS infection reported after pump implantation has raised the concerns with 
potential contamination of the compounded formulation and noncompliance 
with sterile precautions during intrathecal pump refilling (365, 392, 393). 
In this study, all samples either commercial or compounded, underwent 
microbiological analysis and were confirmed to be sterile after administration 
into the ITB pump which indicates strict implementation of sterile precautions 
during pump refills.  
3.4.7 Administration modes and dose tailoring  
Infusion mode of ITB can be either continuous or be programmed for variable 
dosing. The latter allows for dose variations throughout the 24-hour period 
which could help in reducing the daily need ITB (167, 394). Contrasting this, 
simple continuous mode provides consistent delivery of drug over the time. 
There is some suggestion in the literature that the majority of patients are well 
managed with this mode of delivery (351, 395). However, the therapeutic 
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outcomes of ITB could be optimised by tailoring the daily dosing according to 
an individual child‟s daily routine and needs (351). Heetla et al. indicated that 
intermittent boluses may result in an overall better clinical response compared 
to simple continuous mode of ITB delivery, and even permitting a reduction in 
total daily dose (394). 
3.4.7.1 Flex dosing 
If the patient has a predictable spasticity pattern, flex dosing would be 
recommended to optimise the therapeutic outcome. The flex mode adjusts the 
ITB dosing based on the variable spasticity pattern and daily schedule of the 
patient to maintain functional spasticity control (396, 397). These patients 
usually need moderate degree of spasticity during the day to help their 
transfers and mobility. However, this spasticity could interfere with evening or 
night sleep. Thus, an increase in dose before bedtime would be convenient to 
give overnight relief of spasticity and to reduce morning stiffness. Usually, the 
increase in dose would not exceed 10% to 15% of the baseline dose (351), 
Figure 3-9. 
 
Figure 3-9 an example of flex dose in 24 hours 
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escalation to reach four to six times the screening test dose. In these cases, 
the patient has not yet experienced an effect similar to that of the screening 
test. A few studies have recommended a periodic bolus dosing mode to 
increase clinical response (180, 351, 396, 398). The periodic bolus mode 
maintains the total daily dose but the basal rate is lowered while part of the 
total dose (15% to 20%) is infused via periodic boluses. Boster et al. stated 
that the consensus of expert clinicians with ITB practice recommended to 
divide the periodic bolus into four separate doses to be given in equal doses 
every 6 hours as the elimination half-life of the ITB ranges from 0.9-5.0 hours 
(161), Figure 3-10.   
Historically, one of the reasons for trying periodic bolus dosing was the 
feedback from individuals who had an improvement in their muscle tone after 
ITB pump implantation, but they did not feel as good as when they had 
received their trial bolus dose (396). 
 
Figure 3-10 An example of periodic bolus dosing in 24 hour 
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boluses to simple continuous dosing (399). In addition, the pulsatile ITB bolus 
infusion could cause an increase in the fluctuations of ITB concentrations over 
time around the catheter tip. These fluctuations may induce receptor 
resensitisation, which could explain the reduction of the overall daily dose of 
ITB (178, 394).  
3.4.8 Further work 
Trissel et al. in a patent (2013) have reported their attempts to prepare 
aqueous baclofen solutions at higher concentrations up to 6000 mcg/ml by 
direct dissolution in 0.9% sodium chloride injection. They increased the 
solubility of baclofen in the solution by using either high temperature or 
changing the pH (by acidification or alkalisation) and back titration of the 
solution after producing the compound. They have claimed that a solution of 
baclofen at concentrations ranging from 3000mcg/ml up to 4000 mcg/ml is 
stable for at least 60 days at 37°C (387).  
Current solution of IT baclofen utilises preservative-free normal saline as an 
excipient (182). However, the normal saline pH (roughly 5.5) (400) differs from 
that of the CSF (7.33) (401). Moreover, osmolality, concentration of inorganic 
salts, and the absence of glucose, protein, cholesterol, and other lipids, are 
other differences between saline and CSF (402, 403). This might cause 
potential adverse effect to the neural tissues and the subarachnoid 
space.(403-405). Recently, Meythaler and co-workers have attempted to 
develop a stable high concentration of ITB in a solution similar to the CSF. 
The artificial CSF solution is similar to CSF but without protein or bicarbonate, 
as the presence of bicarbonate (HCO3) in the artificial CSF might cause shifts 
in the pH of the solution as it converts to CO2. Furthermore; CO2 bubbles can 
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develop inside the pump can affect pumping rate unpredictably (369). 
Meythaler et al. were able to manufacture IT baclofen 4 mg/ml formulation that 
remained stable after 18 months in the artificial CSF solution (369). In 
addition, they claim that the artificial CSF may also be less toxic to the CNS 
tissue (369), in comparison to normal saline that could cause possible harmful 
effects on CNS cells (403-405). 
In another study, the role of microspheres coated in baclofen, administered as 
a gel, was examined as an alternative vector of baclofen delivery. This new 
method may enable delivery of higher baclofen concentrations than the 
currently available products (183, 406). 
3.4.9 Study Limitations 
This is a quality control study of the refill practice in Nottingham University 
Hospitals. It assessed only one source of compounded baclofen that has been 
used for more than 10 years. We did not assess other sources of 
compounded IT baclofen at higher concentrations. 
Thus, the results of this study are neither applicable to the quality of ITB from 
other compounding suppliers, nor establish the general standards for both 
commercial and compounded products. 
The number of the commercial ITB samples is relatively small in comparison 
to the compounded group. In addition, other pharmaceutical features such as 
pH, ionic strength, osmolality, specific gravity and density of the solution were 
not examined. 
This study is liable to selection bias as we did not retrieve and examine all 
samples from ITB pumps that were refilled by compounded ITB 3000mcg/ml 
concentration.     
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3.5 CONCLUSIONS 
We report a quality control study on the 3000 mcg/ml concentration of ITB 
used at NUH for treatment of severe spasticity in children. 
1. The study showed that commercial ITB concentration is more 
accurately matching the label in comparison to compounded baclofen. 
However, the compounded baclofen concentration is still in a 
satisfactory range. 
2. We found that baclofen concentration can change inside the ITB pump 
especially after a long duration.  
3. Commercial baclofen is more liable to degradation compared to the 
compounded one. 
4. The number of particles in compounded solution is higher than the 
commercial product. However, it is still in an acceptable range.  
5. There was no significant correlation between baclofen degradation, and 
particulate formation.  
6. Both commercial and compounded products are safe regarding sterility 
for intrathecal injection. 
7. Although we did not find any clinical or device complications related to 
compounded baclofen, it could have a potential risk of pump failure or 
catheter obstruction due to its greater number of particulates in 
comparison to the commercial baclofen. 
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4.1 Introduction 
4.1.1 Health and Quality of Life Outcomes 
Health outcome was defined by Donabedian (1985) as “a change in patients' 
current and future health status that can be attributed to precedent health 
care” (407, 408). Traditional outcome measures include: symptoms and pain 
relief, adverse reactions, survival data, morbidity and mortality ratios, and 
other indicators such as laboratory and diagnostic tests‟ results. These 
outcome measures are conventionally the main endpoints in clinical trials and 
they gained themselves a reputation of being objective or „hard data‟ (409). 
On the other hand, clinical trials do not usually include patients‟ self-reported 
health status as it is considered subjective or „soft data‟ (410). However, 
measuring the patients‟ perception of their well-being may be the most 
important health outcome measure especially in those diseases where there is 
no known cure, yet the experience of having the disease can be dramatic. 
Neurological diseases fall into this category. For instance, for patients with 
CP, the negative emotional feeling could be prevented or reduced if health 
related quality of life issues are considered in their management plans (411).  
Over the last 20 years, there has been a rapid increase in the development 
and use of quality of life (QOL) evaluations in an effort to enhance patients‟ 
health and determine the value of healthcare services (412, 413). 
Consequently, inclusion of QOL measurements in clinical trials has become a 
priority. Different clinical trial groups such as the U.K. Medical Research 
Council (MRC), National Cancer Institute of Canada (NCIC), and the 
European Organization for Research and Treatment of Cancer (EORTC), 
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suggested that QOL should be considered as an endpoint in all new trials 
(414). 
In 1994, in order to organise quality of life research, the World Health 
Organization (WHO) proposed the following definition: “an individual‟s 
perception of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, 
standards and concerns”(415). The QOL concept is shaped by five domains 
involving all aspects of the human condition: 1) physical status and functional 
abilities; 2) psychological status and well-being; 3) social interactions; 4) 
economic and/or vocational status and; 5) spiritual status (416). 
Health related quality of life (HRQOL) is considered to be a sub-domain of the 
overall concept of QOL (417, 418). HRQOL has been defined as “the 
functional effect of an illness and its consequent therapy on a patient, as 
perceived by that patient” (416).    
4.1.2 Relationship between quality of life and functional assessments in 
children with cerebral palsy 
The concept of intervention outcomes was changed after the publication of a 
new model for specifying function and disability by the World Health 
Organization (WHO), known as the International Classification of Functioning, 
Disability and Healthw (ICF) (419). So physicians became more interested in 
functional outcomes than improving the motor milestones such as range of 
                                                 
 
wAccording to the ICF, a person‟s functioning is a result of dynamic interactions of three 
dimensions with the environment. The three dimensions are (1) impairments of body 
structures or body functions; (2) activity limitations such as difficulties in performing a specific 
task or lacking the skills required for everyday living; and (3) participation restrictions with 
respect to social roles. Furthermore, the ICF addresses the effect of personal and 
environmental contextual factors on the three dimensions. Current literature on disability 
research highlights the importance of addressing performance enhancement in all three 
dimensions of the ICF (i.e., function, activity, and participation) (419).  . 
Chapter 4                       Long Term Effect of ITB on Functional Status and Quality of Life 
 
 
152 
motion (ROM), decrease in muscle tone, or optimising other physiological 
measures (420). In recent studies, children‟s feeling about their capability to 
achieve daily activities has been considered in the assessment of functional 
disability. Measuring how people feel about aspects of their lives directly 
related to health is known as health-related quality of life (HRQOL) (421). The 
difference between functional and HRQOL measurements can be examined 
by the example of children who have the same functional disabilities, who do 
not have the same experience of QOL. The patient‟s self-assessment and 
perception of their personal HRQOL may be considerably different from the 
judgment of healthcare staff. Therefore, it is important to measure HRQOL 
from the patients‟ perspective (412, 413, 422). 
Generally, the measurement of HRQOL aims to give a more detailed picture 
about the patient‟s status that is complementary to the conventional effort of 
the physician to describe specific functional assessments (421).   
4.1.3 Reasons for measuring QOL in children with CP  
“Measurement is the first step that leads to control and eventually to 
improvement. If you can’t measure something, you can’t understand it. If you 
can’t understand it, you can’t control it. If you can’t control it, you can’t improve 
it.”    H James Harrington (423, 424). 
Currently, there are a number of rationales to include HRQOL in clinical 
research and practice. Firstly, children with advanced CP usually undergo 
different health interventions to enhance their quality of life and to facilitate 
their caregiving. These interventions are resource-intensive. So, it is 
necessary to evaluate these interventions using outcome measures that are 
more purposeful to the children and their caregivers (425). Secondly, HRQOL 
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can correspondingly be used to establishing clinical guidelines, and in 
economic evaluations alongside clinical trials to assess the cost-effectiveness 
of new health technologies (426). Lastly, studying HRQOL in long-term 
survivors of children with CP can detect unnoticed long-term ongoing 
problems even after intervention especially late problems of psychosocial 
adaptation (427). 
In addition it can be utilized as an early predictor of survival in these patients 
(428-432) and a guide to appropriate alteration in management according to 
the patient‟s status (433-436).  
4.1.4 Challenges in Measuring HRQOL in Children with Disabilities 
Measuring HRQOL in children with severe developmental disabilities is 
challenging due to their inability to communicate. This leads to relying on 
parents or caregivers to report their perception of their child‟s quality of life 
(437).  
4.1.5 Quality of life measuring instruments 
Quality of life measuring instruments are either generic or condition-specific 
scales. Generic scales are designed to be applicable in general populations or 
through populations of people with varied conditions (438). They are not 
convenient to assess the effectiveness of intervention for a specific disability 
as they do not comprise domains that are specific to the condition. Hence, if a 
child with CP completed a generic HRQOL instrument, the scores might not 
completely capture the real quality of life because some important domains 
that have an influence on his or her life (such as pain, discomfort, and 
communication) would not be evaluated (439). For instance, the Child Health 
Questionnaire (CHQ) is a widely used generic instrument which has been 
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utilised to assess HRQOL in CP (440). However, the physical function items 
within the CHQ were not pertinent to children with severe CP (421). 
On the other hand, condition-specific instruments are designed to be 
applicable to one specific disease, and they are tailored to detect subtle 
features of this disease. They also evaluate small changes following any 
intervention and determine factors associated with it (441). Caregiver 
Questionnaire (CQ) is a disease-specific instrument that was designed by the 
Rehabilitation Institute of Chicago (USA), for evaluation of quadriplegic CP 
children who had undergone selective dorsal rhizotomy. Neither the reliability 
nor the validity of the CQ has been formally examined. In addition, it does not 
include several items related to the quality of life of severely disabled children, 
such as health, emotional and behavioural aspects (442, 443). 
Recently, four disease specific instruments have been designed to measure 
the QOL of children with CP. These include: the Caregiver Priorities and Child 
Health Index of Life with Disabilities (CPCHILD™) (443), the Paediatric 
Quality of Life Inventory (PedsQL) CP Module (444), the DISABKIDS CP 
Module (445), and the Cerebral Palsy Quality of Life Questionnaire-(CP QOL) 
(446). In a systematic review, Carlon et al. appraised the psychometric 
properties and clinical effectiveness of these new instruments. From points of 
reliability and validity, the ease of access, the free availability, and the time of 
completion, the CP QOL-Child and the CPCHILD™ were found to be the most 
appropriate measures to evaluate the QOL in CP children (447). 
Nevertheless, the validity and reliability were superior in CPCHILD™ than in 
CP QOL instrument (447). 
The WeeFIM® Instrument and Paediatric Evaluation of Disability Inventory 
(PEDI) are well known and are the most commonly recommended in 
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published literature for standardised assessment of functional disabilities in 
CP children (448-450). 
The PEDI was created to evaluate rehabilitation of children with disabilities 
between the ages of 6 months to 7.5 years. Three aspects are combined into 
the PEDI; functional skill level, amount of caregiver assistance and adaptive 
equipment used. A total of 237 items are administered by a trained individual 
that requires 45-60 minutes for completion (444). While the PEDI has been 
validated in the CP population (451), the large number of items included 
makes this a cumbersome instrument. Moreover, the PEDI is only valid in 
young children (younger than 7.5 years), and it also needs specialist training 
for administration (452). 
WeeFIM® is an evaluative measure of rehabilitation outcomes in children with 
severe disability. WeeFIM® was validated for use in CP children from the age 
of 0 to 18 years. Although WeeFIM® is a brief and easy instrument to 
administer (453), it requires specialised training and accreditation, in addition 
to the costs associated with using a copyrighted instrument (452).  
4.1.6 Measuring approaches to changes in HRQOL 
HRQOL responsiveness or change following intervention can be evaluated 
either by direct or indirect approaches. In the direct approach; the clinicians 
solicit the patient‟s judgment of the change directly, whether the symptoms 
improved, remained the same, or deteriorated (454, 455). 
In clinical research, the „indirect‟ measures of change are favoured. This is 
because the researchers measure the patient‟s status at different time points 
as for instance, before intervention and after intervention (pre-test to post-test 
measurement), then compute the change between the two tests (456, 457). 
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While this method is a common approach in QOL research, the „test then-test‟ 
or Quasi-experimental study (458, 459) has been designed as another indirect 
approach in an effort to reduce the response-shift phenomenonx which 
sometimes happens with ordinary indirect approach (460). In the „then-test‟ 
method, the patients are requested at one time point to rate their 
contemporary condition and also retrospectively rate their former status (455). 
Recall bias is a theoretical concern regarding the then-test approach. 
However in multi-item scales, the agreement between pre status and 
retrospective pre status (“then-test”) was remarkably high. Thus, recall bias 
did not appear to play a major role in this regard (455). 
4.1.7 Quality of life in patients with intrathecal baclofen therapy 
Since the introduction of ITB therapy as an effective treatment for spasticity, 
HRQOL has been examined as a clinical outcome of ITB intervention (460, 
461).  
Borowski et al. directly asked the patients or their caregiver about their 
satisfaction after receiving the ITB therapy. More than 85% of caregivers were 
satisfied and willing to recommend it to other patients (462). However, this 
evaluation was simple and subjective (462). In their study, Tassel et al. 
retrospectively assessed the effect of ITB therapy on HRQOL and showed 
that wheelchair comfort and nursing care improved after ITB therapy. Although 
this study covered several items of the activities of daily living, it used a 
subjective non-validated questionnaire (463). Vles et al., have prospectively 
evaluated HRQOL in 17 patients after implanting ITB pump, using CHQ and 
                                                 
 
x Response shift: is a subjective change of patients’ perceptions due to 
recalibration of their internal standard and values as a result of intervention 
(460). 
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Visual Analogue Scale (VAS), to assess parent satisfaction with ITB therapy. 
This study presented positive effects on pain, ease of care, emotional and the 
physical activities. Although this study was a prospective designed research, 
the sample was small and it did not correlate the results with other factors that 
might affect the outcome (440).    
4.1.8 Aim of the work 
This study aims to answer these questions:  
1. Does the HRQOL and functional status outcomes of CP children 
improve after ITB pump implantation?  
2. Which health related quality of life domain has good outcomes? 
3. Are the HRQOL changes related to functional improvement? 
4. What is the extent of responsiveness of functional status and HRQOL 
to ITB therapy? 
5. What are the determining factors that influence ITB outcomes? 
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4.2 Materials and Methods 
4.2.1 Patient Population 
Seventy five patients who received ITB therapy in Nottingham University 
Hospitals between January 2008 and January 2011 were recruited to evaluate 
the effect of ITB therapy on their HRQOL and functional status. The children 
were interviewed after at least one year of ITB implantation assuming that the 
child had achieved the therapeutic effect after titration of ITB daily dose. 
4.2.2 Study design 
This is a quasi-experimental study (test then-test approach) to evaluate the 
HRQOL and functional status outcomes of ITB therapy. The expected 
outcomes were the change in the total scores of each instrument. The study 
was conducted as an audit for service evaluation of routine practice in 
Nottingham University Hospitals (registered audit number 14-338C). 
4.2.3 Data collection setting 
The data were gathered via direct interview with patients or their caregivers 
after signing written consent. The interviews were conducted in the outpatient 
clinic during their routine visits for ITB pump refills. 
The demographic and comorbidity variables of this group of patients were 
collected retrospectively from their medical records. The method of data 
extraction and verification (including how the cases were ascertained, how the 
notes were retrieved, and the way of defining the comorbidities e.g. cognitive 
impairment and orthopaedic complications), are discussed in detail in chapter 
two. 
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4.2.4 Outcome Measurement tools 
The WHO developed the “International Classification of Functioning, Disability, 
and Health” (ICF) which is a classification scheme of health and functional 
disabilities. This is done by coding a wide range of information about health in 
an effort to utilise a consistent mutual language facilitating global 
communication about health and functional status. In addition, it allows for 
assessment and comparison of HRQOL instruments that measure outcomes 
after health intervention in disabled populations (458). The ICF Child and 
Youth version (ICF-CY) is geared towards children and young adults and is 
designed to be sensitive to changes associated with growth and development 
(464, 465). 
The ICF-CY has moved the focus of clinicians toward enabling the individual 
to overcome activity and participation restrictions. The most important feature 
of ICF-CY is that it is a classifier model instead of being hierarchical. For 
example, a person with limited functionality and activity might not encounter 
any problems in participation due to personal and environmental factors.  
ICF has two parts, each with two components:  
Part 1- Functioning and Disability which includes: 
Body functions and structures  
Body functions are the physiological functions of body systems (including 
psychological functions) while body structures are anatomical parts of the 
body such as organs, limbs and their components. Impairments are limitations 
in body function or structure that result in a significant deviation or loss of that 
organ or system (464). 
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Both body functions and body structures are classified in two different sections 
which are organised according to the body systems. These two classifications 
are designed for use in parallel. For example, body functions include basic 
human senses such as hearing and vestibular functions and their structural 
correlates exist in the form of  ear and its structures (464). 
Activities and Participation 
Activity is defined by WHO as the execution of a task or action by an 
individual, and activity limitations are difficulties in executing activities (464). 
Participation is defined as involvement in a life situation, and participation 
restrictions are problems an individual encounters in a life situation. Activity 
limitations often lead to participation restrictions and both are associated with 
disability (464). 
Activities and participation are given in a single section that covers the full 
range of life areas (from basic learning, communication and mobility to 
composite areas such as interpersonal interactions and social and civic life). 
Participation is a key construct of the ICF (464). Participation for children 
includes domains of learning and applying knowledge, communication, home 
life, school life, social life, relationships, and leisure and recreation. The ICF 
offers two qualifiers for activities and participation. These are: (1) capacity, 
which indicates the highest probable level of functioning that a child can do in 
a standardised environment, and (2) performance which is defined as how a 
child actually performs activities in everyday life situation and is measured in a 
person‟s current environment (464). Inconsistencies between children‟s 
capacity and performance are presumed to be due to environmental or 
personal „contextual‟ factors. Hence, differences in aspects of children‟s 
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participation have been attributed to movement, manual and intellectual 
abilities, and also to the environment in which they live (466).  
Capacity to perform an action only partially explains children‟s activity and 
participation. To focus on activity, rather than participation will divide people 
into groups based on disability type. Participation is something other than 
being able to perform activities. Persons, who are not capable of performing 
the activity (activity restrictions), can still participate, even if someone else, 
such as an assistant, performs the activity for them. The individual alone can 
determine his/her own level of participation (467). 
The ICF emphasises the level of an individual‟s health rather than disability 
level and presents participation as one of the main areas of a person‟s 
functioning, along with body structure, function and activities. Different areas 
such as communication, mobility, domestic life and social relationships 
comprise some of the elements of participation. These activities reflect how an 
individual functions within his or her environment in different life roles. 
Focusing on how they function in their close environment will provide more 
information about their health and well-being than focusing on the diagnosis, 
degree and type of disability as characteristics for participation and health 
(468). 
Part 2: Contextual Factors which include: 
Environmental factors:  
Environmental factors constitute the physical, social and attitudinal 
environment in which people live and conduct their lives. These factors are 
external to individuals and can have a positive or negative influence on the 
individual‟s performance as a member of society. 
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The categories listed under environmental factors include: (i) products and 
technology, (ii) natural environments and human made changes to 
environment, (iii) support and relationships, (iv) attitudes, and (v) services, 
systems and policies. 
Personal factors:  
Personal factors are the particular background of an individual‟s life and living, 
and comprise features of the individual that are not part of a health condition 
or health states. These factors may include gender, race, age, other health 
conditions, fitness, lifestyle, social background, education, profession, past 
and current experience (past life events and concurrent events), overall 
behaviour pattern and character style, individual psychological assets and 
other characteristics, all or any of which may play a role in disability at any 
level (464, 469). 
The current study was based on the ICF model dimensions to identify the level 
of activities and participation and the level of body functions, Figure 4-1 
illustrates the items to be assessed according to the ICF-model of CP. 
CPCHILD™ was utilised to assess the impact of ITB therapy on HRQOL, and 
the Paediatric Functional Independence Measure (WeeFIM) was applied to 
assess the functional outcomes. Both of these instruments were selected due 
to their established responsivenessy (443, 470), reliabilityz (443, 471) and 
validity (443, 471). 
 
                                                 
 
y Responsiveness is sensitivity to change or ability to discover alterations over time.  
z Reliability is ability of the measurement to produce the same results when repeated in the 
same population. Validity is the ability of the measurement to assess what it intends to 
measure e.g. functional status. 
 
 
Figure 4-1   Illustration of the assumed assessment procedure according to the ICF-model 
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Health Condition 
Cerebral Palsy 
Activity limitation 
Difficulty learning, walking or play 
 
Participation restriction 
Difficulty in communication and 
engaging with his peers 
 
 
Environmental 
Support from family and school 
Physical environment and accessibility 
Environment 
e325 Acquaintances, peers,  neighbours and 
community  
CPCHILD, 
WeeFIM 
e310Family support WeeFIM 
e150Design, construction and building 
products and technology of buildings for 
public use 
WeeFim 
e5800 health sevices CPCHILD 
e1101 drugs  CPCHILD 
e1201 Assistive products and 
technology for personal indoor and 
outdoor mobility and transportation 
WeeFIM 
 
Personal 
Attention and cognitive motivation,  
Understanding disability 
Body structure and function 
x Abnormal and asymmetric hands muscle tone, 
joint deformities and Spasticity  
x Deficit in fine motor coordination 
x Cognitive impairment 
Body structures and functions 
b2 Sensory functions and pain CPCHID 
b152 Emotional functions:  CPCHILD 
b280 Sensory functions and pain CPCHILD 
b156 Perceptual functions 
b144Memory functions 
CPCHILD 
WEEFIM 
b144 Memory functions CPCHILD 
WEEFIM 
b525Defecation functions CPCHILD 
WEEFIM 
b620  Urination functions 
s6102Urinary bladder 
WEEFIM 
 
Activities and participation 
d530 Eating    CPCHILD WeeFIM d175 Solving problems CPCHILD WEEFIM 
d510 Washing oneself CPCHILD WeeFIM d450 walking CPCHILD WEEFIM 
d540 Dressing CPCHILD WeeFIM d4602 Moving out and inside 
buildings 
CPCHILD 
d530 Toileting CPCHILD d4600 Moving around within 
the home 
 
CPCHILD  
d420 Transferring oneself 
d4200 Transferring oneself while sitting 
CPCHILD WeeFim d4601 Moving around within 
buildings other than home 
CPCHILD 
d310-d329 Communicating - receivin 
 
CPCHILD d920 Recreation and leisure CPCHILD 
d330-d349 Communicating - producing 
 
CPCHILD WEEFIM d9201 Sports CPCHILD 
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4.2.4.1 WeeFIM®  
WeeFIM® is the child version of Functional Independence Measure (FIM), 
which was designed by the National Task Force for Medical Rehabilitation to 
assess functional independence of severely disabled adults. Its aim was to 
track the rehabilitation progress in patients with acquired disability as in spinal 
cord injury and traumatic brain injury patients. WeeFIM® consists of 18 items 
that were designed to evaluate the ability of the child to perform the main 
functional skills, not to evaluate the impairment, and to follow the outcome 
changes across health interventions. The 18 items are categorised into three 
main areas; self-care, mobility, and cognition. These domains comprise all 
developmental features. WeeFIM® assessment can be attained either by 
interview or by direct observation of the patient performing the tasks 
according to standard criteria (453).  
The „Self-care‟ domain consists of 8 items: eating, grooming, bathing, 
dressing the upper body, dressing lower body, toileting hygiene, and 
maintaining sphincter control of both bladder and bowel in two separate items 
(453). „Mobility and locomotion‟ includes five items: transferring (changing 
position) from chairs, toilet seats and tubs, walking indoors and outdoors, self-
mobility (crawl or wheelchair), and using stairs (453). „Cognition‟ domain is 
includes five items: language comprehension, expression, social interaction, 
problem solving, and memory retention (453). The minimum score is 18 and 
the maximum score is 126 (453, 472). 
WeeFIM® rating scale is very concise. It is seven levels of specific ordinal 
criterion which classifies the functional status into two categories; 
independent and dependent. The higher level of independence is level seven 
where the child does not need assistance to achieve the task without any 
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equipment. At level six, the child can achieve the task independently but 
needs aiding equipment, or there is a concern to complete it safely or in time.  
The dependent category lies from level 1 - 5 and the patient needs partial to 
full assistance to complete the task. At level five, the patient needs 
supervision. At level four the patient can do more than 75% of tasks but 
needs minimal physical contact or promotion. At level three, the child can 
achieve 50-74% of the task with moderate contact assistance, achieving 
between 25-49% with maximal contact assistance is scored level 2, and the 
complete dependency (effort less than 24%) with total support is level one.  
WeeFIM® has several advantages, i) it is a less time consuming measure 
requiring 20-30 minutes to carry out, ii) its validity and reliability have been 
examined for use in severely disabled children with CP, and iii) the 
administrator needs to be trained and certified before starting to interview the 
patients to ensure consistency in the rating process (473). 
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4.2.4.2 CPCHILD™ 
The CPCHILD™ is a disease-specific measure that was designed to assess 
and trace the change of HRQOL in children with severe CP disability after 
health intervention from the perspective of their caregivers (443). It contains 
37 items covering six domains: Personal Care; Positioning, Transferring and 
Mobility; Comfort and Emotions; Communication and Social Interaction; 
Health issues; and Overall quality of life (443). Each CPCHILD™ item is rated 
in two aspects: the degree of difficulty to achieve the task which is graded on 
a 7-point ordinal scale from zero as impossible to 6 as no problem. Then the 
level of assistance from the caregiver is graded on a 4-point ordinal scale 
rated zero as totally dependent to 3 which is completely independent. The 
minimum score of each item is zero and the highest score is 9. However, in 
the comfort and emotions domain, the rating of the level of assistance 
modifier aspect is omitted due to the difficulty to interpret by the caregiver and 
only rating is zero through 6. In the Comfort and Emotions domain, the 
maximum score is 8 only (474).  
It is noteworthy that test re-test reliability of CPCHILD™ is high. The 
Intraclass Correlation Coefficient (ICC) for the overall score is 0.97 (95% CI: 
0.95-0.99). The ICC range of the main 6 domains ranged from 0.88 to 0.96 
(443). 
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4.2.5 Statistical analysis 
1- Paired sample t- test was used to compare changes between pre-
implantation and post-implantation scores for each instrument. 
2- To compare the responsiveness of both CPCHID and WeeFIM® to ITB 
therapy, the effect size (Cohen‟s d score) was calculated  
d                                                                                           
 
Pooled (SD) =               
                 
  
A Cohen‟s d score of zero means that the intervention has no effect. The 
effect is considered small if Cohen‟s d is between 0.2 and 0.5, moderate 
between 0.5 to 0.8, and large if more than 0.8 (475, 476). 
3- Multivariate linear regression analysis was used to determine the influence 
of independent variables (such as cognitive state, orthopaedic deformities, 
age of the patient, and epilepsy) in the evolution of each outcome. 
SPSS 21 for Windows was used for data analysis. Gardner‟s Effect Size 
Illustrator (version 1.1) was used to calculate Cohen‟s d scores (477). 
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4.3 Results 
The data set includes 75 patients with ITB pump implantation performed 
between January 2008 and January 2011. They were interviewed by one 
investigator (AA) to assess the outcomes of ITB therapy on HRQOL and 
functional status. Participant demographic characteristics are summarised in . 
Table 4-1. 
Table 4-1 General characteristics of the subjects in this study (N=75). 
Age at implantation 10.8 (3.5-18) SD± 4.325 
Sex 
Male 
Female  
 
51 
24 
Indication of ITB pump 
implantation: 
CP 
Primary dystonia 
Hereditary paraplegia   
 
 
71 
 2  
 2  
Cognitive status 
Intact  
Fair  
Impaired  
 
10 
24 
41 
Associated epilepsy 37/75 (49%) 
Visual impairment 14/75 (18%) 
Orthopaedic deformity  36/75 (48%) 
VP shunt 7/75 (9%) 
Injection of Botulism 27/75 (36%) 
 
4.3.1 Changes in health-related quality of life outcomes (CPCHILD™)  
There was an overall improvement in HRQOL measurement after 
implantation of ITB therapy. All aspects of CPCHILD™ instrument revealed a 
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significant difference between baseline and post-implantation. Radar plotsaa 
illustrate the changes that occurred in each subclass of the main domains of 
CPCHILD™ instrument. 
 
Figure 4-2 Changes after implantation in personal care and ADL domain 
(CPCHILD™). 
 
Figure 4-2 illustrates the difference between pre-implantation and post-
implantation scores. Each spoke on the plot represents an individual subscale 
of personal care and ADL domain. Changing diapers, eating and dressing 
were the most responsive items in this domain. Total change of personal care 
domain was ≈ 19%, representing the second most significant change after 
comfort and emotions domain from improvement aspect. 
  
                                                 
 
aaPlots are read from the center outward along each spoke. Scores are shown on 
concentric circles beginning with 0 at the center and increasing toward outer line  
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Figure 4-3 Changes after implantation in mobility and transferring domain 
(CPCHILD™). 
 
Figure 4-3 shows the changes in mobility and transferring domains and its 
individual subscales after implantation. Transferring in/out of bed, transfer 
from a wheelchair and getting in/out of the vehicle showed the most 
prominent improvement after implantation. However standing was the least 
affected by ITB therapy. There was an overall moderate change of ≈17% in 
the entire domain. 
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Figure 4-4 Changes after implantation in comfort & emotions domain (CPCHILD™)  
 
Figure 4-4 represents the changes in comfort and emotion domain. There 
was a uniform large improvement across all subscales. From the plot, it can 
be noticed that the comfort and emotion domain has the greatest change 
across all CPCHILD™ domains ≈ 22 %. 
 
 
0
10
20
30
40
50
60
70
Eating and
drinking
During toileting
While dressing
Transfer position
While seated
In bed
Sleep
disturbance
Agitation
Sad
Total comfort
domain
Post implantation
Preimplantation
Chapter 4                     Long Term Effect of ITB on Functional Status and Quality of Life  
 172 
 
Figure 4-5 Changes after implantation in communication & social interaction domain 
(CPCHILD™) 
 
Figure 4-5 shows the changes across the communication and social 
interaction domain. Communication with caregiver and playing with others are 
the most prominent items before and after implantation. Nevertheless, there 
was a consistent mild change through this domain by 15 %. 
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4.3.2 Which domain has the best outcome? 
 
 
Figure 4-6 Changes after implantation in main domains and total score of 
CPCHILD™ 
 
The radar plot in Figure 4-6 revealed the changes throughout all 
CPCHILD™domains. From the graph, the ITB response was maximal in the 
comfort and emotions domain 22%, followed by self-care ≈19%, mobility 
≈17%, communication ≈12%, while the least change was observed in the 
overall health domains 10%. Similar score gains were detected in the quality 
of life domain. The overall change in CPCHILD™ was 16%. 
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Generally, the pre-implanting and post-implanting scores were around 40 and 
60 % of normative value, and the changes were approximately 20 %, Figure 
4-7. 
 
Figure 4-7 Graph comparing the CPCHILD™ scores in each domain, pre and post 
implantation and compared with normative values of the CPCHILD™ instrument 
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4.3.2.1 Student‟s t- test for changes in CPCHILD™ scores 
The paired sample Student's t-test revealed a significant difference between 
pre-implantation and post- implantation measures in all CPCHILD™ domains. 
Post-implantation score represents the change in total CPCHILD™ 
(mean59.5: SD 14.7) from pre-implantation score (Mean: 42.9 SD± 14.4), 
t(74): 20.5 and p<0.05, Table 4-2. 
Table 4-2 CPCHILD™ mean of pre and post implantation measures and results of 
Student‟s paired t- test between the two scores 
 Pre-
implantation 
mean ±SD 
Post-
implantation 
mean ±SD 
Difference 
of mean 
95% CI 
t- value P value 
Personal care 
and ADL 35.25±14 54.78±15 
19.8 (15.1 
- 24.5) 16.896 <0.001 
Positioning, 
transferring, 
locomotion  
31.50±15.7 48.455±16.7 16.9 (7.7 - 18.2) 12.746 <0.001 
Comfort and 
emotions 43.24±16.14 65.51±13.14 
22.3 (17.5 
- 26.9) 16.945 <0.001 
Communication 
and participation 44.53±20.9 59.36±25.15 15.2 (4.3 - 40.4) 11.984 <0.001 
Health status 
56.45±18.27 67.46±16.5 
11.01(-
20.3 - 
16.6) 
10.115 <0.001 
Quality of life 43.73±17.18 60.26±19.7 16.5 (10.1 - 21.9) 10.723 <.001 
Total 
CPCHILD™score 42.9±14.43 59.49±14.7 16.53 (0.5 - 43.3) 20.500 <0.001 
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4.3.3 Functional status outcome (changes in WeeFIM® score) 
WeeFIM® measurements showed improvement after ITB implantation. 
Figures (4-8 to 4-10) represent the results of the three main WeeFIM ® 
domain and their sub-items.   
4.3.3.1 Self-care Domain  
 
 
Figure 4-8 Changes in Self-care domain (WeeFIM ®). 
 
 
 
 
Figure 4-8 shows a radar plot of changes in the self-care domain after 
implantation. The mean score increased from 16.98 SD± 1.45 preoperatively 
to 20.73 SD± 1.32 postoperatively (3.75 points improving is equivalent to a 
5.7% compared to normative value). All subscales showed uniform 
improvements, 5 points in eating, 4 points in grooming, bathing, dressing the 
upper limbs, toileting and bowel management, and lastly 3 points in dressing 
lower limbs and bladder management.   
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4.3.3.2 Change in mobility domain 
 
 
Figure 4-9 Changes in mobility domain (WeeFIM II®). 
 
The pre-operative WeeFIM II® score increased from 10.2, SD±0.75 to 12.4, 
SD±0.98 postoperatively (2.12 points equivalent to 6% from normative value). 
Transferring from chairs, toilet and tub or shower represented the biggest 
improvement in this domain by 3 points, then walking and climbing stairs by 1 
and 2 points respectively, Figure 4-9.  
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4.3.3.3 Changes in cognition domain 
 
 
Figure 4-10 Change in cognition domain (WeeFIM II®) 
The radar plot in Figure 4-10 represents changes in cognitive function after 
implantation. The total mean score increased from 14.4 SD±1.4 
preoperatively to 17.2 SD±1.7 postoperatively (2.8 point improvement that 
equivalent to 7.7% of normative value=35). Social interaction subscale 
revealed the best improvement by increasing 4 points, and the remaining 
subscales increased by 3 points. 
In general, the value of WeeFIM scores (pre- and post-implantation), were 
low in comparison to normative value, Figure 4-11. 
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Figure 4-11: Values of WeeFIM II® scores compared to normal  
4.3.3.4 Student‟s t- test for changes in WeeFIM scores.  
The overall average of WeeFIM II® score increased from 42.01 SD±21.07 
preoperatively to 50.5 SD±28.46 postoperatively. The paired sample t–test 
result was significant (p<0.001), Table 4-3.   
Table 4-3 WeeFIM mean of pre and post implantation measures and results of 
Student‟s paired t- test between the two scores 
 Pre-
implantation 
mean ±SD 
Post-
implantation 
mean ±SD 
Difference in 
mean 95%CI t P value 
Self-care 16.75±1.3 20.75±1.2 3.70 (0.05 - 6.13) 6.534 <.001 
Locomotion 
and 
transferring 
10.38±5.61 12.51±7.80 2.12 (-0.243 - 4.103) 5.786 <.001 
Cognitive 
function 14.46±8.13 17.27±9.23 
2.81 (0.15 - 
5.41) 9.300 <.001 
Total Score 42. ±21.07 50.5±28.46 8.62 (0.17 -16.20) 8.900 <.001 
personal
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4.3.4 Responsiveness extent (effect size measurment) of health related 
quality of life (CPCHILD™) and functional status (WeeFIM II®)  
 
Measuring the effect size, between pre- and post-implantation scores to 
distinguish the response effect of CPCHILD™and WeeFIM II® instruments, 
revealed:  
4.3.4.1 CPCHILD™ 
The responsiveness of the CPCHILD™ instrument was moderate to large in 
CPCHILD™ individual domains (Cohen‟s d range 0.5-1.5). The largest 
response effects were in self-care and comfort domains (>1.3), followed by 
the total CPCHILD™ score (Cohen‟s d: 1.14). The lowest effect was in the 
communication domain, Table 4-4. 
Table 4-4 Effect size of each domain of CPCHILD™ questionnaire 
CPCHILD™domain Cohen‟s d 
(effect size) 
p-value 
Self-care  1.36 0.001 
Positioning 1.05 
 
<0.001 
Comfort 1.52 <0.001 
Communication 0.50 0.002 
heath 0.64 <0.001 
Quality of life 0.90) <0.001 
Total score of 
CPCHILD™™ 
1.14 <0.001 
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4.3.4.2 WeeFIM® 
The response effect of ITB on functional status (as measured by effect size of 
change in WeeFIM®) shows a small effect in all domains (Cohen‟s d range 
0.28-0.32) and in the total score (Cohen‟s d: 0.32.), Table 4-5.  
An interesting observation driven from the aforementioned results is that the 
ITB effect on HRQOL is larger than its effect on functional status. 
 
Table 4-5 Effect size of each domain in WeeFIM® 
WeeFIM II® domains Cohen‟s d (effect 
size)  
p-value 
Self-care 0.339  p = 0.039 
Mobility and transferring 0.316  p = 0.055 
cognition 0.326  p = 0.065 
Total Score of WeeFIM 
II® 
0.371 p = 0.049 
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4.3.5 The relation between HRQOL and functional status 
Significant correlations were found between pre-implantation status of 
CPCHILD™ and WeeFIM scores (r=0.829 p=<.001), as well as their post 
implantation scores (r=0. 785 p <001). However, no significant correlation (r 
=0. 217 and p=0. 061) was found between the changes of HRQOL (total 
gained score of CPCHID) and functional state (total gained score of 
WeeFIM), Table 4-6.  
Table 4-6 The Spearman‟s rank correlation coefficients between CPCHILD™ and 
WeeFIM® instruments 
Parameters tested   Pearson 
Correlation  
Significance  
(2-tailed) 
Correlation between Pre-implant 
WeeFIM score and Pre CHCHILD 
scores 
0.829** 
 
<0.001 
 
Correlation between Post Implant 
WeeFIM and  Post implant 
CPCHILD™ scores 
0.785** 
 
< 0.001 
 
Correlation between the gained 
WeeFIM and gained CPCHILD™ 
score 
0.217 
 
0.061 
 
4.3.6 The relationship between functional baseline and changes in 
HRQOL aspects 
The correlation between the gained scoresbb of individual CPCHILD™ 
domains and the pre-implant WeeFIM individual scores (a baseline of 
functional state) revealed a significant positive correlation between cognitive 
domain and the change in communication and social participation domain in 
CPCHILD™ (r=0.416 p=<0.001), personal care domain (r=0.337 p=0.003), 
and locomotion and transferring (r=0.319 p=0.005).  
                                                 
 
bb Gained score= postimplant score – preimplant score 
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Moreover, a significant positive correlation was found between mobility 
domain (in WeeFIM score) before implantation and changes in personal care 
domain, and locomotion and transferring domain in CPCHILD™ instrument 
(r=0.31 p 0.007) and (r=0.253 p=0.023), respectively, Table 4-7. 
Table 4-7 Spearman‟s rank correlation coefficients between CPCHILD™ gained 
scores and pre WeeFIM II® instruments 
Gained score of 
CPCHILD™ 
domains 
 
Pre 
self-
care 
function 
WeeFIM 
Pre 
Mobility 
function 
WeeFIM 
Pre 
Cognitive 
function 
WeeFIM 
Pre 
Wee 
FIM 
Total 
Score 
Personal care r value 0.226 0.310
** 0.337** 0.320** 
p value 0.051 0.007 0.003 0.005 
Locomotion 
and transferring 
r value 0.249* 0.253* 0.319** 0.295* 
p value 0.031 0.028 0.005 0.010 
Comfort and 
emotion 
r value -0.195 -0.255* -0.311** -0.279* 
p value 0.093 0.027 0.007 0.015 
Communication 
and 
participation 
r value 0.307** 0.334** 0.416** 0.382** 
p value 0.007 0.003 0.000 0.001 
health r value -0.146 -0.132 -0.213 -0.177 P value 0.211 0.258 0.066 0.128 
Overall QOL r value 0.198 0.211 0.092 0.178 p value 0.088 0.069 0.430 0.127 
Total score of 
CHCHILD 
r value 0.153 0.173 0.147 0.170 
p value 0.189 0.138 0.208 0.145 
r: correlation coefficient 
** significant  at 0.01 
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4.3.7 Predicting factors of HRQOL and functional status 
4.3.7.1 HRQL predicting factors (CPCHILD™ changes) 
Multivariate linear regression analysis for CPHCILD™ model revealed that 
epilepsy is a negative predictive factor for HRQOL improvement. Interestingly, 
the total functional state before implantation (pre-implant WEEFIM score) was 
not significantly related to change in CPCHILD™ Score, Table 4-8. 
Table 4-8 Multivariate linear regression analysis of post-implantation changes in 
CPCHILD™ total score 
Coefficientsa 
Model 
Unstandardised 
Coefficients 
Standardised 
Coefficients t p value Beta Std. Error Beta 
 
orthopaedic 
complications -0.894 2.416 -0.051 -0.30 0.713 
Epilepsy -8.783 3.826 -0.499 -2.29 0.025* 
FIM Pre-
cognition -0.511 0.374 -0.474 -1.46 0.176 
FIM pretotal 1 0.076 0.124 0.182 0.60 0.545 
implant age/m 0.012 0.020 0.071 0.61 0.541 
V-P shunt -0.472 3.489 -0.016 -0.13 0.893 
Visual 
impairment -0.339 2.404 -0.018 -0.141 0.888 
Sex -4.010 2.145 -0.214 -1.83 0.066 
a. Dependent Variable: Difference in CP child score 
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4.3.7.2 Functional status predicting factors (WeeFIM change) 
Multivariate linear regression analysis showed that good cognitive state and 
absence of orthopaedic complications were significant predicting factors of 
WeeFIM score gains (p=value 0.006 and 0.004, respectively), Table 4-9. 
Table 4-9 Multivariate linear regression analysis of post-implantation changes in 
WeeFIM total score 
Coefficientsa 
Model 
Unstandardised 
Coefficients 
Standardised 
Coefficients t p value 
Beta Std. Error Beta 
1 
(Constant) 10.507 7.159  1.468 0.147 
Sex -1.868 1.538 -0.099 -1.214 0.229 
Visual 
impairment -0.667 1.709 -0.034 -0.390 0.698 
V-P shunt -0.054 2.497 -0.002 -0.022 0.983 
botox injection 0.708 1.403 0.041 0.504 0.616 
epilepsy -0.574 1.663 -0.032 -.0345 0.731 
Presence of 
orthopaedic 
complication 
-7.533 2.505 -0.415 -3.0 0.004 
WeeFIM Pre-
cognition 0.440 0.154 0.405 2.851 0.006 
implant age/m -0.004 0.014 -0.020 -0.251 0.802 
a. Dependent Variable: total Difference 
a. Dependent Variable: WeeFIM change 
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4.4 Discussion 
Evaluating outcomes is the sole method of assessing the effectiveness of 
health interventions and quality of services. HRQOL measurement in CP 
research is more informative than other clinical measures, which do not 
express the wellbeing of children and their caregivers. This chapter has 
focussed upon the impact of ITB on the patients‟ HRQOL and functional 
status. These were assessed by using two standardised measures (WeeFIM 
and CPCHILD™) of evaluating quality of life for children with CP. We have 
shown that using WeeFIM and CPCHILD™ described the positive impact of 
ITB upon different domains of quality of life.  
The baseline (pre-implantation score) scores of CPCHILD™ and WeeFIM 
(42.3 and 41, respectively) were slightly less than the expected values 
reported in the instruments‟ manuals. The CPCHILD‟s manual reported the 
total scores of severely disabled CP patients lie between 44.4 ±8.1- 56.3±12. 
In this cohort the baseline score was 42.3. WeeFIM total score in quadriplegic 
CP patients was reported as 43 ± 23 in a pilot study by Marshall et al. (453). 
However, in the current study the WeeFIM baseline scores was 41. This 
difference possibly indicates the higher severity of CP in this cohort.  
4.4.1 Effectiveness of ITB on HRQOL and functional status 
Intrathecal baclofen therapy showed significant improvement in HRQOL 
through increasing all domains of CPCHILD™ as well as its total scores. The 
best improvement was shown in the comfort and emotional domain which 
correspond with the previous findings reported by Gooch et al. However, they 
used a non-validated questionnaire to score the comfort and pain relief (225). 
Hoving et al. used generic instrument (CHQ-PF50) in a randomised controlled 
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study to report the ITB therapy effects. They stated that relief of pain and 
discomfort was the most responsive items in CHQ-PF50cc questionnaire to 
ITB therapy in comparison to the control group (457). 
This improvement in comfort and relief of pain is critical in these patients as 
more than 60% of them usually experiences pain and discomfort, particularly 
during sleep. In addition, patients also sit for extended periods of time in the 
same position (478, 479). 
The next significant improvement after ITB therapy was observed in the self-
care and mobility domain which matches previous findings. Awaad et al. 
described ITB therapy benefits in self-care and mobility domains of the PEDI 
instrument especially in patients with high pre-implantation scores (285). This 
also correlates with another study by Ward et al, using the Canadian 
Occupational Performance Measure (COPM) and goal attainment scaling 
(GAS), who showed the improvement in these domains especially positioning 
and transfers (266). In contrast to these findings, Hoving et al. in an RCT 
found no significant change in either the PEDI or GMFM scores that 
evaluated self-care and mobility (457). Similarly, Campbell et al. showed no 
GMFM improvement after ITB therapy and the PEDI only showed small 
changes in patients‟ mobility (209).  
The health domain is unique for CPCHILD™ questionnaire, and is the most 
objective domain in this instrument as its score depends on frequency of 
hospital visits and number of medications. In the current study, the 
                                                 
 
cc The Child Health Questionnaire™ (CHQ) is a family of general quality of life surveys that 
have been designed and normed for children from 5-to-18 years of age. The parent form is 
available in 2 lengths - the CHQ-PF50 and the CHQ-PF28 (457). 
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improvement in health domain after ITB therapy could be related to omitting 
or reducing some of the routine medications used in CP such as oral baclofen 
and diazepam (480). Furthermore, the hospital visits may have declined due 
to improvement in other consequences of spasticity as for instance 
orthopaedic deformities and correction operations (47).  
Communication ability is frequently compromised in CP children (481), which 
affects their social integration (482). The current study showed significant 
change in perception of communication and social interaction. This has been 
reported in other studies. Awaad et al demonstrated improvement of the 
social domain in the PEDI scale (285). 
In the current study a significant positive correlation was found between 
gained score in communication and social interaction domains in CPCHILD™ 
and pre-implantation scores of cognitive function on WeeFIM scale. This is in 
accordance with previous studies that linked the communication disabilities to 
the cognitive state (481). 
Cognition domain scores in WeeFIM showed mild improvement after ITB 
implantation. This result supports previous findings of positive changes in the 
cognition domain of FIM instrument (adult version of WeeFIM) after 
implanting the ITB pump in traumatic brain injury (TBI) patients (483). 
Furthermore, recovery of vegetative patients with TBI after ITB pump 
implantation has also been reported (484, 485). This observation could 
support the idea of a positive effect of ITB on cognition. In acquired brain 
injury, the brain and function were already established (486). However, in CP 
the brain injury occurred very early in life and so the brain did not have the 
opportunity for natural development of its function (28, 30). Powell et al stated 
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that executive functiondd is the latest cognitive area to develop until reaching 
adolescence (487). Nevertheless, a recent study examined the efficacy of ITB 
therapy in improving mobility and cognition on a rat model of CP showed only 
a significant effect on mobility but not on the cognition (486).  
Further neuroscience research should focus on exploring the effect of ITB on 
cognitive function. Natale et al. have commenced an experimental study to 
measure cortical activity by functional magnetic resonance imaging (fMRI) in 
patients with severe spasticity to compare these results after ITB therapy 
aiming at finding new motor and sensory activities (397). 
4.4.2 Measuring the effect size of ITB therapy on HRQOL and functional 
status 
Null hypothesis significant testing (NHST) is deemed to be a core of statistical 
method that verifies an established null hypothesis according to the given 
significance level. Using of NHST only indicates if an effect exists but does 
not inform of the size of that effect (488). 
In this study, the effect size of CPCHILD™ changes was large, in contrast to 
small effect size of the functional changes in WeeFIM scores.  
Effect size (ES) is a simple method to quantify the effect of an intervention. It 
is easy to calculate, readily understood and can be applied to the HRQOL 
outcome. It allows us to move beyond the simplistic, 'Does it work or not?' to 
the far more sophisticated, 'How well does it work in a range of contexts? 
(489).  
                                                 
 
dd Executive function in CP is impaired due to early damage of the white matter 
tracts, which connect the prefrontal and posterior brain regions (487). 
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It is noteworthy that ES measuring was pioneered by Jacob Cohenee. 
However, Cohen did not create anything which was not already in statistics, 
but rather gave a means to spread the concept of statistical power and size of 
an effect among non-statisticians. He derived Cohen‟s d score directly from 
the already known statistical test such as Students t-test (490). 
Cohen‟s d is an estimate measure of ES in terms of number of standard 
deviations that mean scores shifted above or below the population mean 
stated by the null hypothesis. The larger the value of d, the larger the effect in 
the population (491). It estimates the size of a shift in the population as a 
number of standard deviations that scores shifted. The numerator is the 
sample mean difference between pre- and post-intervention scores. The 
denominator is the pooled standard deviation for two scores (491).   
The limitation of ES is that the characteristics of the distribution, particularly at 
baseline, may strongly influence the ES. Accordingly, the same amount of 
individual change produces different effect sizes depending upon 
heterogeneity of the sample at baseline. Therefore, the larger the baseline 
SD, the smaller would be the resultant effect. Therefore, when using ES for 
an individual or group to determine clinically meaningful change, we should 
be aware that the conclusion might be influenced by sample heterogeneity 
(492, 493). 
4.4.3 The relationship between changes in HRQOL and functional status 
Using the CPCHILD™ and WeeFIM measures permitted a correlation 
between the different domains in the two instruments. This in particular 
                                                 
 
ee Jacob Cohen was a United States statistician and psychologist. He laid the foundations for 
current statistical meta-analysis and the methods of estimation statistics(490). 
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highlighted a surprising lack of correlation between changes in physical 
functioning and perception of HRQOL.  
In the current study, there was a significant correlation between both 
baselines of CPCHILD™ and WeeFIM scores and also between the post-
implantation scores of both instruments that may give an impression of a 
reciprocal relationship between HRQOL and functional status. Nevertheless, 
the correlation between gained scores of both instruments was not 
statistically significant which means improving quality of life is not dependant 
on the functional improvement of patients.  
This discrepancy of improvement between HRQOL and functional status 
could be explained by the nature of WeeFIM instrument as an evaluation tool 
of disability, focusing objectively on the ability to perform certain tasks against 
predetermined criterion (494). In contrast, CPCHILD™ is a proxy tool 
measuring caregivers‟ perceptions of the HRQOL of their children, which is 
based on their feelings about functioning, participation, social, and emotional 
well-being (443). Another possible explanation is the disability paradox 
phenomenon where patients reported better QOL that did not correspond to 
their disability. This phenomenon could occur because: firstly, patients or their 
caregivers understand and accept the functional disabilities (495); secondly, 
overcoming the functional disabilities by adapting external factors and 
modifying environmental factors to improve the social interaction of the 
patients, can lead to intensification and improvement in QOL feeling (496).  
4.4.4 The relationship between functional independence and quality of life 
Reduced activity levels and participation restrictions due to multiple 
impairments in children with CP may lead to a reduced QOL (497). In this 
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study, the baseline functional status (especially pre-implantation cognitive and 
mobility status) is positively correlated with some domains in CPCHILD™ in 
particular communication and participation, and locomotion and transferring 
domains. These findings suggest that children with CP who are more 
independent in performing basic activities of daily living before implantation 
will feel better about their social life, community interaction, transferring and 
mobility. This finding corroborates the ideas of Chulliyil et al. who concluded 
that children with CP children who were more functionally dependent were 
found to have worse QOL (497). 
Parkes et al. also stated that children with CP and severe impairments 
participated significantly less in most activities of daily living (498).The neural 
lesions and subsequent cognitive impairments of children with CP can impact 
their ability to develop the mental skills needed to engage in unrestricted 
social interaction. This dynamic is reciprocal, as restrictions in social 
participation can negatively impact the development of cognitive functioning 
(30). 
4.4.4.1 Overlap between WeeFIM and CPCHILD™ 
Functional status and QOL are important health outcomes. Functional 
outcomes were used to measure objective dimensions such as mobility and 
activities of daily living (ADL). However, HRQOL outcomes have gained their 
popularity from evaluation of both objective and subjective dimensions. The 
subjective component tends to be more valued by children and their parents, 
while the objective component is classically more informative for the service 
provider‟s needs (499). 
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The International Classification of Functioning Disability and Health for 
Children and Youth (ICF-CY), provides a universal language to measure 
health, education, and social activities of children and youth. All the 
components of the ICF-CY are linked to each other in bi-directional 
relationship (469). WeeFIM as functional status instrument and CPCHILD™ 
as HRQOL instrument seem to be overlapping in measuring different 
categories in ICF-CY model. In self-care domain, both instruments share 
assessment of eating (ICF code: d550) and drinking (d560); washing (d5100); 
oral hygiene (d5210); toileting activities (d530), and wearing upper (d5400) 
and lower limbs (d5401).  
The cognitive domain of WeeFIM assesses these categories in ICF 
framework: comprehension (Communicating-receiving d310-d329), 
expression (Communicating-producing 330-d349) and social interaction 
(d710-d729). CPCHILD™ also covers these items in communication & social 
interaction domain i.e. understanding; understood; and playing alone and with 
others.  
CPCHILD™ is designed to evaluate HRQOL, and covers a broader concept 
of health. It measures caregivers‟ perspectives of the health status, comfort, 
wellbeing, functional abilities and ease of caregiving of children with severe 
developmental disabilities (443). Unlike the CPCHILD™, the WeeFIM was 
designed only to measure the functional performance and identify what the 
child can actually do within a specific environment. However, it was not 
designed to measure well-being (500). Given the fact that individuals with 
similar functional disabilities may show a range of different scores for HRQOL 
(421, 499), therefore, the CPCHILD™ can be used as a complementary 
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measure to the WeeFIM to provide a more comprehensive description of the 
child‟s well being, more than the functional measure offers (443, 501).      
4.4.5 Factors affecting functional status and HRQOL outcomes  
In this study, multivariate linear regression (MLR) revealed that good 
cognitive status and absence of orthopaedic complications are significant 
predictors of improving the functional status. The relationship between 
cognitive state and improving the functional status after ITB therapy was 
reported previously by Scheinberg et al. who noted the significant 
improvement in upper limb function in cognitive intact patients (502). 
Similarly, Groden et al. reported the associations between cognitive state and 
functional activity (279). Furthermore, Wong et al. studied risk factors 
affecting functional independence in children with CP by using the WeeFIM 
instrument. Their result showed that epilepsy and cognitive state are the 
factors that influence the functional status (503). Moreover, Chiang-Soon 
Song et al. reported the positive correlation between cognitive functioning in 
children with CP and activities of daily living in children with CP (326). 
However, the effect of baclofen on cognitive function is poorly understood. 
Some studies suggested GABAβ receptor agonists, e.g. baclofen, can elevate 
the hippocampal content of the brain-derived neurotrophic factor (BDNF) 
which is essential for cognitive function (415, 418). Furthermore, baclofen 
was suggested to have neuronal neuroprotective effects (504). 
Song et al. recommended that the significant correlation between physical 
and cognitive function should be considered during setting of goals of ITB 
therapy before implantation. This is because rehabilitation exercises for 
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cognitively intact children, like standing and active movement are different 
from the goals for less active child with cognitive impairment (326). 
In the current study, orthopaedic complications of spasticity, for instance 
deformity and muscle contraction, were found to have a negative effect on the 
functional outcome of ITB therapy. Previous studies stated that correction of 
orthopaedic complications improve the functional state in children with CP 
(505, 506). Furthermore, the presence of epilepsy was a negative predicting 
factor of HRQOL outcomes in CPCHILD™ score. Epilepsy occurred in more 
than one third of children with CP (507). This group of patients need long-
term antiepileptic mono or polytherapy. Moreover, they have a tendency for 
frequent hospital admissions due to status epilepticus and refractory seizures 
(407), which subsequently has a negative effect on health related QOL. This 
highlighted the importance of good seizure control to enhance the efficacy of 
health interventions in optimising the quality of life (503). 
Arnaud et al. suggested that multiple comorbidities in children are obstacles 
to participation in school or to engagement in social activities. Consequently, 
they lead to a decline in children‟s QOL (508). However, in this study, 
comorbidities such as visual impairment and hydrocephalus did not 
significantly influence changes in HRQOL or functional status after 
implantation. 
The conclusion emerging from these findings is that children with intact 
cognition and without orthopaedic deformity or refractory epilepsy would have 
the best functional and HRQOL prognosis after ITB therapy. Therefore, to 
optimise the HRQOL after ITB therapy, efforts should be directed to modify 
these comorbidities by controlling intractable epilepsy (509) and correction of 
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musculoskeletal deformities (510). New therapies such as pantocalcin and 
erythropoiesis-stimulating agents (ESAs) have been suggested for improving 
cognitive function (327, 332). 
4.4.6 Novelty of this study 
The strength of this study was its single centre cohort studied over a 
prolonged period using standardised measures and different method of 
collecting the data. This study is a quasi-experimental (test then-test) design 
that has several advantages: 1) the interview is implemented at only one point 
to assess two points in time which is time and cost saving, 2) the test then-
test is not prone to response shift bias as the patients‟ standard about their 
state and changes after the interventions become consistent (455, 495), 3) 
the then-test studies are less prone to have missing data which could affect 
the power of statistical analysis (511). 
This study attempted to find the relationship between HRQOL on functional 
status. This was achieved by using CPCHILD™ and WeeFIM instruments 
which are validated, reliable and sensitive to changes after health 
intervention(443).   
4.4.7 Limitations and future considerations 
The present study is subject to a number of limitations. Firstly, this study 
depends mainly on proxy report (parent-report data) whereas the WHO and 
the International Association for Child Psychology and Psychiatry stated that 
children should address their own QOL (512, 513). Nevertheless, it was 
suggested that if the children have obstacles like young age, cognitive 
impairments, or disabilities, then the proxy-report is the only method to 
assess their QOL using their caregivers in assuming they have intimate 
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knowledge of the children (514). The CPCHILD™ instrument used in this 
study was designed and validated as a proxy reporting instrument for 
severely disabled children.  
Secondly, the retrospective design of this study might be prone to recall bias.  
However, Hassan et al. reported that recall bias was not such a burden in 
parent-reported data as has often been suggested (515). Interviewing 
techniques and choosing the validated and specific questionnaire should 
reduce the recall bias (516).  
However, a prospectiveff (517) QOL study might be considered to measure 
outcome over time, and to capture the impact of long-term outcomes. It can 
be considered as an alternative to the conventional randomised clinical trial 
that may provide results more generalisable to clinical practice (518).   
The major advantage of using a prospective cohort study is the accuracy of 
data collection and its resistance to patient recall bias as data are collected 
during the progress of the study rather than after the patient has developed 
the outcomes. Due to the longitudinal nature of the prospective cohort study, 
it also has the advantage of documenting a clear timeline of progression from 
intervention to outcomes (519). In addition, Prospective, longitudinal data 
collection may reveal time-dependent evolution of HRQOL domains. Patients 
may then serve as their own controls (518).  
Thirdly, the impact of ITB therapy on caregivers‟ stress was not evaluated 
despite that having a severely disabled child with CP can affect caregivers' 
                                                 
 
ff The prospective quality of life study is longitudinal survey that takes place over the forward 
passage of time. The data are collected at baseline of study before any intervention then the 
subjects are followed into the future in order to record the development of any of the 
outcomes of interest (517). 
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QOL and mental health (520, 521). Caregivers of children with CP may be 
under more physical, psychological, and financial burdens compared with 
those who provide care for children who develop in a typical manner because 
their greater responsibilities (522, 523).  
Care and Comfort Caregiver Questionnaire (CareQ), was developed to 
measure difficulty of care experienced by caregivers of children with 
moderate to severe functional limitations due to CP. The CareQ also eases 
the communication between the caregiver and the clinician in setting 
therapeutic goals for the child (524). 
The Coping Health Inventory for Parents (CHIP) is a well-recognised measure 
of coping among parents of chronically ill children (525). It is an appraisal of 
caregivers‟ cognitive and behavioural efforts to manage the demands of a 
stressful situation and coping responses to management of family life (525). 
The Measure of Processes of Care (MPOC) is a well validated and reliable 
self-report measure of parents' perceptions of the extent to which the health 
services they and their children receive from children's rehabilitation treatment 
centres. It is a way to assess family-centred behaviours of health care 
provider (526). 
Lastly, WeeFIM instrument and CPCHILD™ cover most aspects of ICF model 
for CP except the personal aspect. Other disease specific instruments for CP 
such as CP QOL cover all domains so should be considered in further 
studies. 
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4.5 Conclusions  
This study defines the health related quality of life and functional outcomes for 
a cohort of 75 patients with CP who have received intrathecal baclofen. Four 
main findings emerge from this study:  
Firstly, intrathecal baclofen can change and enhance health related quality of 
life and functional status, even though the former has a greater 
responsiveness than the later.  
Secondly, the pre-implantation cognitive state and absence of orthopaedic 
deformity are predictors of functional response to ITB therapy.  
Thirdly, controlling comorbidities such as epilepsy would enhance the impact 
of the ITB therapy on HRQOL.  
Fourthly, the pre-operative functional state is correlated with improved 
communication and social participation in disabled children, which could 
facilitate their integration in society. 
In future investigations, it might be possible to examine more closely the 
effect of ITB therapy on cognitive states and also the relationship between 
cognition and physical function. Large randomised controlled trials using the 
tools applied in this study could provide more definitive evidence and this data 
could be used to calculate the power of such studies. 
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5.1 Introduction 
This thesis addresses the results of studying one of the largest cohorts of 
children who received intrathecal baclofen (ITB) therapy for spasticity and 
dystonia, mainly as a consequence of cerebral palsy (CP), but also for some 
other indications. This patient group was characterised by being consecutive 
as it included all children presenting to Nottingham University Hospitals (NUH) 
between 1998 and 2011. All the patients were from a single tertiary centre, 
more than 90% of them had CP as the indication for ITB therapy, and lastly all 
of the patients were screened, operated on, and followed up by one 
neurosurgeon (MHV). 
I retrospectively studied the safety and efficacy of the ITB therapy aiming 
firstly, to audit ITB service performance at NUH, and secondly to determine 
the effect of using ITB therapy. 
5.1.1 ITB therapy and impact on NHS practice 
This thesis was conducted as an audit. A Cochrane review stated that an audit 
can develop the practice of health care professionals (527, 528). Furthermore, 
it helps the physicians to implement evidence based medicine and optimise 
health care interventions regularly in the face of increasing pressure to justify 
treatment costs (260, 527).  
The main aim of this study was to evaluate our selection criteria and 
complication rates against standards. The standard criteria were driven from 
NICE guidelines and Cochrane Database of Systematic Reviews.  
In this cohort, the compliance with NICE guidelines selection criteria was 96%. 
In Only nine patients the age was below the recommended age of 4 years. 
NICE guidelines recommended that the child would need to be physically big 
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enough for implanting the ITB pump to be comfortably accommodated. 
However, the guidelines did not give a precise age at which an infusion pump 
should first be implanted. Rather, it pointed out that prescribers will use the 
drug‟s summary of product characteristics (SPC) to inform decisions made 
with individual patients (113). According to SPCs of ITB, it is indicated in 
paediatric population aged ≥ 4 years with severe chronic spasticity of cerebral 
origin or of spinal origin (11, 529). Furthermore, the pump manufacturer 
(Medtronic Inc.) advised that safety and effectiveness in paediatric patients 
below the age of 4 years of age have not been established and children 
should have adequate body mass to accommodate the implantable pump for 
chronic infusion (324).    
The aim of ITB implant in this young group (<4 years) was to prevent the 
progression of spasticity and its long-term consequences such as muscle 
contracture and fixed deformity. In this young group, deep infection was 
reported in two patients that required explanting the ITB device. One of them 
had experienced infection twice.  The rate of infection in this group was 22% 
in comparison to 9.4% in the whole study cohort. In multivariate analysis, the 
lower age was found as a risk factor for ITB infection. Early implantation of ITB 
in children below the age of 4 years had been reported in previous studies (5, 
6). Albright et al. have implanted ITB pump into few children younger than 4 
years of age including a 9-month-old, 18-lb infant who suffered from severe 
spasticity (164). Although the ITB procedure should not be the standard 
modality in children below the age of 4 years, the decision to do otherwise 
should come ideally from a multidisciplinary team with expertise in all of the 
various treatment modalities. This decision should take in consideration the 
child size and the suitability to other treatment options. A re-audit to evaluate 
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the compliance with the selection criteria is therefore advised to make sure 
that this recommendation is implemented in routine practice. 
Secondly the complication rate associated with ITB therapy in NUH was in 
accordance with the published figures in Cochrane Database of Systematic 
Reviews. This study was the first to audit ITB practice at NUH and the 
complication rate is considered as benchmarking for future evaluation in 
monitoring of the service. It is also a quality assurance tool that indicates that 
the outcome is similar to other ITB service providers. 
5.1.2 Usefulness of long-term follow-up of this cohort 
This study presented outcome data associated with a median follow-up of 
4.02 years. A longer follow-up period will help in evaluating the sustainable 
effect of ITB therapy and compare the outcomes of ITB treatment over 
variable lengths of time.  
Other advantages of a longer follow-up may include: 
x It could provide detailed understanding and evaluation of the 
relationship between risk factors and the development of adverse 
events of ITB treatments over different lengths of time (1). 
x The effect of ITB on the overall survival of children with CP can only be 
evaluated through a lifelong follow up of this cohort. Furthermore, such 
follow-up data would allow a comparison between the prognostic effect 
of ITB treatment and other therapeutic modalities in CP (530). 
x It might demonstrate if the ITB intervention affects the natural history of 
the disease e.g. evaluating scoliosis progression in quadriplegic spastic 
CP after long-term insertion of ITB pumps (240, 242, 243). 
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x It would demonstrate the long-term durability and safety of ITB therapy, 
in addition to long-term patient satisfaction (531). 
x It would allow more a realistic estimation of the relative costs and 
benefits of ITB intervention (532). Saulino et al. evaluated the long-term 
economic effects of intrathecal baclofen (ITB) based on costs of care 
before and after implantation and concluded that patients receiving ITB 
would expect to experience a reduction in cumulative future medical 
costs relative to anticipated costs in the absence of a pump implant 
(533). 
x Certain outcomes could be related to other variables over time such as 
changes in body composition and body weight (323, 534, 535).  
5.1.3 ITB and selective dorsal rhizotomy for treating spasticity in children 
ITB therapy is an expensive intervention, however many studies have shown 
its cost effectiveness. In a study from the UK about the cost-benefit ratio of 
ITB in severe spasticity, the authors concluded that the cost per QALY lies in 
the range of £6900 to £12800; which was considered to be acceptable in the 
context of other NHS funded interventions (245).   
Nevertheless, there has been a re-introduction of selective dorsal rhizotomy 
as another modality for treating spasticity. Few studies tried to compare the 
effectiveness of both modalities (536, 537). However, these comparative 
studies have been performed before the release of NICE guidelines of 
indications and contraindication of both modalities. NICE guidelines produced 
in July 2012 clearly recommend considering ITB therapy for children and 
young people who typically have:  moderate or severe motor function 
problems (GMFCS level III, IV or V) and bilateral spasticity affecting upper and 
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lower limbs (quadriplegic child) (11). On the other hand, they consider 
selective dorsal rhizotomy to improve walking ability in children and young 
people with spasticity at GMFCS level II or III with pure spasticity in lower 
limbs. NICE guidelines give predominant dystonia, athetosis, ataxia, and 
severe cognitive delay, severe scoliosis or hip dislocation, as exclusion criteria 
for SDR surgery (113). 
5.1.4 Clinical distinction between dystonic cerebral palsy and primary 
dystonia 
The motor dysfunction in children with CP is not simply attributable to 
spasticity or corticospinal tract dysfunction but also, it might include disruption 
of the complex integration of multiple areas of the brain such as the cortex, 
cerebellum, basal ganglia, and brainstem. Thus, a child with CP may manifest 
other kinds of hypertonia and movement disorders such as dystonia and 
ataxia. It is becoming increasingly apparent that mixed movement disorders 
are more common than isolated pure spasticity or dystonia (538). Once one 
type of movement or tone abnormality is treated, another underlying 
movement may become more apparent (539). Therefore, selecting and 
evaluating appropriate treatments for children with CP has been challenging, 
due to difficulty in identifying the presence and importance of coexisting motor 
disorders e.g. dystonia, athetosis, and ataxia (540). Albright et al. stated that 
dystonia is frequently misdiagnosed to the extent that it is common for a child 
to be referred after a selective lumbar rhizotomy with a diagnosis of “recurrent 
spasticity” when, in fact, the child has undiagnosed dystonia (541).  
Dystonia is defined as „„a movement disorder in which involuntary sustained or 
intermittent muscle contractions cause twisting and repetitive movements, 
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abnormal postures, or both ”(542, 543). Dystonia is often initiated or worsened 
by voluntary action and associated with overflow muscle activation (544). 
Types of dystonia  
There are numerous systems for the classification of dystonia. Considering 
the underlying pathological process, dystonia may be defined as: 
(i) Primary dystonia which occurs in patients who have no signs of 
structural abnormality in the CNS. Tremor may or may not be present.  
(ii) Dystonia plus syndrome which occurs when dystonia is combined with 
other pathological changes (these include dopa-responsive dystonia 
and myoclonic dystonia) (545). 
(iiI) Secondary dystonia is seen when there is a demonstrable structural or 
metabolic disorder e.g. dystonic CP. 
Dystonia, like other movement disorders in children, are more often secondary 
than primary, and more often associated with lesions of the brain such as 
those of CP (541). 
Lin et al. systematically reviewed the characteristics of the dystonia in 279 
children who were referred for possible DBS or ITB neurosurgical intervention. 
The results showed that 230/279 (77.4%) of the patients were referred due to 
secondary dystonia, 30/279 (10.7%) were primary dystonia, and 19/279 
(6.8%) were dystonia-plus syndrome. The dystonic CP was the main cause of 
secondary dystonias (150/230) 65%, and spasticity coexists with dystonia in 
one third of this group (79/230) 34.3% (335). 
Dystonic CP is the second most common type of CP after purely spastic forms 
(546), affecting 15%-20% of patients with CP (547). It is usually bilateral, and 
abnormal movements and postures, mostly begin after the first year of life, 
and progress slowly over several years. In children with severe CP, dystonia 
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may be so profound and sustained that it manifests as hypertonia rather than 
abnormal involuntary movements (548). Although the brain insult that causes 
secondary dystonia does not progress in CP, it is clear that dystonia can 
worsen as the brain matures (549, 550). 
Age of onset of dystonic postures in CP varies between 2 and 6 years. It is 
usually preceded by a period of developmental motor delay (544), and 
associated with impairments such as learning disability and epilepsy (32). 
Brain MRI demonstrates abnormal findings in about 80% of individuals with 
CP (551), which include abnormalities of  the basal ganglia or thalamus 
abnormalities or bothgg (546, 552). 
On neurological examination of individuals with CP, dystonia is characterised 
by the presence of fluctuating hypertonia and/or involuntary postures and 
movements triggered by arousal, such as wakening from sleep, tiredness, and 
lack of sleep, cognitive tasks, emotional state; and physiological phenomena, 
such as hunger and temperature, tactile stimulation, or voluntary movement 
(553). 
Primary dystonia is rare. The incidence of early-onset primary dystonia was 
estimated to range between 2 and 50 per million (554). Primary dystonia is not 
associated with other neurologic abnormalities apart from tremor and 
occasionally myoclonus (555). Primary dystonias are often attributable to a 
genetic mutation in the DYT1 gene on chromosome 9q34 (556). This is 
characterised by: (a) a normal perinatal and developmental history, (b) no 
precipitating illnesses or exposure to drugs known to cause dystonia, (c) no 
                                                 
 
gg The basal ganglia and thalamic lesions can be associated with the higher vulnerability of 
these regions because of high metabolic demand during the late third trimester of pregnancy 
or the perinatal period (546, 552). 
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evidence of intellectual, pyramidal, cerebellar, or sensory deficits, and (d) 
negative results of investigation for secondary causes of dystonia (especially 
Wilson Disease) (557). 
Primary dystonia often begins in children 6 to 12 years old. It starts in one 
lower extremity as an involuntary foot deviation (usually plantar flexion and 
inversion) during walking but not at rest. It progresses slowly to affect the 
entire leg, then the other leg, and ultimately becomes generalised in 60-70% 
of patients. One tenth of patients develop segmental dystonia and only 25% 
remain focal. The early onset of dystonia, especially if it started in the legs, 
has more inclination to progress into generalised and severe dystonia (557-
559). Importantly, Conventional or structural MRI studies in primary dystonia 
are normal (560). 
The primary-plus dystonia category includes individuals with dopa-responsive 
dystonia (Segawa‟s disease) and myoclonus-dystonia syndrome (561). The 
biopterin and homovanillic acid levels are often low and the dopa 
decarboxylation may be disordered (562). Dystonia plus has a diurnal 
variation in 75% that worsens by the end of the day (563). 
Dopa-responsive dystonia begins at 1 to 12 years of age, with a median onset 
at 6.5 years, presents most often with dystonia in a foot with gait changes, and 
then progresses to involve the entire body over the next few years (541). 
Primary-plus dystonia may be associated with spasticity and may be 
misdiagnosed as cerebral palsy, although it is not associated with prematurity. 
In the series reported by Nygaard et al., 24% of patients with dopa-responsive 
dystonia had been misdiagnosed as having cerebral palsy (564). Dopa-
responsive dystonia should be considered in any child who presents with 
dystonia or even spasticity of unknown aetiology as it responds dramatically to 
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L-dopa (541). Every child with dystonia or even spasticity who does not have 
a history consistent with CP (e.g., prematurity, intraventricular hemorrhage, 
perinatal hypoxia) should be given a trial of oral levodopa for 2 to 3 months to 
exclude the possibility of dopa-responsive dystonia (541, 565). 
Other significant differences between primary and secondary dystonia:  
Patients with secondary dystonia often have more dystonic posturing (that is, 
fixed dystonic postures), and the appearance of slow athetoid movements. 
However, those with primary dystonia have more frequently jerky clonic 
contractions. Also, dystonic tremor was observed in 60% of patients with 
primary and in only 24% of those with secondary dystonia (566). 
Spontaneous remissions and the ability to suppress dystonic movement by 
sensory tricks can also help differentiate primary from secondary dystonias. 
Both phenomena were more frequently recorded in primary dystonia, 
confirming the suggestion that they are typical for its clinical course (566). 
The presence of dystonia at rest suggests a secondary form of the disease 
(566). 
Intelligence and cognitive functions are preserved in primary dystonia. In 
contrast, patients with secondary dystonia caused by focal lesions may have 
serious cognitive impairments and intellectual deficits (567). 
Recommendations: 
It is important not to dismiss dystonia in a child with CP without appropriate 
investigation. To make a diagnosis of primary dystonia, known causes of 
dystonia must be excluded. Clues to the diagnosis of a secondary dystonia 
can be revealed with a thorough history and physical examination, 
neuropsychology assessment, imaging, and laboratory testing (557).  
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Structural brain imaging (MRI) is recommended as good practice for 
identifying secondary forms of dystonia, in addition to predicting the functional 
outcome of any neurosurgical intervention such as ITB or selective dorsal 
rhizotomy (SDR) in children with spasticity (560, 568, 569). Grunt et al. stated 
that the improvements after SDR are good in patients with no MRI 
abnormalities (569). 
Genetic analysis is also suggested in those cases where no specific cause 
can be determined as several monogenetic diseases present with clinical 
features similar to CP (550). 
Assessing the cognitive function in patients with childhood dystonia, by using 
standardised neuropsychological tools, is essential for establishing the 
diagnosis and selecting the appropriate intervention to the specific needs of 
individual patient (567). 
Selective dorsal rhizotomy is not considered appropriate for children younger 
than 2 years of age because CP cannot be diagnosed with certainty in young 
children. In addition dystonia that is concomitant with spasticity becomes 
clinically apparent by the age of 5 years (118).  
Clinicians may choose ITB and DBS for treating severe generalised dystonia 
in children with CP. ITB is often considered over DBS in the presence of 
severe hypertonia where the tonal patterns are mixed with the presence of 
both dystonia and spasticity. Further studies are required to evaluate the 
choice of ITB versus DBS in individuals with CP and severe generalised 
dystonia (553). 
The topic would benefit from building consensus similar to the one completed 
through the National Institute for Health and Care Excellence (NICE), in order 
to establish a pathway for spasticity for children and young people (553). 
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5.1.5 Screening stage 
The ITB practice in NUH includes a screening stage. In this cohort more than 
90% had a positive response to a test dose. Recently, some experts in the ITB 
therapy raised a question about the benefits from ITB screening. Albright and 
Ferson reported that they no longer screen the patients before ITB therapy as 
practically all the patients respond well to a test dose (570). 
At NUH, we advocate continuing with screening patients before implantation 
for the following reasons: firstly, it gives the children and their caregivers an 
idea about what to expect from ITB therapy. Secondly, the degree of response 
to the ITB test dose gives us an idea about the initial ITB daily effective dose 
required. Lastly, ITB therapy will require a long-term relationship between the 
patient and health service provider more than implantation of a pump and 
catheter system. It will include long-term follow-up and regular pump refills. 
Accordingly, the test dose, the child‟s response, and parents‟ opinion are 
important components of the selection for this expensive drug delivery system. 
5.1.6 Future clinical audit of baclofen withdrawal 
While intrathecal baclofen therapy (ITB) is an established treatment for 
spasticity, complications can lead to loss of delivery and, accordingly, baclofen 
withdrawal. Since untreated withdrawal syndrome can be painful, or even 
fatal, prompt diagnosis and management of ITB withdrawal is essential (571). 
There is no established consensus on the definition of ITB withdrawal, 
representing an unmet need in the field of ITB practice. Moreover, 
identification of withdrawal syndrome is very difficult in patients with cerebral 
palsy (207), especially if they present to a clinician who is unfamiliar with ITB 
therapy (206). 
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Loss of efficacy usually presents either by: a) return of pathologic tone 
following adequate spasticity control on stable ITB dosing, or b) inability to 
optimise ITB therapy despite adequate dose escalation (571).  
Medtronic, Inc emphasised the importance of observing the warning signs of 
ITB under-dose as it can be a result of ITB device malfunction. These warning 
sings include increase or return of spasticity, itching, low blood pressure, 
lightheadedness, and tingling sensation. These symptoms are often early 
signs of baclofen withdrawal (572). 
Baclofen withdrawal syndrome covers a wide spectrum of signs and 
symptoms with a variable degree of intensity (205, 571). Future audit is 
required to establish the actual incidence of intrathecal baclofen withdrawal. A 
consensus; standardised definition of withdrawal syndrome and its 
manifestations, is required to help in planning a prospective study in 
multicentre or national clinical audit of outcomes. 
This audit should aim to evaluate the ITB patients by on-going and consistent 
clinical assessment to optimise the patient‟s response to ITB therapy and to 
early detect recurrence of spasticity early. An expert panel, who were 
managing more than 3,200 ITB patients, suggested subjective, objective, and 
goal achievement assessments during routine refill visits (351). 
- Subjective assessments: by asking the patient about variations in spasticity 
control, ease of care, comfort, and potential adverse effects. Various scales, 
such as the Care and Comfort Caregiver Questionnaire (442) or the Spasticity 
Visual Analog Scale (351, 573) can be used to quantify patients subjective 
opinion (351).  
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- Objective assessments: by regular and consistent clinical evaluation of 
spasticity (using Ashworth Scale), muscle stretch reflexes, clonus, muscle 
strength, range of motion, quality of gait, and transfer abilities (351). 
- Goal Attainment: by using measures such as the Canadian Occupational 
Performance Measure and Goal Attainment Scale (351, 574, 575). 
Such regular assessment should be able to detect any suboptimal ITB therapy 
in patients who were previously had well-controlled spasticity. These patients 
should be examined carefully (205). The examination should start in an 
approach similar to all medical assessments: a targeted medical history, a 
focused physical examination, and use of radiologic/laboratory testing, as well 
as telemetry data derived from the pump programmer (205). 
Saulino et al. categorised the wide spectrum of baclofen withdrawal symptoms 
into three levels: mild, moderate and severe (205). 
Mild ITB withdrawal (incipient withdrawal), presents with increased muscle 
tone following adequate spasticity control on stable ITB dosing, pruritus 
without rash, and irritability (205). As pruritus is a frequent symptom after ITB 
withdrawal, it can be considered as an early predictor of a malfunctioning 
pump system, and can differentiate between increased spasticity resulting 
from drug tolerance or irritating factors (pressure ulcers or urinary tract 
infection) (576). 
Moderate withdrawal syndrome includes return of pathologic tone, altered 
mental state, mild dysphoria, elevated creatine phosphokinase level, 
hypotension, paraesthesia and fever (205).  
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Severe or established withdrawal presents with severe increase in muscle 
tone, stupor and coma, rhabomyolysis, elevated creatine phosphokinase level, 
and seizures (205). 
ITB withdrawal should be also differentiated from other syndromes with similar 
symptoms such as autonomic dysreﬂexia, malignant hyperthermia (MH), and 
neuroleptic-malignant syndrome (NMS) (207). 
Autonomic dysreﬂexiahh occurs in patients with spinal cord injury (SCI) above 
the level of the major splanchnic outﬂow (T6 level or higher). It presents with 
paradoxical bradycardia with hypertension, absence of fever, lack of 
exaggerated rebound spasticity, and a normal level of consciousness (577). 
Signs of Piloerection and cutaneous vasoconstriction are present below the 
level of injury, whereas vasodilation and perspiration appear above the level of 
injury (578). Autonomic dysreﬂexia could overlap with ITB withdrawal. The 
cessation of oral or ITB in such individuals causes a return of spasticity that 
can provoke an episode of autonomic dysreﬂexia (579). However, the 
patient‟s vital signs (tachycardia and hypotension), mental state (delirium), 
and severe degree of spasticity is the characteristic of the withdrawal 
syndrome and differentiate it from autonomic dysreﬂexia (579). 
Malignant hyperthermia (MH) is a familial disorder caused by a mutation in 
ryanodine receptor gene causing a defective in calcium-release channel of the 
sarcoplasmic reticulum (SR) membrane (580). Certain anaesthetics, 
especially halothane, cause calcium leakage from the sarcoplasmic reticulum 
                                                 
 
hh Autonomic dysreﬂexia is caused by loss of supraspinal sympathetic control. Any 
non-specific stimuli below the level of injury (for example, bladder distension, 
rectal manipulation, painful stimuli to the skin) can induce excessive sympathetic 
spinal outflow below the level of lesion, which causes the cardiovascular changes 
(Bradycardia, sometimes followed by tachycardia Hypertension) (577). 
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in affected individuals resulting in sustained, rigorous muscle contraction 
associated with high fever. If not treated promptly with dantrolene, MH can 
progress to rhabdomyolysis, multiple organ failure, and death. Laboratory 
evidence of disordered calcium metabolism and the occurrence of previous 
episodes in family members strongly suggest MH. A muscle biopsy can 
sometimes establish the diagnosis and differentiate it from Baclofen 
withdrawal (581). 
Neuroleptic-malignant syndrome (NMS) consists of high fever, muscular 
rigidity, and potentially life-threatening autonomic hyperactivity. It is 
precipitated by the commencement of dopaminergic antagonist drugs (e.g. 
haloperidol) or the withdrawal of dopaminergic agonists (e.g. levodopa, 
bromocriptine) (582). Treatment consists of administering a dopaminergic 
agonist (bromocriptine, amantadine, levodopa) in combination with 
intravenous dantrolene (207).  
5.1.7 Future study of care givers quality of life  
Looking after a child with disability is challenging both physically and 
psychosocially given that such disability usually spans the course of a child‟s 
life, exceeding typical child development needs and parents, as well as 
families are not at all prepared for it (525).  
Caregivers of children with CP may be under more physical, psychological, 
and financial burdens compared with those who provide care for children who 
develop in a typical manner because their responsibilities are greater. In 
addition to providing direct daily care and support, the caregivers of children 
with CP invest time and effort in assisting with interventions such as physical, 
occupational, and speech therapy (524). These burdens can be associated 
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with an impairment of caregivers‟ physical and psychological health. A 
considerable research has been published on high levels of caregiver burden 
which show that caregivers of children with disabilities are more likely to 
experience depression and distress (583), poorer general emotional health 
and feel pessimistic about the future (584). They also feel that their caregiving 
prevents them from taking time for themselves (33, 34, 585, 586). 
Onses et al. evaluated the quality of life and psychological aspect in mothers 
of children with CP, and concluded that their quality of life is significantly lower 
than their peers (521). This result was also supported by Eker and Tuzun who 
demonstrated that mothers of children with CP have poorer QOL than mothers 
of children who had a minor health problem (587). 
Children with CP have more sleep problems than typically developing 
children. Recent studies have shown that mothers of children with CP also 
experience impaired sleep because they may encounter more frequent night 
disruptions related to their child‟s sleep (588). In addition, poor sleep quality in 
mothers of children with CP is commonly reported and has been significantly 
associated with high levels of maternal stress difficulties (588), depressive 
symptoms (589), and poor psychological well-being (590).  
The ICF framework emphasises the environment as critical to health and well-
being. This framework highlights the important relationship between the health 
of the caregiver and the health of the child (34). In addition, there has been a 
shift in health care service delivery away from child-centred models that focus 
primarily on treating the disability toward family-centred services and family-
centred well-being. This shift recognises the primary role of the family in child 
development (591, 592). 
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Physicians and other health care professionals should be aware of the 
significant association between child disability and caregiver health and QOL. 
Future work should address the extent to determine whether intrathecal 
baclofen therapy among children with CP is effective in reducing caregiver 
burden in parallel to its effects on their children, in order to clarify if there is an 
association between parents' QOL and children's well-being. This work will 
also assess the impact of ITB intervention on caregiver‟s work productivity, 
and to evaluate if it decreases the healthcare costs for the caregiver (34).  
Several quality of life instruments could be used to assess the caregivers' 
QOL which include: 
1-Care and Comfort Caregiver Questionnaire (CareQ) 
CareQ was developed to measure difficulty of care experienced by caregivers 
of children with moderate to severe functional limitations due to CP. The 
CareQ also eases the communication between the caregiver and the clinician 
in setting therapeutic goals for the child (524). 
2-The Coping Health Inventory for Parents (CHIP) is a well-recognised 
measure of coping among parents of chronically ill children (525). It is an 
appraisal of caregivers‟ cognitive and behavioural efforts to manage the 
demands of a stressful situation and coping responses to management of 
family life (525). 
3-The Measure of Processes of Care (MPOC) is a well-validated and reliable 
self-report measure of parents' perceptions of the health services they receive 
along with their children from children's rehabilitation treatment centres. It is a 
way to assess family-centred behaviours of health care providers (526). 
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4-Pittsburgh Sleep Quality Index (PSQI) provides caregiver ratings of their 
own sleep. It is a self-report questionnaire that assesses sleep quality over a 
1-month time interval (593). 
5-The modified caregiver strain index (MCSI-13) is an ordinal scale, used to 
identify families with potential care-giving strain (594). 
5.1.8 Intrathecal therapy uses and future prospects 
There is still a major challenge for the treatment of several central nervous 
system (CNS) disorders such as recurrent brain tumour, multiple sclerosis and 
Hunter syndromeii(595). This challenge is related to the absence of convenient 
and effective methods of delivering the required medications. The two main 
routes of direct drug delivery to the CNS are intrathecal and direct intra-
ventricular (IV) injection. These methods of drug delivery allow direct drug 
administration to the CSF by circumventing the blood-brain barrier, therefore 
allowing delivery of smaller drug doses. This consequently reduces the 
occurrence of side effects compared with systemic routes of drug 
administration, e.g. oral, intravenous and epidural. Continuous intrathecal 
infusion therapy is established in the treatment of intractable spasticity and 
chronic pain by implanting programmable infusion pumps (166, 596). IV 
therapy has also been tried unsuccessfully to deliver the glial cell line-derived 
neurotrophic factor (GDNF) for treatment of Parkinson‟s disease (597). 
However, intraventricular baclofen was found effective and safe treatment for 
intractable dystonia (337). 
Intrathecal injection of chemotherapy agents like methotrexate, cytosine-
arabinoside and thio-TEPA were introduced as treatment options for brain 
                                                 
 
ii Hunter syndrome is a rare inherited lysosomal storage disorder resulting from a deficiency of 
iduronate-2-sulfatase (I2S) (595).  . 
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tumours including lymphoma (598), leptomeningeal medulloblastoma 
relapse(599), and leptomeningeal metastases (LM) (600). The intrathecal 
chemotherapy could be infused either by Ommaya reservoir or, if only a few 
injections are necessary, it can be injected via a lumbar puncture (601). 
However, continuous intrathecal programmable pumps are not currently used 
for chemotherapy, possibly due to the short treatment duration or due to poor 
prognosis of this patient group. 
Prager et al. suggested using external infusion pumps to be connected with 
subcutaneous tunnelled catheters to the intrathecal sac for the delivery of pain 
control medication. They stated that external infusion pumps are cost-effective 
when life expectancy is a matter of weeks to months, but a fully implanted 
pump is economical if life expectancy is longer than 3 months (602). The 
value of using continuous infusion pumps for treating CNS disorders is a 
topical issue for future research. 
5.1.9 Introduction of a new clinical procedure, intervention or technique. 
The clinical care of patients evolves continually through developments in 
equipment, investigation and procedures. This development will necessitate 
clinicians to introduce new approaches of treatment and new interventional 
procedures. Patients and their families need to be assured that their treatment 
is up to date and effective. Professional self-regulation gives health 
professionals the ability to set their own standards of professional practice, 
conduct and discipline. However to justify this freedom and maintain the trust 
of patients and their families, the professionals must be openly accountable 
for the standards they set and the way these are enforced. 
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The NICE has been given the responsibility for managing the UK “National 
Interventional Procedures Programme (NIPP)”
 
which assesses the safety and 
efficacy of new interventional procedures. The programme‟s aims are to 
protect the safety of patients and to support doctors, other clinicians, Clinical 
Governance Committees (CGC), healthcare organisations and the NHS as a 
whole in managing clinical innovation responsibly (603).   
From 13th November 2003, medical practitioners planning to undertake newjj 
interventional procedureskk should seek approval from their NHS Trust and 
CGC before doing so. The Chair of the CGC should notify the new procedure 
to the NIPP at the NICE unless it is already listed there. In case where the 
procedure has to be used as an emergency, the procedure should be notified 
to the trust CGC within 72 hours. The committee will consider approval of the 
procedure for future use as above. The only exception to the process is when 
the procedure is being used only within a protocol approved by a Research 
Ethics Committee (REC) (603, 604).  
If there no available guidance from NICE on the procedure, the Committee 
should only approve its use if: 
1. The doctor has met externally set standards of training. 
2. All patients offered the procedure are made aware of the special status of 
the procedure and the lack of experience of its use. Patients also need to 
recognise that the procedure‟s safety and efficacy is uncertain and be 
                                                 
 
jj An interventional procedure should be considered new if a doctor no longer in a training post 
is using it for the first time in his or her NHS clinical practice (603, 604). 
kk HSC2003/011 defines an interventional procedure as one used for diagnosis or treatment 
that involves incision, puncture, entry into a body cavity (beyond the oropharynx), 
electromagnetic or acoustic energy (603, 604). 
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informed about the anticipated benefits and potential adverse effects of the 
procedure, and any other alternatives, including no treatment. 
3. The Committee is satisfied that the proposed arrangements for clinical audit 
are sound and will capture data on clinical outcomes that will be used to 
review continued use of the procedure. 
When NICE is collecting data under this Programme, doctors should supply 
the information requested on every patient undergoing the procedure. NHS 
Trusts are encouraged to support this to enable the NHS to have access more 
speedily to guidance on the procedure‟s safety and efficacy. The collection of 
data from patients will be governed by the Data Protection Act (603, 604).  
If an adverse incident occurs in association with a new interventional 
procedure, this should be reported to the National Patient Safety Agency via 
the national reporting and learning system for adverse events to be 
implemented across the NHS (603, 604). 
Duties and Responsibilities  
Individual clinicians have the responsibility to determine if there is existing 
NICE guidance for the proposed procedure. If there is an existing guidance, 
then the proposal should comply with this guidance. They should also provide 
information on the intended new interventional procedure including the 
rationale for the development, intended benefits, and potential risks. Further, 
resource implications, information that will be provided to patients, and 
methodology to audit clinical outcome should also be provided. In addition, it 
is imperative to provide information on how the clinician will be trained and 
assessed as competent in the new interventional procedure including 
information on the external standards for training (603, 604).  
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Clinical lead and responsible managers have the responsibility to review the 
information provided by the clinician about the proposed new interventional 
procedure, to clarify if the proposal complies with NICE guidance if this exists 
for the procedure in question. Moreover, they have to assess the requirement 
for the proposed procedure and also evaluate any resource implications within 
the health organisation or the Trust e.g. any impact on other services such as 
diagnostic or imaging services. 
If the Clinical lead and responsible managers support the proposed new 
interventional procedure, the proposal should be forwarded to the Medical 
Director for support prior to consideration by the Clinical Governance 
Committee (603, 604). The Clinical Governance Committee will have 
responsibility for the formal approval of any proposed new interventional 
procedure before it is introduced. If the procedure is entirely novel, the Clinical 
Governance Committee should notify the procedure to the Interventional 
procedures Programme at the NICE website (603, 604). If the interventional 
procedure is approved by the Clinical Governance Committee then the 
clinician must register and undertake an audit of the effectiveness and 
outcomes of the new interventional procedure. Auditing the new procedure is 
to collect and report outcome data on all patients who undergo the procedure. 
The Clinical lead must ensure that an audit programme is in place to obtain 
information on clinical outcomes, to continually review the procedure and to 
obtain information on any adverse outcomes (603, 604).  
Importantly, NICE will collect data on the procedure via the Interventional 
Procedures Programme. Clinicians should supply the information requested 
on every patient undergoing the procedure. The collection of data on patients 
will be governed by the Data Protection Act (603, 604).  
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5.1.10 ITB tolerance 
Although ITB is safe and effective in the majority of patients, tolerance has 
been reported in approximately 10% of patients during long-term treatment 
(303, 605). Tolerance is deﬁned as the condition requiring gradual dose 
escalation of the ITB to obtain the same therapeutic effect. This physiological 
tolerance usually occurs in the ﬁrst few months of ITB delivery and normally 
stabilises within the ﬁrst year following pump implantation. However, in some 
cases of long-term baclofen infusion, a decreasing effect is seen, which 
persists even with progressive dose increment (606). 
There is insufﬁcient experience to establish clear guidelines for the 
management of baclofen tolerance. However, „„a drug holiday‟‟ has been used 
to treat ITB tolerance. During this holiday, the baclofen infusion is gradually 
reduced and stopped over a two-week period, substituting it with an 
alternative method of spasticity management. After the drug holiday, the 
sensitivity to baclofen may be resumed and ITB may be restarted at the initial 
continuous infusion dose (607, 608).  
Tolerance to ITB could be due to continuous persistent binding of GABAβ 
receptors by baclofen leading to down regulation of the GABAβ receptors 
(202, 609). However, the precise mechanism by which tolerance develops 
remains unexplained. It may be due to genetic variation in GABAβ receptor 
isoforms or variation in the processes of baclofen metabolism (321). This area 
could be a valuable focus for future experimental investigations.  
Heetla et al. successfully treated four patients with ITB tolerance by switching 
the infusion mode to a six times bolus regimen per day instead of continuous 
infusion (394).  
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Considerably more research will need to be performed to establish the effects 
of bolus infusions of ITB. It would be interesting to compare bolus infusions 
with continuous infusion in a randomised controlled trial, looking for 
differences in the incidence of tolerance between these two infusion modes. 
5.1.11 The relationship between cognition and ITB  
Over the last two decades, prior studies have indicated that GABAβ receptor 
agonist (baclofen) might impair learning and memory in animals, whilst 
GABAβ antagonist improves cognitive processes (610, 611). In contrast to 
these earlier findings, recent studies have reported the baclofen effects to 
mediate neuroprotection and neuroplasticity (612, 613). Li et al. demonstrated 
that activation of GABAβ receptors ameliorates cognitive impairment in rats 
with chronic cerebral hypo-perfusion (614). They also showed the regulative 
effects of GABAβ receptor activation by baclofen, to reverse the neuronal 
damage and cognitive impairment induced by chronic cerebral hypo-perfusion, 
via mediating neuroprotection on hippocampal CA1ll(615) pyramidal cells 
(612).   
Cognitive impairments in children with CP make evaluation of cognition 
difficult in this population. They are often misinterpreted as being impaired 
even when they may have typically developing cognition. Therefore, it is 
important that any spasticity treatment should not induce nor worsen existing 
cognitive impairments (616). Ayyangar et al. examined the cognitive effects of 
ITB in 14 children with CP in a prospective pilot study. They used three 
                                                 
 
ll The CA1 Pyramidal Neuron is found in the CA1 region of the mammalian hippocampus in 
the medial temporal lobe. "CA" refers to cornu Ammon, latin for Ammon's horn (so named for 
the shape of the hippocampus). The neurons in the CA1 region provide a significant output 
pathway from the hippocampus, which plays an important role in long-term memory and 
spatially related tasks. CA1 pyramidal neurons, in particular, are thought to be critical to object 
differentiation in long-term memory (615). 
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different cognitive measures to cover a wide range of cognitive functions. 
They reported that cognitive function remained stable from baseline to 
implantation state with some improvement being noted in cognitive function 
such as choice reaction time mm (616, 617). A Presumed mechanism of 
enhancing the cognition in children with CP after treatment with ITB could be 
related to the reciprocal relationships between sleep, pain and cognition (618-
621). 
Sleep disturbances, is a common problem in children with CP (21). These 
disturbances include: difficulty in initiating and maintaining sleep, sleep wake 
transition, sleep breathing disorders, sleep bruxismnn (622), excessive day 
time sleeping, nightmares and sleep talking (21, 623-627). Needless to say, 
sleep is a necessary element of human life, and is essential for good mental 
health development (628). Many studies reported the crucial role of sleep in 
brain maturation and in the development of important cognitive functions, such 
as memory consolidation and learning (629). Kurdziel and co-workers 
reported that classroom naps consolidate learning in preschool children by 
improving memories acquired earlier in the day (630). 
It is optimal for infants to get 14 to 15 hours of sleep a night, for toddlers to 
receive 12 to 14 hours, for pre-schoolers to obtain 11 to 13 hours a night, and 
school-aged children to get 10 to 11 hours per night (631, 632). Sleep 
deprivation has been reported to have a negative impact on cognitive 
functions such as cognitive speed, executive attention, working memory, and 
                                                 
 
mm Choice Reaction Time evaluates general alertness and motor speed. It is the time elapses 
between presentation of several possible stimuli and the beginning of one of several possible 
responses (617). 
nn Sleep bruxism  (SB) is defined  as a  parafunctional behaviour of the mandible, 
characterized by clenching  and/or grinding of the teeth (622). 
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social development (628, 633). Reciprocally, other studies have found that the 
degree of cognitive impairment could be a risk of increased sleep 
disturbances in children with CP (634, 635). The neurophysiological basis of 
the association between sleep and cognition is poorly understood. However, 
functional MRI studies have demonstrated that neural systems involved in 
executive function (i.e. prefrontal cortex) are more susceptible to sleep 
deprivation (636, 637). 
While there are many factors related to CP that can interfere with sleep such 
as spasticity, dystonia, epilepsy and seizures. However, pain is reported to be 
the strongest contributing factor to sleep disturbances in children with physical 
disabilities (618, 638). Similarly, sleep deprivation was found to increase pain 
experience (639). Chronic pain has psycho-social implications for children with 
CP such as interference with the sleep (640), negative effects on their social 
participation (641, 642), and less quality of life in comparison to their peers 
who are not suffering from pain (643). Interestingly, cognitive performance has 
been frequently report to be decreased in chronic pain and to be improved 
after pain relief (644-646).  
Chronic pain affects cognitive areas such as attention, learning and memory, 
speed of processing the information psychomotor ability and executive 
function (645-648). 
Pain is an intrinsically attention demanding sensory process. Dick and 
colleagues reported a significant disruption of attention associated with 
impaired working memory by chronic pain (646). It was proposed that a high 
level of pain interferes with attentional processes during the completion of 
demanding tasks (649), and also interferes with information processing and 
retention of information (650). Brain areas constituting the network for 
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perception of pain include: primary and secondary somatosensory, insular 
cortex, anterior cingulate cortex, thalamus, and prefrontal cortex. The 
periaqueductal area, basal ganglia, cerebellum, amygdala and hippocampus 
were also found involved during pain process (651). This pain perception 
network has also critical role in cognitive process. (621, 652).  
Other studies found a decrease of grey matter volume in pain-processing 
structures in chronic pain patients in comparison to healthy subjects (653-
655). A grey matter loss could be a feature of cognitive status decline 
especially in speed of information processing and executive functions (621, 
656).  
Previous research has established that ITB reduces pain in children with CP, 
in addition to significantly reducing muscle tone which consequently improves 
the quality of life and facilitates ease of care (225, 461, 463, 657, 658). 
Moreover, Ramstad et al. reported a significant improvement in the frequency 
of night-time awakening along with objective severity of pain within 6 months 
following the implantation of an ITB pump (659). Similar results have been 
reported by Jan et al. who noticed an improvement in sleep quality and 
quantity after treating spasticity with ITB (660). 
Baker et al. reported improvement in the comfort in children with CP after 
implanting ITB pump (661). In a randomised controlled trial by Hoving and co-
investigators, reported a signiﬁcant improvement in the domains of pain and 
discomfort; mental health; and psychosocial status after six months of ITB 
administration compared with the control group (259). These results are 
consistent with the finding of our study, which shows the most significant 
improvement after treatment with ITB was in the comfort and emotions 
domain. This domain assesses the pain and discomfort during day and night 
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activities e.g. during sleep, in bed, while seated or transferring; sadness and 
agitation (443). Previous studies have recommended that more comfort and 
painless times could enhance the cognition (649, 650). Accordingly, more 
research is warranted for better understanding the cognitive effect of ITB. 
5.1.12 The role of neuropsychologists and occupational therapists (OT) in 
future ITB clinical practise 
The intellectual disability (ID) is defined as impairment in “general mental 
abilities such as reasoning, problem solving, abstract thinking, judgment, 
planning, and learning from experience,” with a guideline of an IQ score of ≤ 
70 (662).  
IQ is critical for independent participation in core activities such as education, 
self‐ care, and living independently (663). Patients with intellectual disability 
are characterised by a decline of socialisation functions; and difficulty in 
adaptation to the environment (664).  
It has been reported that between 34% and 64% of children with CP have an 
intellectual disability (intelligence quotient, IQ < 70) (665). These data were 
based on different methods such as :(a) presumptions from clinical 
observation, from cognitive description provided by parents; (b) application of 
developmental scales; or (c) through formal IQ evaluations which are based 
on psychometric tests (666).  
However, the paediatric IQ assessments are generally evolved for, and 
standardised with, typically developing children who do not have any physical 
impairments. As IQ scales require both verbal and manipulative responses, it 
will be difficult to apply them to children with CP (663). This lack of an 
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established objective assessment for people with CP may lead to over- or 
underestimation of their real intellectual ability.  
In this study, the cognitive function was divided into three categories 
according to the assessment provided by the referring paediatrician. 
Importantly, a neuropsychologist involvement, in pre and post implantation 
assessment, is recommended to provide an objective quantification of the 
children‟s cognitive function to establish a pre-implantation baseline of 
neurocognitive status. This benchmark will help tracing any changes in 
cognitive function through post-implantation follow-up and to disentangle 
which factors may account for post-implantation outcomes.  
Neuropsychologists could help in selecting tests, modifying test administration 
to accommodate disability, and interpreting results from non-standard test 
administration.(6). The most widely used tests by neuropsychologists in the 
field of CP are the Raven‟s Coloured Progressive Matrices (RCPM) and the 
Peabody Picture Vocabulary Test (PPVT) (666). 
A more thorough and detailed assessment of cognitive function by a 
neuropsychologist, will not only clarify efficacy of ITB on the cognitive function 
but also will help to identify the most suitable instruments for creating an 
individual learning programme. The inappropriate evaluation of the child's 
competence, may lead to inappropriate goals being set. Similarly, there is a 
risk of under evaluating a child's performance without checking basic abilities 
and without using suitable aids to compensate for the motor and 
communicative deficit. Thus, the importance of knowing a child's real abilities 
in the various cognitive areas is imperative in order to plan an adequate 
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rehabilitation programme that identifies objectives which can be attained (666-
668). 
Occupational therapists (OT) focus on assessing and developing an 
individual‟s ability to function day-to-day to their highest level in normal daily 
activities at home, in school, out in public, and at work. The goal is to 
encourage the development of independence, productivity, and self-care. OT 
will help a person improve strength, dexterity, and coordination while 
performing tasks. Moreover, they will also help in decision-making, abstract 
reasoning, problem solving, perception, memory, and sequencing (669). 
For children with CP, occupational therapy can help with muscle and joint 
coordination problems that can make everyday tasks difficult. Some of these 
tasks include eating, brushing teeth and bathing. OT can help to improve 
physical, cognitive and social abilities, as well as fine motor skills and posture. 
This therapy can also help address difficulties with processing sensory 
information (670, 671).  
Parents and caregivers spend extended periods of time helping children with 
cerebral palsy in performing basic day-to-day activities. OT can help parents 
and care givers through reducing the demand on them, providing a sense of 
security and enhancing their quality of life by improving the CP child is 
independence (671-673). 
Each child‟s occupational therapy treatment plan is highly individualised and 
tailored to their individual physical, intellectual and social-emotional abilities 
(671). Occupational therapist should be involved in ITB assessment process, 
where he/she could perform a complete evaluation before ITB implantation. 
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This includes testing the child‟s fine motor, perceptual and oral-motor 
development, and observing how the child responds to touch and movement. 
The occupational therapist will also interview the parents to find out about the 
child‟s strengths and weaknesses while performing daily activities in order to 
set a postoperative learning and rehabilitation plan based on each child needs 
and abilities (669, 671-673). 
OT could also evaluate the child post-ITB implantation and periodically during 
the follow-up period to modify the OT treatment plan based on progress and 
response to ITB therapy (669, 671-673). 
REFERENCES   
 232 
6 References 
 
1. Bhimani, R. and L. Anderson. Clinical understanding of spasticity: 
implications for practice. Rehabil Res Pract, 2014. DOI: 
10.1155/2014/279175. 
2. Mukherjee, A. and A. Chakravarty. Spasticity mechanisms - for the clinician. 
Front Neurol, 2010. 1: 149. 
3. Wyke, B. Neurological mechanisms in spasticity: a brief review of some 
current concepts. Physiotherapy, 1976. 62(10): 316-9. 
4. Kheder, A. and K.P. Nair. Spasticity: pathophysiology, evaluation and 
management. Pract Neurol, 2012. 12(5): 289-98. 
5. Nielsen, J.B., C. Crone, and H. Hultborn. The spinal pathophysiology of 
spasticity-from a basic science point of view. Acta Physiol (Oxf), 2007. 189(2): 
171-80. 
6. Sheean, G. The pathophysiology of spasticity. Eur J Neurol, 2002. 9(1): 3-9. 
7. Katz, R.T. and W.Z. Rymer. Spastic hypertonia: mechanisms and 
measurement. Arch Phys Med Rehabil, 1989. 70(2): 144-55. 
8. Hattori, N., T. Hirayama, and Y. Katayama. Cost-effectiveness analysis of 
intrathecal baclofen therapy in Japan. Neurol Med Chir (Tokyo), 2012. 52(7): 
482-7. 
9. Roberts, A. Surgical management of spasticity. J Child Orthop, 2013. 7(5): 
389-94. 
10. Hutchinson, R. and H.K. Graham. Management of spasticity in children, in 
Upper motor neurone syndrome and spasticity : clinical management and 
neurophysiology, M.P. Barnes and G.R. Johnson, Editors. 2008, Cambridge 
University Press: Cambridge ; New York. p. 215. 
11. Mugglestone, M.A., et al. Spasticity in children and young people with non-
progressive brain disorders: summary of NICE guidance. BMJ, 2012. 345: 
e4845. 
12. Wichers, M.J., et al. Clinical presentation, associated disorders and 
aetiological moments in Cerebral Palsy: a Dutch population-based study. 
Disabil Rehabil, 2005. 27(10): 583-9. 
13. U.S. Pharmacopeial Convention. Compounding: A Guide for the 
Compounding Practitioner. 2008; Available from: 
http://www.usp.org/store/products-services/usp-compounding. 
14. Williams, P.E. Effect of intermittent stretch on immobilised muscle. Ann 
Rheum Dis, 1988. 47(12): 1014-6. 
15. Tardieu, G., et al. Effects of muscle length on an increased stretch reflex in 
children with cerebral palsy. J Neurol Neurosurg Psychiatry, 1982. 45(4): 348-
52. 
16. Koman, L.A., B.P. Smith, and J.S. Shilt. Cerebral palsy. Lancet, 2004. 
363(9421): 1619-31. 
17. Grosse, S.D. Assessing cost-effectiveness in healthcare: history of the $50,000 
per QALY threshold. Expert Rev Pharmacoecon Outcomes Res, 2008. 8(2): 
165-78. 
18. Thompson, A.J., et al. Clinical management of spasticity. J Neurol Neurosurg 
Psychiatry, 2005. 76(4): 459-63. 
REFERENCES   
 233 
19. Dantas, M.S., et al. [Family's abilities and diffculties in caring for children 
with cerebral palsy]. Rev Gaucha Enferm, 2012. 33(3): 73-80. 
20. Romeo, D.M., et al. Sleep disorders in children with cerebral palsy: 
neurodevelopmental and behavioral correlates. Sleep Med, 2014. 15(2): 213-8. 
21. Newman, C.J., M. O'Regan, and O. Hensey. Sleep disorders in children with 
cerebral palsy. Dev Med Child Neurol, 2006. 48(7): 564-8. 
22. Parkinson, K.N., et al. Pain in children with cerebral palsy: a cross-sectional 
multicentre European study. Acta Paediatr, 2010. 99(3): 446-51. 
23. Galland, B.C., D.E. Elder, and B.J. Taylor. Interventions with a sleep outcome 
for children with cerebral palsy or a post-traumatic brain injury: a systematic 
review. Sleep Med Rev, 2012. 16(6): 561-73. 
24. Bax, M., et al. Proposed definition and classification of cerebral palsy, April 
2005. Dev Med Child Neurol, 2005. 47(8): 571-6. 
25. Bottcher, L., E.M. Flachs, and P. Uldall. Attentional and executive 
impairments in children with spastic cerebral palsy. Dev Med Child Neurol, 
2010. 52(2): e42-7. 
26. Anderson, V. Childhood white matter injuries: what are the issues? Dev 
Neuropsychol, 2007. 32(2): 619-23. 
27. Luciana, M. Cognitive development in children born preterm: implications for 
theories of brain plasticity following early injury. Dev Psychopathol, 2003. 
15(4): 1017-47. 
28. Christ, S.E., et al. Inhibitory control following perinatal brain injury. 
Neuropsychology, 2003. 17(1): 171-8. 
29. Golomb, M.R., et al. Association of cerebral palsy with other disabilities in 
children with perinatal arterial ischemic stroke. Pediatr Neurol, 2007. 37(4): 
245-9. 
30. Bottcher, L. Children with spastic cerebral palsy, their cognitive functioning, 
and social participation: a review. Child Neuropsychol, 2010. 16(3): 209-28. 
31. Straub, K. and J.E. Obrzut. Effects of Cerebral Palsy on Neuropsychological 
Function. Journal of Developmental and Physical Disabilities, 2009. 21(2): 
153-167. 
32. Himmelmann, K., et al. Gross and fine motor function and accompanying 
impairments in cerebral palsy. Dev Med Child Neurol, 2006. 48(6): 417-23. 
33. Raina, P., et al. The health and well-being of caregivers of children with 
cerebral palsy. Pediatrics, 2005. 115(6): e626-36. 
34. Brehaut, J.C., et al. The health of primary caregivers of children with cerebral 
palsy: how does it compare with that of other Canadian caregivers? Pediatrics, 
2004. 114(2): e182-91. 
35. Davis, E., et al. The impact of caring for a child with cerebral palsy: quality of 
life for mothers and fathers. Child Care Health Dev, 2010. 36(1): 63-73. 
36. Rekand, T. Clinical assessment and management of spasticity: a review. Acta 
Neurol Scand Suppl, 2010(190): 62-6. 
37. Mutlu, A., A. Livanelioglu, and M.K. Gunel. Reliability of Ashworth and 
Modified Ashworth scales in children with spastic cerebral palsy. BMC 
Musculoskelet Disord, 2008. 9: 44. 
38. Haugh, A.B., A.D. Pandyan, and G.R. Johnson. A systematic review of the 
Tardieu Scale for the measurement of spasticity. Disabil Rehabil, 2006. 
28(15): 899-907. 
39. Scholtes, V.A., et al. Clinical assessment of spasticity in children with cerebral 
palsy: a critical review of available instruments. Dev Med Child Neurol, 2006. 
48(1): 64-73. 
REFERENCES   
 234 
40. Akbayrak, T., et al. Assessment of the short-term effect of antispastic 
positioning on spasticity. Pediatr Int, 2005. 47(4): 440-5. 
41. Bowden, M. and D.S. Stokic. Clinical and neurophysiologic assessment of 
strength and spasticity during intrathecal baclofen titration in incomplete 
spinal cord injury: single-subject design. J Spinal Cord Med, 2009. 32(2): 183-
90. 
42. Steinbok, P. Selection of treatment modalities in children with spastic cerebral 
palsy. Neurosurg Focus, 2006. 21(2): e4. 
43. Mandigo, C.E. and R.C. Anderson. Management of childhood spasticity: a 
neurosurgical perspective. Pediatr Ann, 2006. 35(5): 354-62. 
44. Gormley, M.E., Jr., C.F. O'Brien, and S.A. Yablon. A clinical overview of 
treatment decisions in the management of spasticity. Muscle Nerve Suppl, 
1997. 6(20): S14-20. 
45. Ward, A.B. A summary of spasticity management-a treatment algorithm. Eur J 
Neurol, 2002. 9 Suppl 1: 48-52; dicussion 53-61. 
46. Kaplan, M.C., et al. Surgical correction of contracture: the costs of failed joint 
management in acquired brain injury. in Arch Phys Med Rehabil 1995. 
47. Gerszten, P.C., A.L. Albright, and G.F. Johnstone. Intrathecal baclofen 
infusion and subsequent orthopedic surgery in patients with spastic cerebral 
palsy. J Neurosurg, 1998. 88(6): 1009-13. 
48. Sindou, M. Neurosurgery for spasticity. J Neurosurg Sci, 2003. 47(1 Suppl 1): 
57-9. 
49. Steinbok, P. Selection of treatment modalities in children with spastic cerebral 
palsy. Neurosurg Focus, 2006. 21(2). 
50. Martin, L., R. Baker, and A. Harvey. A systematic review of common 
physiotherapy interventions in school-aged children with cerebral palsy. Phys 
Occup Ther Pediatr, 2010. 30(4): 294-312. 
51. O’Donnell, M. and R. Armstrong. Pharmacologic interventions for 
management of spasticity in cerebral palsy. Mental Retardation And 
Developmental Disabilities, 1997. 3(2): 204–211  
52. Ward, A.B. Long-term modification of spasticity. J Rehabil Med, 2003(41 
Suppl): 60-5. 
53. Gracies, J.M., et al. Traditional pharmacological treatments for spasticity. Part 
II: General and regional treatments. Muscle Nerve Suppl, 1997. 6: S92-120. 
54. Patel, D.R. and O. Soyode. Pharmacologic interventions for reducing spasticity 
in cerebral palsy. Indian J Pediatr, 2005. 72(10): 869-72. 
55. Krach, L.E. Pharmacotherapy of spasticity: oral medications and intrathecal 
baclofen. J Child Neurol, 2001. 16(1): 31-6. 
56. Morris, J.G., et al. Athetosis II: the syndrome of mild athetoid cerebral palsy. 
Mov Disord, 2002. 17(6): 1281-7. 
57. Angara, V.S. and J.S. Whittaker. Diazepam: A Preliminary Study of Its Effects 
on Patients with Athetoid Cerebral Palsy. Can Med Assoc J, 1965. 93: 364-6. 
58. Denhoff, E. Diazepam (Valium) in Cerebral Palsy. A Comparison of 
Uncontrolled Office Studies Versus a Controlled Team Study. R I Med J, 
1964. 47: 429-31. 
59. Mathew, A., et al. The efficacy of diazepam in enhancing motor function in 
children with spastic cerebral palsy. J Trop Pediatr, 2005. 51(2): 109-13. 
60. Mathew, A. and M.C. Mathew. Bedtime diazepam enhances well-being in 
children with spastic cerebral palsy. Pediatr Rehabil, 2005. 8(1): 63-6. 
61. Murray, J.B. Effects of valium and librium on human psychomotor and 
cognitive functions. Genet Psychol Monogr, 1984. 109(2D Half): 167-97. 
REFERENCES   
 235 
62. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy 
in drug-resistant partial epilepsy. The US Gabapentin Study Group. Epilepsy 
Res, 1994. 18(1): 67-73. 
63. Scheinfeld, N. The role of gabapentin in treating diseases with cutaneous 
manifestations and pain. Int J Dermatol, 2003. 42(6): 491-5. 
64. Rose, M.A. and P.C. Kam. Gabapentin: pharmacology and its use in pain 
management. Anaesthesia, 2002. 57(5): 451-62. 
65. Rabchevsky, A.G. and P.H. Kitzman. Latest approaches for the treatment of 
spasticity and autonomic dysreflexia in chronic spinal cord injury. 
Neurotherapeutics, 2011. 8(2): 274-82. 
66. Belverud, S., A. Mogilner, and M. Schulder. Intrathecal pumps. 
Neurotherapeutics, 2008. 5(1): 114-22. 
67. Olpe, H.R., et al. The biological activity of d- and l-baclofen (Lioresal). Eur J 
Pharmacol, 1978. 52(1): 133-6. 
68. Couve, A., S.J. Moss, and M.N. Pangalos. GABAB receptors: a new paradigm 
in G protein signaling. Mol Cell Neurosci, 2000. 16(4): 296-312. 
69. Azouvi, P., et al. Effect of intrathecal baclofen on the monosynaptic reflex in 
humans: evidence for a postsynaptic action. J Neurol Neurosurg Psychiatry, 
1993. 56(5): 515-9. 
70. Bowery, N.G., A.L. Hudson, and G.W. Price. GABAA and GABAB receptor 
site distribution in the rat central nervous system. Neuroscience, 1987. 20(2): 
365-83. 
71. Davidoff, R.A. Antispasticity drugs: mechanisms of action. Ann Neurol, 1985. 
17(2): 107-16. 
72. Misgeld, U., M. Bijak, and W. Jarolimek. A physiological role for GABAB 
receptors and the effects of baclofen in the mammalian central nervous system. 
Prog Neurobiol, 1995. 46(4): 423-62. 
73. Saito, K., S. Konishi, and M. Otsuka. Antagonism between Lioresal and 
substance P in rat spinal cord. Brain Res, 1975. 97(1): 177-80. 
74. Henry, J.L. Pharmacological studies on the prolonged depressant effects of 
baclofen on lumbar dorsal horn units in the cat. Neuropharmacology, 1982. 
21(11): 1085-93. 
75. Nakajima, Y., S. Nakajima, and M. Inoue. Pertussis toxin-insensitive G protein 
mediates substance P-induced inhibition of potassium channels in brain 
neurons. Proc Natl Acad Sci U S A, 1988. 85(10): 3643-7. 
76. Sanchez-Ponce, R., et al. Metabolic and Pharmacokinetic Differentiation of 
STX209 and Racemic Baclofen in Humans. Metabolites, 2012. 2(3): 596-613. 
77. Knutsson, E., U. Lindblom, and A. Martensson. Plasma and cerebrospinal 
fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic 
paresis. J Neurol Sci, 1974. 23(3): 473-84. 
78. Faigle, J.W. and H. Keberle. The chemistry and kinetics of Lioresal. Postgrad 
Med J, 1972. 48: Suppl 5:9-13. 
79. Wuis, E.W., et al. Plasma and urinary excretion kinetics of oral baclofen in 
healthy subjects. Eur J Clin Pharmacol, 1989. 37(2): 181-4. 
80. Duncan, G.W., B.T. Shahani, and R.R. Young. An evaluation of baclofen 
treatment for certain symptoms in patients with spinal cord lesions. A double-
blind, cross-over study. Neurology, 1976. 26(5): 441-6. 
81. Feldman, R.G., et al. Baclofen for spasticity in multiple sclerosis. Double-
blind crossover and three-year study. Neurology, 1978. 28(11): 1094-8. 
REFERENCES   
 236 
82. Sachais, B.A., J.N. Logue, and M.S. Carey. Baclofen, a new antispastic drug. 
A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol, 
1977. 34(7): 422-8. 
83. Milla, P.J. and A.D. Jackson. A controlled trial of baclofen in children with 
cerebral palsy. J Int Med Res, 1977. 5(6): 398-404. 
84. Schwartzman JS, T.G., Kogler E et al. Effects of Lioresal in cerebral palsy. 
Fohla Medica 1976(72): 297–302. 
85. Young., J. Clinical experience in the use of baclofen in children with spastic 
cerebral palsy. Scott. Med. J. , 1980. S23–5. 
86. From, A. and A. Heltberg. A double-blind trial with baclofen (Lioresal) and 
diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand, 1975. 
51(2): 158-66. 
87. Pedersen, E., et al. Gaba derivative in spasticity. (Beta-(4-chlorophenyl)-
gamma-aminobutyric acid, Ciba 34.647-Ba). Acta Neurol Scand, 1970. 46(3): 
257-66. 
88. Cartlidge, N.E., P. Hudgson, and D. Weightman. A comparison of baclofen 
and diazepam in the treatment of spasticity. J Neurol Sci, 1974. 23(1): 17-24. 
89. Roussan, M., C. Terrence, and G. Fromm. Baclofen versus diazepam for the 
treatment of spasticity and long-term follow-up of baclofen therapy. 
Pharmatherapeutica, 1985. 4(5): 278-84. 
90. Aisen, M.L., et al. Clinical and pharmacokinetic aspects of high dose oral 
baclofen therapy. J Am Paraplegia Soc, 1992. 15(4): 211-6. 
91. Dario, A. and G. Tomei. A benefit-risk assessment of baclofen in severe spinal 
spasticity. Drug Saf, 2004. 27(11): 799-818. 
92. Ryan, D.M. and F.S. Blumenthal. Baclofen-induced dyskinesia. Arch Phys 
Med Rehabil, 1993. 74(7): 766-7. 
93. Roy, C.W. and I.R. Wakefield. Baclofen pseudopsychosis: case report. 
Paraplegia, 1986. 24(5): 318-21. 
94. Hansel, D.E., et al. Oral baclofen in cerebral palsy: possible seizure 
potentiation? Pediatr Neurol, 2003. 29(3): 203-6. 
95. Bass, B., et al. Tizanidine versus baclofen in the treatment of spasticity in 
patients with multiple sclerosis. Can J Neurol Sci, 1988. 15(1): 15-9. 
96. Coward, D.M. Tizanidine: neuropharmacology and mechanism of action. 
Neurology, 1994. 44(11 Suppl 9): S6-10; discussion S10-1. 
97. Verrotti, A., et al. Pharmacotherapy of spasticity in children with cerebral 
palsy. Pediatr Neurol, 2006. 34(1): 1-6. 
98. Miglietta, O. Effect of dantrolene sodium on muscle contraction. Am J Phys 
Med, 1977. 56(6): 293-9. 
99. Novacheck, T.F. and J.R. Gage. Orthopedic management of spasticity in 
cerebral palsy. Childs Nerv Syst, 2007. 23(9): 1015-31. 
100. Sindou, M.P. and P. Mertens. Neurosurgery for spasticity. Stereotact Funct 
Neurosurg, 2000. 74(3-4): 217-21. 
101. Lazorthes, Y., et al. The surgical management of spasticity. Eur J Neurol, 
2002. 9 Suppl 1: 35-41; dicussion 53-61. 
102. Lazorthes, Y., et al. The surgical management of spasticity. Eur J Neurol, 
2002. 1: 35-41. 
103. Smyth, M.D. and W.J. Peacock. The surgical treatment of spasticity. Muscle 
Nerve, 2000. 23(2): 153-63. 
104. McCrea, P.H., J.J. Eng, and R. Willms. Phenol reduces hypertonia and 
enhances strength: a longitudinal case study. Neurorehabil Neural Repair, 
2004. 18(2): 112-6. 
REFERENCES   
 237 
105. Cormack, J. and C.M. Powers. Is there evidence that botulinum toxin 
injections are more effective than phenol injections in relieving poststroke 
reflex activity during plantar flexion, thereby increasing ankle range of motion 
and improving gait function? Phys Ther, 2004. 84(1): 76-84. 
106. Calderon-Gonzalez, R. and R.F. Calderon-Sepulveda. [Treatment of spasticity 
in cerebral palsy with botulinum toxin]. Rev Neurol, 2002. 34(1): 52-9. 
107. Bares, M., et al. Correspondence on ''Outcome measures used in studies of 
botulinum toxin in childhood cerebral palsy: a systematic review''. J Child 
Neurol, 2010. 25(6): 793-4; author reply 794. 
108. Coutinho dos Santos, L.H., et al. Effective results with botulinum toxin in 
cerebral palsy. Pediatr Neurol, 2011. 44(5): 357-63. 
109. Thorley, M., et al. Evaluation of the effects of botulinum toxin A injections 
when used to improve ease of care and comfort in children with cerebral palsy 
whom are non-ambulant: a double blind randomized controlled trial. BMC 
Pediatr, 2012. 12: 120. 
110. Aquilina, K., D. Graham, and N. Wimalasundera. Selective dorsal rhizotomy: 
an old treatment re-emerging. Arch Dis Child, 2015. 100(8): 798-802. 
111. Steinbok, P. Selective dorsal rhizotomy for spastic cerebral palsy: a review. 
Childs Nerv Syst, 2007. 23(9): 981-90. 
112. Grunt, S., et al. Selection criteria for selective dorsal rhizotomy in children 
with spastic cerebral palsy: a systematic review of the literature. Dev Med 
Child Neurol, 2014. 56(4): 302-12. 
113. The National Institute for Health and Care Excellence. Spasticity in Children 
and Young People with Non-Progressive Brain Disorders: Management of 
Spasticity and Co-Existing Motor Disorders and Their Early Musculoskeletal 
Complications. 2012, RCOG Press at the Royal College of Obstetricians and 
Gynaecologists: Sussex, UK.Pages 
114. Peacock, W.J., L.J. Arens, and B. Berman. Cerebral palsy spasticity. Selective 
posterior rhizotomy. Pediatr Neurosci, 1987. 13(2): 61-6. 
115. Rosenbaum, P.L., et al. Development of the Gross Motor Function 
Classification System for cerebral palsy. Dev Med Child Neurol, 2008. 50(4): 
249-53. 
116. Dudgeon, B.J., et al. Prospective measurement of functional changes after 
selective dorsal rhizotomy. Arch Phys Med Rehabil, 1994. 75(1): 46-53. 
117. Farmer, J.-P. and P.D. McNeely. Surgery in the Dorsal Roots for Children with 
Cerebral Palsy. Oper Tech Neurosurg, 2005. 7: 153-156  
118. Park, T.S. and J.M. Johnston. Surgical techniques of selective dorsal 
rhizotomy for spastic cerebral palsy. Technical note. Neurosurg Focus, 2006. 
21(2): e7. 
119. Farmer, J.P. and A.J. Sabbagh. Selective dorsal rhizotomies in the treatment of 
spasticity related to cerebral palsy. Childs Nerv Syst, 2007. 23(9): 991-1002. 
120. McLaughlin, J.F., et al. The role of selective dorsal rhizotomy in cerebral 
palsy: critical evaluation of a prospective clinical series. Dev Med Child 
Neurol, 1994. 36(9): 755-69. 
121. Abbott, R., et al. Selective dorsal rhizotomy: outcome and complications in 
treating spastic cerebral palsy. Neurosurgery, 1993. 33(5): 851-7; discussion 
857. 
122. Deletis, V., et al. Intraoperative monitoring of the dorsal sacral roots: 
minimizing the risk of iatrogenic micturition disorders. Neurosurgery, 1992. 
30(1): 72-5. 
REFERENCES   
 238 
123. Houle, A.M., et al. Bladder function before and after selective dorsal 
rhizotomy in children with cerebral palsy. J Urol, 1998. 160(3 Pt 2): 1088-91. 
124. Huang, J.C., et al. Preservation of pudendal afferents in sacral rhizotomies. 
Neurosurgery, 1997. 41(2): 411-5. 
125. Grunt, S., J.G. Becher, and R.J. Vermeulen. Long-term outcome and adverse 
effects of selective dorsal rhizotomy in children with cerebral palsy: a 
systematic review. Dev Med Child Neurol, 2011. 53(6): 490-8. 
126. McLaughlin, J.F., et al. Selective dorsal rhizotomy: efficacy and safety in an 
investigator-masked randomized clinical trial. Dev Med Child Neurol, 1998. 
40(4): 220-32. 
127. Steinbok, P. and K. McLeod. Comparison of motor outcomes after selective 
dorsal rhizotomy with and without preoperative intensified physiotherapy in 
children with spastic diplegic cerebral palsy. Pediatr Neurosurg, 2002. 36(3): 
142-7. 
128. Wright, F.V., et al. Evaluation of selective dorsal rhizotomy for the reduction 
of spasticity in cerebral palsy: a randomized controlled tria. Dev Med Child 
Neurol, 1998. 40(4): 239-47. 
129. Subramanian, N., et al. Gait before and 10 years after rhizotomy in children 
with cerebral palsy spasticity. J Neurosurg, 1998. 88(6): 1014-9. 
130. Langerak, N.G., et al. A prospective gait analysis study in patients with 
diplegic cerebral palsy 20 years after selective dorsal rhizotomy. J Neurosurg 
Pediatr, 2008. 1(3): 180-6. 
131. Wong, A.M., et al. Comparison between botulinum toxin type A injection and 
selective posterior rhizotomy in improving gait performance in children with 
cerebral palsy. J Neurosurg, 2005. 102(4 Suppl): 385-9. 
132. Fasano, V.A., G. Broggi, and S. Zeme. Intraoperative electrical stimulation for 
functional posterior rhizotomy. Scand J Rehabil Med Suppl, 1988. 17: 149-54. 
133. Loewen, P., et al. Upper extremity performance and self-care skill changes in 
children with spastic cerebral palsy following selective posterior rhizotomy. 
Pediatr Neurosurg, 1998. 29(4): 191-8. 
134. Mittal, S., et al. Impact of selective posterior rhizotomy on fine motor skills. 
Long-term results using a validated evaluative measure. Pediatr Neurosurg, 
2002. 36(3): 133-41. 
135. Craft, S., et al. Changes in cognitive performance in children with spastic 
diplegic cerebral palsy following selective dorsal rhizotomy. Pediatr 
Neurosurg, 1995. 23(2): 68-74; discussion 75. 
136. Kurpad, S.N. and A.R. Cohen. Rhizotomy for spasticity, in Operative 
Neurosurgery, A.H. Kaye and P.M. Black, Editors. 2000, Churchill 
Livingstone.129. p. 1591. 
137. Hagglund, G., et al. Prevention of severe contractures might replace multilevel 
surgery in cerebral palsy: results of a population-based health care programme 
and new techniques to reduce spasticity. J Pediatr Orthop B, 2005. 14(4): 269-
73. 
138. Chicoine, M.R., T.S. Park, and B.A. Kaufman. Selective dorsal rhizotomy and 
rates of orthopedic surgery in children with spastic cerebral palsy. J 
Neurosurg, 1997. 86(1): 34-9. 
139. W. De Rouck, P.D.C., L. Lagae1 , G. Molenaers, A. Van Campenhout, P. 
auwels, E. Ortibus. Bladder function and proprioception before and after 
selective dorsal rhizotomy in children with spastic diplegia European Journal 
of Paediatric Neurology, 2009. 13(Supplement 1): S47. 
REFERENCES   
 239 
140. Chiu, P.K., et al. Does selective dorsal rhizotomy improve bladder function in 
children with cerebral palsy? Int Urol Nephrol, 2014. 46(10): 1929-33. 
141. Albright, A.L., et al. Cerebrospinal fluid baclofen concentrations in patients 
undergoing continuous intrathecal baclofen therapy. Dev Med Child Neurol, 
2007. 49(6): 423-5. 
142. Albright, A.L. and B.L. Shultz. Plasma baclofen levels in children receiving 
continuous intrathecal baclofen infusion. J Child Neurol, 1999. 14(6): 408-9. 
143. Coffey, R.J., et al. Abrupt withdrawal from intrathecal baclofen: recognition 
and management of a potentially life-threatening syndrome. Arch Phys Med 
Rehabil, 2002. 83(6): 735-41. 
144. Mohammed, I. and A. Hussain. Intrathecal baclofen withdrawal syndrome- a 
life-threatening complication of baclofen pump: a case report. BMC Clin 
Pharmacol, 2004. 4: 6. 
145. Penn, R.D. Intrathecal baclofen for spasticity of spinal origin: seven years of 
experience. J Neurosurg, 1992. 77(2): 236-40. 
146. Van Schaeybroeck, P., et al. Intrathecal baclofen for intractable cerebral 
spasticity: a prospective placebo-controlled, double-blind study. Neurosurgery, 
2000. 46(3): 603-9; discussion 609-12. 
147. Penn, R.D. and J.S. Kroin. Intrathecal baclofen alleviates spinal cord 
spasticity. Lancet, 1984. 1(8385): 1078. 
148. Penn, R.D. and J.S. Kroin. Continuous intrathecal baclofen for severe 
spasticity. Lancet, 1985. 2(8447): 125-7. 
149. Dralle, D., et al. Intrathecal baclofen for spasticity. Lancet, 1985. 2(8462): 
1003. 
150. Albright, A.L., A. Cervi, and J. Singletary. Intrathecal baclofen for spasticity 
in cerebral palsy. Jama, 1991. 265(11): 1418-22. 
151. Albright, A.L. Baclofen in the treatment of cerebral palsy. J Child Neurol, 
1996. 11(2): 77-83. 
152. Albright, A.L., et al. Continuous intrathecal baclofen infusion for symptomatic 
generalized dystonia. Neurosurgery, 1996. 38(5): 934-8; discussion 938-9. 
153. Ordia, J.I., et al. Chronic intrathecal delivery of baclofen by a programmable 
pump for the treatment of severe spasticity. J Neurosurg, 1996. 85(3): 452-7. 
154. Dones, I. Intrathecal baclofen for the treatment of spasticity. Acta Neurochir 
Suppl, 2007. 97(Pt 1): 185-8. 
155. Kroin, J.S. Intrathecal drug administration. Present use and future trends. Clin 
Pharmacokinet, 1992. 22(5): 319-26. 
156. Castro, J.d., J. Meynadier, and M. Zenz. Regional opioid analgesia : 
physiopharmacological basis, drugs, equipment and clinical application. 1991, 
Dordrecht ; London: Kluwer Academic 
157. Bernards, C.M. and H.F. Hill. Physical and chemical properties of drug 
molecules governing their diffusion through the spinal meninges. 
Anesthesiology, 1992. 77(4): 750-6. 
158. Bernards, C.M. Epidural and intrathecal drug movement, in spinal drug 
delivery, T.L. Yaksh, Editor. 1999, elsevier: California.9. p. 245-251. 
159. Kroin, J.S., et al. The distribution of medication along the spinal canal after 
chronic intrathecal administration. Neurosurgery, 1993. 33(2): 226-30; 
discussion 230. 
160. Linninger, A.A., et al. Pulsatile cerebrospinal fluid dynamics in the human 
brain. IEEE Trans Biomed Eng, 2005. 52(4): 557-65. 
REFERENCES   
 240 
161. Hurlbut, K.M. General Muscle Relaxants, in Medical toxicology, R.C. Dart, 
Editor. 2004, Lippincott Williams & Wilkins: Philadelphia, Pa. ; London.104. 
p. 596. 
162. Salim Michel Haek, P.N.J., and Nagy A. Mekhail. Pharmacology of 
intrathecally administered agents for treatment of spasticity and pain. Seminars 
in Pain Medicine, 2004. 1(4): 238-253. 
163. M Vloeberghs, M.C., S Bassi. The Use of Intrathecal Baclofen in the 
Management of Spasticity in Children with Cerebral Palsy. Child’s Nervous 
System, 2002. 18(8): 540. 
164. Albright, A.L. and S.S. Ferson. Intrathecal baclofen therapy in children. 
Neurosurg Focus, 2006. 21(2): e3. 
165. Hoving, M.A., et al. Intrathecal baclofen therapy in children with intractable 
spastic cerebral palsy: a cost-effectiveness analysis. Dev Med Child Neurol, 
2008. 50(6): 450-5. 
166. Albright, A.L. Intrathecal baclofen for childhood hypertonia. Childs Nerv Syst, 
2007. 23(9): 971-9. 
167. Brennan, P.M. and I.R. Whittle. Intrathecal baclofen therapy for neurological 
disorders: a sound knowledge base but many challenges remain. Br J 
Neurosurg, 2008. 22(4): 508-19. 
168. Murphy, N.A., M.C. Irwin, and C. Hoff. Intrathecal baclofen therapy in 
children with cerebral palsy: efficacy and complications. Arch Phys Med 
Rehabil, 2002. 83(12): 1721-5. 
169. Kopell, B.H., et al. Subfascial implantation of intrathecal baclofen pumps in 
children: technical note. Neurosurgery, 2001. 49(3): 753-6; discussion 756-7. 
170. Ammar, A., et al. Intrathecal baclofen therapy--how we do it. J Neurosurg 
Pediatr, 2012. 10(5): 439-44. 
171. Albright, A.L., M. Turner, and J.V. Pattisapu. Best-practice surgical 
techniques for intrathecal baclofen therapy. J Neurosurg, 2006. 104(4 Suppl): 
233-9. 
172. A.L.Albright. Pump insertion, in Operative Techniques in Pediatric 
Neurosurgery, A. Albright, et al., Editors. 2001, Thieme: New Yorkp. . p276-
290. 
173. Borowski, A., et al. Complications of intrathecal baclofen pump therapy in 
pediatric patients. J Pediatr Orthop, 2010. 30(1): 76-81. 
174. Haranhalli, N., et al. Intrathecal baclofen therapy: complication avoidance and 
management. Childs Nerv Syst. 27(3): 421-7. 
175. Ughratdar, I., et al. Cervical implantation of intrathecal baclofen pump catheter 
in children with severe scoliosis. J Neurosurg Pediatr. 10(1): 34-8. 
176. Middel, B., et al. Effect of intrathecal baclofen delivered by an implanted 
programmable pump on health related quality of life in patients with severe 
spasticity. J Neurol Neurosurg Psychiatry, 1997. 63(2): 204-9. 
177. Plassat, R., et al. Treatment of spasticity with intrathecal Baclofen 
administration: long-term follow-up, review of 40 patients. Spinal Cord, 2004. 
42(12): 686-93. 
178. Cooper, J.A. and B. Ridley. Response of intrathecal baclofen resistance to dose 
reduction. Neurology, 2006. 67(8): 1495-6. 
179. Moberg-Wolff, E. Potential clinical impact of compounded versus 
noncompounded intrathecal baclofen. Arch Phys Med Rehabil, 2009. 90(11): 
1815-20. 
180. Rawlins, P.K. Intrathecal baclofen therapy over 10 years. J Neurosci Nurs, 
2004. 36(6): 322-7. 
REFERENCES   
 241 
181. Albright, A.L., et al. Performance and complications associated with the 
synchromed 10-ml infusion pump for intrathecal baclofen administration in 
children. J Neurosurg, 2004. 101(1 Suppl): 64-8. 
182. Sigg., J., J. Sonntag., and J.L. . Solubility and stability of intrathecal baclofen 
solutions at high concentrations: implications for chronic use in the 
synchromed infusion system, in White Paper 2007, M.N. Minneapolis, Editor. 
2007. 
183. Lagarce, F., et al. Baclofen-loaded microspheres: preparation and efficacy 
testing in a new rabbit model. Eur J Pharm Biopharm, 2005. 59(3): 449-59. 
184. Mullarkey, T. Considerations in the treatment of spasticity with intrathecal 
baclofen. Am J Health Syst Pharm, 2009. 66(17 Suppl 5): S14-22. 
185. Vender, J.R., et al. Identification and management of intrathecal baclofen 
pump complications: a comparison of pediatric and adult patients. J 
Neurosurg, 2006. 104(1 Suppl): 9-15. 
186. Ivanhoe, C.B., A.H. Tilton, and G.E. Francisco. Intrathecal baclofen therapy 
for spastic hypertonia. Phys Med Rehabil Clin N Am, 2001. 12(4): 923-38, viii-
ix. 
187. Couture, D. and C.L. Branch, Jr. Spinal pseudomeningoceles and 
cerebrospinal fluid fistulas. Neurosurg Focus, 2003. 15(6): E6. 
188. Gilmartin, R., et al. Intrathecal baclofen for management of spastic cerebral 
palsy: multicenter trial. J Child Neurol, 2000. 15(2): 71-7. 
189. Atiyeh, B.S., et al. Baclofen pump pocket infection: a case report of successful 
salvage with muscle flap. Int Wound J, 2006. 3(1): 23-8. 
190. Staats, P.S. Complications of Intrathecal Therapy. pain medicine 2008. 9(21): 
S103. 
191. Butler, C. and S. Campbell. Evidence of the effects of intrathecal baclofen for 
spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes 
Committee Review Panel. Dev Med Child Neurol, 2000. 42(9): 634-45. 
192. Kofler, M., H. Matzak, and L. Saltuari. The impact of intrathecal baclofen on 
gastrointestinal function. Brain Inj, 2002. 16(9): 825-36. 
193. Murphy, N.A. Deep venous thrombosis as a result of hypotonia secondary to 
intrathecal baclofen therapy: a case report. Arch Phys Med Rehabil, 2002. 
83(9): 1311-2. 
194. Carda, S., et al. Intrathecal baclofen bolus complicated by deep vein 
thrombosis and pulmonary embolism. A case report. Eur J Phys Rehabil Med, 
2008. 44(1): 87-8. 
195. Watve, S.V., et al. Management of acute overdose or withdrawal state in 
intrathecal baclofen therapy. Spinal Cord. 50(2): 107-11. 
196. Tunali, Y., et al. Intrathecal baclofen toxicity and deep coma in minutes. J 
Spinal Cord Med, 2006. 29(3): 237-9. 
197. Anderson, K.J., J.P. Farmer, and K. Brown. Reversible coma in children after 
improper baclofen pump insertion. Paediatr Anaesth, 2002. 12(5): 454-60. 
198. Lorrain, D.S., et al. Activation of spinal group I metabotropic glutamate 
receptors in rats evokes local glutamate release and spontaneous nociceptive 
behaviors: effects of 2-methyl-6-(phenylethynyl)-pyridine pretreatment. 
Neurosci Lett, 2002. 327(3): 198-202. 
199. FDA. MedWatch Safety Alert – Lioresal (baclofen injection). 
http://www.fda.gov/medwatch/safety/2002/baclofen.htm. . 2002  [cited 2013 
10th Oct. ]. 
200. Kao, L.W., et al. Intrathecal baclofen withdrawal mimicking sepsis. J Emerg 
Med, 2003. 24(4): 423-7. 
REFERENCES   
 242 
201. Sampathkumar, P., P.D. Scanlon, and D.J. Plevak. Baclofen withdrawal 
presenting as multiorgan system failure. Anesth Analg, 1998. 87(3): 562-3. 
202. Kroin, J.S., G.D. Bianchi, and R.D. Penn. Intrathecal baclofen down-regulates 
GABAB receptors in the rat substantia gelatinosa. J Neurosurg, 1993. 79(4): 
544-9. 
203. Olmedo, R. and R.S. Hoffman. Withdrawal syndromes. Emerg Med Clin North 
Am, 2000. 18(2): 273-88. 
204. Leo, R.J. and D. Baer. Delirium associated with baclofen withdrawal: a review 
of common presentations and management strategies. Psychosomatics, 2005. 
46(6): 503-7. 
205. Saulino, M., et al. Best Practices for Intrathecal Baclofen Therapy: 
Troubleshooting. Neuromodulation, 2016. 19(6): 632-41. 
206. Kolaski, K. and L.R. Logan. A review of the complications of intrathecal 
baclofen in patients with cerebral palsy. NeuroRehabilitation, 2007. 22(5): 
383-95. 
207. Samson-Fang, L., J. Gooch, and C. Norlin. Intrathecal baclofen withdrawal 
simulating neuroepileptic malignant syndrome in a child with cerebral palsy. 
Dev Med Child Neurol, 2000. 42(8): 561-5. 
208. Greenberg, M.I. and R.G. Hendrickson. Baclofen withdrawal following 
removal of an intrathecal baclofen pump despite oral baclofen replacement. J 
Toxicol Clin Toxicol, 2003. 41(1): 83-5. 
209. Campbell, W.M., et al. Long-term safety and efficacy of continuous intrathecal 
baclofen. Dev Med Child Neurol, 2002. 44(10): 660-5. 
210. Gooch, J.L., et al. Complications of intrathecal baclofen pumps in children. 
Pediatr Neurosurg, 2003. 39(1): 1-6. 
211. Vender., J.R., et al. Baclofen Intrathecal Pump Delivery Systems, Avoidance 
and Management of Complications in Adult and Pediatric Patients: Part I 
Contemporary Neurosurgery, 2005. 27(1): 1-7. 
212. Penn, R.D., M. M.York, and J.A. Paice. Catheter systems for intrathecal drug 
delivery. J Neurosurg, 1995. 83(2): 215-7. 
213. Penn, R.D., J.M. Gianino, and M.M. York. Intrathecal baclofen for motor 
disorders. Mov Disord, 1995. 10(5): 675-7. 
214. Albright, A.L., et al. Intrathecal baclofen for generalized dystonia. Dev Med 
Child Neurol, 2001. 43(10): 652-7. 
215. Ochs, G., et al. Intrathecal baclofen for long-term treatment of spasticity: a 
multi-centre study. J Neurol Neurosurg Psychiatry, 1989. 52(8): 933-9. 
216. Follett, K.A., et al. Prevention and management of intrathecal drug delivery 
and spinal cord stimulation system infections. Anesthesiology, 2004. 100(6): 
1582-94. 
217. Ross, D.A., C. Byers, and T. Hall. A novel approach to prevent repeated 
catheter migration in a patient with a baclofen pump: a case report. Arch Phys 
Med Rehabil, 2005. 86(5): 1060-1. 
218. Muller., H. Treatment of severe spasticity: results of a multi-center trial 
conducted in Germany involving the intrathecal infusion of baclofen by an 
implantable drug delivery system. Dev Med Child Neurol, 1992. 34: 739–745  
219. Albright, A.L., et al. Continuous intrathecal baclofen infusion for spasticity of 
cerebral origin. Jama, 1993. 270(20): 2475-7. 
220. Fitzgerald, J.J., M. Tsegaye, and M.H. Vloeberghs. Treatment of childhood 
spasticity of cerebral origin with intrathecal baclofen: a series of 52 cases. Br J 
Neurosurg, 2004. 18(3): 240-5. 
REFERENCES   
 243 
221. Vloeberghs, M., R. Keetley, and R. Morton. Intrathecal baclofen in the 
management of spasticity due to cerebral palsy. Pediatr Rehabil, 2005. 8(3): 
172-9. 
222. Gerszten, P.C., A.L. Albright, and M.J. Barry. Effect on ambulation of 
continuous intrathecal baclofen infusion. Pediatr Neurosurg, 1997. 27(1): 40-
4. 
223. Guillaume, D., et al. A clinical study of intrathecal baclofen using a 
programmable pump for intractable spasticity. Arch Phys Med Rehabil, 2005. 
86(11): 2165-71. 
224. Krach, L.E., A. Nettleton, and B. Klempka. Satisfaction of individuals treated 
long-term with continuous infusion of intrathecal baclofen by implanted 
programmable pump. Pediatr Rehabil, 2006. 9(3): 210-8. 
225. Gooch, J.L., et al. Care provider assessment of intrathecal baclofen in children. 
Dev Med Child Neurol, 2004. 46(8): 548-52. 
226. Narayan, R.K., et al. Intrathecal baclofen for intractable axial dystonia. 
Neurology, 1991. 41(7): 1141-2. 
227. Woon, K., M. Tsegaye, and M.H. Vloeberghs. The role of intrathecal baclofen 
in the management of primary and secondary dystonia in children. Br J 
Neurosurg, 2007. 21(4): 355-8. 
228. Dykstra, D.D., et al. Treatment of cervical dystonia and focal hand dystonia by 
high cervical continuously infused intrathecal baclofen: a report of 2 cases. 
Arch Phys Med Rehabil, 2005. 86(4): 830-3. 
229. Lara-Sires, N., J. Chacon, and J.M. Garcia-Moreno. [The intrathecal baclofen 
pump in the long-term treatment of generalised dystonias]. Rev Neurol, 2005. 
40(1): 30-3. 
230. Richard, I. and P. Menei. Intrathecal baclofen in the treatment of spasticity, 
dystonia and vegetative disorders. Acta Neurochir Suppl, 2007. 97(Pt 1): 213-
8. 
231. Motta, F., C. Stignani, and C.E. Antonello. Effect of intrathecal baclofen on 
dystonia in children with cerebral palsy and the use of functional scales. J 
Pediatr Orthop, 2008. 28(2): 213-7. 
232. Salazar-Tortolero, G., et al. [Intrathecal baclofen in generalised dystonia 
secondary to cerebral hypoxia]. Rev Neurol, 2008. 47(1): 53-5. 
233. Albright, A.L. and S.S. Ferson. Intraventricular baclofen for dystonia: 
techniques and outcomes. Clinical article. J Neurosurg Pediatr, 2009. 3(1): 11-
4. 
234. Albright, A.L. Intraventricular baclofen infusion for dystonia. Report of two 
cases. J Neurosurg, 2006. 105(1 Suppl): 71-4. 
235. Stallings, V.A., et al. Energy expenditure of children and adolescents with 
severe disabilities: a cerebral palsy model. Am J Clin Nutr, 1996. 64(4): 627-
34. 
236. Stallings, V.A., et al. Body composition in children with spastic quadriplegic 
cerebral palsy. J Pediatr, 1995. 126(5 Pt 1): 833-9. 
237. Hemingway, C., J. McGrogan, and J.M. Freeman. Energy requirements of 
spasticity. Dev Med Child Neurol, 2001. 43(4): 277-8. 
238. McCoy, A.A., et al. Weight gain in children with hypertonia of cerebral origin 
receiving intrathecal baclofen therapy. Arch Phys Med Rehabil, 2006. 87(11): 
1503-8. 
239. Sansone, J.M., et al. Rapid progression of scoliosis following insertion of 
intrathecal baclofen pump. J Pediatr Orthop, 2006. 26(1): 125-8. 
REFERENCES   
 244 
240. Ginsburg, G.M. and A.J. Lauder. Progression of scoliosis in patients with 
spastic quadriplegia after the insertion of an intrathecal baclofen pump. Spine, 
2007. 32(24): 2745-50. 
241. Hart, A.R., et al. 'Rapid progression of scoliosis complicating intrathecal 
baclofen pump insertion'. Dev Med Child Neurol, 2007. 49(9): 717. 
242. Shilt, J.S., et al. The impact of intrathecal baclofen on the natural history of 
scoliosis in cerebral palsy. J Pediatr Orthop, 2008. 28(6): 684-7. 
243. Rushton, P.R., et al. Intrathecal baclofen pumps do not accelerate progression 
of scoliosis in quadriplegic spastic cerebral palsy. Eur Spine J, 2016. 
244. Peyser, J.M., et al. Guidelines for neuropsychological research in multiple 
sclerosis. Arch Neurol, 1990. 47(1): 94-7. 
245. Sampson, F.C., et al. Functional benefits and cost/benefit analysis of 
continuous intrathecal baclofen infusion for the management of severe 
spasticity. J Neurosurg, 2002. 96(6): 1052-7. 
246. Bravo Vergel, Y. and M. Sculpher. Quality-adjusted life years. Pract Neurol, 
2008. 8(3): 175-82. 
247. Neumann, P.J., J.T. Cohen, and M.C. Weinstein. Updating cost-effectiveness--
the curious resilience of the $50,000-per-QALY threshold. N Engl J Med, 
2014. 371(9): 796-7. 
248. de Lissovoy, G., et al. Cost-effectiveness of intrathecal baclofen therapy for 
the treatment of severe spasticity associated with cerebral palsy. J Child 
Neurol, 2007. 22(1): 49-59. 
249. Hoving, M.A., et al. Intrathecal baclofen therapy in children with intractable 
spastic cerebral palsy: a cost-effectiveness analysis. Dev Med Child Neurol, 
2008. 50(6): 450-5. 
250. Bensmail, D., et al. Cost-effectiveness Modeling of Intrathecal Baclofen 
Therapy Versus Other Interventions for Disabling Spasticity. Neurorehabil 
Neural Repair, 2009. 23(6): 546-52. 
251. Booth, C.M. and I.F. Tannock. Randomised controlled trials and population-
based observational research: partners in the evolution of medical evidence. Br 
J Cancer, 2014. 110(3): 551-5. 
252. Meyer, R.M. Generalizing the results of cancer clinical trials. J Clin Oncol, 
2010. 28(2): 187-9. 
253. Price, D., et al. Complementing the randomized controlled trial evidence base. 
Evolution not revolution. Ann Am Thorac Soc, 2014. 11 Suppl 2: S92-8. 
254. Yang, W., et al. Observational studies: going beyond the boundaries of 
randomized controlled trials. Diabetes Res Clin Pract, 2010. 88 Suppl 1: S3-9. 
255. Mariani, A.W. and P.M. Pego-Fernandes. Observational studies: why are they 
so important? Sao Paulo Med J, 2014. 132(1): 1-2. 
256. Hannan, E.L. Randomized clinical trials and observational studies: guidelines 
for assessing respective strengths and limitations. JACC Cardiovasc Interv, 
2008. 1(3): 211-7. 
257. Goulart, B.H., S.D. Ramsey, and U. Parvathaneni. Observational study designs 
for comparative effectiveness research: an alternative approach to close 
evidence gaps in head-and-neck cancer. Int J Radiat Oncol Biol Phys, 2014. 
88(1): 106-14. 
258. Hoving, M.A., et al. Safety and one-year efficacy of intrathecal baclofen 
therapy in children with intractable spastic cerebral palsy. Eur J Paediatr 
Neurol, 2009. 13(3): 247-56. 
REFERENCES   
 245 
259. Hoving, M.A., et al. Efficacy of intrathecal baclofen therapy in children with 
intractable spastic cerebral palsy: a randomised controlled trial. Eur J Paediatr 
Neurol, 2009. 13(3): 240-6. 
260. Johnston, G., et al. Reviewing audit: barriers and facilitating factors for 
effective clinical audit. Qual Health Care, 2000. 9(1): 23-36. 
261. Bull, A. Audit and research. BMJ, 1993. 306(6869): 67. 
262. Twycross, A. and A. Shorten. Service evaluation, audit and research: what is 
the difference? Evid Based Nurs, 2014. 17(3): 65-6. 
263. RCPsych. The Royal College of Psychiatrists. Undertaking a clinical audit 
project: a step-by-step guide. The Royal College of Psychiatrists  12th 
December 2016]; Available from: 
http://www.rcpsych.ac.uk/pdf/clinauditchap2.pdf. 
264. Benjamin, A. Audit: how to do it in practice. Bmj, 2008. 336(7655): 1241-5. 
265. Hasnat, M.J. and J.E. Rice. Intrathecal baclofen for treating spasticity in 
children with cerebral palsy. Cochrane Database Syst Rev, 2015(11): 
CD004552. 
266. Ward, A., et al. Continuous intrathecal baclofen for children with spasticity 
and/or dystonia: Goal attainment and complications associated with treatment. 
J Paediatr Child Health, 2009. 45(12): 720-6. 
267. Motta, F., V. Buonaguro, and C. Stignani. The use of intrathecal baclofen 
pump implants in children and adolescents: safety and complications in 200 
consecutive cases. J Neurosurg, 2007. 107(1 Suppl): 32-5. 
268. Hulley, S.B. Designing clinical research. 4th ed. 2013, Philadelphia: Wolters 
Kluwer/Lippincott Williams & Wilkins.80. 
269. Banks, N.J. Designing medical record abstraction forms. Int J Qual Health 
Care, 1998. 10(2): 163-7. 
270. Worster, A. and T. Haines. Advanced statistics: understanding medical record 
review (MRR) studies. Acad Emerg Med, 2004. 11(2): 187-92. 
271. Gearing, R.E., et al. A methodology for conducting retrospective chart review 
research in child and adolescent psychiatry. J Can Acad Child Adolesc 
Psychiatry, 2006. 15(3): 126-34. 
272. Matt, V. and H. Matthew. The retrospective chart review: important 
methodological considerations. J Educ Eval Health Prof, 2013. 10: 12. 
273. Wilson, D.K.S.Æ.J. What is a Surgical Complication? World J Surg, 2008. 32: 
942–944. 
274. Dickey, M.P., et al. Infectious Complications of Intrathecal Baclofen Pump 
Devices in a Pediatric Population. Pediatr Infect Dis J, 2013. 32(7): 715-22. 
275. Horan, T.C., M. Andrus, and M.A. Dudeck. CDC/NHSN surveillance 
definition of health care-associated infection and criteria for specific types of 
infections in the acute care setting. Am J Infect Control, 2008. 36(5): 309-32. 
276. Mangram, A.J., et al. Guideline for prevention of surgical site infection, 1999. 
Hospital Infection Control Practices Advisory Committee. Infect Control Hosp 
Epidemiol, 1999. 20(4): 250-78; quiz 279-80. 
277. Ghosh, D., et al. Complications of intrathecal baclofen pumps in children: 
experience from a tertiary care center. Pediatr Neurosurg, 2013. 49: 138-44. 
278. Motta, F. and C.E. Antonello. Analysis of complications in 430 consecutive 
pediatric patients treated with intrathecal baclofen therapy: 14-year experience. 
J Neurosurg Pediatr, 2014. 13(3): 301-6. 
279. Groden, G. Relationships between intelligence, simple, and complex motor 
proficiency. Am J Ment Defic, 1969. 74(3): 373-5. 
REFERENCES   
 246 
280. Hadden, K.L. and C.L. von Baeyer. Global and specific behavioral measures 
of pain in children with cerebral palsy. Clin J Pain, 2005. 21(2): 140-6. 
281. Hagglund, G. and P. Wagner. Development of spasticity with age in a total 
population of children with cerebral palsy. BMC Musculoskelet Disord, 2008. 
9: 150. 
282. Phillips, M.M., et al. Clinical Experience With Continuous Intrathecal 
Baclofen Trials Prior to Pump Implantation. PM R, 2015. 7(10): 1052-8. 
283. Salomon, L.J. and Y. Ville. [Twin-to-twin transfusion syndrome: diagnosis 
and treatment]. Bull Acad Natl Med, 2008. 192(8): 1575-86; discussion 1586-
7. 
284. Abel, E.L. Cerebral palsy and alcohol consumption during pregnancy: is there 
a connection? Alcohol Alcohol, 2010. 45(6): 592-4. 
285. Awaad, Y., et al. Functional assessment following intrathecal baclofen therapy 
in children with spastic cerebral palsy. J Child Neurol, 2003. 18(1): 26-34. 
286. Buonaguro, V., et al. Epilepsy and intrathecal baclofen therapy in children 
with cerebral palsy. Pediatr Neurol, 2005. 33(2): 110-3. 
287. Faleiros-Castro, F.S. and E.D. de Paula. [Constipation in patients with 
quadriplegic cerebral palsy: intestinal reeducation using massage and a 
laxative diet]. Rev Esc Enferm USP, 2013. 47(4): 836-42. 
288. Cardoso, A.L., et al. Cardiac arrest due to baclofen withdrawal syndrome. BMJ 
Case Rep, 2014. 14(10): 2014-204322. 
289. Alden, T.D., et al. Intrathecal baclofen withdrawal: a case report and review of 
the literature. Childs Nerv Syst, 2002. 18(9-10): 522-5. 
290. Zuckerbraun, N.S., et al. Intrathecal baclofen withdrawal: emergent 
recognition and management. Pediatr Emerg Care, 2004. 20(11): 759-64. 
291. Shirley, K.W., et al. Intrathecal baclofen overdose and withdrawal. Pediatr 
Emerg Care, 2006. 22(4): 258-61. 
292. Fernandes, P., L. Dolan, and S.L. Weinstein. Intrathecal baclofen withdrawal 
syndrome following posterior spinal fusion for neuromuscular scoliosis: a case 
report. Iowa Orthop J, 2008. 28: 77-80. 
293. Al-Khodairy, A.T., H. Vuagnat, and D. Uebelhart. Symptoms of recurrent 
intrathecal baclofen withdrawal resulting from drug delivery failure: a case 
report. Am J Phys Med Rehabil, 1999. 78(3): 272-7. 
294. Dawes, W.J., J.M. Drake, and D. Fehlings. Microfracture of a baclofen pump 
catheter with intermittent under- and overdose. Pediatr Neurosurg, 2003. 
39(3): 144-8. 
295. Salazar, M.L. and L.S. Eiland. Intrathecal baclofen withdrawal resembling 
serotonin syndrome in an adolescent boy with cerebral palsy. Pediatr Emerg 
Care, 2008. 24(10): 691-3. 
296. Muirhead, W., I. Jalloh, and M. Vloeberghs. Status dystonicus resembling the 
intrathecal baclofen withdrawal syndrome: a case report and review of the 
literature. J Med Case Reports, 2010. 31(4): 294. 
297. Awaad, Y., et al. Complications of intrathecal baclofen pump: prevention and 
cure. ISRN Neurol. 2012: 575168. 
298. Dan, B., et al. Consensus on the appropriate use of intrathecal baclofen (ITB) 
therapy in paediatric spasticity. Eur J Paediatr Neurol, 2009. 
299. Penn, R.D. Catheter implant systems for intrathecal drug delivery. J 
Neurosurg, 1996. 84(4): 713. 
300. Hitt, J.M. and O. de Leon-Casasola. Complications of intrathecal drug delivery 
systems. Techniques in Regional Anesthesia and Pain Management 2011. 
15(4): 162-166. 
REFERENCES   
 247 
301. Albright, A.L., et al. Long-term intrathecal baclofen therapy for severe 
spasticity of cerebral origin. J Neurosurg, 2003. 98(2): 291-5. 
302. Fluckiger, B., et al. Device-related complications of long-term intrathecal drug 
therapy via implanted pumps. Spinal Cord, 2008. 46(9): 639-43. 
303. Coffey, J.R., et al. Intrathecal baclofen for intractable spasticity of spinal 
origin: results of a long-term multicenter study. J Neurosurg, 1993. 78(2): 226-
32. 
304. Taira, T., et al. Rate of Complications Among the Recipients of Intrathecal 
Baclofen Pump in Japan: A Multicenter Study. Neuromodulation, 2012. 3: 
266-72. 
305. Follett, K.A. and C.P. Naumann. A prospective study of catheter-related 
complications of intrathecal drug delivery systems. J Pain Symptom Manage, 
2000. 19(3): 209-15. 
306. Krach, L.E., et al. Hip status in cerebral palsy after one year of continuous 
intrathecal baclofen infusion. Pediatr Neurol, 2004. 30(3): 163-8. 
307. Fjelstad, A.B., J. Hommelstad, and A. Sorteberg. Infections related to 
intrathecal baclofen therapy in children and adults: frequency and risk factors. 
J Neurosurg Pediatr, 2009. 4(5): 487-93. 
308. Bayhan, I.A., et al. Infection as a Complication of Intrathecal Baclofen 
Treatment in Children With Cerebral Palsy. J Pediatr Orthop, 2016. 36(3): 
305-9. 
309. Boviatsis, E.J., et al. Infected CNS infusion pumps. Is there a chance for 
treatment without removal? Acta Neurochir (Wien), 2004. 146(5): 463-7. 
310. von Eiff, C., et al. Infections associated with medical devices: pathogenesis, 
management and prophylaxis. Drugs, 2005. 65(2): 179-214. 
311. Duhaime, A.C. Evaluation and management of shunt infections in children 
with hydrocephalus. Clin Pediatr (Phila), 2006. 45(8): 705-13. 
312. Athanasakis, E. and D. Ermidou. Post-Operative Complications of 
Ventriculoperitoneal Shunt in Hydrocephalic Pediatric Patients-Nursing Care. 
International Journal of Caring Sciences, 2011. 4(2): 66-71. 
313. Kouyialis, A.T., et al. Long-term air-exposed functioning hydrocephalus valve 
with no infection. South Med J, 2006. 99(10): 1127-9. 
314. Hester, S.M., et al. Evaluation of salvage techniques for infected baclofen 
pumps in pediatric patients with cerebral palsy. J Neurosurg Pediatr, 2012. 
10(6): 548-54. 
315. Reddy, B.R. Management of culture-negative surgical site infections. Journal 
of Medical and Allied Sciences 2012. 2 ( 1 )(1). 
316. Cazanave, C., et al. Corynebacterium prosthetic joint infection. J Clin 
Microbiol, 2012. 50(5): 1518-23. 
317. Otto, M. Staphylococcus epidermidis--the 'accidental' pathogen. Nat Rev 
Microbiol, 2009. 7(8): 555-67. 
318. Reilly, J., et al. An economic analysis of surgical wound infection. J Hosp 
Infect, 2001. 49(4): 245-9. 
319. Perencevich, E.N., et al. Health and economic impact of surgical site infections 
diagnosed after hospital discharge. Emerg Infect Dis, 2003. 9(2): 196-203. 
320. Plowman, R. The socioeconomic burden of hospital acquired infection. Euro 
Surveill, 2000. 5(4): 49-50. 
321. Heetla, H.W., et al. Clinical relevance of pharmacological and physiological 
data in intrathecal baclofen therapy. Arch Phys Med Rehabil, 2014. 95(11): 
2199-206. 
REFERENCES   
 248 
322. Li, T.C., et al. Catheter migration after implantation of an intrathecal baclofen 
infusion pump for severe spasticity: a case report. Kaohsiung J Med Sci, 2008. 
24(9): 492-7. 
323. Pritula, S.L., M.A. Fox, and R. Ayyangar. Weight changes in children 
receiving intrathecal baclofen for the treatment of spasticity. J Pediatr Rehabil 
Med, 2012. 5(3): 197-201. 
324. Medtronic, I. Patient Selection. Intrathecal Baclofen Therapy 2013  [cited 
2014 Nov. 15th]; Available from: 
http://professional.medtronic.com/pt/neuro/itb/edu/patient-
selection/#.WPNClmfTW70. 
325. Jevsevar, D.S. and L.I. Karlin. The relationship between preoperative 
nutritional status and complications after an operation for scoliosis in patients 
who have cerebral palsy. J Bone Joint Surg Am, 1993. 75(6): 880-4. 
326. Song, C.S. Relationships between Physical and Cognitive Functioning and 
Activities of Daily Living in Children with Cerebral Palsy. J Phys Ther Sci, 
2013. 25(5): 619-22. 
327. Ohls, R.K., et al. Cognitive outcomes of preterm infants randomized to 
darbepoetin, erythropoietin, or placebo. Pediatrics, 2014. 133(6): 1023-30. 
328. Beech, I.B., et al. Microbially-influenced corrosion: damage to prostheses, 
delight for bacteria. Int J Artif Organs, 2006. 29(4): 443-52. 
329. DeLegge, R.L. and M.H. DeLegge. Percutaneous endoscopic gastrostomy 
evaluation of device materials: are we "failsafe"? Nutr Clin Pract, 2005. 20(6): 
613-7. 
330. Brook, I. Microbiology and management of post-surgical wounds infection in 
children. Pediatr Rehabil, 2002. 5(3): 171-6. 
331. Friedman, J.N., et al. Complications associated with image-guided 
gastrostomy and gastrojejunostomy tubes in children. Pediatrics, 2004. 114(2): 
458-61. 
332. Batysheva, T.T., et al. [Management of cognitive impairment in children and 
adolescents with cerebral palsy treated with pantocalcin]. Zh Nevrol Psikhiatr 
Im S S Korsakova, 2013. 113(9): 48-53. 
333. Ferraz, H.B. and L.A. Andrade. Symptomatic dystonia: clinical profile of 46 
Brazilian patients. Can J Neurol Sci, 1992. 19(4): 504-7. 
334. Albright, A.L., et al. Infusion of intrathecal baclofen for generalized dystonia 
in cerebral palsy. J Neurosurg, 1998. 88(1): 73-6. 
335. Lin, J.P., et al. The impact and prognosis for dystonia in childhood including 
dystonic cerebral palsy: a clinical and demographic tertiary cohort study. J 
Neurol Neurosurg Psychiatry, 2014. 85 (11): 1239-44. 
336. Turner, M., H.S. Nguyen, and A.A. Cohen-Gadol. Intraventricular baclofen as 
an alternative to intrathecal baclofen for intractable spasticity or dystonia: 
outcomes and technical considerations. J Neurosurg Pediatr, 2012. 10(4): 315-
9. 
337. Rocque, B.G. and A. Leland Albright. Intraventricular vs intrathecal baclofen 
for secondary dystonia: a comparison of complications. Neurosurgery, 2012. 
70(2 Suppl Operative): 321-5; discussion 325-6. 
338. Medtronic, I. Ascenda Intrathecal Catheter for intrathecal baclofen therapy. 
2015  [cited 2016 10th October]; Available from: 
http://professional.medtronic.com/pt/neuro/itb/prod/ascenda-intrathecal-
catheter/index.htm#.WLe7_vKZlv0. 
339. Vanhauwaert, D.J., et al. Migration of pump for intrathecal drug delivery into 
the peritoneal cavity. Case report. Surg Neurol, 2009. 71(5): 610-2. 
REFERENCES   
 249 
340. Brooks, J., et al. Low weight, morbidity, and mortality in children with 
cerebral palsy: new clinical growth charts. Pediatrics, 2011. 128(2): e299-307. 
341. Garrouste-Orgeas, M., et al. Body mass index. An additional prognostic factor 
in ICU patients. Intensive Care Med, 2004. 30(3): 437-43. 
342. Samson-Fang, L.J. and R.D. Stevenson. Identification of malnutrition in 
children with cerebral palsy: poor performance of weight-for-height centiles. 
Dev Med Child Neurol, 2000. 42(3): 162-8. 
343. Amezquita, G.M. and B.M. Hodgson. [Alternatives to estimate stature during 
nutritional assessment of children with cerebral palsy]. Rev Chil Pediatr, 2014. 
85(1): 22-30. 
344. Kong, C.K. and H.S. Wong. Weight-for-height values and limb 
anthropometric composition of tube-fed children with quadriplegic cerebral 
palsy. Pediatrics, 2005. 116(6): e839-45. 
345. Simon, T.D., et al. Infection rates following initial cerebrospinal fluid shunt 
placement across pediatric hospitals in the United States. Clinical article. J 
Neurosurg Pediatr, 2009. 4(2): 156-65. 
346. Cochrane, D.D. and J.R. Kestle. The influence of surgical operative experience 
on the duration of first ventriculoperitoneal shunt function and infection. 
Pediatr Neurosurg, 2003. 38(6): 295-301. 
347. Ciric, I., et al. Complications of transsphenoidal surgery: results of a national 
survey, review of the literature, and personal experience. Neurosurgery, 1997. 
40(2): 225-36; discussion 236-7. 
348. Voges, J., et al. Deep-brain stimulation: long-term analysis of complications 
caused by hardware and surgery-experiences from a single centre. J Neurol 
Neurosurg Psychiatry, 2006. 77(7): 868-72. 
349. Katz, R.T. Life expectancy for children with cerebral palsy and mental 
retardation: Implications for life care planning. NeuroRehabilitation, 2003. 18: 
261-270. 
350. Watve, S.V., et al. Management of acute overdose or withdrawal state in 
intrathecal baclofen therapy. Spinal Cord, 2012. 50(2): 107-11. 
351. Boster, A.L., et al. Best Practices for Intrathecal Baclofen Therapy: Dosing 
and Long-Term Management. Neuromodulation, 2016. 19(6): 623-31. 
352. WHO. International Classification of Diseases (ICD). 2010; Available from: 
http://www.who.int/classifications/icd/en/. 
353. Ventola, C.L. Challenges in evaluating and standardizing medical devices in 
health care facilities. P T, 2008. 33(6): 348-59. 
354. Ngo, K. and J.R. McGuire. eds. Failure to identify intrathecal baclofen 
pump/catheter problems can lead to unnecessary healthcare costs: A case 
report 2009 ed. Vol. 1. 2009. S122-S123.Pages 
355. Bardutzky, J., et al. Intrathecal baclofen for stiff-person syndrome: life-
threatening intermittent catheter leakage. Neurology, 2003. 60(12): 1976-8. 
356. Dvorak, E.M., J.R. McGuire, and M.E. Nelson. Incidence and identification of 
intrathecal baclofen catheter malfunction. PM R, 2010. 2(8): 751-6. 
357. Miracle, A.C., et al. Imaging evaluation of intrathecal baclofen pump-catheter 
systems. AJNR Am J Neuroradiol. 32(7): 1158-64. 
358. Rehman, A.U., et al. A simple method to reduce infection of 
ventriculoperitoneal shunts. J Neurosurg Pediatr, 2010. 5(6): 569-72. 
359. Faillace, W.J. A no-touch technique protocol to diminish cerebrospinal fluid 
shunt infection. Surg Neurol, 1995. 43(4): 344-50. 
360. Vassar, M. and M. Holzmann. The retrospective chart review: important 
methodological considerations. J Educ Eval Health Prof, 2013. 10: 12. 
REFERENCES   
 250 
361. Morton, R.E., N. Gray, and M. Vloeberghs. Controlled study of the effects of 
continuous intrathecal baclofen infusion in non-ambulant children with 
cerebral palsy. Dev Med Child Neurol. 53(8): 736-41. 
362. Diederich, N.J., et al. Sustained effect of high-dose intrathecal baclofen in 
primary generalized dystonia: a 2-year follow-up study. Mov Disord, 1997. 
12(6): 1100-2. 
363. Jaffe, M.S. and L.J. Nienstedt. Intrathecal baclofen for generalized dystonia: a 
case report. Arch Phys Med Rehabil, 2001. 82(6): 853-5. 
364. Samuel, M., G.T. Finnerty, and P. Rudge. Intrathecal baclofen pump infection 
treated by adjunct intrareservoir antibiotic instillation. J Neurol Neurosurg 
Psychiatry, 1994. 57(9): 1146-7. 
365. Herranz Gordo, A., et al. [Continuous infusion of baclofen and an antibiotic 
for treating meningitis related to refilling of an intrathecal infusion pump 
reservoir]. Rev Esp Anestesiol Reanim, 2008. 55(1): 43-6. 
366. Dario, A., et al. Chronic Intrathecal Baclofen Infusion for Spasticity: 
Relationship between Pump and Host. Neuromodulation, 2004. 7(3): 201-4. 
367. FDA. Compounding and the FDA: Questions and Answers. Compounding 
2013  [cited 2013 23rd Aug.]; Available from: 
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Pharm
acyCompounding/ucm339764.htm#what. 
368. FDA. Limited FDA Survey of Compounded Drug Products. 2006  [cited 2015 
July 2015]; Available from: 
http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmac
ycompounding/ucm204237.htm. 
369. Meythaler, J.M. and J.D. Peduzzi. Baclofen Solution for Low-Volume 
Therapeutic Delivery. Neuromodulation, 2016. 10.1111/ner.12528. 
370. Cutrignelli, A., et al. Comparative effects of some hydrophilic excipients on 
the rate of gabapentin and baclofen lactamization in lyophilized formulations. 
Int J Pharm, 2007. 332(1-2): 98-106. 
371. Yue, B., et al. Solubility and Stability of Baclofen 3 mg/mL Intrathecal 
Formulation and Its Compatibility With Implantable Programmable Intrathecal 
Infusion Systems, in Neuromodulation. 2016. 
372. Commission, B.P. British Pharmacopoeia, T.d.o. health, Editor. 2012, The 
Stationery Office on behalf of Medicines and Health care Products Regulatory 
Agency (MHRA): London. 2477. 
373. Commission, B.P. British pharmacopoeia, T.d.o. health, Editor. 2012, (TSO) 
Stationary office on behalf of Medicine and Health care products Regulatory 
Agency (MHRA): London. A359-A361, http://www.pharmacopoeia.co.uk/. 
374. European pharmacopoeia 5.0; , in 2:9 Pharmaceutical technical procedures 
[2:9:19 Particulate Contamination: Sub-Visible Particles]. 2005, Sainte 
Ruffine : Maisonneuve, 1969. 253. 
375. Narhi, L.O., et al. A critical review of analytical methods for subvisible and 
visible particles. Curr Pharm Biotechnol, 2009. 10(4): 373-81. 
376. Hobbie, R.K. Intermediate physics for medicine and biology. 4th ed. 2007, 
New York, NY: Springer. xix, 616 p. 
377. Bahl, A., et al. Novel Use of Intrathecal Baclofen Drug Delivery System for 
Periodic Focal Dystonia in a Teenager. Neuromodulation, 2012. 
10.1111/j.1525-1403.2012.00510.x. 
378. Moehring, R.W., et al. Outbreak of Bacteremia Due to Burkholderia 
contaminans Linked to Intravenous Fentanyl From an Institutional 
Compounding Pharmacy. JAMA Intern Med, 2014. 
REFERENCES   
 251 
379. Civen, R., et al. Outbreak of Serratia marcescens infections following injection 
of betamethasone compounded at a community pharmacy. Clin Infect Dis, 
2006. 43(7): 831-7. 
380. Sheyman, A.T., et al. An outbreak of fungal endophthalmitis after intravitreal 
injection of compounded combined bevacizumab and triamcinolone. JAMA 
Ophthalmol, 2013. 131(7): 864-9. 
381. Johnson, C.E. and S.M. Hart. Stability of an extemporaneously compounded 
baclofen oral liquid. Am J Hosp Pharm, 1993. 50(11): 2353-5. 
382. Ahuja, S. Pharmaceutical Analysis and Control Section, in Analytical profiles 
of drug substances, K. Florey, Editor. 1985, Academic Press: New York.527. 
p. 527-548. 
383. Trissel, L.A., American Society of Hospital Pharmacists., and American 
Society of Health-System Pharmacists. Handbook on injectable drugs. 
American Society of Hospital Pharmacists: Bethesda, MD. v. 
384. Alvarez, J.C., et al. Drug stability testing to support clinical feasibility 
investigations for intrathecal baclofen-clonidine admixture. J Pain Symptom 
Manage, 2004. 28(3): 268-72. 
385. Shields, D., R. Montenegro, and J. Aclan. Chemical stability of admixtures 
combining ziconotide with baclofen during simulated intrathecal 
administration. Neuromodulation, 2007. 10 Suppl 1: 12-7. 
386. Farid, R., et al. Quality of intrathecal baclofen from different sources. Pm r, 
2012. 4(3): 182-9. 
387. Trissel, L.A. and Y. Zhang. High concentration baclofen preparations. 2013. 
US7824697(US 11/156,370)http://www.google.com/patents/US7824697. 
388. Medtronic, I. Compounding. Intrathecal Baclofen therapy 2012  [cited 2013 
Sept, 2nd.]; Available from: 
https://professional.medtronic.com/pt/neuro/itb/prod/lioresal-
intrathecal/compounding/index.htm#.WPNA_mfTW72. 
389. Prentice, T.R. and A.A. Strantz. Intrathecal baclofen pharmaceutical dosage 
forms with fewer degradation products. Oct 25, 2016  [cited US 9474732 B2 
US 14/574,733]; A61K31/197, A61K31/195, A61K31/4015, A61K9/00:[ 
390. Mikosz, C.A., et al. Fungal endophthalmitis associated with compounded 
products. Emerg Infect Dis, 2014. 20(2): 248-56. 
391. Centers for Disease, Control Prevention (CDC). Multistate outbreak of fungal 
infection associated with injection of methylprednisolone acetate solution from 
a single compounding pharmacy - United States. MMWR Morb Mortal Wkly 
Rep, 2012. 61(41): 839-42. 
392. Mullarkey, T. Pharmacy compounding of high-risk level products and patient 
safety. Am J Health Syst Pharm, 2009. 66(17 Suppl 5): S4-13. 
393. Jones, T.F., et al. Neurologic complications including paralysis after a 
medication error involving implanted intrathecal catheters. Am J Med, 2002. 
112(1): 31-6. 
394. Heetla, H.W., M.J. Staal, and T. van Laar. Tolerance to continuous intrathecal 
baclofen infusion can be reversed by pulsatile bolus infusion. Spinal Cord, 
2010. 48(6): 483-6. 
395. Francisco, G.E., et al. Consensus panel guidelines for the use of intrathecal 
baclofen therapy in poststroke spastic hypertonia. Top Stroke Rehabil, 2006. 
13(4): 74-85. 
396. Krach, L.E., R.L. Kriel, and A.C. Nugent. Complex dosing schedules for 
continuous intrathecal baclofen infusion. Pediatr Neurol, 2007. 37(5): 354-9. 
REFERENCES   
 252 
397. Natale, M., et al. Intrathecal baclofen therapy for severe spasticity: analysis on 
a series of 112 consecutive patients and future prospectives. Clin Neurol 
Neurosurg, 2012. 114(4): 321-5. 
398. Ridley, B. and P.K. Rawlins. Intrathecal baclofen therapy: ten steps toward 
best practice. J Neurosci Nurs, 2006. 38(2): 72-82. 
399. Bernards, C.M. Cerebrospinal fluid and spinal cord distribution of baclofen 
and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology, 
2006. 105(1): 169-78. 
400. Reddi, B.A. Why is saline so acidic (and does it really matter?). Int J Med Sci, 
2013. 10(6): 747-50. 
401. Andrews, R.J., J.R. Bringas, and G. Alonzo. Cerebrospinal fluid pH and PCO2 
rapidly follow arterial blood pH and PCO2 with changes in ventilation. 
Neurosurgery, 1994. 34(3): 466-70; discussion 470. 
402. Smith, S.V. and D.T. Forman. Laboratory analysis of cerebrospinal fluid. Clin 
Lab Sci, 1994. 7(1): 32-8. 
403. Kazim, S.F., S.A. Enam, and M.S. Shamim. Possible detrimental effects of 
neurosurgical irrigation fluids on neural tissue: an evidence based analysis of 
various irrigants used in contemporary neurosurgical practice. Int J Surg, 
2010. 8(8): 586-90. 
404. Uchida, K., et al. Possible harmful effects on central nervous system cells in 
the use of physiological saline as an irrigant during neurosurgical procedures. 
Surg Neurol, 2004. 62(2): 96-105; discussion 105. 
405. Oka, K., et al. The significance of artificial cerebrospinal fluid as perfusate and 
endoneurosurgery. Neurosurgery, 1996. 38(4): 733-6. 
406. Lagarce, F., et al. Baclofen-loaded microspheres in gel suspensions for 
intrathecal drug delivery: in vitro and in vivo evaluation. Eur J Pharm 
Biopharm, 2005. 61(3): 171-80. 
407. Gururaj, A.K., et al. Epilepsy in children with cerebral palsy. Seizure, 2003. 
12(2): 110-4. 
408. Donabedian, A. Twenty years of research on the quality of medical care: 1964-
1984. Eval Health Prof, 1985. 8(3): 243-65. 
409. Krousel-Wood, M.A. Practical considerations in the measurement of outcomes 
in healthcare. Ochsner J, 1999. 1(4): 187-94. 
410. Kraemer, H.C., et al. Mediators and moderators of treatment effects in 
randomized clinical trials. Arch Gen Psychiatry, 2002. 59(10): 877-83. 
411. Viehweger, E., et al. Measuring quality of life in cerebral palsy children. Ann 
Readapt Med Phys, 2008. 51(2): 119-37. 
412. Thastum, M. [Quality of life assessment and children]. Ugeskr Laeger, 2008. 
170(10): 834-8. 
413. Varni, J.W., T.M. Burwinkle, and M.M. Lane. Health-related quality of life 
measurement in pediatric clinical practice: an appraisal and precept for future 
research and application. Health Qual Life Outcomes, 2005. 3: 34. 
414. Fayers, P.M., et al. Quality of life assessment in clinical trials--guidelines and 
a checklist for protocol writers: the U.K. Medical Research Council 
experience. MRC Cancer Trials Office. Eur J Cancer, 1997. 33(1): 20-8. 
415. Nagahara, A.H. and M.H. Tuszynski. Potential therapeutic uses of BDNF in 
neurological and psychiatric disorders. Nat Rev Drug Discov, 2011. 10(3): 
209-19. 
416. Spilker, B. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. 
Introduction, ed. B. Spilker. 1996, Philadelphia: Lippincott-Raven. xlv, 1259 
p.1-10.
REFERENCES   
 253 
417. Sherman, E.M., et al. Validity of three measures of health-related quality of 
life in children with intractable epilepsy. Epilepsia, 2002. 43(10): 1230-8. 
418. Heese, K., et al. GABA(B) receptor antagonists elevate both mRNA and 
protein levels of the neurotrophins nerve growth factor (NGF) and brain-
derived neurotrophic factor (BDNF) but not neurotrophin-3 (NT-3) in brain 
and spinal cord of rats. Neuropharmacology, 2000. 39(3): 449-62. 
419. Stucki, G., A. Cieza, and J. Melvin. The International Classification of 
Functioning, Disability and Health (ICF): a unifying model for the conceptual 
description of the rehabilitation strategy. J Rehabil Med, 2007. 39(4): 279-85. 
420. Valvano, J. Activity-focused motor interventions for children with 
neurological conditions. Phys Occup Ther Pediatr, 2004. 24(1-2): 79-107. 
421. Schneider, J.W., et al. Health-related quality of life and functional outcome 
measures for children with cerebral palsy. Dev Med Child Neurol, 2001. 43(9): 
601-8. 
422. Liu, W.Y., et al. A Preliminary study of the development, validity, and 
reliability of a caregiver questionnaire for the health-related quality of life in 
children with cerebral palsy. Chang Gung Med J, 2010. 33(6): 646-58. 
423. Harrington, H.J. and T. McNellis. Mobilizing the right lean metrics for 
success. Quality Digest 2006  [cited 2014 Sep. 25th ]; Available from: 
https://www.qualitydigest.com/may06/articles/02_article.shtml. 
424. Murphy, M.F. and M.H. Yazer. Measuring and monitoring blood utilization. 
Transfusion, 2013. 53(12): 3025-8. 
425. Butler, C. Outcomes that matter. Dev Med Child Neurol, 1995. 37(9): 753-4. 
426. Brodtkorb, T.-H. Cost-effectiveness analysis of health technologies when 
evidence is scarce, in Linköping University, Department of Medicine and 
Health Sciences, Health Technology Assessment. 2010, Linköping University: 
Linköping. 51. 
427. Chang, S.C., et al. The association of drooling and health-related quality of life 
in children with cerebral palsy. Neuropsychiatr Dis Treat, 2012. 8: 599-604. 
428. Osthus, A.A., et al. Head and neck specific Health Related Quality of Life 
scores predict subsequent survival in successfully treated head and neck cancer 
patients: a prospective cohort study. Oral Oncol, 2011. 47(10): 974-9. 
429. Urba, S., et al. Quality of life scores as prognostic factors of overall survival in 
advanced head and neck cancer: analysis of a phase III randomized trial of 
pemetrexed plus cisplatin versus cisplatin monotherapy. Oral Oncol, 2012. 
48(8): 723-9. 
430. Shields, L.B., A. Choucair, and A.K. Choucair. Quality of life measures as a 
preliminary clinical indicator in patients with primary brain tumors. Surg 
Neurol Int, 2013. 4: 48. 
431. Svensson, H., et al. Health-related quality of life as prognostic factor for 
response, progression-free survival, and survival in women with metastatic 
breast cancer. Med Oncol, 2012. 29(2): 432-8. 
432. Osthus, A.A., et al. Prediction of survival by pretreatment health-related 
quality-of-life scores in a prospective cohort of patients with head and neck 
squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg, 2013. 139(1): 
14-20. 
433. Bellavia, M., et al. Is secondary hyperparathyroidism-related myelofibrosis a 
negative prognostic factor for kidney transplant outcome? Med Hypotheses, 
2011. 77(4): 557-9. 
REFERENCES   
 254 
434. Fujitani, K., et al. Optimal indications of surgical palliation for incurable 
advanced gastric cancer presenting with malignant gastrointestinal obstruction. 
Gastric Cancer, 2011. 14(4): 353-9. 
435. Varni, J.W. and Y. Setoguchi. Screening for behavioral and emotional 
problems in children and adolescents with congenital or acquired limb 
deficiencies. Am J Dis Child, 1992. 146(1): 103-7. 
436. Ravens-Sieberer, U., et al. [Health-related quality of life and mental health of 
children and adolescents in Germany: results from the German HBSC Study 
2006-2010]. Gesundheitswesen, 2012. 74 Suppl: S33-41. 
437. Waters, E., et al. Psychometric properties of the quality of life questionnaire 
for children with CP. Dev Med Child Neurol, 2007. 49(1): 49-55. 
438. Guyatt, G.H., et al. Users' guides to the medical literature. XII. How to use 
articles about health-related quality of life. Evidence-Based Medicine Working 
Group. JAMA, 1997. 277(15): 1232-7. 
439. Bjornson, K.F. and J.F. McLaughlin. The measurement of health-related 
quality of life (HRQL) in children with cerebral palsy. Eur J Neurol, 2001. 8 
Suppl 5: 183-93. 
440. Vles, G.F., et al. Long-term follow-up on continuous intrathecal Baclofen 
therapy in non-ambulant children with intractable spastic Cerebral Palsy. Eur J 
Paediatr Neurol, 2013. 17(6): 639-44. 
441. Davis, E., et al. Paediatric quality of life instruments: a review of the impact of 
the conceptual framework on outcomes. Dev Med Child Neurol, 2006. 48(4): 
311-8. 
442. Nemer McCoy, R., et al. Validation of a care and comfort hypertonicity 
questionnaire. Dev Med Child Neurol, 2006. 48(3): 181-7. 
443. Narayanan, U.G., et al. Initial development and validation of the Caregiver 
Priorities and Child Health Index of Life with Disabilities (CPCHILD). Dev 
Med Child Neurol, 2006. 48(10): 804-12. 
444. Varni, J.W., et al. The PedsQL in pediatric cerebral palsy: reliability, validity, 
and sensitivity of the Generic Core Scales and Cerebral Palsy Module. Dev 
Med Child Neurol, 2006. 48(6): 442-9. 
445. Baars, R.M., et al. The European DISABKIDS project: development of seven 
condition-specific modules to measure health related quality of life in children 
and adolescents. Health Qual Life Outcomes, 2005. 3: 70. 
446. Waters, E., et al. Development of a condition-specific measure of quality of 
life for children with cerebral palsy: empirical thematic data reported by 
parents and children. Child Care Health Dev, 2005. 31(2): 127-35. 
447. Carlon, S., et al. A systematic review of the psychometric properties of Quality 
of Life measures for school aged children with cerebral palsy. BMC Pediatr, 
2010. 10: 81. 
448. Ziviani, J., et al. Concurrent validity of the Functional Independence Measure 
for Children (WeeFIM) and the Pediatric Evaluation of Disabilities Inventory 
in children with developmental disabilities and acquired brain injuries. Phys 
Occup Ther Pediatr, 2001. 21(2-3): 91-101. 
449. Steinbok, P. Outcomes after selective dorsal rhizotomy for spastic cerebral 
palsy. Childs Nerv Syst, 2001. 17(1-2): 1-18. 
450. Msall, M.E. Measuring functional skills in preschool children at risk for 
neurodevelopmental disabilities. Ment Retard Dev Disabil Res Rev, 2005. 
11(3): 263-73. 
REFERENCES   
 255 
451. James, S., J. Ziviani, and R. Boyd. A systematic review of activities of daily 
living measures for children and adolescents with cerebral palsy. Dev Med 
Child Neurol, 2014. 56(3): 233-44. 
452. Willis, C.D., et al. Assessing outcomes in paediatric trauma populations. 
Injury, 2006. 37(12): 1185-96. 
453. Msall, M.E., et al. The Functional Independence Measure for Children 
(WeeFIM). Conceptual basis and pilot use in children with developmental 
disabilities. Clin Pediatr (Phila), 1994. 33(7): 421-30. 
454. Zdolsek, H.A., et al. Intrathecal baclofen therapy: benefits and complications. 
J Intellect Dev Disabil. 36(3): 207-13. 
455. Meyer, T., S. Richter, and H. Raspe. Agreement between pre-post measures of 
change and transition ratings as well as then-tests. BMC Med Res Methodol, 
2013. 13(52). 
456. Bramanti, P., et al. Quality of life of patients with telemetric pumps for 
intrathecal baclofen infusion: data and limitations of assessment scales. Funct 
Neurol, 2004. 19(4): 227-31. 
457. Hoving, M.A., et al. Efficacy of intrathecal baclofen therapy in children with 
intractable spastic cerebral palsy: a randomised controlled trial. Eur J Paediatr 
Neurol, 2009. 13(3): 240-6. 
458. Ho, P.M., P.N. Peterson, and F.A. Masoudi. Evaluating the evidence: is there a 
rigid hierarchy? Circulation, 2008. 118(16): 1675-84. 
459. Campbell, D.T. and J.C. Stanley. Experimental and quasi-experimental designs 
for research. 1963, Chicago: Rand McNally.34. 
460. Jelitte, M. and M. Schuler. [Do we always measure the same? On 
measurement invariance and response shift in rehabilitation research - part 2]. 
Rehabilitation (Stuttg), 2012. 51(6): 415-23. 
461. Borowski, A., et al. [Quality of life in cerebral palsy children treated with 
intrathecal baclofen pump implantation in parents' opinion]. Chir Narzadow 
Ruchu Ortop Pol, 2010. 75(5): 318-22. 
462. Borowski, A., et al. Evaluation of satisfaction with surgical treatment for 
musculoskeletal dysfunction in children with cerebral palsy. Ortop Traumatol 
Rehabil, 2010. 12(4): 347-52. 
463. Tasseel Ponche, S., et al. Intrathecal baclofen in cerebral palsy. A retrospective 
study of 25 wheelchair-assisted adults. Ann Phys Rehabil Med, 2010. 53(8): 
483-98. 
464. International Classification of Functioning, Disability, and Health : Children & 
Youth version. 2007, Geneva: World Health Organization 
465. Hwang, A.W., et al. Applying the ICF-CY framework to examine biological 
and environmental factors in early childhood development. J Formos Med 
Assoc, 2014. 113(5): 303-12. 
466. Field, D.A., et al. Measuring Participation for Children and Youth With Power 
Mobility Needs: A Systematic Review of Potential Health Measurement Tools. 
Arch Phys Med Rehabil, 2016. 97(3): 462-477 e40. 
467. Perenboom, R.J. and A.M. Chorus. Measuring participation according to the 
International Classification of Functioning, Disability and Health (ICF). 
Disabil Rehabil, 2003. 25(11-12): 577-87. 
468. Law, M. Participation in the occupations of everyday life. Am J Occup Ther, 
2002. 56(6): 640-9. 
469. Schiariti, V., et al. International Classification of Functioning, Disability and 
Health Core Sets for children and youth with cerebral palsy: a consensus 
meeting. Dev Med Child Neurol, 2015. 57(2): 149-58. 
REFERENCES   
 256 
470. Ottenbacher, K.J., et al. The WeeFIM instrument: its utility in detecting 
change in children with developmental disabilities. Arch Phys Med Rehabil, 
2000. 81(10): 1317-26. 
471. Park, E.Y., W.H. Kim, and Y.I. Choi. Factor analysis of the WeeFIM in 
children with spastic cerebral palsy. Disabil Rehabil, 2013. 35(17): 1466-71. 
472. Msall, M.E., et al. WeeFIM. Normative sample of an instrument for tracking 
functional independence in children. Clin Pediatr (Phila), 1994. 33(7): 431-8. 
473. Wong, S.S. and V.C. Wong. Functional Independence Measure for Children: a 
comparison of Chinese and Japanese children. Neurorehabil Neural Repair, 
2007. 21(1): 91-6. 
474. Narayanan, U.G., D. Fehlings, and S. Weir. Caregiver Priorities and Child 
Health Index of Life with Disabilities (CPCHILD©): Manual & Interpretation 
Guide. 2007. 
475. Cohen, J. Statistical power analysis for the behavioral sciences. 2nd ed. 1988, 
Hillsdale, N.J.: L. Erlbaum Associates. xxi, 567 p. 
476. McGough, J.J. and S.V. Faraone. Estimating the size of treatment effects: 
moving beyond p values. Psychiatry (Edgmont), 2009. 6(10): 21-9. 
477. Gardner, D. and A. Murphy. Gardner’s Effect Size Illustrator (version 1.1). 
2014; Available from: http://esi.medicine.dal.ca/index.html. 
478. Ramstad, K., et al. Characteristics of recurrent musculoskeletal pain in 
children with cerebral palsy aged 8 to 18 years. Dev Med Child Neurol, 2011. 
53(11): 1013-8. 
479. Morton, R.E., N. Gray, and M. Vloeberghs. Controlled study of the effects of 
continuous intrathecal baclofen infusion in non-ambulant children with 
cerebral palsy. Dev Med Child Neurol, 2011. 53(8): 736-41. 
480. McClelland, S., 3rd, et al. Intrathecal baclofen for spasticity-related pain in 
amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. 
Muscle Nerve, 2008. 37(3): 396-8. 
481. Himmelmann, K., K. Lindh, and M.J. Hidecker. Communication ability in 
cerebral palsy: a study from the CP register of western Sweden. Eur J Paediatr 
Neurol, 2013. 17(6): 568-74. 
482. Hirsh, A.T., et al. Symptom burden in individuals with cerebral palsy. J 
Rehabil Res Dev, 2010. 47(9): 863-76. 
483. Francisco, G.E., J.M. Latorre, and C.B. Ivanhoe. Intrathecal baclofen therapy 
for spastic hypertonia in chronic traumatic brain injury. Brain Inj, 2007. 21(3): 
335-8. 
484. Margetis, K., et al. Intrathecal baclofen associated with improvement of 
consciousness disorders in spasticity patients. Neuromodulation, 2014. 17(7): 
699-704. 
485. Sara, M., et al. Intrathecal baclofen in patients with persistent vegetative state: 
2 hypotheses. Arch Phys Med Rehabil, 2009. 90(7): 1245-9. 
486. Walker, K.R. and G. Tesco. Molecular mechanisms of cognitive dysfunction 
following traumatic brain injury. Front Aging Neurosci, 2013. 5(29). 
487. Powell, K.B. and K.K. Voeller. Prefrontal executive function syndromes in 
children. J Child Neurol, 2004. 19(10): 785-97. 
488. Lee, S. Avoiding negative reviewer comments: common statistical errors in 
anesthesia journals. Korean J Anesthesiol, 2016. 69(3): 219-26. 
489. Coe, R. It's the Effect Size, Stupid What effect size is and why it is important, 
in Annual Conference of the British Educational Research Association. 2002: 
University of Exeter, England, 12-14 September  
REFERENCES   
 257 
490. Ialongo, C. Understanding the effect size and its measures. Biochem Med 
(Zagreb), 2016. 26(2): 150-63. 
491. Privitera, G.J. Research methods for the behavioral sciences. 2016.449. 
492. Crosby, R.D., R.L. Kolotkin, and G.R. Williams. Defining clinically 
meaningful change in health-related quality of life. J Clin Epidemiol, 2003. 
56(5): 395-407. 
493. Kazis, L.E., J.J. Anderson, and R.F. Meenan. Effect sizes for interpreting 
changes in health status. Med Care, 1989. 27(3 Suppl): S178-89. 
494. Ivanhoe, C.B., et al. Intrathecal baclofen management of poststroke spastic 
hypertonia: implications for function and quality of life. Arch Phys Med 
Rehabil, 2006. 87(11): 1509-15. 
495. Schwartz, C.E. and M.A. Sprangers. Guidelines for improving the stringency 
of response shift research using the thentest. Qual Life Res, 2010. 19(4): 455-
64. 
496. Hogan, D.P., M.L. Rogers, and M.E. Msall. Functional limitations and key 
indicators of well-being in children with disability. Arch Pediatr Adolesc Med, 
2000. 154(10): 1042-8. 
497. Shikha Chandrabose Chulliyil, S.J.D., Megha Sandeep Sheth, Neeta 
Jayprakash Vyas. Correlation of functional independence and quality of life in 
school aged children with cerebral palsy. International Journal of 
Contemporary Pediatrics, 2014. 1(1): 32-36. 
498. Parkes, J., N. McCullough, and A. Madden. To what extent do children with 
cerebral palsy participate in everyday life situations? Health Soc Care 
Community, 2010. 18(3): 304-15. 
499. Grilli, L., et al. Associations between a functional independence measure 
(WeeFIM) and the pediatric quality of life inventory (PedsQL4.0) in young 
children with physical disabilities. Qual Life Res, 2006. 15(6): 1023-31. 
500. Sperle, P.A., et al. Equivalence reliability of the functional independence 
measure for children (WeeFIM) administration methods. Am J Occup Ther, 
1997. 51(1): 35-41. 
501. Akodu, A.K., et al. Relationship between spasticity and health related quality 
of life in individuals with cerebral palsy. Nig Q J Hosp Med, 2012. 22(2): 99-
102. 
502. Scheinberg, A., et al. Continuous intrathecal baclofen infusion for children 
with cerebral palsy: a pilot study. J Paediatr Child Health, 2001. 37(3): 283-8. 
503. Wong, V., et al. Cerebral palsy: correlation of risk factors and functional 
performance using the Functional Independence Measure for Children 
(WeeFIM). J Child Neurol, 2004. 19(11): 887-93. 
504. Dario, A., et al. Relationship between intrathecal baclofen and the central 
nervous system. Acta Neurochir Suppl, 2007. 97(Pt 1): 461-4. 
505. Ganjwala, D. Multilevel orthopedic surgery for crouch gait in cerebral palsy: 
An evaluation using functional mobility and energy cost. Indian J Orthop, 
2011. 45(4): 314-9. 
506. Kokkonen, J., et al. Social outcome of handicapped children as adults. Dev 
Med Child Neurol, 1991. 33(12): 1095-100. 
507. Carlsson, M., G. Hagberg, and I. Olsson. Clinical and aetiological aspects of 
epilepsy in children with cerebral palsy. Dev Med Child Neurol, 2003. 45(6): 
371-6. 
508. Arnaud, C., et al. Parent-reported quality of life of children with cerebral palsy 
in Europe. Pediatrics, 2008. 121(1): 54-64. 
REFERENCES   
 258 
509. Tessier, D.W., J.L. Hefner, and A. Newmeyer. Factors related to psychosocial 
quality of life for children with cerebral palsy. Int J Pediatr, 2014. 2014: 
204386. 
510. Abel, M.F., et al. Relationships among musculoskeletal impairments and 
functional health status in ambulatory cerebral palsy. J Pediatr Orthop, 2003. 
23(4): 535-41. 
511. Raidl, M., et al. Use Retrospective Surveys to Obtain Complete Data Sets and 
Measure Impact in Extension Programs. Journal of Extension, 2004. 72(2). 
512. White-Koning, M., et al. Determinants of child-parent agreement in quality-of-
life reports: a European study of children with cerebral palsy. Pediatrics, 2007. 
120(4): e804-14. 
513. WHO. Measurement of Quality of Life in children. Division of mental health.  
World Health Organization. 1993, World Health Organization: Geneva, 
Switzerland. 
514. le Coq, E.M., et al. Which source should we use to measure quality of life in 
children with asthma: the children themselves or their parents? Qual Life Res, 
2000. 9(6): 625-36. 
515. Hassan, E. Recall Bias can be a threat to retrospective and prospective research 
designs. The Internet Journal of Epidemiolog, 2005. 3(2). 
516. Lopez-Gigosos, R., et al. Effectiveness and economic analysis of the whole 
cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the 
prevention of traveller's diarrhoea. BMC Infect Dis, 2009. 9: 65. 
517. Euser, A.M., et al. Cohort studies: prospective versus retrospective. Nephron 
Clin Pract, 2009. 113(3): c214-7. 
518. Penson, D.F. and J.T. Wei. Clinical research methods for surgeons. 2006, 
Totowa, N.J.: Humana ; Oxford : Blackwell [distributor] 
519. Bhandari, M. and A. Joensson. Clinical research for surgeons. 2009, Stuttgart ; 
New York: Thieme 
520. Basaran, A., et al. The effect of having a children with cerebral palsy on 
quality of life, burn-out, depression and anxiety scores: a comparative study. 
Eur J Phys Rehabil Med, 2013. 49(6): 815-22. 
521. Ones, K., et al. Assessment of the quality of life of mothers of children with 
cerebral palsy (primary caregivers). Neurorehabil Neural Repair, 2005. 19(3): 
232-7. 
522. Curran, A.L., et al. Time costs of caring for children with severe disabilities 
compared with caring for children without disabilities. Dev Med Child Neurol, 
2001. 43(8): 529-33. 
523. Ostensjo, S., E.B. Carlberg, and N.K. Vollestad. Everyday functioning in 
young children with cerebral palsy: functional skills, caregiver assistance, and 
modifications of the environment. Dev Med Child Neurol, 2003. 45(9): 603-
12. 
524. Hwang, M., et al. Measuring care and comfort in children with cerebral palsy: 
the care and comfort caregiver questionnaire. PM R, 2011. 3(10): 912-9. 
525. Gothwal, V.K., S. Bharani, and S.P. Reddy. Measuring coping in parents of 
children with disabilities: a rasch model approach. PLoS One, 2015. 10(3): 
e0118189. 
526. Cunningham, B.J. and P.L. Rosenbaum. Measure of processes of care: a 
review of 20 years of research. Dev Med Child Neurol, 2014. 56(5): 445-52. 
527. Jamtvedt, G., et al. Audit and feedback: effects on professional practice and 
health care outcomes. Cochrane Database Syst Rev, 2003(3): Cd000259. 
REFERENCES   
 259 
528. Ivers, N., et al. Audit and feedback: effects on professional practice and 
healthcare outcomes. Cochrane Database of Systematic Reviews, 2012(6). 
529. Pharma, N. Lioresal Intrathecal Summary of Product Characteristic. 2011  
10th Oct. 2016]; Available from: 
http://www.medicines.org.uk/emc/medicine/1295/SPC/lioresal+intrathecal#CL
INICAL_PRECAUTIONS. 
530. Farrington, D.P. Longitudinal research strategies: advantages, problems, and 
prospects. J Am Acad Child Adolesc Psychiatry, 1991. 30(3): 369-74. 
531. Mathur, S.N., et al. Long-term intrathecal baclofen: outcomes after more than 
10 years of treatment. PM R, 2014. 6(6): 506-513 e1. 
532. Hill, K.G., et al. Planning for Long-Term Follow-Up: Strategies Learned from 
Longitudinal Studies. Prev Sci, 2016. 17(7): 806-18. 
533. Saulino, M., et al. Medical cost impact of intrathecal baclofen therapy for 
severe spasticity. Neuromodulation, 2015. 18(2): 141-9; discussion 149. 
534. Twisk, J.W.R. Applied longitudinal data analysis for epidemiology : a 
practical guide. 2003, Cambridge: Cambridge University Press 
535. Skogberg, O., et al. Changes in body composition after spasticity treatment 
with intrathecal baclofen. J Rehabil Med, 2017. 49(1): 36-39. 
536. von Koch, C.S., et al. Selective posterior rhizotomy and intrathecal baclofen 
for the treatment of spasticity. Pediatr Neurosurg, 2001. 35(2): 57-65. 
537. Kan, P., et al. Surgical treatment of spasticity in children: comparison of 
selective dorsal rhizotomy and intrathecal baclofen pump implantation. Childs 
Nerv Syst, 2008. 24(2): 239-43. 
538. Ronan, S. and J.T. Gold. Nonoperative management of spasticity in children. 
Childs Nerv Syst, 2007. 23(9): 943-56. 
539. Pavone, L., J. Burton, and D. Gaebler-Spira. Dystonia in childhood: clinical 
and objective measures and functional implications. J Child Neurol, 2013. 
28(3): 340-50. 
540. Gordon, L.M., et al. Can spasticity and dystonia be independently measured in 
cerebral palsy? Pediatr Neurol, 2006. 35(6): 375-81. 
541. Delgado, M.R. and A.L. Albright. Movement disorders in children: definitions, 
classifications, and grading systems. J Child Neurol, 2003. 18 Suppl 1: S1-8. 
542. Sanger, T.D., et al. Definition and classification of hyperkinetic movements in 
childhood. Mov Disord, 2010. 25(11): 1538-49. 
543. Sanger, T.D., et al. Classification and definition of disorders causing 
hypertonia in childhood. Pediatrics, 2003. 111(1): e89-97. 
544. Albanese, A., et al. Phenomenology and classification of dystonia: a consensus 
update. Mov Disord, 2013. 28(7): 863-73. 
545. Berardelli, A., et al. The pathophysiology of primary dystonia. Brain, 1998. 
121 ( Pt 7): 1195-212. 
546. Monbaliu, E., et al. Clinical presentation and management of dyskinetic 
cerebral palsy. Lancet Neurol, 2017. 16(9): 741-749. 
547. Aravamuthan, B.R. and J.L. Waugh. Localization of Basal Ganglia and 
Thalamic Damage in Dyskinetic Cerebral Palsy. Pediatr Neurol, 2016. 54: 11-
21. 
548. Mink, J.W. Special concerns in defining, studying, and treating dystonia in 
children. Mov Disord, 2013. 28(7): 921-5. 
549. Moreno-De-Luca, A., D.H. Ledbetter, and C.L. Martin. Genetic insights into 
the causes and classification of cerebral palsies. Lancet Neurol, 2012. 11(3): 
283-92. 
REFERENCES   
 260 
550. van Egmond, M.E., et al. Dystonia in children and adolescents: a systematic 
review and a new diagnostic algorithm. J Neurol Neurosurg Psychiatry, 2015. 
86(7): 774-81. 
551. Bax, M., C. Tydeman, and O. Flodmark. Clinical and MRI correlates of 
cerebral palsy: the European Cerebral Palsy Study. Jama, 2006. 296(13): 
1602-8. 
552. Krageloh-Mann, I., et al. Bilateral lesions of thalamus and basal ganglia: origin 
and outcome. Dev Med Child Neurol, 2002. 44(7): 477-84. 
553. Fehlings, D., et al. Pharmacological and neurosurgical interventions for 
managing dystonia in cerebral palsy: a systematic review. 2018. 60(4): 356-
366. 
554. Defazio, G., et al. Epidemiology of primary dystonia. Lancet Neurol, 2004. 
3(11): 673-8. 
555. Lundy, C., D. Lumsden, and C. Fairhurst. Treating complex movement 
disorders in children with cerebral palsy. Ulster Med J, 2009. 78(3): 157-63. 
556. de Carvalho Aguiar, P.M. and L.J. Ozelius. Classification and genetics of 
dystonia. Lancet Neurol, 2002. 1(5): 316-25. 
557. Weiner, W.J. and E. Tolosa. Hyperkinetic movement disorders. 2011, 
Edinburgh: Elsevier.p 468-469. 
558. Bhidayasiri, R., M.F. Waters, and C.C. Giza. Neurological differential 
diagnosis : a prioritized approach. 2005, Oxford: Blackwell.2014. 
559. Schapira, A.H.V. and E. Byrne. Neurology and clinical neuroscience. 2007, 
Philadelphia: Mosby Elsevier.444. 
560. Albanese, A., et al. EFNS guidelines on diagnosis and treatment of primary 
dystonias. Eur J Neurol, 2011. 18(1): 5-18. 
561. Phukan, J., et al. Primary dystonia and dystonia-plus syndromes: clinical 
characteristics, diagnosis, and pathogenesis. Lancet Neurol, 2011. 10(12): 
1074-85. 
562. Lee, W.W. and B.S. Jeon. Clinical spectrum of dopa-responsive dystonia and 
related disorders. Curr Neurol Neurosci Rep, 2014. 14(7): 461. 
563. Nygaard, T.G., C.D. Marsden, and S. Fahn. Dopa-responsive dystonia: long-
term treatment response and prognosis. Neurology, 1991. 41(2 ( Pt 1)): 174-81. 
564. Nygaard, T.G., et al. Dopa-responsive dystonia simulating cerebral palsy. 
Pediatr Neurol, 1994. 11(3): 236-40. 
565. Maas, R., et al. l-Dopa in dystonia: A modern perspective. Neurology, 2017. 
88(19): 1865-1871. 
566. Svetel, M., et al. Characteristics of dystonic movements in primary and 
symptomatic dystonias. J Neurol Neurosurg Psychiatry, 2004. 75(2): 329-30. 
567. Coenen, M.A. and H. Eggink. Cognition in childhood dystonia: a systematic 
review. 2018. 60(3): 244-255. 
568. Meunier, S., et al. Dystonia: lessons from brain mapping. Neuroscientist, 2003. 
9(1): 76-81. 
569. Grunt, S., et al. Preoperative MRI findings and functional outcome after 
selective dorsal rhizotomy in children with bilateral spasticity. Childs Nerv 
Syst, 2010. 26(2): 191-8. 
570. Albright, A.L. and S.S. Ferson. Intrathecal baclofen therapy in children. 
Neurosurg Focus, 2006. 21(2). 
571. Ordia, J. and J. Vaisman. Managing loss of intrathecal baclofen efficacy: 
Review of the literature and proposed troubleshooting algorithm. Neurol Clin 
Pract, 2014. 4(5): 371-372. 
REFERENCES   
 261 
572. Medtronic, I. Living With ITB Therapy-Warning Signs of Underdose and 
Overdose. 2015; Available from: https://www.medtronic.com/uk-
en/patients/treatments-therapies/drug-pump-severe-spasticity/living-
with/safety-warning-signs-of-underdose-and-overdose.html. 
573. Platz, T., et al. Clinical scales for the assessment of spasticity, associated 
phenomena, and function: a systematic review of the literature. Disabil 
Rehabil, 2005. 27(1-2): 7-18. 
574. Hurn, J., I. Kneebone, and M. Cropley. Goal setting as an outcome measure: A 
systematic review. Clin Rehabil, 2006. 20(9): 756-72. 
575. Law, M., et al. The Canadian occupational performance measure: an outcome 
measure for occupational therapy. Can J Occup Ther, 1990. 57(2): 82-7. 
576. Ben Smail, D., et al. Pruritus after intrathecal baclofen withdrawal: A 
retrospective study. Arch Phys Med Rehabil, 2005. 86(3): 494-7. 
577. Teasell, R.W., et al. Cardiovascular consequences of loss of supraspinal 
control of the sympathetic nervous system after spinal cord injury. Arch Phys 
Med Rehabil, 2000. 81(4): 506-16. 
578. Curt, A., et al. Assessment of autonomic dysreflexia in patients with spinal 
cord injury. J Neurol Neurosurg Psychiatry, 1997. 62(5): 473-7. 
579. Mandac, B.R., E.A. Hurvitz, and V.S. Nelson. Hyperthermia associated with 
baclofen withdrawal and increased spasticity. Arch Phys Med Rehabil, 1993. 
74(1): 96-7. 
580. Rosenberg, H., et al. Malignant hyperthermia. Orphanet J Rare Dis, 2007. 2: 
21. 
581. Grenier, B., et al. [Severe hyperthermia caused by sudden withdrawal of 
continuous intrathecal administration of baclofen]. Ann Fr Anesth Reanim, 
1996. 15(5): 659-62. 
582. Caroff., S. and S. Mann. Nenroleptic malignant syndrome. . Med Clin North 
Am, 1993. 77: 185-202. . 
583. Cadman, D., et al. Children with chronic illness: family and parent 
demographic characteristics and psychosocial adjustment. Pediatrics, 1991. 
87(6): 884-9. 
584. Dyson, L.L. Response to the presence of a child with disabilities: parental 
stress and family functioning over time. Am J Ment Retard, 1993. 98(2): 207-
18. 
585. Brehaut, J.C., et al. Changes over time in the health of caregivers of children 
with health problems: growth-curve findings from a 10-year Canadian 
population-based study. Am J Public Health, 2011. 101(12): 2308-16. 
586. Brehaut, J.C., et al. Health among caregivers of children with health problems: 
findings from a Canadian population-based study. Am J Public Health, 2009. 
99(7): 1254-62. 
587. Eker, L. and E.H. Tuzun. An evaluation of quality of life of mothers of 
children with cerebral palsy. Disabil Rehabil, 2004. 26(23): 1354-9. 
588. Lee, J., R. Spratling, and A. Helvig. Sleep Characteristics in Mothers of 
Children With Developmental Disabilities. J Pediatr Health Care, 2018. 
32(1): e9-e18. 
589. Wayte, S., et al. Sleep problems in children with cerebral palsy and their 
relationship with maternal sleep and depression. Acta Paediatr, 2012. 101(6): 
618-23. 
590. Bourke-Taylor, H., et al. Relationships between sleep disruptions, health and 
care responsibilities among mothers of school-aged children with disabilities. J 
Paediatr Child Health, 2013. 49(9): 775-82. 
REFERENCES   
 262 
591. Perrin, J.M., et al. A family-centered, community-based system of services for 
children and youth with special health care needs. Arch Pediatr Adolesc Med, 
2007. 161(10): 933-6. 
592. King, S., et al. Family-centered service for children with cerebral palsy and 
their families: a review of the literature. Semin Pediatr Neurol, 2004. 11(1): 
78-86. 
593. Buysse, D.J., et al. The Pittsburgh Sleep Quality Index: a new instrument for 
psychiatric practice and research. Psychiatry Res, 1989. 28(2): 193-213. 
594. Chiluba, B.C. and G. Moyo. Caring for a cerebral palsy child: a caregivers 
perspective at the University Teaching Hospital, Zambia. BMC Res Notes, 
2017. 10(1): 724. 
595. Giugliani, R., et al. Guidelines for diagnosis and treatment of Hunter 
Syndrome for clinicians in Latin America. Genet Mol Biol, 2014. 37(2): 315-
29. 
596. Wilkes, D. Programmable intrathecal pumps for the management of chronic 
pain: recommendations for improved efficiency. J Pain Res, 2014. 7: 571-7. 
597. Patel, N.K. and S.S. Gill. GDNF delivery for Parkinson's disease. Acta 
Neurochir Suppl, 2007. 97(Pt 2): 135-54. 
598. Tomita, N., et al. Intrathecal methotrexate prophylaxis and central nervous 
system relapse in patients with diffuse large B-cell lymphoma following 
rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. 
Leuk Lymphoma, 2014. 6: 1-5. 
599. Mastronuzzi, A., et al. Intrathecal liposomal cytarabine and leptomeningeal 
medulloblastoma relapse: a valuable therapeutic option. Anticancer Res, 2013. 
33(8): 3515-8. 
600. Fisher, P.G., N.S. Kadan-Lottick, and D.N. Korones. Intrathecal thiotepa: 
reappraisal of an established therapy. J Pediatr Hematol Oncol, 2002. 24(4): 
274-8. 
601. Kerr, J.Z., S. Berg, and S.M. Blaney. Intrathecal chemotherapy. Crit Rev 
Oncol Hematol, 2001. 37(3): 227-36. 
602. Prager, J.P. Neuraxial medication delivery: the development and maturity of a 
concept for treating chronic pain of spinal origin. Spine (Phila Pa 1976), 1976. 
27(22): 2593-605. 
603. NICE. Interventional Procedures Programme process guide  2009  [cited 2016 
1st January ]; Available from: 
https://www.nice.org.uk/media/default/about/what-we-do/nice-guidance/nice-
interventional-procedures/interventional-procedures-programme-process-
guide.pdf. 
604. Department of Health. 2003. Health Service Circular: The Interventional 
Procedures Programme  Series Number: HSC 2003/011. 
605. Penn, R.D. and J.S. Kroin. Long-term intrathecal baclofen infusion for 
treatment of spasticity. J Neurosurg, 1987. 66(2): 181-5. 
606. Nielsen, J.F., et al. Evidence of tolerance to baclofen in treatment of severe 
spasticity with intrathecal baclofen. Clin Neurol Neurosurg, 2002. 104(2): 
142-5. 
607. Vidal, J., et al. Efficacy of intrathecal morphine in the treatment of baclofen 
tolerance in a patient on intrathecal baclofen therapy (ITB). Spinal Cord, 2004. 
42(1): 50-1. 
608. Soni, B.M., et al. Treatment of spasticity in a spinal cord-injured patient with 
intrathecal morphine due to intrathecal baclofen tolerance--a case report and 
review of literature. Spinal Cord, 2003. 41(10): 586-9. 
REFERENCES   
 263 
609. Abel, N.A. and R.A. Smith. Intrathecal baclofen for treatment of intractable 
spinal spasticity. Arch Phys Med Rehabil, 1994. 75(1): 54-8. 
610. Enna, S.J. and H. Mohler. The GABA receptors. 3rd ed. ed. 2007, Totowa, 
N.J.: Humana ; [Paisley : Quantum, distributor].295. 
611. Tang, A.C. and M.E. Hasselmo. Effect of long term baclofen treatment on 
recognition memory and novelty detection. Behav Brain Res, 1996. 74(1-2): 
145-52. 
612. Liu, L., et al. Baclofen mediates neuroprotection on hippocampal CA1 
pyramidal cells through the regulation of autophagy under chronic cerebral 
hypoperfusion. Sci Rep, 2015. 5: 14474. 
613. Hodor, A., et al. Baclofen facilitates sleep, neuroplasticity, and recovery after 
stroke in rats. Ann Clin Transl Neurol, 2014. 1(10): 765-77. 
614. Li, C.J., et al. Activation of GABAB receptors ameliorates cognitive 
impairment via restoring the balance of HCN1/HCN2 surface expression in the 
hippocampal CA1 area in rats with chronic cerebral hypoperfusion. Mol 
Neurobiol, 2014. 50(2): 704-20. 
615. Andersen, P. The hippocampus book. 2007, New York ; Oxford: Oxford 
University Press. p74 
616. Ayyangar R; Fox, M.W.S.G., B; Garton, H; Damodaran A. Cognitive effects 
of intrathecal baclofen therapy in adolescents with cerebral palsy, in 65th 
Annual Meeting of American Academy for Cerebral Palsy and Developmental 
Medicine. 2011, Developmental Medicine & Child Neurology. 53 
(Supplement 5):7-8: Las Vegas, USA. 7-8. 
617. Jahanshahi, M., R.G. Brown, and C.D. Marsden. Simple and choice reaction 
time and the use of advance information for motor preparation in Parkinson's 
disease. Brain, 1992. 115 ( Pt 2): 539-64. 
618. Dutt, R., M. Roduta-Roberts, and C.A. Brown. Sleep and Children with 
Cerebral Palsy: A Review of Current Evidence and Environmental Non-
Pharmacological Interventions. Children (Basel), 2015. 2(1): 78-88. 
619. Dick, B.D. and R. Pillai Riddell. Cognitive and school functioning in children 
and adolescents with chronic pain: a critical review. Pain Res Manag, 2010. 
15(4): 238-44. 
620. Hart, R.P., J.B. Wade, and M.F. Martelli. Cognitive impairment in patients 
with chronic pain: the significance of stress. Curr Pain Headache Rep, 2003. 
7(2): 116-26. 
621. Moriarty, O., B.E. McGuire, and D.P. Finn. The effect of pain on cognitive 
function: a review of clinical and preclinical research. Prog Neurobiol, 2011. 
93(3): 385-404. 
622. Miamoto, C.B., et al. Prevalence and predictive factors of sleep bruxism in 
children with and without cognitive impairment. Braz Oral Res, 2011. 25(5): 
439-45. 
623. Elsayed, R.M., et al. Sleep assessment of children with cerebral palsy: Using 
validated sleep questionnaire. Ann Indian Acad Neurol, 2013. 16(1): 62-5. 
624. Zuculo, G.M., C.C. Knap, and L. Pinato. Correlation between sleep and quality 
of life in cerebral palsy. Codas, 2014. 26(6): 447-56. 
625. Simard-Tremblay, E., et al. Sleep in children with cerebral palsy: a review. J 
Child Neurol, 2011. 26(10): 1303-10. 
626. Sandella, D.E., et al. Sleep and quality of life in children with cerebral palsy. 
Sleep Med, 2011. 12(3): 252-6. 
627. Romeo, D.M., et al. Sleep disturbances in preschool age children with cerebral 
palsy: a questionnaire study. Sleep Med, 2014. 15(9): 1089-93. 
REFERENCES   
 264 
628. Baweja, R., et al. Sleep problems in children. Minerva Pediatr, 2013. 65(5): 
457-72. 
629. Ednick, M., et al. A review of the effects of sleep during the first year of life 
on cognitive, psychomotor, and temperament development. Sleep, 2009. 
32(11): 1449-58. 
630. Kurdziel, L., K. Duclos, and R.M. Spencer. Sleep spindles in midday naps 
enhance learning in preschool children. Proc Natl Acad Sci U S A, 2013. 
110(43): 17267-72. 
631. Iglowstein, I., et al. Sleep duration from infancy to adolescence: reference 
values and generational trends. Pediatrics, 2003. 111(2): 302-7. 
632. McLaughlin Crabtree, V. and N.A. Williams. Normal sleep in children and 
adolescents. Child Adolesc Psychiatr Clin N Am, 2009. 18(4): 799-811. 
633. Goel, N., et al. Neurocognitive consequences of sleep deprivation. Semin 
Neurol, 2009. 29(4): 320-39. 
634. Shibagaki, M., S. Kiyono, and T. Takeuchi. Nocturnal sleep in mentally 
retarded infants with cerebral palsy. Electroencephalogr Clin Neurophysiol, 
1985. 61(6): 465-71. 
635. Lindblom, N., et al. Neurological impairments and sleep-wake behaviour 
among the mentally retarded. J Sleep Res, 2001. 10(4): 309-18. 
636. Drummond, S.P. and G.G. Brown. The effects of total sleep deprivation on 
cerebral responses to cognitive performance. Neuropsychopharmacology, 
2001. 25(5 Suppl): S68-73. 
637. Durmer, J.S. and D.F. Dinges. Neurocognitive consequences of sleep 
deprivation. Semin Neurol, 2005. 25(1): 117-29. 
638. Wright, M., et al. Sleep issues in children with physical disabilities and their 
families. Phys Occup Ther Pediatr, 2006. 26(3): 55-72. 
639. Schuh-Hofer, S., et al. One night of total sleep deprivation promotes a state of 
generalized hyperalgesia: a surrogate pain model to study the relationship of 
insomnia and pain. Pain, 2013. 154(9): 1613-21. 
640. Engel, J.M., et al. Cerebral palsy and chronic pain: a descriptive study of 
children and adolescents. Phys Occup Ther Pediatr, 2005. 25(4): 73-84. 
641. Houlihan, C.M., et al. Bodily pain and health-related quality of life in children 
with cerebral palsy. Dev Med Child Neurol, 2004. 46(5): 305-10. 
642. Fauconnier, J., et al. Participation in life situations of 8-12 year old children 
with cerebral palsy: cross sectional European study. BMJ, 2009. 338: b1458. 
643. Dickinson, H.O., et al. Self-reported quality of life of 8-12-year-old children 
with cerebral palsy: a cross-sectional European study. Lancet, 2007. 
369(9580): 2171-8. 
644. Tassain, V., et al. Long term effects of oral sustained release morphine on 
neuropsychological performance in patients with chronic non-cancer pain. 
Pain, 2003. 104(1-2): 389-400. 
645. Harman, K. and P. Ruyak. Working through the pain: a controlled study of the 
impact of persistent pain on performing a computer task. Clin J Pain, 2005. 
21(3): 216-22. 
646. Dick, B.D. and S. Rashiq. Disruption of attention and working memory traces 
in individuals with chronic pain. Anesth Analg, 2007. 104(5): 1223-9. 
647. Grisart, J., M. Van der Linden, and C. Bastin. The contribution of recollection 
and familiarity to recognition memory performance in chronic pain patients. 
Behav Res Ther, 2007. 45(5): 1077-84. 
648. Karp, J.F., et al. The relationship between pain and mental flexibility in older 
adult pain clinic patients. Pain Med, 2006. 7(5): 444-52. 
REFERENCES   
 265 
649. Dick, B., C. Eccleston, and G. Crombez. Attentional functioning in 
fibromyalgia, rheumatoid arthritis, and musculoskeletal pain patients. Arthritis 
Rheum, 2002. 47(6): 639-44. 
650. Leavitt, F. and R.S. Katz. Distraction as a key determinant of impaired 
memory in patients with fibromyalgia. J Rheumatol, 2006. 33(1): 127-32. 
651. Apkarian, A.V., et al. Human brain mechanisms of pain perception and 
regulation in health and disease. Eur J Pain, 2005. 9(4): 463-84. 
652. Franklin, D.J. and S. Grossberg. A neural model of normal and abnormal 
learning and memory consolidation: adaptively timed conditioning, 
hippocampus, amnesia, neurotrophins, and consciousness. Cogn Affect Behav 
Neurosci, 2017. 17(1): 24-76. 
653. Burgmer, M., et al. Decreased gray matter volumes in the cingulo-frontal 
cortex and the amygdala in patients with fibromyalgia. Psychosom Med, 2009. 
71(5): 566-73. 
654. Luerding, R., et al. Working memory performance is correlated with local 
brain morphology in the medial frontal and anterior cingulate cortex in 
fibromyalgia patients: structural correlates of pain-cognition interaction. Brain, 
2008. 131(Pt 12): 3222-31. 
655. Valet, M., et al. Patients with pain disorder show gray-matter loss in pain-
processing structures: a voxel-based morphometric study. Psychosom Med, 
2009. 71(1): 49-56. 
656. Salthouse, T.A. The processing-speed theory of adult age differences in 
cognition. Psychol Rev, 1996. 103(3): 403-28. 
657. Hoving, M.A., et al. Intrathecal baclofen in children with spastic cerebral 
palsy: a double-blind, randomized, placebo-controlled, dose-finding study. 
Dev Med Child Neurol, 2007. 49(9): 654-9. 
658. Zuniga, R.E., C.R. Schlicht, and S.E. Abram. Intrathecal baclofen is analgesic 
in patients with chronic pain. Anesthesiology, 2000. 92(3): 876-80. 
659. Ramstad, K., et al. Continuous intrathecal baclofen therapy in children with 
cerebral palsy - when does improvement emerge? Acta Paediatr, 2010. 99(11): 
1661-5. 
660. Jan, M.M. Cerebral palsy: comprehensive review and update. Ann Saudi Med, 
2006. 26(2): 123-32. 
661. Baker, K.W., et al. Improvements in children with cerebral palsy following 
intrathecal baclofen: use of the Rehabilitation Institute of Chicago Care and 
Comfort Caregiver Questionnaire (RIC CareQ). J Child Neurol, 2014. 29(3): 
312-7. 
662. Morgan, J.E. and J.H. Ricker. Textbook of clinical neuropsychology. 2nd 
edition. ed. p. 
663. Yin Foo, R., M. Guppy, and L.M. Johnston. Intelligence assessments for 
children with cerebral palsy: a systematic review. Dev Med Child Neurol, 
2013. 55(10): 911-8. 
664. Katz, G. and E. Lazcano-Ponce. Intellectual disability: definition, etiological 
factors, classification, diagnosis, treatment and prognosis. Salud Publica Mex, 
2008. 50 Suppl 2: s132-41. 
665. Novak, I., et al. Clinical prognostic messages from a systematic review on 
cerebral palsy. Pediatrics, 2012. 130(5): e1285-312. 
666. Ballester-Plane, J., et al. Measuring intellectual ability in cerebral palsy: The 
comparison of three tests and their neuroimaging correlates. Res Dev Disabil, 
2016. 56: 83-98. 
REFERENCES   
 266 
667. Stadskleiv, K., et al. Neuropsychological profiles of children with cerebral 
palsy. Dev Neurorehabil, 2018. 21(2): 108-120. 
668. Zhang, H., et al. The effects of motor and intellectual functions on the 
effectiveness of comprehensive rehabilitation in young children with cerebral 
palsy. J Int Med Res, 2015. 43(1): 125-38. 
669. Hammond, A. What is the role of the occupational therapist? Best Pract Res 
Clin Rheumatol, 2004. 18(4): 491-505. 
670. Darrah, J., L. Wiart, and J. Magill-Evans. Do therapists' goals and 
interventions for children with cerebral palsy reflect principles in 
contemporary literature? Pediatr Phys Ther, 2008. 20(4): 334-9. 
671. Steultjens, E.M., et al. Occupational therapy for children with cerebral palsy: a 
systematic review. Clin Rehabil, 2004. 18(1): 1-14. 
672. Palisano, R.J., L.M. Snider, and M.N. Orlin. Recent advances in physical and 
occupational therapy for children with cerebral palsy. Semin Pediatr Neurol, 
2004. 11(1): 66-77. 
673. Kruijsen-Terpstra, A.J., et al. Parents' experiences with physical and 
occupational therapy for their young child with cerebral palsy: a mixed studies 
review. Child Care Health Dev, 2014. 40(6): 787-96. 
 
                                                 
 
 
